{"PMC7508540": [["Compared to rural areas, the problem of compound air pollution in urban regions has received increasing attention in recent decades due to the numerous emission sources and focused intensity of pollutants (Li et al., 2019b, 2019c; Song et al., 2017; Wang et al., 2014b, 2020d).", [["compound air pollution in urban regions", "PROBLEM", 40, 79], ["the numerous emission sources", "PROBLEM", 139, 168], ["compound", "OBSERVATION_MODIFIER", 40, 48], ["air pollution", "OBSERVATION", 49, 62], ["increasing", "OBSERVATION_MODIFIER", 93, 103]]], ["As one of the countries with the fastest economic development in the world, the urbanization in China is rapidly developing, resulting in groups of megacities with permanent residents exceeding 10 million, around which urban agglomeration has evolved in areas such as the North China Plain (NCP), Yangtze River Delta (YRD), and Pearl River Delta (PRD).", [["megacities", "DISEASE", 148, 158], ["agglomeration", "DISEASE", 225, 238], ["Yangtze River Delta (YRD)", "TREATMENT", 297, 322], ["urbanization", "OBSERVATION_MODIFIER", 80, 92], ["rapidly", "OBSERVATION_MODIFIER", 105, 112], ["agglomeration", "OBSERVATION", 225, 238]]], ["As such, these regions feature the worst air pollution in China (An et al., 2019; Chan and Yao, 2008; Ding et al., 2016; Ge et al., 2018; Guo et al., 2020; Huang et al., 2014).IntroductionThe compound air pollution in urban agglomeration has received much attention since the large scale explosion of regional haze events in Central and Eastern China (CEC) in January 2013 (An et al., 2019; Cheng et al., 2016; Ding et al., 2016; Huang et al., 2014; Wang et al., 2014b; Zhang et al., 2014).", [["The compound air pollution in urban agglomeration", "TREATMENT", 188, 237], ["regional haze events", "PROBLEM", 301, 321], ["worst", "OBSERVATION_MODIFIER", 35, 40], ["air pollution", "OBSERVATION", 41, 54], ["compound", "OBSERVATION_MODIFIER", 192, 200], ["air pollution", "OBSERVATION", 201, 214], ["large", "OBSERVATION_MODIFIER", 276, 281], ["regional haze", "OBSERVATION", 301, 314], ["Central", "ANATOMY_MODIFIER", 325, 332]]], ["In September 2013, the State Council issued the Action Plan for Prevention and Control of Air Pollution, demanding that PM10 concentrations decrease by more than 10% in 2017 compared to the level in 2012 in cities at the prefectural level and above; additionally, a target number of excellent and good days with an air quality index (AQI) less than 100 was required, following the China Environmental Protection Standard \u2018HJ 633-2012\u2019 (http://www.gov.cn/zhengce/content/2013-09/13/content_4561.htm).", [["PM10", "CHEMICAL", 120, 124], ["PM10", "CHEMICAL", 120, 124], ["PM10", "SIMPLE_CHEMICAL", 120, 124], ["Prevention", "TREATMENT", 64, 74], ["an air quality index", "TEST", 312, 332], ["Air Pollution", "OBSERVATION", 90, 103]]], ["Noticeably, these regulatory measures have resulted in significant reduction in primary PM emissions, but the secondary pollutant ozone (O3) remains prominent (Huang et al., 2021; Li et al., 2019b; Wang et al., 2020d; Zeng et al., 2019).", [["ozone", "CHEMICAL", 130, 135], ["O3", "CHEMICAL", 137, 139], ["ozone", "CHEMICAL", 130, 135], ["O3", "CHEMICAL", 137, 139], ["ozone", "SIMPLE_CHEMICAL", 130, 135], ["O3", "SIMPLE_CHEMICAL", 137, 139], ["significant reduction in primary PM emissions", "PROBLEM", 55, 100], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["reduction", "OBSERVATION_MODIFIER", 67, 76], ["primary PM emissions", "OBSERVATION", 80, 100], ["pollutant ozone", "OBSERVATION", 120, 135]]], ["Numerous studies have indicated that compound air pollution has resulted from the primary pollutants emitted by industry, power plants, traffic and heating processes and from the secondary pollutants generated by complex physical, chemical and biological processes (An et al., 2019; Fenger, 2009; Guo et al., 2020; Li et al., 2019c; Zhang et al., 2020; Zhu et al., 2011).", [["Numerous studies", "TEST", 0, 16], ["compound air pollution", "PROBLEM", 37, 59], ["traffic and heating processes", "TREATMENT", 136, 165], ["air pollution", "OBSERVATION", 46, 59]]], ["These pollutants may quickly accumulate at high concentrations under static meteorological conditions and then undergo cross border transport processes, leading to complicated effects on human health and the environment (Huang et al., 2014; Lou et al., 2020; Wang et al., 2014b; Xu et al., 2013; Zhang et al., 2020).", [["human", "ORGANISM", 187, 192], ["human", "SPECIES", 187, 192], ["human", "SPECIES", 187, 192]]], ["Additionally, air pollution also has complex interactions with large scale weather and climate (Cai et al., 2017; Lou et al., 2019; Quinn and Bates, 2003).IntroductionThe contributions of distinct emission sources should first be clarified when implementing the joint prevention and control of regional air pollution.", [["air pollution", "PROBLEM", 14, 27], ["the joint prevention", "TREATMENT", 258, 278], ["regional air pollution", "PROBLEM", 294, 316], ["air pollution", "OBSERVATION", 14, 27], ["complex", "OBSERVATION_MODIFIER", 37, 44], ["large", "OBSERVATION_MODIFIER", 63, 68], ["scale", "OBSERVATION_MODIFIER", 69, 74], ["distinct", "OBSERVATION_MODIFIER", 188, 196], ["emission sources", "OBSERVATION", 197, 213], ["joint", "ANATOMY", 262, 267], ["regional", "OBSERVATION_MODIFIER", 294, 302], ["air pollution", "OBSERVATION", 303, 316]]], ["For now, the impacts of emission reduction measurements on air quality have been discussed for several important activity periods (Beijing Olympics, APEC, G20 Summit) (Cai and Xie, 2011; Li et al., 2017a; Shen et al., 2017; Wang et al., 2016, 2018; Xu et al., 2016; Zhang et al., 2016).IntroductionHowever, previous emission reductions were mostly aimed at a certain region with a relatively low reduction extent and accordingly cannot eliminate the impacts of regional pollutant transport processes (Li et al., 2017b, 2019a; Shen et al., 2017; Wang et al., 2010).", [["emission reduction measurements on air quality", "TREATMENT", 24, 70], ["previous emission reductions", "PROBLEM", 307, 335]]], ["To control the spread of COVID-19, China launched a level-I response to this public health emergency in 31 provinces, autonomous regions and municipalities as early as January 27, 2020, when it was the first country to shut down commercial activities, restrict travel, and require its people to stay home (Tian et al., 2020; Wang et al., 2020a, 2020b, 2020c, 2020e).", [["people", "ORGANISM", 285, 291], ["people", "SPECIES", 285, 291]]], ["The lockdown policy is believed to have yielded great reductions in air pollutants, especially in China, and thus it provides a favorable opportunity to assess the impacts of anthropogenic sources on air quality in urban agglomerations.", [["great reductions in air pollutants", "PROBLEM", 48, 82], ["great", "OBSERVATION_MODIFIER", 48, 53], ["reductions", "OBSERVATION_MODIFIER", 54, 64], ["air pollutants", "OBSERVATION", 68, 82], ["anthropogenic sources", "OBSERVATION", 175, 196], ["air quality", "OBSERVATION", 200, 211]]], ["Many studies have revealed that air pollutants including aerosol optical depth (AOD), particle matter (PM), nitrogen dioxide (NO2) and carbon monoxide (CO) decreased significantly during the global lockdown, while the secondary pollutant O3 increased (Filonchyk et al., 2020; Kerimray et al., 2020; Nakada and Urban, 2020; Wang et al., 2020c).", [["nitrogen dioxide", "CHEMICAL", 108, 124], ["NO2", "CHEMICAL", 126, 129], ["carbon monoxide", "CHEMICAL", 135, 150], ["O3", "CHEMICAL", 238, 240], ["nitrogen dioxide", "CHEMICAL", 108, 124], ["NO2", "CHEMICAL", 126, 129], ["carbon monoxide", "CHEMICAL", 135, 150], ["CO", "CHEMICAL", 152, 154], ["O3", "CHEMICAL", 238, 240], ["nitrogen dioxide", "SIMPLE_CHEMICAL", 108, 124], ["NO2", "SIMPLE_CHEMICAL", 126, 129], ["carbon monoxide", "SIMPLE_CHEMICAL", 135, 150], ["CO", "SIMPLE_CHEMICAL", 152, 154], ["O3", "SIMPLE_CHEMICAL", 238, 240], ["Many studies", "TEST", 0, 12], ["air pollutants", "PROBLEM", 32, 46], ["aerosol optical depth (AOD)", "TREATMENT", 57, 84], ["nitrogen dioxide (NO2", "TREATMENT", 108, 129], ["carbon monoxide (CO", "TREATMENT", 135, 154], ["air pollutants", "OBSERVATION", 32, 46]]], ["These related studies were more directed at satellite and ground-based routine data, and observations of aerosol chemical compositions have rarely been investigated to date.", [["aerosol chemical compositions", "TREATMENT", 105, 134]]], ["In this study, we evaluated the change in air quality during the COVID-19 lockdown period using satellite and ground-based data; the temporal evolution of PM, trace gases, water-soluble ions (WSIs) and BC were analyzed in detail before, during and after the lockdown in Suzhou.Sample sites ::: Materials and methodsThe observation site was located at the Suzhou South Gate Station (31.29 \u00b0N, 120.63 \u00b0E), which is a national control point of the China Environmental Monitoring Station.", [["this study", "TEST", 3, 13], ["the change in air quality", "PROBLEM", 28, 53], ["trace gases", "PROBLEM", 159, 170], ["water-soluble ions (WSIs", "TREATMENT", 172, 196], ["BC", "TEST", 202, 204], ["air quality", "OBSERVATION", 42, 53]]], ["Situated in the Gusu District of Suzhou, the site is surrounded by residential areas and is 100 m away from the South West Road of Suzhou to the south, making it a mixed region of commercial and residential areas.", [["surrounded", "OBSERVATION_MODIFIER", 53, 63], ["residential", "OBSERVATION_MODIFIER", 67, 78], ["areas", "OBSERVATION_MODIFIER", 79, 84], ["mixed", "OBSERVATION_MODIFIER", 164, 169]]], ["The observation time period was from December 1, 2019 to March 31, 2020.Satellite data ::: Materials and methodsThe MODIS is a detector mounted on the Terra and Aqua satellites of the EOS.", [["EOS", "ANATOMY", 184, 187]]], ["In this study, Terra MODIS C6.1 Level 3 aerosol products (MOD08_M3) at 1\u00b0 \u00d7 1\u00b0 were used, and data were downloaded from the NASA Level 1 and Atmosphere Archive and Distribution System (https://ladsweb.nascom.nasa.gov/data/search.html).", [["this study", "TEST", 3, 13], ["Terra MODIS", "TREATMENT", 15, 26], ["Level 3 aerosol products", "TREATMENT", 32, 56]]], ["The dark target and deep blue merged AOD data at 550 nm (hereafter referred to as AOD) were principally used.", [["dark target", "OBSERVATION", 4, 15], ["deep blue", "OBSERVATION", 20, 29]]], ["We also used tropospheric NO2 vertical column density (VCD) data from the GOME-2 (METOP-B) (http://www.temis.nl/index.php) with a resolution of 0.25\u00b0 \u00d7 0.25\u00b0, and the observations were averaged on a monthly basis.", [["NO2", "CHEMICAL", 26, 29], ["NO2", "CHEMICAL", 26, 29], ["tropospheric NO2 vertical column density", "TREATMENT", 13, 53], ["the GOME", "TEST", 70, 78], ["tropospheric", "OBSERVATION_MODIFIER", 13, 25], ["vertical", "OBSERVATION_MODIFIER", 30, 38], ["column density", "OBSERVATION", 39, 53]]], ["Detailed information about the GOME-2 can be found in the related literature (Georgoulias et al., 2019).Ground-based observation data ::: Materials and methodsWSIs in PM2.5 were detected by using the Ambient Ion Monitor-Ion Chromatograph (AIM-IC, URG-9000D, Thermo Scientific \u2122), which can continuously measure the mass concentration of ions including Na+, NH4+, K+, Mg2+, Ca2+, Cl\u2212, NO3\u2212 and SO42\u2212.", [["PM2.5", "CHEMICAL", 167, 172], ["Na+", "CHEMICAL", 352, 355], ["NH4", "CHEMICAL", 357, 360], ["K", "CHEMICAL", 363, 364], ["Mg2", "CHEMICAL", 367, 370], ["Ca2", "CHEMICAL", 373, 376], ["NO3", "CHEMICAL", 384, 387], ["Na+", "CHEMICAL", 352, 355], ["NH4+", "CHEMICAL", 357, 361], ["K+", "CHEMICAL", 363, 365], ["Mg2+", "CHEMICAL", 367, 371], ["Ca2+", "CHEMICAL", 373, 377], ["Cl\u2212", "CHEMICAL", 379, 382], ["NO3", "CHEMICAL", 384, 387], ["SO42", "CHEMICAL", 393, 397], ["PM2.5", "SIMPLE_CHEMICAL", 167, 172], ["ions", "SIMPLE_CHEMICAL", 337, 341], ["Na+", "SIMPLE_CHEMICAL", 352, 355], ["NH4+", "SIMPLE_CHEMICAL", 357, 361], ["K+", "SIMPLE_CHEMICAL", 363, 365], ["Mg2+", "SIMPLE_CHEMICAL", 367, 371], ["Ca2+", "SIMPLE_CHEMICAL", 373, 377], ["Cl\u2212", "SIMPLE_CHEMICAL", 379, 382], ["NO3\u2212", "SIMPLE_CHEMICAL", 384, 388], ["SO42\u2212", "SIMPLE_CHEMICAL", 393, 398], ["GOME-2", "DNA", 31, 37], ["the Ambient Ion Monitor", "TEST", 196, 219], ["Ion Chromatograph", "TEST", 220, 237], ["URG", "TEST", 247, 250], ["Na+", "TEST", 352, 355], ["NH4", "TEST", 357, 360], ["K", "TEST", 363, 364], ["Mg2", "TEST", 367, 370], ["Ca2", "TEST", 373, 376], ["Cl\u2212", "TEST", 379, 382], ["mass", "OBSERVATION", 315, 319]]], ["The instrument configuration includes a sample collection unit (URG-9000D) for collecting water-soluble particles into solution and a sample detection unit (IC, Dionex ICS-5000) for analyzing ions (Malaguti et al., 2015).", [["URG", "TEST", 64, 67], ["collecting water-soluble particles", "TREATMENT", 79, 113], ["IC, Dionex ICS", "TREATMENT", 157, 171]]], ["For quality control and assurance of the anion and cation particles in the system, collection efficiency, flow calibration and air tightness tests were performed each month.", [["anion", "SIMPLE_CHEMICAL", 41, 46], ["cation particles", "SIMPLE_CHEMICAL", 51, 67], ["the anion and cation particles", "TREATMENT", 37, 67], ["collection efficiency", "TEST", 83, 104], ["flow calibration and air tightness tests", "TEST", 106, 146], ["system", "ANATOMY", 75, 81], ["flow calibration", "OBSERVATION", 106, 122], ["air tightness", "OBSERVATION", 127, 140]]], ["The accuracy of the IC analysis is verified by an internal check standard of lithium bromide that is injected with each sample.", [["lithium bromide", "CHEMICAL", 77, 92], ["lithium bromide", "CHEMICAL", 77, 92], ["lithium bromide", "SIMPLE_CHEMICAL", 77, 92], ["the IC analysis", "TEST", 16, 31], ["lithium bromide", "TREATMENT", 77, 92]]], ["In the external calibration method, ICs were calibrated by measuring varying concentrations of the standard agent (Merck, Germany) (Tang et al., 2020).", [["ICs", "PROTEIN", 36, 39], ["ICs", "TREATMENT", 36, 39]]], ["The detection limits of Na+, NH4+, K+, Mg2+, Ca2+, Cl\u2212, NO3\u2212 and SO42\u2212 were 0.02, 0.02, 0.02, 0.02, 0.02, 0.02, 0.03 and 0.05 \u03bcg/m3, respectively.", [["Na+", "CHEMICAL", 24, 27], ["NH4", "CHEMICAL", 29, 32], ["K", "CHEMICAL", 35, 36], ["Mg2", "CHEMICAL", 39, 42], ["Ca2", "CHEMICAL", 45, 48], ["Cl\u2212", "CHEMICAL", 51, 54], ["NO3", "CHEMICAL", 56, 59], ["SO42", "CHEMICAL", 65, 69], ["Na+", "CHEMICAL", 24, 27], ["NH4", "CHEMICAL", 29, 32], ["K+", "CHEMICAL", 35, 37], ["Mg2+", "CHEMICAL", 39, 43], ["Ca2+", "CHEMICAL", 45, 49], ["Cl\u2212", "CHEMICAL", 51, 54], ["NO3", "CHEMICAL", 56, 59], ["SO42\u2212", "CHEMICAL", 65, 70], ["Na+", "SIMPLE_CHEMICAL", 24, 27], ["NH4+", "SIMPLE_CHEMICAL", 29, 33], ["K+", "SIMPLE_CHEMICAL", 35, 37], ["Mg2+", "SIMPLE_CHEMICAL", 39, 43], ["Ca2+", "SIMPLE_CHEMICAL", 45, 49], ["Cl\u2212", "SIMPLE_CHEMICAL", 51, 54], ["NO3\u2212", "SIMPLE_CHEMICAL", 56, 60], ["SO42\u2212", "SIMPLE_CHEMICAL", 65, 70], ["The detection", "TEST", 0, 13], ["Na+", "TEST", 24, 27], ["NH4", "TEST", 29, 32], ["K", "TEST", 35, 36], ["Mg2", "TEST", 39, 42], ["Ca2", "TEST", 45, 48], ["Cl\u2212", "TEST", 51, 54], ["NO3", "TEST", 56, 59], ["SO42", "TEST", 65, 69]]], ["BC mass concentrations were observed with a Model AE-31 aethalometer (Magee Scientific, USA) that uses two-point measurement technology and dynamic zero-point calibration to provide continuous observations at fixed points at seven wavelengths (370, 470, 520, 590, 660, 880, and 950 nm).", [["BC mass concentrations", "PROBLEM", 0, 22], ["a Model AE", "TEST", 42, 52], ["dynamic zero-point calibration", "TREATMENT", 140, 170], ["mass", "OBSERVATION", 3, 7]]], ["Instrument principles can be found in Hansen and Schnell (2005).", [["Instrument principles", "TREATMENT", 0, 21]]], ["Although the measurements were made every 5-min, the data were averaged at a resolution of 1 h to reduce the uncertainties derived from instrumental noise, flow rate, filter spot area and detector response (Corrigan et al., 2006).", [["the measurements", "TEST", 9, 25], ["the data", "TEST", 49, 57], ["instrumental noise", "TEST", 136, 154], ["flow rate", "TEST", 156, 165], ["filter spot area", "TEST", 167, 183]]], ["The silica gel in the drier was routinely changed according to the monitored relative humidity (RH), in order to ensure the RH of the sample air below 40%.", [["silica gel", "CHEMICAL", 4, 14], ["silica", "CHEMICAL", 4, 10], ["silica", "SIMPLE_CHEMICAL", 4, 10], ["The silica gel", "TREATMENT", 0, 14], ["silica gel", "OBSERVATION", 4, 14]]], ["The air in the container was sent to the surrounding area of the drier to reduce the temperature difference between the inside of the container and the drier.", [["The air in the container", "PROBLEM", 0, 24], ["the temperature difference", "PROBLEM", 81, 107], ["air", "OBSERVATION", 4, 7]]], ["The temperature inside the container was maintained around 25\u00b0C. PM2.5 and PM10 were measured by the Synchronized Hybrid Ambient Real-time Particulate Monitor (SHARP Model 5030i, Thermo Scientific\u2122), and the trace gases NO2, sulfur dioxide (SO2), CO and O3 were monitored by a series of monitors (42i, 43i, 48i, and 49i, Thermo Scientific\u2122).", [["PM2.5", "CHEMICAL", 65, 70], ["PM10", "CHEMICAL", 75, 79], ["NO2", "CHEMICAL", 220, 223], ["sulfur dioxide", "CHEMICAL", 225, 239], ["SO2", "CHEMICAL", 241, 244], ["O3", "CHEMICAL", 254, 256], ["PM10", "CHEMICAL", 75, 79], ["NO2", "CHEMICAL", 220, 223], ["sulfur dioxide", "CHEMICAL", 225, 239], ["SO2", "CHEMICAL", 241, 244], ["CO", "CHEMICAL", 247, 249], ["O3", "CHEMICAL", 254, 256], ["PM10", "SIMPLE_CHEMICAL", 75, 79], ["NO2", "SIMPLE_CHEMICAL", 220, 223], ["sulfur dioxide", "SIMPLE_CHEMICAL", 225, 239], ["SO2", "SIMPLE_CHEMICAL", 241, 244], ["CO", "SIMPLE_CHEMICAL", 247, 249], ["O3", "SIMPLE_CHEMICAL", 254, 256], ["the trace gases NO2", "TEST", 204, 223], ["sulfur dioxide", "TEST", 225, 239], ["CO", "TEST", 247, 249]]], ["Ding et al. (2013) provides a more detailed introduction to this instrumentation.", [["this instrumentation", "TREATMENT", 60, 80]]], ["The time resolution is 1 hour.Overview of the AOD and tropospheric NO2 VCD ::: Results and discussionThe regional distribution of AOD values is significant in the CEC as shown in Fig. S1, and high AOD values were observed in the NCP, YRD and Twain-Hu Basin (THB), where megacities such as Shanghai, Shijiazhuang, Tianjing and Wuhan dominated.", [["NO2", "CHEMICAL", 67, 70], ["NO2", "CHEMICAL", 67, 70], ["S1", "GENE_OR_GENE_PRODUCT", 184, 186], ["AOD values", "TEST", 130, 140], ["regional", "OBSERVATION_MODIFIER", 105, 113], ["distribution", "OBSERVATION_MODIFIER", 114, 126], ["AOD values", "OBSERVATION", 130, 140], ["significant", "OBSERVATION_MODIFIER", 144, 155]]], ["Notable AOD boundaries in these megacities were noticed when the pollution was relatively weak (Fig. S1a) and disappeared under heavy pollution periods (Fig. S1b), revealing a regional transport process of aerosols.Overview of the AOD and tropospheric NO2 VCD ::: Results and discussionFig.", [["NO2", "CHEMICAL", 252, 255], ["NO2", "CHEMICAL", 252, 255], ["AOD", "OBSERVATION_MODIFIER", 8, 11], ["boundaries", "OBSERVATION_MODIFIER", 12, 22]]], ["S1c exhibits an obvious reduction in AOD values in the CEC due to the COVID-19 lockdown policy, while high AOD value centers were still found in the YRD, NCP and THB, mostly due to heavy industrial emissions, such as fuel-burning power generation and iron, steel, and coking processes.", [["NCP", "CHEMICAL", 154, 157], ["iron", "CHEMICAL", 251, 255], ["iron", "CHEMICAL", 251, 255], ["iron", "SIMPLE_CHEMICAL", 251, 255], ["an obvious reduction in AOD values", "PROBLEM", 13, 47], ["the COVID", "TEST", 66, 75], ["heavy industrial emissions", "PROBLEM", 181, 207], ["iron, steel", "TREATMENT", 251, 262], ["obvious", "OBSERVATION_MODIFIER", 16, 23], ["reduction", "OBSERVATION", 24, 33], ["AOD", "OBSERVATION", 37, 40]]], ["Although almost all medium and small industries except power plants and large-scale enterprises were closed during the lockdown, the manufacturing sector did not actually show major slowdown: according to the industrial production data published by the bureau of statistics in the provinces of the YRD, the production of iron and other non-ferrous materials, medical and pharamaceutical remained roughly constant.", [["YRD", "DISEASE", 298, 301], ["iron", "CHEMICAL", 321, 325], ["iron", "CHEMICAL", 321, 325], ["iron", "SIMPLE_CHEMICAL", 321, 325], ["power plants", "TREATMENT", 55, 67], ["large-scale enterprises", "TREATMENT", 72, 95], ["iron and other non-ferrous materials", "PROBLEM", 321, 357], ["medium", "OBSERVATION_MODIFIER", 20, 26], ["small", "OBSERVATION_MODIFIER", 31, 36], ["industries", "OBSERVATION_MODIFIER", 37, 47], ["large", "OBSERVATION_MODIFIER", 72, 77]]], ["The impact of the COVID-19 epidemic on industrial production can be seen in the sharp decline of 29% and 32% in industrial electricity consumption in January-February 2020 in Anhui and Zhejiang provinces.", [["the COVID", "TREATMENT", 14, 23], ["sharp", "OBSERVATION_MODIFIER", 80, 85]]], ["Industry (32.2%-61.1%) and residential emissions (2.1%-28.5%) were the major sources of PM2.5 in YRD during the lockdown (Li et al. 2020).", [["PM2.5", "CHEMICAL", 88, 93], ["PM2.5", "SIMPLE_CHEMICAL", 88, 93], ["Industry", "TEST", 0, 8], ["residential emissions", "TEST", 27, 48]]], ["People started back to work in March while the AOD values were relatively low (Fig. S1d).", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["the AOD values", "TEST", 43, 57]]], ["Conditions in the atmospheric boundary layer (convection and mixing layer height), pollutant lifetime and properties, source regions and transport patterns, and wet scavenging all could result in differences between satellite and surface pollutant observations (Qu et al., 2016; Shen et al., 2020; Yang et al., 2019).", [["transport patterns", "TEST", 137, 155]]], ["As satellite inversion data, AOD is related to surface particles as well as other factors, for example, moisture content in the air (Shen et al., 2020), and as such, the AOD values cannot well reflect the changes in surface particles.", [["surface particles", "ANATOMY", 47, 64], ["surface", "ANATOMY", 216, 223], ["surface particles", "CELLULAR_COMPONENT", 216, 233], ["AOD", "PROBLEM", 29, 32], ["surface particles", "PROBLEM", 47, 64], ["the changes in surface particles", "PROBLEM", 201, 233], ["air", "ANATOMY", 128, 131], ["surface particles", "OBSERVATION", 216, 233]]], ["Therefore, the impacts of the lockdown policy on air quality cannot be accurately assessed using MODIS AOD data.Overview of the AOD and tropospheric NO2 VCD ::: Results and discussionThe distribution of tropospheric NO2 VCD can well reflect the impacts of the lockdown policy on human activities, as shown in Fig. 1.", [["NO2", "CHEMICAL", 149, 152], ["NO2", "CHEMICAL", 216, 219], ["NO2", "CHEMICAL", 149, 152], ["NO2", "CHEMICAL", 216, 219], ["NO2", "SIMPLE_CHEMICAL", 216, 219], ["human", "ORGANISM", 279, 284], ["human", "SPECIES", 279, 284], ["human", "SPECIES", 279, 284], ["the lockdown policy", "TREATMENT", 26, 45], ["MODIS AOD data", "TEST", 97, 111], ["tropospheric NO2 VCD", "PROBLEM", 203, 223], ["distribution", "OBSERVATION_MODIFIER", 187, 199], ["tropospheric NO2 VCD", "OBSERVATION", 203, 223]]], ["Before the lockdown and the Chinese Spring Festival (SF), high NO2 values had a regional distribution in the CEC (Fig. 1a), which is in accordance with the economy, population and vehicle ownership.", [["NO2", "CHEMICAL", 63, 66], ["NO2", "CHEMICAL", 63, 66], ["NO2", "SIMPLE_CHEMICAL", 63, 66], ["high NO2 values", "PROBLEM", 58, 73], ["regional", "OBSERVATION_MODIFIER", 80, 88], ["distribution", "OBSERVATION_MODIFIER", 89, 101], ["CEC", "ANATOMY", 109, 112]]], ["In January 2020, high NO2 values were still observed in Shandong, Hebei, Henan, Shanxi and Anhui, where an inflow of populations usually occurs during the SF without a ban on fireworks.", [["NO2", "CHEMICAL", 22, 25], ["NO2", "CHEMICAL", 22, 25], ["NO2", "SIMPLE_CHEMICAL", 22, 25], ["high NO2 values", "PROBLEM", 17, 32], ["inflow", "OBSERVATION", 107, 113]]], ["With an outflow of population and no fireworks, the YRD had a remarkable reduction in NO2 values.", [["YRD", "CHEMICAL", 52, 55], ["NO2", "CHEMICAL", 86, 89], ["NO2", "CHEMICAL", 86, 89], ["NO2", "SIMPLE_CHEMICAL", 86, 89], ["a remarkable reduction in NO2 values", "PROBLEM", 60, 96], ["outflow", "OBSERVATION", 8, 15], ["population", "OBSERVATION", 19, 29], ["no", "UNCERTAINTY", 34, 36], ["remarkable", "OBSERVATION_MODIFIER", 62, 72], ["reduction", "OBSERVATION_MODIFIER", 73, 82], ["NO2 values", "OBSERVATION", 86, 96]]], ["Moreover, a continuous and strong precipitation process south of the Yellow River during January was also responsible for this notable reduction (Jiang et al., 2020).Overview of the AOD and tropospheric NO2 VCD ::: Results and discussionThe restrictions on traffic sources are believed to be the main drivers of the decreased NO2 during the lockdown.", [["NO2", "CHEMICAL", 203, 206], ["NO2", "CHEMICAL", 326, 329], ["NO2", "CHEMICAL", 203, 206], ["NO2", "CHEMICAL", 326, 329], ["NO2", "SIMPLE_CHEMICAL", 326, 329], ["this notable reduction", "TREATMENT", 122, 144], ["the decreased NO2", "PROBLEM", 312, 329], ["the lockdown", "TREATMENT", 337, 349], ["decreased", "OBSERVATION_MODIFIER", 316, 325], ["NO2", "OBSERVATION", 326, 329]]], ["In February, the latitudinal circulations dominated in the middle and high latitudes of Europe and Asia, accompanied by low East Asian winter monsoonal winds and weak East Asian trough, such synoptic condition resulted in fewer cold air fronts than previous years with weaker intensity, which was favorable to pollutant accumulation (Cao et al., 2020).", [["the latitudinal circulations", "TEST", 13, 41], ["weak East Asian trough", "PROBLEM", 162, 184], ["such synoptic condition", "PROBLEM", 186, 209], ["fewer cold air fronts", "PROBLEM", 222, 243], ["weaker intensity", "PROBLEM", 269, 285], ["middle", "ANATOMY_MODIFIER", 59, 65], ["high latitudes", "OBSERVATION", 70, 84], ["weaker intensity", "OBSERVATION_MODIFIER", 269, 285]]], ["Meanwhile, the YRD region was controlled by a uniform pressure field with low wind speeds in the range of 2-4 m/sec, high RH exceeding 70% was also observed even over 90% in several time segments.", [["YRD region", "DNA", 15, 25], ["uniform", "OBSERVATION_MODIFIER", 46, 53], ["pressure", "OBSERVATION_MODIFIER", 54, 62]]], ["As such, the tropospheric NO2 VCD was still high despite the rigorous restrictions in February.", [["NO2", "CHEMICAL", 26, 29], ["NO2", "CHEMICAL", 26, 29], ["NO2", "SIMPLE_CHEMICAL", 26, 29], ["the tropospheric NO2 VCD", "TEST", 9, 33]]], ["Meanwhile, the traffic emissions increased again when people started back to work, leading to the high NO2 values in the NCP and YRD in March (Fig. 1d); a similar pattern is observed for the surface NO2 change in Suzhou (Fig. 2), which had a sharp reduction on January 25 that began to rise on February 24.Overview of the AOD and tropospheric NO2 VCD ::: Results and discussionAir pollutants decreased noticeably during the lockdown in Suzhou (Fig. 2).", [["surface", "ANATOMY", 191, 198], ["NO2", "CHEMICAL", 103, 106], ["NO2", "CHEMICAL", 199, 202], ["NO2", "CHEMICAL", 343, 346], ["NO2", "CHEMICAL", 103, 106], ["NO2", "CHEMICAL", 199, 202], ["NO2", "CHEMICAL", 343, 346], ["people", "ORGANISM", 54, 60], ["NO2", "SIMPLE_CHEMICAL", 103, 106], ["NO2", "SIMPLE_CHEMICAL", 199, 202], ["people", "SPECIES", 54, 60], ["the high NO2 values", "PROBLEM", 94, 113], ["the surface NO2 change", "PROBLEM", 187, 209], ["a sharp reduction", "PROBLEM", 240, 257], ["discussionAir pollutants", "PROBLEM", 367, 391], ["sharp", "OBSERVATION_MODIFIER", 242, 247], ["reduction", "OBSERVATION_MODIFIER", 248, 257]]], ["Concentrations of WSIs and PM2.5 were lower than those before and after the lockdown.", [["PM2.5", "CHEMICAL", 27, 32], ["WSIs", "SIMPLE_CHEMICAL", 18, 22], ["PM2.5", "SIMPLE_CHEMICAL", 27, 32], ["Concentrations of WSIs", "PROBLEM", 0, 22]]], ["However, the ions/PM2.5 ratio peaked during February 11-17.", [["PM2.5", "CHEMICAL", 18, 23], ["ions", "SIMPLE_CHEMICAL", 13, 17], ["PM2.5", "SIMPLE_CHEMICAL", 18, 23], ["the ions/PM2.5 ratio", "TEST", 9, 29]]], ["In contrast to the change in SO2, NO2 and CO, with a remarkable reduction during the lockdown, O3 was substantially enhanced, resulting from the sharp decrease in NOx during the COVID-19 lockdown, which had weaker NO-titration effects on O3.", [["SO2", "CHEMICAL", 29, 32], ["NO2", "CHEMICAL", 34, 37], ["O3", "CHEMICAL", 95, 97], ["NOx", "CHEMICAL", 163, 166], ["NO", "CHEMICAL", 214, 216], ["O3", "CHEMICAL", 238, 240], ["SO2", "CHEMICAL", 29, 32], ["NO2", "CHEMICAL", 34, 37], ["CO", "CHEMICAL", 42, 44], ["O3", "CHEMICAL", 95, 97], ["NOx", "CHEMICAL", 163, 166], ["COVID-19", "CHEMICAL", 178, 186], ["NO", "CHEMICAL", 214, 216], ["O3", "CHEMICAL", 238, 240], ["SO2", "SIMPLE_CHEMICAL", 29, 32], ["NO2", "SIMPLE_CHEMICAL", 34, 37], ["CO", "SIMPLE_CHEMICAL", 42, 44], ["O3", "SIMPLE_CHEMICAL", 95, 97], ["NOx", "SIMPLE_CHEMICAL", 163, 166], ["NO", "SIMPLE_CHEMICAL", 214, 216], ["O3", "SIMPLE_CHEMICAL", 238, 240], ["SO2", "TEST", 29, 32], ["NO2", "TEST", 34, 37], ["CO", "TEST", 42, 44], ["the sharp decrease in NOx", "PROBLEM", 141, 166], ["the COVID", "TEST", 174, 183], ["O3", "TREATMENT", 238, 240], ["change", "OBSERVATION_MODIFIER", 19, 25], ["remarkable", "OBSERVATION_MODIFIER", 53, 63], ["reduction", "OBSERVATION_MODIFIER", 64, 73], ["sharp", "OBSERVATION_MODIFIER", 145, 150], ["decrease", "OBSERVATION_MODIFIER", 151, 159]]], ["As an atmospheric oxidant, increased O3 concentration will enhance the formation of secondary inorganic and organic particulate matter.", [["O3", "CHEMICAL", 37, 39], ["O3", "CHEMICAL", 37, 39], ["O3", "SIMPLE_CHEMICAL", 37, 39], ["inorganic", "SIMPLE_CHEMICAL", 94, 103], ["an atmospheric oxidant", "TREATMENT", 3, 25], ["increased O3 concentration", "TREATMENT", 27, 53], ["secondary inorganic and organic particulate matter", "PROBLEM", 84, 134], ["atmospheric oxidant", "OBSERVATION", 6, 25], ["secondary inorganic", "OBSERVATION", 84, 103], ["organic particulate matter", "OBSERVATION", 108, 134]]], ["Huang et al. (2020) also reported large decreases in NOx emissions from transportation increased ozone and nighttime NO3 radical formation during the lockdown, and these increases in atmospheric oxidizing capacity in turn facilitated the formation of secondary particulate matter.Overview of the AOD and tropospheric NO2 VCD ::: Results and discussionAdditionally, the temperature and RH changed slightly before, during and after the lockdown, as the temperature began to rise in March (Fig. 2).", [["NOx", "CHEMICAL", 53, 56], ["ozone", "CHEMICAL", 97, 102], ["NO3", "CHEMICAL", 117, 120], ["NO2", "CHEMICAL", 317, 320], ["NOx", "CHEMICAL", 53, 56], ["ozone", "CHEMICAL", 97, 102], ["NO3", "CHEMICAL", 117, 120], ["NO2", "CHEMICAL", 317, 320], ["NOx", "SIMPLE_CHEMICAL", 53, 56], ["ozone", "SIMPLE_CHEMICAL", 97, 102], ["NO3 radical", "SIMPLE_CHEMICAL", 117, 128], ["large decreases in NOx emissions", "PROBLEM", 34, 66], ["transportation increased ozone", "PROBLEM", 72, 102], ["nighttime NO3 radical formation", "TREATMENT", 107, 138], ["atmospheric oxidizing capacity", "PROBLEM", 183, 213], ["secondary particulate matter", "PROBLEM", 251, 279], ["the temperature", "TEST", 365, 380], ["the temperature", "TEST", 447, 462], ["large", "OBSERVATION_MODIFIER", 34, 39], ["decreases", "OBSERVATION_MODIFIER", 40, 49], ["NOx emissions", "OBSERVATION", 53, 66], ["radical formation", "OBSERVATION", 121, 138], ["increases", "OBSERVATION_MODIFIER", 170, 179], ["atmospheric", "OBSERVATION", 183, 194], ["oxidizing capacity", "OBSERVATION", 195, 213], ["secondary", "OBSERVATION_MODIFIER", 251, 260], ["particulate matter", "OBSERVATION", 261, 279]]], ["The temperature was the lowest in January with an average of 6.5\u00b0C and the highest in March with an average of 12.6\u00b0C and the maximum of 25\u00b0C (Fig. S2).", [["The temperature", "TEST", 0, 15], ["C", "TEST", 116, 117], ["highest", "OBSERVATION_MODIFIER", 75, 82]]], ["The RH has shown a contrary variation to that of temperature, with averages of 81% and 68% in January and March.", [["contrary variation", "OBSERVATION", 19, 37]]], ["Besides, high RH exceeding 60% was normally observed with obvious diurnal variations during the whole period (Fig. 2), which was ascribed to several precipitation processes (Fig. S2).", [["S2", "PROTEIN", 179, 181], ["obvious diurnal variations", "PROBLEM", 58, 84], ["several precipitation processes", "PROBLEM", 141, 172]]], ["The fluctuation of pressure was usually accompanied with these rainfall events.", [["these rainfall events", "PROBLEM", 57, 78], ["fluctuation", "OBSERVATION_MODIFIER", 4, 15], ["pressure", "OBSERVATION_MODIFIER", 19, 27]]], ["Low and high visibility were noticed in January and March with averages of 7.2 km and 17.6 km, respectively.", [["Low and high visibility", "PROBLEM", 0, 23], ["high", "OBSERVATION_MODIFIER", 8, 12], ["visibility", "OBSERVATION_MODIFIER", 13, 23]]], ["As shown in Fig. S2, the lockdown policy exerted great improvement of the visibility after January 26.Overview of the AOD and tropospheric NO2 VCD ::: Results and discussionThe aforementioned discussion revealed that the meteorological conditions were relatively stable during the observation period in Suzhou, especially for the wind speeds and RH that can exert great impacts on air pollutants.", [["NO2", "CHEMICAL", 139, 142], ["NO2", "CHEMICAL", 139, 142], ["the meteorological conditions", "PROBLEM", 217, 246], ["Fig", "OBSERVATION", 12, 15], ["great", "OBSERVATION_MODIFIER", 49, 54], ["improvement", "OBSERVATION_MODIFIER", 55, 66], ["stable", "OBSERVATION_MODIFIER", 263, 269], ["air pollutants", "OBSERVATION", 381, 395]]], ["As such, the pollutant variations in Suzhou might be caused by the changes of emission sources.", [["the pollutant variations", "PROBLEM", 9, 33]]], ["However, the RH exerted great impacts on the sulfate as shown in Fig. 2, with higher RH corresponding to higher sulfate.", [["sulfate", "CHEMICAL", 45, 52], ["sulfate", "CHEMICAL", 112, 119], ["sulfate", "SIMPLE_CHEMICAL", 45, 52], ["sulfate", "SIMPLE_CHEMICAL", 112, 119], ["the sulfate", "TREATMENT", 41, 52], ["higher RH", "PROBLEM", 78, 87], ["higher sulfate", "TREATMENT", 105, 119], ["great", "OBSERVATION_MODIFIER", 24, 29], ["impacts", "OBSERVATION", 30, 37]]], ["Although it was reported that aerosol pollution has shifted from sulfate-dominated to nitrate-dominated in many eastern Chinese cities due to the more rapid decrease in SO2 emissions than NOx in recent years (Chu et al., 2121; Wen et al., 2018).", [["sulfate", "CHEMICAL", 65, 72], ["nitrate", "CHEMICAL", 86, 93], ["SO2", "CHEMICAL", 169, 172], ["NOx", "CHEMICAL", 188, 191], ["sulfate", "CHEMICAL", 65, 72], ["nitrate", "CHEMICAL", 86, 93], ["SO2", "CHEMICAL", 169, 172], ["NOx", "CHEMICAL", 188, 191], ["sulfate", "SIMPLE_CHEMICAL", 65, 72], ["nitrate", "SIMPLE_CHEMICAL", 86, 93], ["SO2", "SIMPLE_CHEMICAL", 169, 172], ["NOx", "SIMPLE_CHEMICAL", 188, 191], ["aerosol pollution", "TREATMENT", 30, 47], ["sulfate", "TREATMENT", 65, 72], ["nitrate", "TREATMENT", 86, 93], ["the more rapid decrease in SO2 emissions", "PROBLEM", 142, 182], ["rapid", "OBSERVATION_MODIFIER", 151, 156], ["decrease", "OBSERVATION_MODIFIER", 157, 165], ["SO2 emissions", "OBSERVATION", 169, 182]]], ["He et al. (2014) discovered that the co-existing of mineral particles and high NOx concentrations in the air can promote the transformation of SO2 to sulfate during the haze process.", [["NOx", "CHEMICAL", 79, 82], ["SO2", "CHEMICAL", 143, 146], ["NOx", "CHEMICAL", 79, 82], ["SO2", "CHEMICAL", 143, 146], ["sulfate", "CHEMICAL", 150, 157], ["NOx", "SIMPLE_CHEMICAL", 79, 82], ["SO2", "SIMPLE_CHEMICAL", 143, 146], ["sulfate", "SIMPLE_CHEMICAL", 150, 157], ["mineral particles", "TREATMENT", 52, 69], ["high NOx concentrations in the air", "PROBLEM", 74, 108], ["sulfate", "TREATMENT", 150, 157], ["the haze process", "PROBLEM", 165, 181], ["high", "OBSERVATION_MODIFIER", 74, 78], ["NOx concentrations", "OBSERVATION", 79, 97], ["air", "ANATOMY", 105, 108], ["haze", "OBSERVATION", 169, 173]]], ["Such phenomenon revealed that the sulfate may be generated sharply under the compound pollution conditions with high RH and air pollutant concentrations.", [["sulfate", "CHEMICAL", 34, 41], ["sulfate", "CHEMICAL", 34, 41], ["sulfate", "SIMPLE_CHEMICAL", 34, 41], ["Such phenomenon", "PROBLEM", 0, 15], ["the sulfate", "TREATMENT", 30, 41], ["high RH and air pollutant concentrations", "PROBLEM", 112, 152], ["air", "OBSERVATION", 124, 127], ["pollutant concentrations", "OBSERVATION", 128, 152]]], ["Hence, we divided the observation period into five stages: the pre-COVID (December 1, 2019-January 22, 2020), SF (January 23-26, 2020), lockdown (January 27-February 24, 2020), secondary response (February 25-March 27, 2020), and tertiary response (March 28-31, 2020).Changes in PM and trace gases during different periods ::: Results and discussionThe SF and lockdown policy were found to have had large impacts on the PM and trace gases, as shown in Fig. 3.", [["PM", "SIMPLE_CHEMICAL", 279, 281], ["trace gases", "PROBLEM", 286, 297], ["trace gases", "TEST", 427, 438], ["trace gases", "OBSERVATION", 286, 297], ["large", "OBSERVATION_MODIFIER", 399, 404], ["impacts", "OBSERVATION", 405, 412]]], ["The pollutants PM2.5, PM10, SO2, NO2 and CO had low concentrations during the SF, with values that were 42.1%, 53.2%, 75.7%, 17.7% and 53.0% of the pre-COVID values, respectively.", [["PM2.5", "CHEMICAL", 15, 20], ["PM10", "CHEMICAL", 22, 26], ["SO2", "CHEMICAL", 28, 31], ["NO2", "CHEMICAL", 33, 36], ["CO", "CHEMICAL", 41, 43], ["PM2.5", "CHEMICAL", 15, 20], ["PM10", "CHEMICAL", 22, 26], ["SO2", "CHEMICAL", 28, 31], ["NO2", "CHEMICAL", 33, 36], ["CO", "CHEMICAL", 41, 43], ["PM2.5", "SIMPLE_CHEMICAL", 15, 20], ["PM10", "SIMPLE_CHEMICAL", 22, 26], ["SO2", "SIMPLE_CHEMICAL", 28, 31], ["NO2", "SIMPLE_CHEMICAL", 33, 36], ["CO", "SIMPLE_CHEMICAL", 41, 43], ["SO2", "TEST", 28, 31], ["NO2", "TEST", 33, 36], ["CO", "TEST", 41, 43], ["low concentrations", "PROBLEM", 48, 66], ["values", "TEST", 87, 93], ["the pre-COVID values", "TEST", 144, 164]]], ["On the one hand, emissions sources had great reductions due to the closed factories and enterprises and outflow of the population from Suzhou; on the other hand, a continuous and strong precipitation process occurred January 21-27, leading to a significant scavenging effect on air pollutants.", [["great reductions", "PROBLEM", 39, 55], ["the closed factories", "PROBLEM", 63, 83], ["a significant scavenging effect on air pollutants", "PROBLEM", 243, 292], ["closed", "OBSERVATION_MODIFIER", 67, 73], ["factories", "OBSERVATION", 74, 83], ["outflow", "OBSERVATION_MODIFIER", 104, 111], ["significant", "OBSERVATION_MODIFIER", 245, 256], ["scavenging effect", "OBSERVATION", 257, 274], ["air pollutants", "OBSERVATION", 278, 292]]], ["During the SF, the diurnal variations in PM2.5, PM10 and CO were noticeably higher in the early morning than in the daytime (Fig. 4), which was mainly caused by the fireworks; in particular, the PM10 concentration at 00:00 during the SF (68.3 \u03bcg/m3) was even higher than that during the pre-COVID period, resulting in a low visibility of 5.8 km at 00:00 (Fig. 5).Changes in PM and trace gases during different periods ::: Results and discussionThe concentrations of PM2.5 and PM10 during the lockdown were 35.9 and 36.5 \u03bcg\u2022m\u22123, which were 37.2% and 38.3% lower than the pre-COVID values, while the diurnal variation in PM during the lockdown was consistent with that pre-COVID, except that the concentrations significantly decreased (Fig. 4).", [["PM10", "CHEMICAL", 48, 52], ["PM10", "CHEMICAL", 195, 199], ["PM2.5", "CHEMICAL", 466, 471], ["PM10", "CHEMICAL", 476, 480], ["PM10", "CHEMICAL", 48, 52], ["CO", "CHEMICAL", 57, 59], ["PM10", "CHEMICAL", 195, 199], ["PM2.5", "CHEMICAL", 466, 471], ["PM10", "CHEMICAL", 476, 480], ["PM2.5", "SIMPLE_CHEMICAL", 41, 46], ["PM10", "SIMPLE_CHEMICAL", 48, 52], ["CO", "SIMPLE_CHEMICAL", 57, 59], ["PM10", "SIMPLE_CHEMICAL", 195, 199], ["PM", "SIMPLE_CHEMICAL", 374, 376], ["PM2.5", "SIMPLE_CHEMICAL", 466, 471], ["PM10", "SIMPLE_CHEMICAL", 476, 480], ["PM", "MULTI-TISSUE_STRUCTURE", 619, 621], ["the diurnal variations", "TEST", 15, 37], ["PM2", "TEST", 41, 44], ["CO", "TEST", 57, 59], ["the PM10 concentration", "TEST", 191, 213], ["the SF", "TEST", 230, 236], ["a low visibility", "PROBLEM", 318, 334], ["trace gases", "PROBLEM", 381, 392], ["the lockdown", "TEST", 488, 500], ["the pre-COVID values", "TEST", 566, 586], ["the diurnal variation", "TEST", 594, 615], ["the concentrations", "PROBLEM", 690, 708], ["higher", "OBSERVATION_MODIFIER", 76, 82], ["low visibility", "OBSERVATION_MODIFIER", 320, 334], ["trace gases", "OBSERVATION", 381, 392], ["consistent with", "UNCERTAINTY", 646, 661], ["concentrations", "OBSERVATION_MODIFIER", 694, 708], ["significantly", "OBSERVATION_MODIFIER", 709, 722], ["decreased", "OBSERVATION_MODIFIER", 723, 732]]], ["Compared to the pre-COVID period, SO2 increased by only 1.5%, with an average of 5.2 \u03bcg/m3 during the lockdown.", [["SO2", "CHEMICAL", 34, 37], ["SO2", "CHEMICAL", 34, 37], ["SO2", "SIMPLE_CHEMICAL", 34, 37], ["SO2", "TEST", 34, 37], ["increased", "OBSERVATION_MODIFIER", 38, 47]]], ["Meanwhile, the diurnal variations in SO2 during the pre-COVID and lockdown periods were consistent (Fig. 4), indicating a small impact of the lockdown policy on the SO2 concentrations.Changes in PM and trace gases during different periods ::: Results and discussion", [["SO2", "CHEMICAL", 37, 40], ["SO2", "CHEMICAL", 165, 168], ["SO2", "CHEMICAL", 37, 40], ["SO2", "CHEMICAL", 165, 168], ["SO2", "SIMPLE_CHEMICAL", 37, 40], ["SO2", "SIMPLE_CHEMICAL", 165, 168], ["PM", "SIMPLE_CHEMICAL", 195, 197], ["the diurnal variations in SO2", "PROBLEM", 11, 40], ["the pre-COVID and lockdown periods", "TREATMENT", 48, 82], ["the SO2 concentrations", "TREATMENT", 161, 183], ["trace gases", "PROBLEM", 202, 213], ["diurnal", "OBSERVATION_MODIFIER", 15, 22], ["variations", "OBSERVATION_MODIFIER", 23, 33], ["small", "OBSERVATION_MODIFIER", 122, 127], ["trace gases", "OBSERVATION", 202, 213]]]], "93d366875c106715f231b6f6cd8508a9a8e00f72": [["IntroductionThe spread of COVID-19 has impacted global economics greatly.", [["COVID-19", "CHEMICAL", 26, 34], ["COVID", "TEST", 26, 31], ["spread", "OBSERVATION_MODIFIER", 16, 22]]], ["Industries like tourism, airline, and manufacturing industry have suffered in the first quarter.", [["tourism", "OBSERVATION_MODIFIER", 16, 23]]], ["Unlike some \"Black Swan\" events [1] , COVID-19 also possesses the characters of \"Grey Rhino\" since the initial outbreak of the coronavirus and all the unprecedented countermeasures taken in China in February already delivered the signal to other countries [2] .", [["coronavirus", "DISEASE", 127, 138], ["coronavirus", "ORGANISM", 127, 138], ["some \"Black Swan\" events", "PROBLEM", 7, 31], ["COVID", "TEST", 38, 43], ["Grey Rhino", "PROBLEM", 81, 91], ["the coronavirus", "PROBLEM", 123, 138]]], ["It is different from SARS that the continuous contagiousness of the coronavirus has imposed profound impact on manufacturing industry, since low-cost country sourcing, globalization and minimal inventory management have been key tenets of supply chain management for industries like auto, electronic, etc. Besides, the bankruptcy of Lehman Brothers would never pose such great damage without the long-term abnormal development of finance and real estate industry in the United States (US).", [["SARS", "DISEASE", 21, 25], ["coronavirus", "DISEASE", 68, 79], ["coronavirus", "ORGANISM", 68, 79], ["the coronavirus", "PROBLEM", 64, 79], ["minimal inventory management", "TREATMENT", 186, 214], ["supply chain management", "TREATMENT", 239, 262], ["different", "OBSERVATION_MODIFIER", 6, 15], ["coronavirus", "OBSERVATION", 68, 79], ["profound", "OBSERVATION_MODIFIER", 92, 100], ["impact", "OBSERVATION_MODIFIER", 101, 107], ["minimal", "OBSERVATION_MODIFIER", 186, 193]]], ["Similarly, the outbreak and spread of COVID-19 could not cause such huge impact without the existence of other \"Grey Rhino\" events like the trade war between China and US, Britain leaving the European Union, etc. In order to cope with COVID-19, action like flight stop, import slowdown and outside activities restriction has been implemented in many countries.", [["COVID-19", "CHEMICAL", 38, 46], ["COVID-19", "CHEMICAL", 38, 46], ["COVID", "TEST", 38, 43], ["COVID", "TREATMENT", 235, 240], ["outbreak", "OBSERVATION_MODIFIER", 15, 23]]], ["For manufacturing industry, risks have risen including supply chain interruption due to production stop for raw material and spare parts, various setbacks in logistics, and the unknown timeline for recovery.", [["supply chain interruption", "TREATMENT", 55, 80]]], ["With continuous escalation of the pandemic, condition has changed from supply and demand recession in China to global supply shortage under which supply chain interruption already happened in auto and semiconductor industry.", [["demand recession", "PROBLEM", 82, 98]]], ["The coronavirus has affected manufacturing industry in China, US, and Germany greatly.", [["coronavirus", "ORGANISM", 4, 15], ["The coronavirus", "PROBLEM", 0, 15], ["coronavirus", "OBSERVATION", 4, 15], ["affected", "OBSERVATION_MODIFIER", 20, 28], ["manufacturing", "OBSERVATION_MODIFIER", 29, 42], ["industry", "OBSERVATION_MODIFIER", 43, 51]]], ["China's manufacturing purchasing managers' index (PMI) in February decreased to 35.7 with 14.3% lower than the PMI in January as reported from National Bureau of Statistics.", [["PMI", "ANATOMY", 111, 114]]], ["According to IHS Markit, flash US manufacturing PMI in March was down to 49.2 which registered as the sharpest drop in output since August, 2009.", [["flash US", "TEST", 25, 33], ["the sharpest drop in output", "PROBLEM", 98, 125], ["output", "OBSERVATION_MODIFIER", 119, 125]]], ["The same index for Germany dropped to 45.7 as well.IntroductionConsulting firms and scholars have explored COVID-19's impact on manufacturing industry.", [["COVID-19's", "CHEMICAL", 107, 117], ["The same index", "TEST", 0, 14], ["index", "OBSERVATION_MODIFIER", 9, 14]]], ["Due to necessary quarantine measures taken in place, the negative impact on countries which are regional industry chain centers will gradually spread to other countries and cause supply chain interruption.", [["quarantine measures", "TREATMENT", 17, 36]]], ["The volume and structure of demand have changed and the supply chain planning for manufacturing industry has been disturbed.", [["volume", "OBSERVATION_MODIFIER", 4, 10], ["chain", "OBSERVATION_MODIFIER", 63, 68]]], ["Ivanov [4] conducted a simulation-based analysis to predict both the short-term and long-term impacts of COVID-19 on global supply chains.", [["a simulation", "TEST", 21, 33], ["COVID", "TEST", 105, 110], ["global supply chains", "TREATMENT", 117, 137]]], ["This paper attempts to analyze COVID-19's initial impact as well as its aftershock on manufacturing supply chain particularly.", [["COVID", "TEST", 31, 36], ["manufacturing supply chain", "TREATMENT", 86, 112]]], ["Then, a twostep approach is explored for the recovery during the pandemic and better preparation for post-COVID-19 period.COVID-19's Initial Impact on Manufacturing Supply ChainThere are two phases of initial impact caused by the outbreak and spread of the coronavirus.", [["coronavirus", "DISEASE", 257, 268], ["coronavirus", "ORGANISM", 257, 268], ["a twostep approach", "TREATMENT", 6, 24], ["COVID", "TEST", 122, 127], ["Manufacturing Supply ChainThere", "TREATMENT", 151, 182], ["the coronavirus", "PROBLEM", 253, 268]]], ["In Phase 1, the production was forced to pause in China and the global supply of raw material and spare parts was shrunk with the delay and decrease of export orders mainly in February and March.", [["pause in China", "PROBLEM", 41, 55], ["the delay", "PROBLEM", 126, 135], ["raw material", "OBSERVATION", 81, 93]]], ["In Phase 2, the supply and demand in manufacturing supply chain are severely impacted with the continuous spread of COVID-19 globally.", [["COVID-19", "CHEMICAL", 116, 124], ["demand in manufacturing supply chain", "TREATMENT", 27, 63], ["severely impacted", "PROBLEM", 68, 85], ["COVID", "TEST", 116, 121], ["chain", "OBSERVATION_MODIFIER", 58, 63], ["severely", "OBSERVATION_MODIFIER", 68, 76], ["impacted", "OBSERVATION_MODIFIER", 77, 85]]], ["COVID-19 has caused plants shutdown in major manufacturing countries due to the action like lockdown, flight stop, outside activities restrictions, etc. Manufacturing supply chain has been or about to be interrupted for some products in industries such as auto, electronics and pharmaceutical industry.", [["COVID-19", "CHEMICAL", 0, 8], ["plants shutdown", "OBSERVATION", 20, 35], ["chain", "OBSERVATION_MODIFIER", 174, 179]]], ["Also, market demand has shown great uncertainty and cannot be satisfied because of the logistics setbacks.", [["great", "OBSERVATION_MODIFIER", 30, 35], ["uncertainty", "OBSERVATION", 36, 47]]], ["Moreover, many small and medium-sized enterprises (SMEs) are at higher risk of bankruptcy than ever.Production Interruption of Raw Materialand Spare Parts Global supply chain has been formed for many manufacturing industries with enterprises closely connected with each other.", [["many small and medium-sized enterprises (SMEs)", "PROBLEM", 10, 56], ["many", "OBSERVATION_MODIFIER", 10, 14], ["small", "OBSERVATION_MODIFIER", 15, 20], ["medium-sized", "OBSERVATION_MODIFIER", 25, 37], ["enterprises", "OBSERVATION_MODIFIER", 38, 49], ["SMEs", "OBSERVATION_MODIFIER", 51, 55], ["bankruptcy", "OBSERVATION", 79, 89]]], ["These countries have contributed over 40% of total export of intermediate products, as shown in Fig. 1 (data source: UN Comtrade, KPMG).", [["intermediate products", "OBSERVATION", 61, 82]]], ["Plenty of plants in above countries are facing production interruption or delay due to COVID-19.", [["facing production interruption", "TREATMENT", 40, 70], ["COVID", "TEST", 87, 92], ["plants", "OBSERVATION", 10, 16]]], ["In short time, a certain number of manufacturing enterprises which are deeply involved in global supply chain will be forced to shut down because of lack of raw material and spare parts supply.", [["lack of raw material", "PROBLEM", 149, 169], ["short time", "OBSERVATION_MODIFIER", 3, 13]]], ["Production may stop for key components such as integrated circuit, engine and chip in semiconductor, electronics and other industries due to the deteriorated situation in these countries.MexicoOn the one hand, China has become the center of global manufacturing and the biggest manufacturing On the other hand, China is the main sourcing site for manufacturing industry.", [["engine and chip in semiconductor, electronics", "TREATMENT", 67, 112], ["the deteriorated situation", "PROBLEM", 141, 167], ["MexicoOn", "TREATMENT", 187, 195], ["global manufacturing", "OBSERVATION", 241, 261], ["biggest manufacturing", "OBSERVATION", 270, 291]]], ["Plant shutdown or production delay within China poses great impacts on enterprises in related industries in other regions.", [["production delay", "PROBLEM", 18, 34], ["shutdown", "OBSERVATION", 6, 14]]], ["Although certain stock is kept, the decrease of China's export will gradually affect downstream enterprises in other regions and lead to supply interruption of raw material and spare parts for industries like machinery, auto, pharmaceutical industry, etc.Unsatisfied Demand Due to Setbacks inLogistics Logistics has become the weak spot for manufacturing industry after the breakout of COVID-19.", [["Setbacks inLogistics", "TREATMENT", 281, 301], ["the weak spot", "PROBLEM", 323, 336], ["COVID", "TEST", 386, 391], ["decrease", "OBSERVATION_MODIFIER", 36, 44]]], ["The demand for logistics services has dropped severely in short time because of the pandemic.", [["logistics services", "TREATMENT", 15, 33], ["the pandemic", "PROBLEM", 80, 92], ["pandemic", "OBSERVATION", 84, 92]]], ["More importantly, the quarantine policy has led to the supply decrease of drivers and trucks since the major source is from countryside in provinces like Hubei, Jiangxi, Henan, Shandong, etc. According to the statistics from China Federation of Logistics and Purchasing, logistics promising index has dropped to 26.2 with 23.7% decrease compared with that in January.Unsatisfied Demand Due to Setbacks inStarting from March, lockdown action has been seen in some major manufacturing countries as well as countries which are international logistics hub due to the global outbreak of COVID-19, as listed in Table 2 (data source: news).", [["COVID", "TEST", 582, 587], ["Setbacks", "OBSERVATION", 393, 401]]], ["Measures including air flight control, import and export restriction, and stricter commodity inspection have caused four challenges for international logistics which are demand recession due to order cancellation or requirement of delayed shipment; cost increase for airfreight, haulage and distribution; supply shortage due to air flight cancellation; lower efficiency due to longer time needed for commodity check and road transportation.", [["airfreight", "DISEASE", 267, 277], ["air flight control", "TREATMENT", 19, 37], ["international logistics", "TREATMENT", 136, 159], ["demand recession", "PROBLEM", 170, 186], ["delayed shipment", "PROBLEM", 231, 247], ["airfreight", "TREATMENT", 267, 277], ["air flight cancellation", "PROBLEM", 328, 351], ["lower efficiency", "PROBLEM", 353, 369], ["air flight", "OBSERVATION", 19, 29]]], ["Hence, a large portion of market consumption of electronic products, cars and fastmoving consumer goods (FMCGs) cannot be satisfied.", [["electronic products", "TREATMENT", 48, 67], ["large", "OBSERVATION_MODIFIER", 9, 14], ["portion", "OBSERVATION_MODIFIER", 15, 22]]], ["Also, ocean shipping demand dropped sharply since many international trade contracts have been cancelled or new ones could not be signed in time.", [["ocean shipping demand", "PROBLEM", 6, 27], ["ocean", "OBSERVATION_MODIFIER", 6, 11], ["shipping demand", "OBSERVATION", 12, 27]]], ["According to the data from Trading Economics, the Baltic Dry Index dropped from 1 000 to 411 on February 10 which is the lowest since April 2016.", [["the Baltic Dry Index", "TEST", 46, 66]]], ["Meanwhile, the ship owner might not be willing to dock at ports due to the offboard forbidden or restricted for staff and stricter examination procedure.", [["stricter examination procedure", "TEST", 122, 152]]], ["And this can lead to the shipping route change, which certainly causes longer lead-time for international logistics.Increasing Bankruptcy Risk for SMEsThe business has been hard for many SMEs due to slowdown of global economic these years.", [["Bankruptcy", "OBSERVATION", 127, 137], ["SMEs", "OBSERVATION_MODIFIER", 147, 151]]], ["With the outbreak of COVID-19, these companies are facing higher bankruptcy risks.Increasing Bankruptcy Risk for SMEsFirstly, it is harder for SMEs to get permit to resume production.", [["COVID", "TEST", 21, 26], ["SMEsFirstly", "PROBLEM", 113, 124], ["Bankruptcy", "OBSERVATION", 93, 103]]], ["The recovery rate for SMEs is relatively smaller than that for big companies due to high standard required for the facility and working condition which many SMEs cannot meet.", [["The recovery rate", "TEST", 0, 17], ["smaller", "OBSERVATION_MODIFIER", 41, 48]]], ["Long time shutdown will impact SMEs' operation and result in bankruptcy due to their limited working capital reserve.", [["SMEs' operation", "TREATMENT", 31, 46]]], ["As shown in Fig. 2 Secondly, the operation cost has increased because of the continuous spread of COVID-19.", [["COVID-19", "CHEMICAL", 98, 106], ["the operation cost", "TREATMENT", 29, 47], ["COVID", "TEST", 98, 103], ["Fig", "OBSERVATION", 12, 15], ["operation", "OBSERVATION", 33, 42], ["increased", "OBSERVATION_MODIFIER", 52, 61]]], ["The raw material cost has also increased because of limited supply from upstream for industries like semiconductor and medicine.", [["The raw material cost", "TREATMENT", 0, 21], ["semiconductor and medicine", "TREATMENT", 101, 127], ["raw", "OBSERVATION_MODIFIER", 4, 7], ["material cost", "OBSERVATION", 8, 21], ["increased", "OBSERVATION_MODIFIER", 31, 40]]], ["Meanwhile, logistics cost has increased because of supply decrease and higher demand from the market especially for last-mile delivery.", [["increased", "OBSERVATION_MODIFIER", 30, 39], ["decrease", "OBSERVATION_MODIFIER", 58, 66], ["higher", "OBSERVATION_MODIFIER", 71, 77]]], ["According to 58 City' research, the average salary for production line worker is 5 197 RMB/month which is 9.78% higher than last year's.Increasing Bankruptcy Risk for SMEsThirdly, market demand has decreased.", [["SMEs", "PROBLEM", 167, 171], ["Bankruptcy Risk", "OBSERVATION", 147, 162], ["SMEs", "OBSERVATION_MODIFIER", 167, 171], ["decreased", "OBSERVATION_MODIFIER", 198, 207]]], ["A certain number of people expect lower incomes in near future or even losing jobs.", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26]]], ["The consumption budget will be cut down accordingly.", [["The consumption budget", "TREATMENT", 0, 22]]], ["Furthermore, international trade income would also be reduced because of the cancellation or pause of many foreign trade orders.Increasing Bankruptcy Risk for SMEsA great number of SMEs are on the edge of bankruptcy due to shrinking orders, increasing operation cost and limited capital reserve.", [["the cancellation", "PROBLEM", 73, 89], ["SMEsA", "PROBLEM", 159, 164], ["increasing operation cost", "TREATMENT", 241, 266], ["foreign trade", "OBSERVATION", 107, 120], ["Bankruptcy", "OBSERVATION", 139, 149], ["SMEs", "OBSERVATION_MODIFIER", 181, 185], ["capital reserve", "OBSERVATION", 279, 294]]], ["If the risk escalates, systemic financial crisis may occur.", [["the risk escalates", "PROBLEM", 3, 21], ["systemic financial crisis", "PROBLEM", 23, 48]]], ["Furthermore, unemployment rate will be higher if SMEs' bankruptcy risks cannot be properly controlled since they account for majority of the employment.Higher Fluctuation of Supply and DemandCOVID-19 has posed different impacts on different industries.", [["DemandCOVID-19", "CHEMICAL", 185, 199], ["DemandCOVID-19", "CHEMICAL", 185, 199], ["unemployment rate", "TREATMENT", 13, 30], ["DemandCOVID", "TEST", 185, 196]]], ["Global economics has been negatively impacted and consumers' confidence has been down.", [["negatively", "OBSERVATION_MODIFIER", 26, 36], ["impacted", "OBSERVATION_MODIFIER", 37, 45]]], ["Besides products which are necessary for daily life and protection against the virus, other consumption can be suppressed because of expected income decrease and unemployment risk.", [["protection", "TREATMENT", 56, 66], ["the virus", "PROBLEM", 75, 84]]], ["As shown in Table 3 , both the supply and demand in industries like auto, textile and electronics will be decreased in short time.", [["auto, textile and electronics", "TREATMENT", 68, 97]]], ["As for semiconductor industry, market supply is greatly impacted because of the outbreak of the coronavirus in Japan and South Korea.", [["coronavirus", "DISEASE", 96, 107], ["the coronavirus", "PROBLEM", 92, 107]]], ["As for FMCGs, the demand for products will differ from kind to kind.", [["FMCGs", "TREATMENT", 7, 12], ["products", "TREATMENT", 29, 37]]], ["Within the period, the demand for products used for COVID-19 protection and food with long qualityguarantee period increases dramatically.", [["COVID-19", "CHEMICAL", 52, 60], ["products", "TREATMENT", 34, 42], ["COVID-19 protection", "TREATMENT", 52, 71]]], ["Hence, panic purchase happens.", [["panic", "DISEASE", 7, 12]]], ["Also, people stock up on daily necessities which are purchased from overseas, such as infant milk powder and diaper.", [["milk", "ANATOMY", 93, 97], ["people", "ORGANISM", 6, 12], ["milk", "ORGANISM_SUBDIVISION", 93, 97], ["people", "SPECIES", 6, 12], ["infant", "SPECIES", 86, 92]]], ["Meanwhile, the consumption of products used for social activities is decreased and the purchase of relatively high-value products will be on hold.COVID-19's Aftershock on Manufacturing Supply ChainThe impact is kept pumping with the globally continuous escalation of COVID-19.", [["COVID-19's", "CHEMICAL", 146, 156], ["COVID-19", "CHEMICAL", 267, 275], ["products", "TREATMENT", 30, 38], ["COVID", "TEST", 146, 151], ["the globally continuous escalation of COVID", "TREATMENT", 229, 272], ["Chain", "OBSERVATION_MODIFIER", 192, 197]]], ["Even though the timeframe and extent of COVID-19's full impact are not fully revealed yet, the pandemic has already posted profound ramifications to manufacturing supply chain in two ways.Transformation from Globalization to RegionalizationNowadays, supply chain has been globally designed and optimized to identify proper lead time with the lowest operation cost for many manufacturing industries.", [["COVID", "TEST", 40, 45], ["manufacturing supply chain", "TREATMENT", 149, 175], ["the lowest operation cost", "TREATMENT", 338, 363], ["many manufacturing industries", "TREATMENT", 368, 397], ["chain", "OBSERVATION_MODIFIER", 170, 175], ["manufacturing industries", "OBSERVATION", 373, 397]]], ["However, the risk of delivery delays emerges greatly because of the dependency on remote sources and more complex logistics network caused by globalization [5] .", [["delivery delays", "PROBLEM", 21, 36], ["the dependency", "PROBLEM", 64, 78]]], ["Over the past months prior to the pandemic, the trade war between China and US has intensified the international trade tensions.", [["trade tensions", "OBSERVATION", 113, 127]]], ["According to A.T. Kearney, the US manufacturing import ratio fell to 12.1 in 2019 which was firstly declined since 2011.", [["the US", "TEST", 27, 33]]], ["The imports of manufactured goods in 2019 have decreased 7.2% from 14 low-cost countries in Asia with a particularly sharp decline from China.", [["a particularly sharp decline", "PROBLEM", 102, 130], ["sharp", "OBSERVATION_MODIFIER", 117, 122], ["decline", "OBSERVATION", 123, 130]]], ["With the rise of protectionism, coupled with increasing cost in less-developed countries and new financial barriers, the reshoring increases.", [["protectionism", "TREATMENT", 17, 30], ["increasing cost", "PROBLEM", 45, 60], ["rise", "OBSERVATION_MODIFIER", 9, 13]]], ["According to the 2019 world machine toll survey from Gardner Intelligence, despite a globally overall consumption reduction of 13.5%, China's figure dropped 25.3%.", [["China's figure", "TEST", 134, 148]]], ["However, the consumption in Mexico increased 9.1%, and the consumption in US only declined 1.6%.Transformation from Globalization to RegionalizationWith the continuous spread of the coronavirus, regionalization can be the new normal of manufacturing supply chain after the crisis.", [["coronavirus", "DISEASE", 182, 193], ["coronavirus", "ORGANISM", 182, 193], ["the coronavirus", "PROBLEM", 178, 193], ["the crisis", "PROBLEM", 269, 279], ["coronavirus", "OBSERVATION", 182, 193], ["chain", "OBSERVATION_MODIFIER", 257, 262]]], ["On the one hand, the weakness in current model of global manufacturing has been fully revealed.", [["the weakness", "PROBLEM", 17, 29], ["weakness", "OBSERVATION", 21, 29]]], ["The recovery of manufacturing supply chain is not likely to be achieved shortly because of unsynchronized recovery pace among the global and continuous restrictions of international flight.", [["manufacturing supply chain", "TREATMENT", 16, 42], ["unsynchronized recovery pace", "TREATMENT", 91, 119], ["not likely to be", "UNCERTAINTY", 46, 62]]], ["On the other hand, the COVID-19 can pose backlash against globalization and aggregate the decoupling afterwards.", [["COVID-19", "DNA", 23, 31], ["the COVID", "TEST", 19, 28]]], ["According to the forecasts by the World Trade Organization, the International Civil Aviation Organization, and the United Nations Conference on Trade and Development, the pandemic will cause 13%-32% decline in merchandise trade, 44%-80% drop in international flow of people in 2020, and 30%-40% reduction in investment and trade during 2020 to 2021.", [["people", "ORGANISM", 267, 273], ["people", "SPECIES", 267, 273]]], ["The trust between China and western countries is diminishing together with the decline of flow of people, fund and trade.", [["people", "SPECIES", 98, 104]]], ["Multinational companies will seek to build manufacturing sites and supply network nearby the end market and form regionalized supply chain.Acceleration of Supply Chain DigitalizationDigital technology and analytics can assist companies to navigate the crisis and better prepare to serve the market.", [["the crisis", "PROBLEM", 248, 258], ["Chain", "OBSERVATION_MODIFIER", 162, 167]]], ["To some extent, the supply chain digitalization has been on the agenda for quite some time.", [["the supply chain digitalization", "PROBLEM", 16, 47], ["some extent", "OBSERVATION_MODIFIER", 3, 14], ["chain digitalization", "OBSERVATION", 27, 47]]], ["Now business is operated in a new context of flux with constant change of external environment which happens on a daily basis due to the pandemic.", [["the pandemic", "PROBLEM", 133, 145]]], ["Digital supply chain will be the prerequisites to success within the pandemic and afterwards to improve the smartness and responsiveness of supply chain.", [["Digital supply chain", "TREATMENT", 0, 20], ["the smartness and responsiveness of supply chain", "PROBLEM", 104, 152]]], ["Technologies such as cloud and big data have already played an important role in the supply chain operation for many industries to anticipate customer's needs, mitigate uncertainty and resume operations quickly during crisis.", [["crisis", "PROBLEM", 218, 224]]], ["The trend would continue because of the necessity and all the benefits gained from every easy and low-cost digital initiative like cloud-meeting.Acceleration of Supply Chain DigitalizationWith more matured development of big data and artificial intelligence as tools coupled with wider adoption of cloud-based technology and radio frequency identification in 5G environment, COVID-19 can spur a leap to the supply chain digitalization for manufacturing industries.Countermeasures for Recovery of Manufacturing Supply ChainAlthough production has been gradually resumed in China since March, the situation may be not that promising in some particular companies, industries or regions.", [["big data", "TEST", 221, 229], ["artificial intelligence", "PROBLEM", 234, 257], ["Chain", "OBSERVATION_MODIFIER", 168, 173]]], ["Many enterprises may face the second wave of impact due to shortage of key materials and decrease of export orders from oversea caused by the continuous spread of COVID-19.", [["oversea", "DISEASE", 120, 127], ["COVID-19", "CHEMICAL", 163, 171], ["COVID", "TEST", 163, 168]]], ["Also, there will be profound changes to economy and social life after the pandemic.", [["profound changes", "PROBLEM", 20, 36], ["profound", "OBSERVATION_MODIFIER", 20, 28]]], ["Hence, a two-step corresponding action is needed including immediate response to address the most pressing impact in order to maintain smooth supply chain operation, and enhance the resilience of the manufacturing supply chain in order to recover and thrive in the post-crisis world.Responding to Crisis and Ensuring Business ContinuityCompanies have to address the most immediate and pressing challenges caused by COVID-19, and ensure the continuous business operation among all supply chain members.", [["smooth supply chain operation", "TREATMENT", 135, 164], ["the manufacturing supply chain", "TREATMENT", 196, 226], ["Crisis", "PROBLEM", 297, 303], ["the continuous business operation", "TREATMENT", 436, 469], ["chain operation", "OBSERVATION", 149, 164]]], ["By ensuring employees' safety, supporting their supply chain partners and maximizing the usage of favorable policies implemented within the period, the supply chain operation is expected to be gradually recovered at some extent.Adjusting Work Mode and Taking NecessaryPrecautions During Operation Recovery Remote work mode can be adapted, such as working from home, online meeting and e-bidding.", [["the supply chain operation", "TREATMENT", 148, 174], ["chain operation", "OBSERVATION", 159, 174], ["some extent", "OBSERVATION_MODIFIER", 216, 227]]], ["In China, on-line telecommuting was adopted in over 18 million companies by more than 300 million people in February.", [["people", "ORGANISM", 98, 104], ["people", "SPECIES", 98, 104]]], ["Unlike industries such as information technology or consulting, remote work mode can only be applied to non-manufacturing departments like research & development, human resources, and finance in manufacturing enterprises with the assistance of smart devices and integrated security system.", [["human", "ORGANISM", 163, 168], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 163, 168], ["smart devices", "TREATMENT", 244, 257]]], ["As for manufacturing related work as well as logistics operation where staff are required to be on the scene of manufacturing site, strict protective measures can be taken as listed in Table 4 to help to create a safe working environment during the pandemic.", [["logistics operation", "TREATMENT", 45, 64], ["strict protective measures", "TREATMENT", 132, 158]]], ["With the implementation of these measures in many industries in China, the average recovery rate for industrial enterprises above designated size reached to 98.6% and the average rate for SMEs reached to 76% on March 28 with average 1% increase daily in March according to the statistics from the Ministry of Industry and Information.Providing Aid to Supply Chain PartnersIt is essential to secure the production recovery for companies which are critical to global supply chain for both China and other countries in order to minimize the total impact.", [["these measures", "TREATMENT", 27, 41], ["industrial enterprises", "TREATMENT", 101, 123], ["size", "OBSERVATION_MODIFIER", 141, 145]]], ["For an example of Lenovo, the spare parts of ThinkPad carbon laptop come from many countries.", [["ThinkPad carbon", "CHEMICAL", 45, 60], ["carbon", "CHEMICAL", 54, 60], ["Lenovo", "TREATMENT", 18, 24], ["ThinkPad carbon laptop", "TREATMENT", 45, 67]]], ["The laptop cannot be manufactured in Hefei plant if any of these components are not made or shipped to China in time.", [["The laptop", "TREATMENT", 0, 10]]], ["As the global leading machinery company, Sanyi Group has established \"Sanyi Mode against COVID-19\" alliance with more than 200 suppliers, and provided advance payment and concessionary loans to partners who have suffered severally with the pandemic.", [["the pandemic", "PROBLEM", 236, 248]]], ["Also, millions of masks as well as other protective materials have been given to domestic and overseas suppliers as reported on the company website.", [["masks", "TREATMENT", 18, 23], ["other protective materials", "TREATMENT", 35, 61], ["millions", "OBSERVATION_MODIFIER", 6, 14], ["masks", "OBSERVATION", 18, 23]]], ["As a result, Sanyi Group has been one of the first companies who resumed operation in February.", [["Sanyi", "CHEMICAL", 13, 18]]], ["As reported on Consumer News and Business Channel (CNBC), US president Donald Trump signed a coronavirus relief bill of 2 \u00d7 10 12 USD to cope with the impact caused by COVID-19.", [["coronavirus", "ORGANISM", 93, 104], ["a coronavirus relief", "TREATMENT", 91, 111], ["COVID", "TEST", 168, 173]]], ["British government also issued 33 \u00d7 10 10 GBP of government-backed loans and guarantees.", [["GBP", "TEST", 42, 45]]], ["Japan also unveiled an economy stimulation plan worth of 20% of its GDP.Maximizing the Benefits of Government Policies to Resume OperationMore and more stimulus plans and policies can be expected from country to country in following months.", [["GDP", "CHEMICAL", 68, 71], ["GDP", "CHEMICAL", 68, 71], ["GDP", "SIMPLE_CHEMICAL", 68, 71], ["an economy stimulation plan", "TREATMENT", 20, 47]]], ["There are three types (supply type, environment type and demand type) of policy tools which have been implemented to cope with COVID-19 [6] .", [["COVID-19", "CHEMICAL", 127, 135], ["COVID", "TEST", 127, 132], ["three", "OBSERVATION_MODIFIER", 10, 15], ["types", "OBSERVATION_MODIFIER", 16, 21], ["supply type", "OBSERVATION_MODIFIER", 23, 34]]], ["With the increasing number of countries affected by the coronavirus, global economy is deteriorating, which may lead to further decrease of credit limit provided to enterprises [8] .", [["coronavirus", "DISEASE", 56, 67], ["coronavirus", "ORGANISM", 56, 67], ["the coronavirus", "PROBLEM", 52, 67], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["number", "OBSERVATION_MODIFIER", 20, 26]]], ["As a result, funding is more likely to be cut off and SMEs go bankruptcy, which can jeopardize the continuous operation of the whole supply chain.", [["the whole supply chain", "TREATMENT", 123, 145], ["more likely", "UNCERTAINTY", 24, 35]]], ["Hence, it is critical for the SMEs to maximize the usage of extra liquidity issued during the pandemic to facilitate their business operation.Enhancing Supply Chain Resilience inPost-COVID-19 World Even though manufacturing companies are busy dealing with immediate shocks currently, they also need to think beyond firefighting plan and start to prepare for the post-crisis world to recover and thrive afterwards.", [["extra liquidity", "TREATMENT", 60, 75], ["their business operation", "TREATMENT", 117, 141], ["Chain", "OBSERVATION_MODIFIER", 159, 164]]], ["COVID-19 has amplified the drawbacks of complex and closely collaborated global manufacturing supply chain and indicated its lack of resilience.", [["COVID-19", "CHEMICAL", 0, 8]]], ["Supply chain resilience is to be enhanced to improve its responsiveness to unforeseen shocks [9] .Enhancing Supply Chain Resilience in(1) Improving supply chain visibility.", [["Chain", "OBSERVATION_MODIFIER", 115, 120], ["Resilience", "OBSERVATION_MODIFIER", 121, 131], ["chain visibility", "OBSERVATION", 155, 171]]], ["The supply chain disruption caused by the coronavirus has under-scored the necessity of end-to-end visibility of the entire manufacturing supply chain.", [["coronavirus", "ORGANISM", 42, 53], ["The supply chain disruption", "PROBLEM", 0, 27], ["the coronavirus", "PROBLEM", 38, 53], ["supply", "OBSERVATION_MODIFIER", 4, 10], ["chain disruption", "OBSERVATION", 11, 27], ["coronavirus", "OBSERVATION", 42, 53], ["chain", "OBSERVATION_MODIFIER", 145, 150]]], ["To do so, the panic buying of toilet paper in Australia can be avoided if consumers had the visibility of the inventory levels.", [["panic", "DISEASE", 14, 19]]], ["However, most companies are having difficulties of possessing end-to-end visibility when managing a multi-tiered supply chain nowadays.", [["a multi-tiered supply chain nowadays", "TREATMENT", 98, 134]]], ["With the acceleration of digital supply chain stimulated by COVID-19, technologies such as radio frequency identification and block chain can be implemented to enhance information sharing and improve the visibility in the supply chain [10] .", [["COVID", "TEST", 60, 65], ["radio frequency identification", "TEST", 91, 121], ["block chain", "TREATMENT", 126, 137]]], ["With better bridge of the physical and the digital information, real-time visibility can be achieved in the network and help to build a more robust supply chain.Enhancing Supply Chain Resilience in(2) Managing supply chain planning with intelligent analyses and simulations.", [["intelligent analyses", "TEST", 237, 257], ["Chain Resilience", "OBSERVATION", 178, 194]]], ["It is hard but critical for enterprises to do a better job of supply chain planning like what P&G did during SARS.", [["SARS", "DISEASE", 109, 113]]], ["With economic stimuli announced in many countries, there are strong needs for infrastructure, auto and electronics, which can help the rebound of many manufacturing industries.", [["economic stimuli", "TEST", 5, 21], ["auto and electronics", "TREATMENT", 94, 114]]], ["Companies should better plan to avoid the bull-whip effect with all the irrational consumer behaviors and stimuli announced during the pandemic [11] .", [["the bull-whip effect", "PROBLEM", 38, 58]]], ["Agile and smart supply chain planning is essential to minimize the disruption and help to balance the severe volatility of supply and demand caused by \"Black Swan\" events.Enhancing Supply Chain Resilience inIn the era of big data, recalibrating and optimizing supply chain planning with extensive data digging and analysis is critical for business success.", [["Agile and smart supply chain planning", "TREATMENT", 0, 37], ["the disruption", "PROBLEM", 63, 77], ["Black Swan\" events", "PROBLEM", 152, 170], ["big data", "TEST", 221, 229], ["recalibrating", "TREATMENT", 231, 244], ["optimizing supply chain planning", "TREATMENT", 249, 281], ["Chain Resilience", "OBSERVATION", 188, 204]]], ["In order to overcome this, intelligent analytical and simulation tools can be beneficial.", [["simulation tools", "TEST", 54, 70]]], ["A wide range of possible scenarios can be computed as a basis for better planning.", [["wide", "OBSERVATION_MODIFIER", 2, 6]]], ["Then, the sourcing strategy is to be re-evaluated and supply network can be redesigned accordingly with the aid of dynamic programming to create a more resilient supply chain.ConclusionAssessing COVID-19's impacts from supply chain perspective and exploring countermeasures is critical for manufacturing industry.", [["network", "MULTI-TISSUE_STRUCTURE", 61, 68], ["dynamic programming", "TREATMENT", 115, 134], ["COVID", "TEST", 195, 200]]], ["Interruption of raw material and spare parts, setbacks in logistics and demand fluctuation are gradually intensified within the period.", [["Interruption of raw material", "PROBLEM", 0, 28], ["spare parts", "PROBLEM", 33, 44], ["demand fluctuation", "PROBLEM", 72, 90], ["raw material", "OBSERVATION", 16, 28], ["demand fluctuation", "OBSERVATION", 72, 90], ["gradually", "OBSERVATION_MODIFIER", 95, 104], ["intensified", "OBSERVATION_MODIFIER", 105, 116]]], ["Also, the manufacturing supply chain is likely to become regionalized and digitalized in the post-crisis world.", [["chain", "OBSERVATION_MODIFIER", 31, 36], ["is likely to", "UNCERTAINTY", 37, 49]]], ["The first step is to ensure the continuous supply chain operation at present.", [["the continuous supply chain operation", "TREATMENT", 28, 65]]]], "PMC7521429": [], "4b1ba87175820f0eab886f0b291a0494782918d9": [["IntroductionInfluenza A (IA) virus is one of the most important human and veterinary pathogens.", [["Influenza A (IA) virus", "DISEASE", 12, 34], ["Influenza A (IA) virus", "ORGANISM", 12, 34], ["human", "ORGANISM", 64, 69], ["human", "SPECIES", 64, 69], ["Influenza A (IA) virus", "SPECIES", 12, 34], ["human", "SPECIES", 64, 69], ["IntroductionInfluenza A (IA) virus", "PROBLEM", 0, 34]]], ["Various IA virus subtypes are causative agents of influenza, which is a significant zoonosis with high morbidity or mortality in different avian and mammal species worldwide involving humans [2, 14] .IntroductionThe IA virus genome consists of eight negative-sense RNA segments.", [["influenza", "DISEASE", 50, 59], ["zoonosis", "DISEASE", 84, 92], ["IA virus", "ORGANISM", 8, 16], ["humans", "ORGANISM", 184, 190], ["IA virus", "ORGANISM", 216, 224], ["IA virus genome", "DNA", 216, 231], ["humans", "SPECIES", 184, 190], ["IA virus", "SPECIES", 8, 16], ["humans", "SPECIES", 184, 190], ["IA virus", "SPECIES", 216, 224], ["Various IA virus subtypes", "PROBLEM", 0, 25], ["influenza", "PROBLEM", 50, 59], ["a significant zoonosis", "PROBLEM", 70, 92], ["high morbidity", "PROBLEM", 98, 112], ["The IA virus genome", "TREATMENT", 212, 231], ["virus subtypes", "OBSERVATION", 11, 25], ["influenza", "OBSERVATION", 50, 59], ["significant", "OBSERVATION_MODIFIER", 72, 83], ["zoonosis", "OBSERVATION", 84, 92], ["high", "OBSERVATION_MODIFIER", 98, 102], ["morbidity", "OBSERVATION", 103, 112], ["mammal species", "OBSERVATION", 149, 163], ["negative", "OBSERVATION", 250, 258], ["sense RNA", "ANATOMY_MODIFIER", 259, 268], ["segments", "ANATOMY_MODIFIER", 269, 277]]], ["The intrinsic genetic instability of the virus results from its high mutability and genetic reassortment, combined with interspecies transmission, establishment of host-specific lineages and geographical separation of host species has led to a considerable genetic and antigenic heterogeneity and evolutionary diversity.", [["The intrinsic genetic instability of the virus", "PROBLEM", 0, 46], ["host species", "PROBLEM", 218, 230], ["a considerable genetic and antigenic heterogeneity", "PROBLEM", 242, 292], ["genetic instability", "OBSERVATION", 14, 33], ["host species", "OBSERVATION", 218, 230], ["antigenic heterogeneity", "OBSERVATION", 269, 292], ["evolutionary diversity", "OBSERVATION", 297, 319]]], ["Therefore, the development of universal methods to detect as many genetic variants of the virus as possible is of crucial importance for IA virus surveillance, especially in avian species, which are considered the natural reservoir of IA virus [11, 14, 19] .IntroductionCurrently, conventional, or more recently, real-time RT-PCR (RRT-PCR) represents the leading technique in IA virus diagnosis, implemented as the first line of screening in many laboratories.", [["IA virus", "ORGANISM", 137, 145], ["IA virus", "ORGANISM", 235, 243], ["IA virus", "ORGANISM", 376, 384], ["IA virus", "SPECIES", 235, 243], ["IA virus", "SPECIES", 376, 384], ["universal methods", "TREATMENT", 30, 47], ["the virus", "PROBLEM", 86, 95], ["IA virus surveillance", "TEST", 137, 158], ["RRT", "TEST", 331, 334], ["screening", "TEST", 429, 438]]], ["Conventionally, these RT-PCR screening methods were designed to detect IA virus on a universal basis by amplifying a selected portion of the membrane protein (MP) gene segment [3-5, 9, 11, 16, 18, 21] .", [["membrane", "ANATOMY", 141, 149], ["membrane", "CELLULAR_COMPONENT", 141, 149], ["MP", "GENE_OR_GENE_PRODUCT", 159, 161], ["membrane protein (MP) gene segment", "DNA", 141, 175], ["IA virus", "SPECIES", 71, 79], ["these RT-PCR screening methods", "TEST", 16, 46], ["IA virus", "PROBLEM", 71, 79]]], ["The MP gene segment is a bicistronic RNA molecule encoding two proteins, M1 and M2.", [["MP", "GENE_OR_GENE_PRODUCT", 4, 6], ["M2", "GENE_OR_GENE_PRODUCT", 80, 82], ["MP gene segment", "DNA", 4, 19], ["bicistronic RNA molecule", "PROTEIN", 25, 49], ["M1", "PROTEIN", 73, 75], ["M2", "PROTEIN", 80, 82], ["segment", "ANATOMY_MODIFIER", 12, 19], ["bicistronic RNA molecule", "OBSERVATION", 25, 49], ["M1", "ANATOMY_MODIFIER", 73, 75], ["M2", "ANATOMY", 80, 82]]], ["The gene that encodes the M1 protein is considered to be highly conserved across various IA virus subtypes and host species.", [["M1", "GENE_OR_GENE_PRODUCT", 26, 28], ["IA virus", "ORGANISM", 89, 97], ["M1 protein", "PROTEIN", 26, 36], ["the M1 protein", "TEST", 22, 36], ["host species", "OBSERVATION", 111, 123]]], ["Nevertheless, phylogenetic analysis of a large panel of MP sequences has revealed that the sequence conservation is at the amino acid rather than the nucleotide sequence level, where the latter exhibits significant variation in both the M1 and M2 genes [8, 20] .", [["amino acid", "CHEMICAL", 123, 133], ["amino acid", "CHEMICAL", 123, 133], ["nucleotide", "CHEMICAL", 150, 160], ["MP", "GENE_OR_GENE_PRODUCT", 56, 58], ["amino acid", "AMINO_ACID", 123, 133], ["M2", "GENE_OR_GENE_PRODUCT", 244, 246], ["MP sequences", "DNA", 56, 68], ["M1 and M2 genes", "DNA", 237, 252], ["phylogenetic analysis", "TEST", 14, 35], ["MP sequences", "TEST", 56, 68], ["the sequence conservation", "TEST", 87, 112], ["the amino acid", "TEST", 119, 133], ["the nucleotide sequence level", "TEST", 146, 175], ["significant variation", "PROBLEM", 203, 224], ["significant", "OBSERVATION_MODIFIER", 203, 214], ["variation", "OBSERVATION_MODIFIER", 215, 224], ["both", "ANATOMY_MODIFIER", 228, 232], ["M1", "ANATOMY_MODIFIER", 237, 239], ["M2", "ANATOMY_MODIFIER", 244, 246]]], ["Accordingly, mutations in the MP gene segment result predominantly in synonymous codon changes, mostly in the M1 gene [8, 17, 20] , which constitutes 73.6% of the whole segment.IntroductionAlthough synonymous codon variation apparently plays a minor evolutionary role, it is of crucial importance in molecular diagnosis of IA viruses.", [["MP", "GENE_OR_GENE_PRODUCT", 30, 32], ["IA viruses", "ORGANISM", 323, 333], ["MP gene segment", "DNA", 30, 45], ["M1 gene", "DNA", 110, 117], ["mutations in the MP gene segment result", "PROBLEM", 13, 52], ["synonymous codon changes", "PROBLEM", 70, 94], ["synonymous codon variation", "PROBLEM", 198, 224], ["IA viruses", "PROBLEM", 323, 333], ["predominantly", "OBSERVATION_MODIFIER", 53, 66], ["synonymous codon", "OBSERVATION", 70, 86], ["M1", "ANATOMY_MODIFIER", 110, 112], ["segment", "ANATOMY_MODIFIER", 169, 176], ["synonymous codon", "OBSERVATION", 198, 214]]], ["The nucleotide mutations falling within the primer-and probe-binding regions may result in false negativity due to amplification or signal detection failure.IntroductionTo date, several universal RT-PCR and RRT-PCR techniques for the detection and monitoring of IA viruses have been developed [3-5, 9, 11, 16, 18, 21] .", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["primer-and probe-binding regions", "DNA", 44, 76], ["The nucleotide mutations", "PROBLEM", 0, 24], ["the primer", "TEST", 40, 50], ["false negativity", "PROBLEM", 91, 107], ["signal detection failure", "PROBLEM", 132, 156], ["several universal RT-PCR", "TREATMENT", 178, 202], ["RRT", "TREATMENT", 207, 210], ["PCR techniques", "TEST", 211, 225], ["the detection", "TEST", 230, 243], ["IA viruses", "PROBLEM", 262, 272], ["nucleotide mutations", "OBSERVATION", 4, 24], ["false negativity", "OBSERVATION", 91, 107]]], ["Although all of these techniques follow a common strategy for universal assay design, i.e. selection of primers and probes on the basis of the most conserved sequences within the MP segment, the sequence complementarity within the primerand probe-binding regions is often not confirmed by comparison of a large set of MP sequences, possibly because only a small number of sequences were available at that time.", [["MP", "GENE_OR_GENE_PRODUCT", 179, 181], ["MP", "GENE_OR_GENE_PRODUCT", 318, 320], ["MP segment", "DNA", 179, 189], ["primerand probe-binding regions", "DNA", 231, 262], ["MP sequences", "DNA", 318, 330], ["universal assay design", "TEST", 62, 84], ["MP sequences", "TEST", 318, 330], ["a small number of sequences", "PROBLEM", 354, 381], ["MP segment", "ANATOMY_MODIFIER", 179, 189], ["small", "OBSERVATION_MODIFIER", 356, 361]]], ["Therefore, it remains unclear how many IA virus strains go undetected and what inclusivity can be expected when a given assay is employed.IntroductionThe aim of this work was to develop an RRT-PCR assay for the universal detection of IA viruses from all known host species and to determine the inclusivity of the assay both on the theoretical and the experimental level.", [["IA virus strains", "ORGANISM", 39, 55], ["IA viruses", "ORGANISM", 234, 244], ["many IA virus strains", "PROBLEM", 34, 55], ["an RRT-PCR assay", "TEST", 186, 202], ["the universal detection", "TEST", 207, 230], ["IA viruses", "PROBLEM", 234, 244], ["all known host species", "PROBLEM", 250, 272], ["the assay", "TEST", 309, 318], ["host species", "OBSERVATION", 260, 272]]], ["The assay was extensively validated for all diagnostic test criteria through the joint efforts of four IA virus reference laboratories.", [["The assay", "TEST", 0, 9], ["all diagnostic test criteria", "TEST", 40, 68], ["joint", "ANATOMY", 81, 86]]], ["The sequences were aligned separately for each main host: avian, human, swine and equine.", [["avian", "ORGANISM", 58, 63], ["human", "ORGANISM", 65, 70], ["swine", "ORGANISM", 72, 77], ["equine", "ORGANISM", 82, 88], ["avian", "SPECIES", 58, 63], ["human", "SPECIES", 65, 70], ["swine", "SPECIES", 72, 77], ["equine", "SPECIES", 82, 88], ["human", "SPECIES", 65, 70], ["swine", "SPECIES", 72, 77]]], ["Multiple sequence alignments were constructed on the basis of 4,125 human, 3,896 avian, 484 swine, 96 equine and 146 other sequences.", [["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["avian", "SPECIES", 81, 86], ["swine", "SPECIES", 92, 97], ["human", "SPECIES", 68, 73], ["swine", "SPECIES", 92, 97], ["Multiple sequence alignments", "TEST", 0, 28], ["other sequences", "TEST", 117, 132]]], ["Each sequence pool was aligned using the MAFFT program (Multiple Alignment using Fast Fourier Transformation) [10] employing the FFT-NS-1 or FFT-NS-2 method.", [["the MAFFT program", "TREATMENT", 37, 54], ["Fast Fourier Transformation", "TREATMENT", 81, 108], ["the FFT", "TEST", 125, 132], ["NS", "TREATMENT", 133, 135], ["FFT", "TEST", 141, 144], ["NS", "TREATMENT", 145, 147]]], ["Subsequently, alignment editing and positional nucleotide numerical summary calculation was performed using the BIOEDIT software [6] .Influenza A virusesIn order to express the degree of nucleotide variation at each position of the MP segment, the amount of variability through a column in the alignment was calculated as informational entropy, H(x), defined by Shannon:Influenza A virusesis the frequency of each base i at any position x in the multiple sequence alignment.", [["nucleotide", "CHEMICAL", 47, 57], ["Influenza A viruses", "DISEASE", 134, 153], ["nucleotide", "CHEMICAL", 187, 197], ["nucleotide", "CHEMICAL", 47, 57], ["nucleotide", "CHEMICAL", 187, 197], ["Influenza A viruses", "ORGANISM", 134, 153], ["MP segment", "DNA", 232, 242], ["Influenza", "SPECIES", 134, 143], ["Influenza A viruses", "SPECIES", 134, 153], ["Influenza A", "SPECIES", 370, 381], ["positional nucleotide numerical summary calculation", "TEST", 36, 87], ["Influenza", "PROBLEM", 134, 143], ["nucleotide variation", "PROBLEM", 187, 207], ["Influenza", "PROBLEM", 370, 379], ["viruses", "OBSERVATION", 146, 153], ["nucleotide variation", "OBSERVATION", 187, 207], ["MP segment", "ANATOMY_MODIFIER", 232, 242], ["amount", "OBSERVATION_MODIFIER", 248, 254], ["variability", "OBSERVATION_MODIFIER", 258, 269], ["column", "OBSERVATION_MODIFIER", 280, 286], ["Influenza", "OBSERVATION", 370, 379]]], ["Accordingly, the most conserved positions are those with the lowest entropy value (the highest informational content) converging on or equal to zero.", [["the lowest entropy value", "TEST", 57, 81], ["positions", "OBSERVATION_MODIFIER", 32, 41]]], ["To reveal the overall nucleotide variation of the MP segment regardless the sequence origin, the partial entropy plots were assembled and visualised as the main entropy plot.", [["nucleotide", "CHEMICAL", 22, 32], ["nucleotide", "CHEMICAL", 22, 32], ["MP segment", "DNA", 50, 60], ["the partial entropy plots", "PROBLEM", 93, 118], ["overall", "OBSERVATION_MODIFIER", 14, 21], ["nucleotide variation", "OBSERVATION", 22, 42], ["MP segment", "ANATOMY_MODIFIER", 50, 60], ["partial", "OBSERVATION_MODIFIER", 97, 104], ["entropy plots", "OBSERVATION", 105, 118], ["main", "OBSERVATION_MODIFIER", 156, 160], ["entropy plot", "OBSERVATION", 161, 173]]], ["Based on extensive bioinformatic analysis, the primers and probe were designed based on regions with extremely low H(x) values, almost equal to zero.", [["extensive bioinformatic analysis", "TEST", 9, 41], ["the primers", "TEST", 43, 54], ["extremely low H(x) values", "PROBLEM", 101, 126]]], ["The forward primer SVIP-MP-F (5 0 -GGCCCCCTCAAAGCCGA-3 0 ) was selected from positions 77 to 93 and the reverse primer SVIP-MP-R (5 0 -CGTCTACGYTGCAGTCC-3 0 ), which contained one degenerated position, was chosen from positions 242 to 258.", [["MP", "DNA", 24, 26], ["positions 77 to 93", "DNA", 77, 95], ["reverse primer SVIP-MP-R", "DNA", 104, 128], ["positions 242 to 258", "DNA", 218, 238], ["The forward primer SVIP", "TEST", 0, 23], ["GGCCCCCTCAAAGCCGA", "TEST", 35, 52], ["CGTCTACGYTGCAGTCC", "TEST", 135, 152], ["one", "OBSERVATION_MODIFIER", 176, 179], ["degenerated", "OBSERVATION", 180, 191], ["position", "OBSERVATION_MODIFIER", 192, 200]]], ["The probe SVIP-MP-UPL104 represented an LNA (locked nucleic acid), modified and duallabelled octanucleotide selected from the 165 Universal Probe Library, probe number 104 (Roche; the rights to the probe sequence are protected).", [["SVIP-MP-UPL104", "CHEMICAL", 10, 24], ["LNA", "CHEMICAL", 40, 43], ["nucleic acid", "CHEMICAL", 52, 64], ["probe SVIP-MP-UPL104", "DNA", 4, 24], ["probe sequence", "DNA", 198, 212], ["The probe SVIP", "TEST", 0, 14], ["an LNA (locked nucleic acid", "TREATMENT", 37, 64], ["LNA", "OBSERVATION", 40, 43]]], ["The 5 0 end of the probe was labelled with FAM (fluorescein), and the 3 0 end with a dark quencher dye.SVIP-MP RRT-PCR assayA TaqMan quantitative real-time RT-PCR assay called SVIP-MP, which amplified a 182-nucleotide-long region of the IA virus MP segment (position 77-258) was developed.", [["FAM", "CHEMICAL", 43, 46], ["fluorescein", "CHEMICAL", 48, 59], ["FAM", "CHEMICAL", 43, 46], ["fluorescein", "CHEMICAL", 48, 59], ["FAM", "SIMPLE_CHEMICAL", 43, 46], ["fluorescein", "SIMPLE_CHEMICAL", 48, 59], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 103, 110], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 176, 183], ["5 0 end", "DNA", 4, 11], ["SVIP-MP", "DNA", 176, 183], ["182-nucleotide-long region", "DNA", 203, 229], ["IA virus MP segment", "DNA", 237, 256], ["position 77-258", "DNA", 258, 273], ["the probe", "TREATMENT", 15, 24], ["FAM (fluorescein", "TREATMENT", 43, 59], ["a dark quencher dye", "TREATMENT", 83, 102], ["SVIP", "TEST", 103, 107], ["MP RRT", "TEST", 108, 114], ["PCR", "TEST", 115, 118], ["PCR assay", "TEST", 159, 168], ["segment", "ANATOMY_MODIFIER", 249, 256]]], ["The SVIP-MP assay was designed as a one-step procedure using samples prepared with a OneStep RT-PCR kit or a QuantiTect Probe RT-PCR kit (both from Qiagen) in a final volume of 25 ll containing 0.6 lM of each primer, 0.2 lM of a probe and 5 ll of sample.", [["samples", "ANATOMY", 61, 68], ["The SVIP-MP assay", "TEST", 0, 17], ["a one-step procedure", "TREATMENT", 34, 54], ["a OneStep RT-PCR kit", "TREATMENT", 83, 103], ["a QuantiTect Probe RT-PCR kit", "TREATMENT", 107, 136], ["a final volume", "TEST", 159, 173], ["a probe", "TEST", 227, 234]]], ["For the OneStep RT-PCR kit, the concentration of MgCl 2 was adjusted to 4 mM.", [["MgCl 2", "CHEMICAL", 49, 55], ["MgCl 2", "CHEMICAL", 49, 55], ["MgCl 2", "SIMPLE_CHEMICAL", 49, 55], ["the OneStep RT-PCR kit", "TEST", 4, 26], ["the concentration of MgCl", "TREATMENT", 28, 53]]], ["The following thermoprofile was used: reverse transcription for 30 min at 50\u00b0C and 15 min at 95\u00b0C, followed by 45 cycles of 10 s at 95\u00b0C, 20 s at 60\u00b0C and 10 s at 72\u00b0C, with signal acquisition at the end of the 60\u00b0C period.", [["signal acquisition", "TEST", 174, 192]]], ["The 60-72\u00b0C ramp temperature was decreased to 1\u00b0C/s.", [["ramp temperature", "TEST", 12, 28]]], ["The assay was evaluated and optimised on a Light Cycler 480 instrument (Roche) using the Simple Probe detection format.", [["The assay", "TEST", 0, 9], ["the Simple Probe detection format", "TEST", 85, 118]]], ["In addition, the assay was examined on several additional real-time platforms: MJ MiniOpticon and iCycler (both from BioRad), Rotor-Gene 2000 and 6000 (Corbett Robotics), Stratagene Mx30005P (Stratagene), Light-Cycler1.2 (Roche) and ABI7000 and ABI7500 (Applied Biosystems).", [["the assay", "TEST", 13, 22], ["MJ MiniOpticon", "TREATMENT", 79, 93], ["iCycler", "TREATMENT", 98, 105], ["Corbett Robotics", "TREATMENT", 152, 168], ["Stratagene Mx30005P (Stratagene)", "TREATMENT", 171, 203], ["Light-Cycler", "TREATMENT", 205, 217]]], ["For the Stratagene Mx30005P and ABI platforms, the 60\u00b0C period was elongated to 30 s.", [["the Stratagene Mx30005P", "TREATMENT", 4, 27], ["ABI platforms", "TEST", 32, 45]]], ["When possible, the 60-72\u00b0C temperature ramp was decreased to 1\u00b0C/s, or as slow as possible.SVIP-MP RRT-PCR assayPreparation of RNA standard for RRT-PCR An RNA standard was prepared from the A/duck/Czech Republic/14516/07 (H3N8) strain (further abbreviated as CZE/H3N8).", [["SVIP", "CHEMICAL", 91, 95], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 91, 98], ["A/duck", "ORGANISM", 190, 196], ["Czech Republic/14516/07 (H3N8)", "ORGANISM", 197, 227], ["A/duck/Czech Republic/14516/07 (H3N8)", "SPECIES", 190, 227], ["SVIP", "TEST", 91, 95], ["MP RRT", "TEST", 96, 102], ["PCR", "TEST", 103, 106], ["RRT", "TEST", 144, 147], ["strain", "PROBLEM", 228, 234], ["CZE", "TEST", 259, 262], ["H3N8", "PROBLEM", 263, 267]]], ["The entire MP segment of CZE/H3N8 was amplified with T7-M-F: Bm-M-1027-R primer combinations.", [["MP", "GENE_OR_GENE_PRODUCT", 11, 13], ["MP segment", "DNA", 11, 21], ["H3N8", "DNA", 29, 33], ["T7", "DNA", 53, 55], ["CZE", "TEST", 25, 28], ["H3N8", "PROBLEM", 29, 33], ["T7", "TEST", 53, 55], ["Bm", "TEST", 61, 63], ["segment", "ANATOMY_MODIFIER", 14, 21]]], ["The primer T7-M-F was modified from the Bm-M-F primer [7] by replacing the first 14-base-long nucleotide tag with a T7 RNA polymerase promoter sequence: TA-ATACGACTCACTATAGGGCGAA.", [["nucleotide", "CHEMICAL", 94, 104], ["nucleotide", "CHEMICAL", 94, 104], ["primer T7-M-F", "DNA", 4, 17], ["Bm", "DNA", 40, 42], ["14-base-long nucleotide tag", "DNA", 81, 108], ["T7 RNA polymerase promoter sequence", "DNA", 116, 151], ["long nucleotide tag", "PROBLEM", 89, 108], ["T7", "ANATOMY", 11, 13], ["Bm", "ANATOMY", 40, 42], ["base", "ANATOMY_MODIFIER", 84, 88], ["T7", "ANATOMY", 116, 118]]], ["The reaction was performed using the OneStep RT-PCR kit (Qiagen) in a final volume of 25 ll with 5 ll of total nucleic acid extract.", [["nucleic acid extract", "CHEMICAL", 111, 131], ["The reaction", "PROBLEM", 0, 12], ["the OneStep RT-PCR kit", "TREATMENT", 33, 55], ["a final volume", "TEST", 68, 82], ["total nucleic acid extract", "TREATMENT", 105, 131], ["nucleic acid", "OBSERVATION", 111, 123]]], ["The amplicon was verified by sequencing.SVIP-MP RRT-PCR assayIn the next step, approximately 1 lg of the CZE/H3N8 MP segment PCR product was transcribed in vitro using the RiboMAX Large Scale RNA Production System with T7 RNA polymerase (Promega) in a final volume of 100 ll.", [["SVIP", "CHEMICAL", 40, 44], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 40, 47], ["T7 RNA polymerase", "PROTEIN", 219, 236], ["The amplicon", "TREATMENT", 0, 12], ["SVIP", "TEST", 40, 44], ["MP RRT", "TEST", 45, 51], ["PCR assay", "TEST", 52, 61], ["the CZE", "TEST", 101, 108], ["H3N8 MP segment PCR product", "TREATMENT", 109, 136], ["the RiboMAX Large Scale RNA Production System", "TREATMENT", 168, 213], ["T7 RNA polymerase", "TREATMENT", 219, 236], ["a final volume", "TEST", 250, 264]]], ["The DNA template was removed by RQ1 DNase treatment, and the transcription mix was diluted to 200 ll and extracted into a final volume of 100 ll (MagNAPure Compact, total nucleic acid extraction kit).", [["nucleic acid", "CHEMICAL", 171, 183], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["DNase", "GENE_OR_GENE_PRODUCT", 36, 41], ["DNA template", "DNA", 4, 16], ["DNase", "PROTEIN", 36, 41], ["The DNA template", "TREATMENT", 0, 16], ["RQ1 DNase treatment", "TREATMENT", 32, 51], ["the transcription mix", "TREATMENT", 57, 78], ["a final volume", "TEST", 120, 134], ["total nucleic acid extraction kit", "TREATMENT", 165, 198]]], ["The amount of RNA template was determined by limiting dilution assay and Poisson analysis [12] .", [["RNA template", "RNA", 14, 26], ["RNA template", "PROBLEM", 14, 26], ["dilution assay", "TEST", 54, 68], ["Poisson analysis", "TEST", 73, 89], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["RNA template", "OBSERVATION", 14, 26]]], ["According to this approach, a diluted extract was subjected to amplification in replicates, and the average copy number of target molecules per unit volume was calculated as:SVIP-MP RRT-PCR assaywhere N 0 is the number of negative results and N T is the total number of tests.", [["extract", "ANATOMY", 38, 45], ["a diluted extract", "TREATMENT", 28, 45], ["unit volume", "TEST", 144, 155], ["SVIP", "TEST", 174, 178], ["MP RRT", "TEST", 179, 185], ["tests", "TEST", 270, 275]]], ["The Poisson analysis indicated an average of 1.1 RNA copies/5 ll in the final dilution of the standard.", [["The Poisson analysis", "TEST", 0, 20], ["RNA copies", "TEST", 49, 59]]], ["For easier expression, this value was rounded to 1 copy/5 ll and was used for backward quantification of the standard stock.SVIP-MP RRT-PCR assayEvaluation of the primers and probe and estimation of the inclusivity of the assay The inclusivity of the assay was tested by two approaches.SVIP-MP RRT-PCR assayThe bioinformatic approach was based on a portion of the MP sequences in each particular alignment that had 100% complementarity to the primers and the probe.", [["SVIP", "CHEMICAL", 124, 128], ["SVIP", "CHEMICAL", 286, 290], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 124, 131], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 286, 293], ["MP", "GENE_OR_GENE_PRODUCT", 364, 366], ["MP sequences", "DNA", 364, 376], ["SVIP", "TEST", 124, 128], ["MP RRT", "TEST", 129, 135], ["PCR", "TEST", 136, 139], ["the primers", "TREATMENT", 159, 170], ["the assay", "TEST", 218, 227], ["the assay", "TEST", 247, 256], ["SVIP", "TEST", 286, 290], ["MP RRT", "TEST", 291, 297], ["PCR assay", "TEST", 298, 307], ["the MP sequences", "TEST", 360, 376]]], ["To this end, a re-evaluation of the sequence stability within the primer and One-step real-time RT-PCR assay for influenza A viruses probe binding regions was performed due to a rapid increase in the number of ISD MP sequences, especially regarding the emergence of the pandemic influenza A of H1N1 subtype in human population since April 2009.", [["influenza", "DISEASE", 279, 288], ["influenza A viruses", "ORGANISM", 113, 132], ["MP", "GENE_OR_GENE_PRODUCT", 214, 216], ["influenza A", "ORGANISM", 279, 290], ["human", "ORGANISM", 310, 315], ["ISD MP sequences", "DNA", 210, 226], ["human", "SPECIES", 310, 315], ["influenza A viruses", "SPECIES", 113, 132], ["human", "SPECIES", 310, 315], ["a re-evaluation", "TEST", 13, 28], ["the sequence stability", "TEST", 32, 54], ["RT-PCR assay", "TEST", 96, 108], ["influenza", "PROBLEM", 113, 122], ["A viruses probe binding regions", "PROBLEM", 123, 154], ["a rapid increase", "PROBLEM", 176, 192], ["ISD MP sequences", "TEST", 210, 226], ["the pandemic influenza", "PROBLEM", 266, 288], ["rapid", "OBSERVATION_MODIFIER", 178, 183], ["increase", "OBSERVATION_MODIFIER", 184, 192]]], ["The re-evaluation was performed by aligning 10,405 MP sequences (downloaded on August 20, 2009) including 4,627 human, 694 pandemic influenza A (H1N1), 4,249 avian, 546 swine, 119 equine and 170 other MP sequences ( Table 1) .SVIP-MP RRT-PCR assayThe experimental approach verified the ability of the SVIP-MP assay to tolerate mutations in the primer sequences.", [["influenza A", "DISEASE", 132, 143], ["SVIP", "CHEMICAL", 226, 230], ["human", "ORGANISM", 112, 117], ["pandemic influenza A", "ORGANISM", 123, 143], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 226, 233], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 301, 308], ["10,405 MP sequences", "DNA", 44, 63], ["primer sequences", "DNA", 344, 360], ["human", "SPECIES", 112, 117], ["pandemic influenza A", "SPECIES", 123, 143], ["avian", "SPECIES", 158, 163], ["swine", "SPECIES", 169, 174], ["equine", "SPECIES", 180, 186], ["human", "SPECIES", 112, 117], ["swine", "SPECIES", 169, 174], ["equine", "SPECIES", 180, 186], ["The re-evaluation", "TEST", 0, 17], ["other MP sequences", "TEST", 195, 213], ["SVIP", "TEST", 226, 230], ["MP RRT", "TEST", 231, 237], ["PCR assay", "TEST", 238, 247], ["mutations in the primer sequences", "PROBLEM", 327, 360]]], ["Sixteen mutated variants of the forward primer SVIP-MP-FX1:FX16 and 14 of the reverse primer SVIP-MP-RX: RX16 were designed that mimicked naturally occurring mutations and were considered as the most critical for primer binding (Fig. 1) .", [["RX16", "SIMPLE_CHEMICAL", 105, 109], ["forward primer SVIP", "DNA", 32, 51], ["MP", "DNA", 52, 54], ["FX1", "DNA", 55, 58], ["FX16", "DNA", 59, 63], ["reverse primer SVIP-MP-RX: RX16", "DNA", 78, 109], ["Sixteen mutated variants", "PROBLEM", 0, 24], ["SVIP", "TEST", 47, 51], ["FX16", "TEST", 59, 63]]], ["Consequently, reactions were set up with each particular mutated SVIP-MP-FX or RX primer coupled with its original SVIP-MP-R or SVIP-MP-F counterpart and used to amplify the CZE/H3N8 RNA standard at three dilutions, 10 2 , 10 4 and 10 6 copies/ reaction, on the LightCycler 480.Sensitivity of the assayTo determine the analytical sensitivity of the assay, a serial dilution of quantified CZE/H3N8 RNA standard (from 10 7 to 10 1 copies/reaction) was prepared.", [["SVIP-MP-FX", "GENE_OR_GENE_PRODUCT", 65, 75], ["MP-R", "GENE_OR_GENE_PRODUCT", 120, 124], ["mutated SVIP-MP-FX or RX primer", "DNA", 57, 88], ["SVIP", "PROTEIN", 115, 119], ["MP", "PROTEIN", 120, 122], ["SVIP", "PROTEIN", 128, 132], ["MP", "PROTEIN", 133, 135], ["CZE", "DNA", 174, 177], ["RX primer", "TREATMENT", 79, 88], ["SVIP", "TEST", 128, 132], ["the CZE", "TEST", 170, 177], ["H3N8 RNA", "TREATMENT", 178, 186], ["the LightCycler", "TEST", 258, 273], ["the assay", "TEST", 293, 302], ["the assay", "TEST", 345, 354], ["a serial dilution of quantified CZE/H3N8 RNA", "TREATMENT", 356, 400]]], ["The standard curve constructed by plotting the cycle threshold values (C t ) against the log of the standard dilution was obtained in two independent runs.", [["plotting the cycle threshold values", "TEST", 34, 69]]], ["Each run was performed in four replicates.Specificity of the asssayTo exclude cross-reactivity with other virus and bacterial species, a panel of 108 isolates representing a total of 24 human, avian, swine and equine viruses and a group of 27 bacteria was tested.", [["avian, swine and equine viruses", "DISEASE", 193, 224], ["human", "ORGANISM", 186, 191], ["avian", "ORGANISM", 193, 198], ["swine", "ORGANISM", 200, 205], ["equine viruses", "ORGANISM", 210, 224], ["human", "SPECIES", 186, 191], ["avian", "SPECIES", 193, 198], ["swine", "SPECIES", 200, 205], ["equine", "SPECIES", 210, 216], ["human", "SPECIES", 186, 191], ["swine", "SPECIES", 200, 205], ["equine viruses", "SPECIES", 210, 224], ["the asssay", "TEST", 57, 67], ["other virus and bacterial species", "PROBLEM", 100, 133], ["a panel", "TEST", 135, 142], ["equine viruses", "PROBLEM", 210, 224], ["bacterial species", "OBSERVATION", 116, 133]]], ["The viruses included: influenza B and C viruses, human respiratory syncytial virus, human adenovirus, human herpes virus, avian infectious bronchitis virus, avian paramyxovirus 1-4, 6-9, pigeon paramyxovirus, psittacine beak and feather disease virus, porcine reproductive and respiratory syndrome vrus, porcine circovirus 2, porcine herpes virus 1, porcine parvovirus, porcine coronavirus, classical swine fever virus, equine arteritis virus and equine herpes virus 1.", [["influenza B", "DISEASE", 22, 33], ["respiratory syncytial virus", "DISEASE", 55, 82], ["human herpes virus", "DISEASE", 102, 120], ["avian infectious bronchitis virus", "DISEASE", 122, 155], ["avian paramyxovirus 1-4, 6-9", "CHEMICAL", 157, 185], ["feather disease", "DISEASE", 229, 244], ["porcine reproductive and respiratory syndrome vrus", "DISEASE", 252, 302], ["porcine herpes virus", "DISEASE", 326, 346], ["porcine parvovirus", "DISEASE", 350, 368], ["porcine coronavirus", "DISEASE", 370, 389], ["swine fever", "DISEASE", 401, 412], ["equine arteritis", "DISEASE", 420, 436], ["equine herpes virus", "DISEASE", 447, 466], ["influenza B and C viruses", "ORGANISM", 22, 47], ["human respiratory syncytial virus", "ORGANISM", 49, 82], ["human adenovirus", "ORGANISM", 84, 100], ["human herpes virus", "ORGANISM", 102, 120], ["avian infectious bronchitis virus", "ORGANISM", 122, 155], ["avian paramyxovirus 1-4", "ORGANISM", 157, 180], ["6-9", "ORGANISM", 182, 185], ["pigeon paramyxovirus", "ORGANISM", 187, 207], ["psittacine beak", "ORGANISM", 209, 224], ["feather disease virus", "ORGANISM", 229, 250], ["porcine reproductive and respiratory syndrome vrus", "ORGANISM", 252, 302], ["porcine circovirus 2", "ORGANISM", 304, 324], ["porcine herpes virus 1", "ORGANISM", 326, 348], ["porcine parvovirus", "ORGANISM", 350, 368], ["porcine coronavirus", "ORGANISM", 370, 389], ["classical swine fever virus", "ORGANISM", 391, 418], ["equine arteritis virus", "ORGANISM", 420, 442], ["equine herpes virus 1", "ORGANISM", 447, 468], ["human", "SPECIES", 49, 54], ["respiratory syncytial virus", "SPECIES", 55, 82], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 102, 107], ["herpes virus", "SPECIES", 108, 120], ["avian infectious bronchitis virus", "SPECIES", 122, 155], ["avian paramyxovirus 1", "SPECIES", 157, 178], ["pigeon paramyxovirus", "SPECIES", 187, 207], ["feather disease virus", "SPECIES", 229, 250], ["porcine", "SPECIES", 252, 259], ["porcine circovirus", "SPECIES", 304, 322], ["porcine herpes virus 1", "SPECIES", 326, 348], ["porcine parvovirus", "SPECIES", 350, 368], ["porcine coronavirus", "SPECIES", 370, 389], ["swine fever virus", "SPECIES", 401, 418], ["equine arteritis virus", "SPECIES", 420, 442], ["equine herpes virus", "SPECIES", 447, 466], ["C viruses", "SPECIES", 38, 47], ["human respiratory syncytial virus", "SPECIES", 49, 82], ["human adenovirus", "SPECIES", 84, 100], ["human herpes virus", "SPECIES", 102, 120], ["infectious bronchitis virus", "SPECIES", 128, 155], ["pigeon paramyxovirus", "SPECIES", 187, 207], ["feather disease virus", "SPECIES", 229, 250], ["porcine circovirus 2", "SPECIES", 304, 324], ["porcine herpes virus 1", "SPECIES", 326, 348], ["porcine parvovirus", "SPECIES", 350, 368], ["porcine coronavirus", "SPECIES", 370, 389], ["swine fever virus", "SPECIES", 401, 418], ["equine arteritis virus", "SPECIES", 420, 442], ["equine herpes virus 1", "SPECIES", 447, 468], ["The viruses", "PROBLEM", 0, 11], ["influenza B", "PROBLEM", 22, 33], ["C viruses", "PROBLEM", 38, 47], ["human respiratory syncytial virus", "PROBLEM", 49, 82], ["human adenovirus", "PROBLEM", 84, 100], ["human herpes virus", "PROBLEM", 102, 120], ["avian infectious bronchitis virus", "PROBLEM", 122, 155], ["avian paramyxovirus", "TREATMENT", 157, 176], ["pigeon paramyxovirus", "PROBLEM", 187, 207], ["psittacine beak", "PROBLEM", 209, 224], ["feather disease virus", "PROBLEM", 229, 250], ["porcine reproductive", "PROBLEM", 252, 272], ["respiratory syndrome vrus", "PROBLEM", 277, 302], ["porcine circovirus", "PROBLEM", 304, 322], ["porcine herpes virus", "PROBLEM", 326, 346], ["porcine parvovirus", "PROBLEM", 350, 368], ["porcine coronavirus", "PROBLEM", 370, 389], ["classical swine fever virus", "PROBLEM", 391, 418], ["equine arteritis virus", "PROBLEM", 420, 442], ["equine herpes virus", "PROBLEM", 447, 466], ["viruses", "OBSERVATION", 4, 11], ["influenza", "OBSERVATION", 22, 31], ["respiratory syncytial virus", "OBSERVATION", 55, 82], ["psittacine beak", "OBSERVATION", 209, 224], ["respiratory syndrome", "OBSERVATION", 277, 297], ["porcine circovirus", "OBSERVATION", 304, 322], ["porcine coronavirus", "OBSERVATION", 370, 389]]], ["The bacterial cultures included Actinobacillus equuli, salpingitidis and pleuropneumoniae, Bordetella bronchyseptica, Campylobacter jejuni, coli and lari, Enterococcus feacalis, Erysipelothrix rhusiopathiae, Escherichia coli, Candida rugosa, Chlamydia sp., Gallibacterium anatis, Klebsiella pneumoniae, Mycobacterium tuberculosis and avium complex, Nicoletella semolina, Ornithobacterium rhinotracheale, Pasteurella mairii and multocida, Pseudomonas aeruginosa, Salmonella serovar Newport, Staphylococcus hyicus and aureus, Streptococcus suis, Taylorella equigenitalis and Volucribacter amazonae.", [["cultures", "ANATOMY", 14, 22], ["Bordetella bronchyseptica", "DISEASE", 91, 116], ["Campylobacter jejuni", "DISEASE", 118, 138], ["Chlamydia sp.", "DISEASE", 242, 255], ["Mycobacterium tuberculosis", "DISEASE", 303, 329], ["Staphylococcus hyicus", "DISEASE", 490, 511], ["Actinobacillus equuli", "ORGANISM", 32, 53], ["salpingitidis and pleuropneumoniae", "ORGANISM", 55, 89], ["Bordetella bronchyseptica", "ORGANISM", 91, 116], ["Campylobacter jejuni", "ORGANISM", 118, 138], ["coli", "ORGANISM", 140, 144], ["lari", "ORGANISM", 149, 153], ["Enterococcus feacalis", "ORGANISM", 155, 176], ["Erysipelothrix rhusiopathiae", "ORGANISM", 178, 206], ["Escherichia coli", "ORGANISM", 208, 224], ["Candida rugosa", "ORGANISM", 226, 240], ["Chlamydia sp.", "ORGANISM", 242, 255], ["Gallibacterium anatis", "ORGANISM", 257, 278], ["Klebsiella pneumoniae", "ORGANISM", 280, 301], ["Mycobacterium tuberculosis", "ORGANISM", 303, 329], ["avium complex", "ORGANISM", 334, 347], ["Nicoletella semolina", "ORGANISM", 349, 369], ["Ornithobacterium rhinotracheale", "ORGANISM", 371, 402], ["Pasteurella mairii", "ORGANISM", 404, 422], ["multocida", "ORGANISM", 427, 436], ["Pseudomonas aeruginosa", "ORGANISM", 438, 460], ["Salmonella serovar Newport", "ORGANISM", 462, 488], ["Staphylococcus hyicus", "ORGANISM", 490, 511], ["aureus", "ORGANISM", 516, 522], ["Streptococcus suis", "ORGANISM", 524, 542], ["Taylorella equigenitalis", "ORGANISM", 544, 568], ["Volucribacter amazonae", "ORGANISM", 573, 595], ["Actinobacillus equuli", "SPECIES", 32, 53], ["salpingitidis and pleuropneumoniae", "SPECIES", 55, 89], ["Bordetella bronchyseptica", "SPECIES", 91, 116], ["Campylobacter jejuni", "SPECIES", 118, 138], [", coli", "SPECIES", 138, 144], ["Enterococcus feacalis", "SPECIES", 155, 176], ["Erysipelothrix rhusiopathiae", "SPECIES", 178, 206], ["Escherichia coli", "SPECIES", 208, 224], ["Candida rugosa", "SPECIES", 226, 240], ["Chlamydia sp.", "SPECIES", 242, 255], ["Gallibacterium anatis", "SPECIES", 257, 278], ["Klebsiella pneumoniae", "SPECIES", 280, 301], ["Mycobacterium tuberculosis", "SPECIES", 303, 329], ["avium", "SPECIES", 334, 339], ["Nicoletella semolina", "SPECIES", 349, 369], ["Ornithobacterium rhinotracheale", "SPECIES", 371, 402], ["Pasteurella mairii", "SPECIES", 404, 422], ["multocida", "SPECIES", 427, 436], ["Pseudomonas aeruginosa", "SPECIES", 438, 460], ["Salmonella serovar", "SPECIES", 462, 480], ["Staphylococcus hyicus", "SPECIES", 490, 511], ["aureus", "SPECIES", 516, 522], ["Streptococcus suis", "SPECIES", 524, 542], ["Taylorella equigenitalis", "SPECIES", 544, 568], ["Volucribacter amazonae", "SPECIES", 573, 595], ["Actinobacillus equuli", "SPECIES", 32, 53], ["Bordetella bronchyseptica", "SPECIES", 91, 116], ["Campylobacter jejuni", "SPECIES", 118, 138], ["Enterococcus feacalis", "SPECIES", 155, 176], ["Erysipelothrix rhusiopathiae", "SPECIES", 178, 206], ["Escherichia coli", "SPECIES", 208, 224], ["Candida rugosa", "SPECIES", 226, 240], ["Chlamydia sp.", "SPECIES", 242, 255], ["Gallibacterium anatis", "SPECIES", 257, 278], ["Klebsiella pneumoniae", "SPECIES", 280, 301], ["Mycobacterium tuberculosis", "SPECIES", 303, 329], ["avium complex", "SPECIES", 334, 347], ["Nicoletella semolina", "SPECIES", 349, 369], ["Ornithobacterium rhinotracheale", "SPECIES", 371, 402], ["Pasteurella mairii", "SPECIES", 404, 422], ["Pseudomonas aeruginosa", "SPECIES", 438, 460], ["Salmonella serovar Newport", "SPECIES", 462, 488], ["Staphylococcus hyicus", "SPECIES", 490, 511], ["Streptococcus suis", "SPECIES", 524, 542], ["Taylorella equigenitalis", "SPECIES", 544, 568], ["Volucribacter amazonae", "SPECIES", 573, 595], ["The bacterial cultures", "TEST", 0, 22], ["Actinobacillus equuli", "PROBLEM", 32, 53], ["salpingitidis", "PROBLEM", 55, 68], ["pleuropneumoniae", "PROBLEM", 73, 89], ["Bordetella bronchyseptica", "PROBLEM", 91, 116], ["Campylobacter jejuni", "PROBLEM", 118, 138], ["coli", "PROBLEM", 140, 144], ["Enterococcus feacalis", "PROBLEM", 155, 176], ["Erysipelothrix rhusiopathiae", "PROBLEM", 178, 206], ["Escherichia coli", "PROBLEM", 208, 224], ["Candida rugosa", "PROBLEM", 226, 240], ["Chlamydia sp.", "PROBLEM", 242, 255], ["Gallibacterium anatis", "PROBLEM", 257, 278], ["Klebsiella pneumoniae", "PROBLEM", 280, 301], ["Mycobacterium tuberculosis", "PROBLEM", 303, 329], ["avium complex", "PROBLEM", 334, 347], ["Nicoletella semolina", "TEST", 349, 369], ["Ornithobacterium", "TEST", 371, 387], ["Pasteurella mairii", "TEST", 404, 422], ["multocida", "PROBLEM", 427, 436], ["Pseudomonas aeruginosa", "PROBLEM", 438, 460], ["Salmonella serovar", "PROBLEM", 462, 480], ["Staphylococcus hyicus", "PROBLEM", 490, 511], ["aureus", "PROBLEM", 516, 522], ["Streptococcus suis", "PROBLEM", 524, 542], ["Taylorella equigenitalis", "PROBLEM", 544, 568], ["Volucribacter amazonae", "PROBLEM", 573, 595], ["bacterial", "OBSERVATION_MODIFIER", 4, 13], ["Actinobacillus equuli", "OBSERVATION", 32, 53], ["Campylobacter jejuni", "OBSERVATION", 118, 138], ["lari", "ANATOMY", 149, 153], ["Enterococcus feacalis", "OBSERVATION", 155, 176], ["Erysipelothrix rhusiopathiae", "OBSERVATION", 178, 206], ["Escherichia coli", "OBSERVATION", 208, 224], ["Candida rugosa", "OBSERVATION", 226, 240], ["Klebsiella pneumoniae", "OBSERVATION", 280, 301], ["Mycobacterium tuberculosis", "OBSERVATION", 303, 329], ["avium complex", "OBSERVATION", 334, 347], ["Staphylococcus hyicus", "OBSERVATION", 490, 511]]], ["The list of virus and bacterial isolates is shown in Supplementary Table S2.", [["virus", "PROBLEM", 12, 17], ["bacterial isolates", "PROBLEM", 22, 40], ["bacterial isolates", "OBSERVATION", 22, 40]]], ["To exclude background hybridization, i. e. interference with avian and mammal genomic nucleic acids, and nonspecific signal generation, a total of 42 IA-virus-negative specimens were tested, representing whole blood of humans and whole blood or pooled organ suspensions of swine, horse, seal, dog, cat, tiger, stone marten and of various bird species origin, including chicken, duck, goose, turkey, swan and gull.Reproducibility of the assayThe intra-and inter-assay reproducibility was determined for three dilutions of the CZE/H3N8 RNA standard: 10 6 , 10 4 and 10 2 copies/reaction.", [["specimens", "ANATOMY", 168, 177], ["whole blood", "ANATOMY", 204, 215], ["whole blood", "ANATOMY", 230, 241], ["organ", "ANATOMY", 252, 257], ["stone", "ANATOMY", 310, 315], ["nucleic acids", "CHEMICAL", 86, 99], ["IA-virus", "ORGANISM", 150, 158], ["specimens", "CANCER", 168, 177], ["blood", "ORGANISM_SUBSTANCE", 210, 215], ["humans", "ORGANISM", 219, 225], ["blood", "ORGANISM_SUBSTANCE", 236, 241], ["organ", "ORGAN", 252, 257], ["swine", "ORGANISM", 273, 278], ["horse", "ORGANISM_SUBDIVISION", 280, 285], ["seal", "ORGANISM_SUBDIVISION", 287, 291], ["dog", "ORGANISM", 293, 296], ["cat", "ORGANISM", 298, 301], ["tiger", "ORGANISM", 303, 308], ["chicken", "ORGANISM", 369, 376], ["duck", "ORGANISM", 378, 382], ["goose", "ORGANISM", 384, 389], ["turkey", "ORGANISM", 391, 397], ["humans", "SPECIES", 219, 225], ["swine", "SPECIES", 273, 278], ["horse", "SPECIES", 280, 285], ["dog", "SPECIES", 293, 296], ["cat", "SPECIES", 298, 301], ["chicken", "SPECIES", 369, 376], ["duck", "SPECIES", 378, 382], ["goose", "SPECIES", 384, 389], ["turkey", "SPECIES", 391, 397], ["humans", "SPECIES", 219, 225], ["swine", "SPECIES", 273, 278], ["chicken", "SPECIES", 369, 376], ["goose", "SPECIES", 384, 389], ["turkey", "SPECIES", 391, 397], ["background hybridization", "PROBLEM", 11, 35], ["mammal genomic nucleic acids", "TEST", 71, 99], ["nonspecific signal generation", "PROBLEM", 105, 134], ["whole blood", "TEST", 230, 241], ["various bird species origin", "PROBLEM", 330, 357], ["the assay", "TEST", 432, 441], ["The intra-and inter-assay reproducibility", "TEST", 441, 482], ["the CZE", "TEST", 521, 528], ["nucleic acids", "OBSERVATION", 86, 99], ["organ", "ANATOMY", 252, 257], ["stone", "OBSERVATION", 310, 315], ["various bird", "OBSERVATION", 330, 342], ["species origin", "OBSERVATION", 343, 357], ["duck", "ANATOMY", 378, 382], ["goose", "OBSERVATION_MODIFIER", 384, 389], ["swan", "ANATOMY", 399, 403], ["gull", "ANATOMY", 408, 412]]], ["The intra-assay variation was analysed in five replicates, and the inter-assay reproducibility was assessed in five independent runs.", [["The intra-assay variation", "TEST", 0, 25], ["the inter-assay reproducibility", "TEST", 63, 94]]], ["The statistical dispersion was expressed as standard deviation (SD) and the repeatability as relative standard deviation (RSD %) within and between the experiments.Reproducibility of the assayComparison of the SVIP-MP RRT-PCR with the recommended method of the European Community Reference Laboratory for Avian InfluenzaReproducibility of the assayThe SVIP-MP assay was compared to the recommended method of the European Community Reference Laboratory (CRL) for Avian Influenza [4, 16] .", [["Influenza", "DISEASE", 468, 477], ["SVIP", "DNA", 210, 214], ["standard deviation (SD)", "PROBLEM", 44, 67], ["the repeatability", "TEST", 72, 89], ["relative standard deviation (RSD %)", "PROBLEM", 93, 128], ["the SVIP", "TEST", 206, 214], ["the assay", "TEST", 339, 348], ["The SVIP-MP assay", "TEST", 348, 365], ["Avian Influenza", "PROBLEM", 462, 477]]], ["In the first approach, seven dilution orders of the CZE/H3N8 RNA standard were prepared in three replicates and analysed on the LightCycler 480 instrument.", [["the CZE/H3N8 RNA", "TREATMENT", 48, 64]]], ["In the second approach, a panel of 62 AI isolates were amplified in two replicates on the Rotorgene 6000 platform, and the mean C t values were compared.", [["a panel", "TEST", 24, 31], ["AI isolates", "TEST", 38, 49], ["the mean C t values", "TEST", 119, 138]]], ["These assays were performed in two different laboratories.Search for conserved regions in the MP sequenceIntegration of the entropy values calculated separately for each MP sequence group into the main entropy plot revealed considerable variation of the IA virus MP segment The entropy values for each position of the MP segment were calculated separately for five sequence groups: avian (blue), human (red), swine (green), equine (brown) and others (black).", [["MP", "GENE_OR_GENE_PRODUCT", 94, 96], ["MP", "GENE_OR_GENE_PRODUCT", 318, 320], ["human", "ORGANISM", 396, 401], ["green", "ORGANISM_SUBDIVISION", 416, 421], ["equine", "ORGANISM", 424, 430], ["brown", "ORGANISM_SUBDIVISION", 432, 437], ["MP sequence", "DNA", 94, 105], ["MP segment", "DNA", 318, 328], ["human", "SPECIES", 396, 401], ["swine", "SPECIES", 409, 414], ["equine", "SPECIES", 424, 430], ["human", "SPECIES", 396, 401], ["swine", "SPECIES", 409, 414], ["These assays", "TEST", 0, 12], ["the MP sequence", "TEST", 90, 105], ["the entropy values", "TEST", 120, 138], ["the main entropy plot", "TEST", 193, 214], ["considerable variation of the IA virus MP segment", "PROBLEM", 224, 273], ["The entropy values", "TEST", 274, 292], ["considerable variation", "OBSERVATION", 224, 246], ["segment", "ANATOMY_MODIFIER", 266, 273]]], ["The partial column height is proportional to the entropy values observed within a given sequence group.Search for conserved regions in the MP sequenceThe overall variation per position resulted from the assembly of the partial columns One-step real-time RT-PCR assay for influenza A viruses 669 at the nucleotide level (Fig. 2) .", [["nucleotide", "CHEMICAL", 302, 312], ["MP", "GENE_OR_GENE_PRODUCT", 139, 141], ["influenza A viruses", "ORGANISM", 271, 290], ["MP sequence", "DNA", 139, 150], ["influenza A viruses", "SPECIES", 271, 290], ["the entropy values", "TEST", 45, 63], ["the MP sequence", "TEST", 135, 150], ["influenza A viruses", "PROBLEM", 271, 290], ["partial", "OBSERVATION_MODIFIER", 4, 11], ["column", "OBSERVATION_MODIFIER", 12, 18], ["height", "OBSERVATION_MODIFIER", 19, 25], ["entropy values", "OBSERVATION", 49, 63], ["overall", "OBSERVATION_MODIFIER", 154, 161], ["variation", "OBSERVATION_MODIFIER", 162, 171]]], ["The main entropy plot further indicated that the positions with elevated nucleotide variation were scattered through the entire segment, with the main stretch of variable sites localised within the central part of the plot, generally delimited by positions 259-819.", [["nucleotide", "CHEMICAL", 73, 83], ["nucleotide", "CHEMICAL", 73, 83], ["elevated nucleotide variation", "PROBLEM", 64, 93], ["variable sites", "PROBLEM", 162, 176], ["main", "OBSERVATION_MODIFIER", 4, 8], ["entropy plot", "OBSERVATION", 9, 21], ["elevated", "OBSERVATION_MODIFIER", 64, 72], ["nucleotide variation", "OBSERVATION", 73, 93], ["entire", "OBSERVATION_MODIFIER", 121, 127], ["segment", "OBSERVATION_MODIFIER", 128, 135], ["main", "OBSERVATION_MODIFIER", 146, 150], ["stretch", "OBSERVATION_MODIFIER", 151, 158], ["variable sites", "OBSERVATION", 162, 176], ["central", "ANATOMY_MODIFIER", 198, 205]]], ["This variable domain was interrupted by short, up to eight-nucleotide-long conserved sequences.", [["nucleotide", "CHEMICAL", 59, 69], ["long conserved sequences", "DNA", 70, 94], ["This variable domain", "PROBLEM", 0, 20]]], ["Longer conserved stretches with H(x) values very close or equal to zero were only found within the termini of the segment enclosed by positions 1-258 and 820-1027.", [["positions 1-258 and 820-1027", "DNA", 134, 162], ["stretches", "OBSERVATION_MODIFIER", 17, 26], ["termini", "ANATOMY_MODIFIER", 99, 106], ["segment", "ANATOMY_MODIFIER", 114, 121], ["positions", "OBSERVATION_MODIFIER", 134, 143]]], ["The SVIP-MP assay was designed by fitting the primers and the probe into the strongly conserved positions of the 1-258 region.Search for conserved regions in the MP sequenceEvaluation of the primers and probe and estimation of the inclusivity of the assaySearch for conserved regions in the MP sequenceThe primers and probe selected were evaluated by both bioinformatics analysis and experimental mutations of primer sequences.", [["MP", "GENE_OR_GENE_PRODUCT", 162, 164], ["MP", "GENE_OR_GENE_PRODUCT", 291, 293], ["SVIP", "PROTEIN", 4, 8], ["1-258 region", "DNA", 113, 125], ["MP sequence", "DNA", 162, 173], ["MP sequence", "DNA", 291, 302], ["primer sequences", "DNA", 410, 426], ["The SVIP-MP assay", "TEST", 0, 17], ["the primers", "TEST", 42, 53], ["the MP sequence", "TEST", 158, 173], ["Evaluation", "TEST", 173, 183], ["the primers", "TEST", 187, 198], ["the MP sequence", "TEST", 287, 302], ["both bioinformatics analysis", "TEST", 351, 379], ["experimental mutations of primer sequences", "TEST", 384, 426], ["positions", "OBSERVATION_MODIFIER", 96, 105]]], ["Bioinformatic analysis of the SVIP-MP primers and probe sequences exhibited full complementarity ranging from 97.07 to 100% of MP strains deposited in the international database ( Table 2) .", [["SVIP-MP", "GENE_OR_GENE_PRODUCT", 30, 37], ["MP", "GENE_OR_GENE_PRODUCT", 127, 129], ["SVIP-MP primers", "DNA", 30, 45], ["probe sequences", "DNA", 50, 65], ["Bioinformatic analysis", "TEST", 0, 22], ["the SVIP", "TEST", 26, 34], ["MP primers", "TEST", 35, 45], ["probe sequences", "TEST", 50, 65], ["MP strains", "PROBLEM", 127, 137]]], ["As shown in Table 2 , the MP sequences of 0.29 and 0.43% of human strains, 0.18 and 0.17% of pandemic influenza A (H1N1) strains, 0.7 and 1.97% of avian strains, 2.93 and 2.59% of swine strains and 1.93 and 0% of strains of other origin had mutations within the forward and reverse primer binding site, respectively.", [["influenza", "DISEASE", 102, 111], ["MP", "GENE_OR_GENE_PRODUCT", 26, 28], ["human", "ORGANISM", 60, 65], ["pandemic influenza A (H1N1) strains", "ORGANISM", 93, 128], ["avian", "ORGANISM", 147, 152], ["swine", "ORGANISM", 180, 185], ["MP sequences", "DNA", 26, 38], ["forward and reverse primer binding site", "DNA", 262, 301], ["human", "SPECIES", 60, 65], ["pandemic influenza A (H1N1", "SPECIES", 93, 119], ["swine", "SPECIES", 180, 185], ["human", "SPECIES", 60, 65], ["pandemic influenza A (H1N1)", "SPECIES", 93, 120], ["swine", "SPECIES", 180, 185], ["the MP sequences", "TEST", 22, 38], ["human strains", "TEST", 60, 73], ["pandemic influenza A", "TEST", 93, 113], ["strains", "TEST", 121, 128], ["avian strains", "TEST", 147, 160], ["swine strains", "TEST", 180, 193], ["mutations", "PROBLEM", 241, 250], ["mutations", "OBSERVATION", 241, 250], ["reverse primer", "OBSERVATION", 274, 288], ["binding site", "OBSERVATION", 289, 301]]], ["The ability of the assay to detect these MP sequences was tested with mutated primers mimicking the observed mutations.", [["MP", "GENE_OR_GENE_PRODUCT", 41, 43], ["MP sequences", "DNA", 41, 53], ["the assay", "TEST", 15, 24], ["these MP sequences", "TEST", 35, 53], ["mutated primers", "PROBLEM", 70, 85], ["the observed mutations", "PROBLEM", 96, 118]]], ["The SVIP-MP reaction set up with the mutated FX and RX primers was able to detect the CZE/H3N8 RNA standard in all combinations, including primers with mutations localised at the very 3 0 end.Search for conserved regions in the MP sequenceOn the other hand, the octanucleotide SVIP-MP-UPL104 probe was apparently too short to tolerate any mutations within the probe-binding region of the MP segment.", [["SVIP-MP", "GENE_OR_GENE_PRODUCT", 4, 11], ["FX", "GENE_OR_GENE_PRODUCT", 45, 47], ["MP", "GENE_OR_GENE_PRODUCT", 228, 230], ["MP", "GENE_OR_GENE_PRODUCT", 388, 390], ["mutated FX and RX primers", "DNA", 37, 62], ["MP sequenceOn", "DNA", 228, 241], ["octanucleotide SVIP-MP-UPL104 probe", "DNA", 262, 297], ["MP segment", "DNA", 388, 398], ["The SVIP", "TEST", 0, 8], ["MP reaction", "PROBLEM", 9, 20], ["the mutated FX", "PROBLEM", 33, 47], ["RX primers", "TREATMENT", 52, 62], ["the CZE", "TEST", 82, 89], ["H3N8 RNA", "TREATMENT", 90, 98], ["mutations", "PROBLEM", 152, 161], ["the octanucleotide SVIP", "TEST", 258, 281], ["any mutations", "PROBLEM", 335, 348], ["FX", "OBSERVATION", 45, 47], ["region", "ANATOMY_MODIFIER", 374, 380], ["MP segment", "ANATOMY_MODIFIER", 388, 398]]], ["However, sequence alignments revealed a low degree of variation in this region as well, i.e. 0.5% in human, 0.16% in pandemic influenza A (H1N1), 0.25% in avian, 1.11% in swine and 0.85% in equine sequence pools, which suggests that these strains may escape detection.", [["influenza A", "DISEASE", 126, 137], ["human", "ORGANISM", 101, 106], ["pandemic influenza A", "ORGANISM", 117, 137], ["human", "SPECIES", 101, 106], ["pandemic influenza A", "SPECIES", 117, 137], ["swine", "SPECIES", 171, 176], ["human", "SPECIES", 101, 106], ["pandemic influenza A (H1N1)", "SPECIES", 117, 144], ["swine", "SPECIES", 171, 176], ["equine", "SPECIES", 190, 196], ["sequence alignments", "TEST", 9, 28], ["a low degree of variation in this region", "PROBLEM", 38, 78], ["equine sequence pools", "TEST", 190, 211], ["these strains", "PROBLEM", 233, 246], ["low degree", "OBSERVATION_MODIFIER", 40, 50], ["variation", "OBSERVATION_MODIFIER", 54, 63]]], ["To test this possibility, the only IA virus strain in our repository known to hold a single point mutation within the probe-binding region, A/duck/Czechoslovakia/ 56 (H4N6), was examined.", [["duck/Czechoslovakia/ 56", "ORGANISM", 142, 165], ["probe-binding region", "DNA", 118, 138], ["A/duck/Czechoslovakia/ 56", "SPECIES", 140, 165], ["IA virus strain", "PROBLEM", 35, 50], ["a single point mutation", "PROBLEM", 83, 106]]], ["As expected, this mutation was deleterious for probe binding and the A/duck/ Czechoslovakia/56 (H4N6) strain escaped detection in the real-time format of the reaction.", [["duck", "ORGANISM", 71, 75], ["Czechoslovakia/56 (H4N6)", "ORGANISM", 77, 101], ["A/duck/ Czechoslovakia/56 (H4N6)", "SPECIES", 69, 101], ["this mutation", "PROBLEM", 13, 26], ["probe binding", "PROBLEM", 47, 60], ["the reaction", "PROBLEM", 154, 166]]], ["However, agarose gel electrophoresis revealed a strong band for PCR amplicon, suggesting that the detection of the viral strain was dependent solely on the probe sequence.", [["agarose", "SIMPLE_CHEMICAL", 9, 16], ["PCR amplicon", "DNA", 64, 76], ["probe sequence", "DNA", 156, 170], ["agarose gel electrophoresis", "TEST", 9, 36], ["a strong band for PCR amplicon", "PROBLEM", 46, 76], ["the viral strain", "PROBLEM", 111, 127], ["the probe sequence", "TEST", 152, 170], ["viral strain", "OBSERVATION", 115, 127]]], ["Overall, we found 21 human, 1 pandemic influenza A (H1N1), 10 avian, 6 swine and 1 equine IA virus strains with mutations in the probe-binding region, which predicts that these strains apparently remain undetectable in this assay (Supplementary Table S3 ).Search for conserved regions in the MP sequenceIn a summary, our results of bioinformatics analysis predicted that the SVIP-MP assay developed in the present study was able to detect 99.5% of human, 99.84% of pandemic influenza A (H1N1), 99.75% of avian, 98.89% of swine, 99.15% of equine and 100% of IA viruses of other origin.", [["influenza A", "DISEASE", 39, 50], ["influenza A", "DISEASE", 474, 485], ["human", "ORGANISM", 21, 26], ["pandemic", "ORGANISM", 30, 38], ["influenza A (H1N1)", "ORGANISM", 39, 57], ["equine IA virus", "ORGANISM", 83, 98], ["MP", "GENE_OR_GENE_PRODUCT", 292, 294], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 375, 382], ["human", "ORGANISM", 448, 453], ["pandemic influenza A", "ORGANISM", 465, 485], ["swine", "ORGANISM", 521, 526], ["equine", "ORGANISM", 538, 544], ["MP sequence", "DNA", 292, 303], ["SVIP", "PROTEIN", 375, 379], ["human", "SPECIES", 21, 26], ["pandemic influenza A (H1N1", "SPECIES", 30, 56], ["avian", "SPECIES", 62, 67], ["swine", "SPECIES", 71, 76], ["equine", "SPECIES", 83, 89], ["human", "SPECIES", 448, 453], ["pandemic influenza A (H1N1", "SPECIES", 465, 491], ["avian", "SPECIES", 504, 509], ["swine", "SPECIES", 521, 526], ["equine", "SPECIES", 538, 544], ["human", "SPECIES", 21, 26], ["swine", "SPECIES", 71, 76], ["equine IA virus", "SPECIES", 83, 98], ["human", "SPECIES", 448, 453], ["pandemic influenza A (H1N1)", "SPECIES", 465, 492], ["swine", "SPECIES", 521, 526], ["equine", "SPECIES", 538, 544], ["1 pandemic influenza A (H1N1)", "PROBLEM", 28, 57], ["1 equine IA virus strains", "TREATMENT", 81, 106], ["mutations in the probe-binding region", "PROBLEM", 112, 149], ["these strains", "PROBLEM", 171, 184], ["the MP sequence", "TEST", 288, 303], ["bioinformatics analysis", "TEST", 332, 355], ["the SVIP", "TEST", 371, 379], ["MP assay", "TEST", 380, 388], ["human", "TEST", 448, 453], ["pandemic influenza A", "PROBLEM", 465, 485], ["avian", "TEST", 504, 509], ["equine", "TEST", 538, 544], ["origin", "ANATOMY_MODIFIER", 577, 583]]], ["The list of IA virus strains with mutations within the regions of interest (primers and probe-binding regions) encompassed a diverse set of IA viruses, which did not shown any significant connections or relationships in terms of IA virus subtype, year of isolation, host species or sampling location.", [["IA virus", "ORGANISM", 12, 20], ["IA", "GENE_OR_GENE_PRODUCT", 140, 142], ["IA virus", "ORGANISM", 229, 237], ["primers and probe-binding regions", "DNA", 76, 109], ["IA virus", "SPECIES", 12, 20], ["IA virus strains", "PROBLEM", 12, 28], ["mutations", "PROBLEM", 34, 43], ["IA viruses", "PROBLEM", 140, 150], ["IA virus subtype", "PROBLEM", 229, 245], ["host species", "PROBLEM", 266, 278], ["host species", "OBSERVATION", 266, 278]]], ["F forward primer, R reverse primer, P probe # Due the large variation in MP sequence length, the inclusivity was calculated by using the number of MP sequences that fully cover the primerand probe-binding regions \u00e0 The influenza A virus strains with mutations within the probe-binding region of the MP segment are listed in Table S3 (electronic supplementary material) Evaluation of the SVIP-MP assaySearch for conserved regions in the MP sequenceThe analytical sensitivity of the assay revealed consistent detection of approximately five RNA copies/reaction.", [["MP", "GENE_OR_GENE_PRODUCT", 73, 75], ["MP", "GENE_OR_GENE_PRODUCT", 147, 149], ["influenza A virus", "ORGANISM", 219, 236], ["R reverse primer", "DNA", 18, 34], ["P probe #", "DNA", 36, 45], ["MP sequences", "DNA", 147, 159], ["primerand probe", "DNA", 181, 196], ["MP segment", "DNA", 299, 309], ["SVIP", "DNA", 387, 391], ["MP assaySearch", "DNA", 392, 406], ["conserved regions", "DNA", 411, 428], ["MP sequence", "DNA", 436, 447], ["influenza A virus", "SPECIES", 219, 236], ["influenza A virus", "SPECIES", 219, 236], ["R reverse primer", "TREATMENT", 18, 34], ["the large variation in MP sequence length", "PROBLEM", 50, 91], ["MP sequences", "TREATMENT", 147, 159], ["The influenza A virus strains", "PROBLEM", 215, 244], ["mutations", "PROBLEM", 250, 259], ["Evaluation", "TEST", 369, 379], ["the SVIP", "TEST", 383, 391], ["the MP sequence", "TEST", 432, 447], ["The analytical sensitivity", "TEST", 447, 473], ["the assay", "TEST", 477, 486], ["approximately five RNA copies/reaction", "PROBLEM", 520, 558], ["large", "OBSERVATION_MODIFIER", 54, 59], ["variation", "OBSERVATION_MODIFIER", 60, 69], ["MP segment", "ANATOMY", 299, 309]]], ["The standard curve indicated a linear correlation (R 2 [ 0.99) with efficiency values of at least 1.93 (96.5%, slope -3.51), obtained in two independent runs (Supplementary Figure F1) .", [["efficiency values", "TEST", 68, 85], ["slope", "TEST", 111, 116]]], ["The specificity and cross-reactivity of the SVIP-MP RRT-PCR assay were tested using 24 avian and mammal viruses and 27 pathogenic or ubiquitous bacteria (Supplementary Table S2 ), and these samples all yielded negative results.", [["samples", "ANATOMY", 190, 197], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 44, 51], ["avian", "ORGANISM", 87, 92], ["The specificity", "TEST", 0, 15], ["cross-reactivity", "TEST", 20, 36], ["the SVIP", "TEST", 40, 48], ["MP RRT", "TEST", 49, 55], ["PCR assay", "TEST", 56, 65], ["27 pathogenic or ubiquitous bacteria", "PROBLEM", 116, 152], ["these samples", "TEST", 184, 197]]], ["Only IA virus isolates were detected; no other viruses or bacteria yielded a specific detection signal.", [["IA virus", "ORGANISM", 5, 13], ["IA virus", "SPECIES", 5, 13], ["IA virus isolates", "PROBLEM", 5, 22], ["other viruses", "PROBLEM", 41, 54], ["bacteria", "PROBLEM", 58, 66], ["virus isolates", "OBSERVATION", 8, 22], ["no other", "UNCERTAINTY", 38, 46], ["viruses", "OBSERVATION", 47, 54]]], ["In addition, no detection signal was observed with 42 IAvirus-negative specimens of avian and mammal origin.Search for conserved regions in the MP sequenceThe assay exhibited satisfactory intra-and inter-assay reproducibility, as reflected in the low SD and RSD % values ( Table 3) .Comparison of the SVIP-MP RRT-PCR with the recommended method of the European Community Reference Laboratory for Avian InfluenzaComparison of the SVIP-MP RRT-PCR with the recommended method of the CRL for Avian Influenza using an in vitro-transcribed RNA standard (diluted from 10 7 to 10 1 copies/ll) revealed relatively similar sensitivity, with deviations in the SVIP-MP C t values ranging from -0.8 to -1.5.Comparison of the SVIP-MP RRT-PCR with the recommended method of the European Community Reference Laboratory for Avian InfluenzaIn contrast, detailed comparison performed on a panel of 62 IA strains revealed strain-, real-time-platform-, and laboratory-dependent variations (data not shown).", [["specimens", "ANATOMY", 71, 80], ["Influenza", "DISEASE", 494, 503], ["IAvirus", "GENE_OR_GENE_PRODUCT", 54, 61], ["avian", "ORGANISM", 84, 89], ["MP", "GENE_OR_GENE_PRODUCT", 144, 146], ["MP sequence", "DNA", 144, 155], ["SVIP", "DNA", 301, 305], ["SVIP", "DNA", 712, 716], ["detection signal", "TEST", 16, 32], ["IAvirus", "TEST", 54, 61], ["the MP sequence", "TEST", 140, 155], ["The assay", "TEST", 155, 164], ["the SVIP", "TEST", 297, 305], ["the SVIP-MP RRT", "TREATMENT", 425, 440], ["the CRL", "TREATMENT", 476, 483], ["Avian Influenza", "PROBLEM", 488, 503], ["the SVIP", "TEST", 645, 653], ["MP C t values", "TEST", 654, 667], ["the SVIP", "TEST", 708, 716], ["a panel", "TEST", 868, 875], ["IA strains", "TEST", 882, 892], ["strain", "TEST", 902, 908], ["no", "UNCERTAINTY", 13, 15], ["mammal origin", "OBSERVATION", 94, 107], ["satisfactory", "OBSERVATION_MODIFIER", 175, 187], ["inter-assay reproducibility", "OBSERVATION", 198, 225], ["similar sensitivity", "OBSERVATION", 605, 624], ["dependent variations", "OBSERVATION", 947, 967]]], ["In this case, however, the SVIP-MP RRT-PCR showed higher sensitivity for the majority of AIV strains.Comparison of the SVIP-MP RRT-PCR with the recommended method of the European Community Reference Laboratory for Avian InfluenzaEvaluation of the SVIP-MP assay using laboratory strains and field samplesComparison of the SVIP-MP RRT-PCR with the recommended method of the European Community Reference Laboratory for Avian InfluenzaThe diagnostic quality of the SVIP-MP assay was tested on a panel of 320 IA virus strains of different origin (Supplementary Table S1 ).", [["Influenza", "DISEASE", 422, 431], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 27, 34], ["AIV", "ORGANISM", 89, 92], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 461, 468], ["SVIP", "DNA", 27, 31], ["SVIP", "DNA", 119, 123], ["SVIP", "PROTEIN", 461, 465], ["Avian Influenza", "SPECIES", 416, 431], ["AIV", "SPECIES", 89, 92], ["Avian Influenza", "SPECIES", 416, 431], ["the SVIP", "TEST", 23, 31], ["MP RRT", "TEST", 32, 38], ["PCR", "TEST", 39, 42], ["higher sensitivity", "PROBLEM", 50, 68], ["AIV strains", "PROBLEM", 89, 100], ["the SVIP", "TEST", 115, 123], ["the SVIP", "TEST", 243, 251], ["laboratory strains", "TEST", 267, 285], ["field samples", "TEST", 290, 303], ["the SVIP", "TEST", 317, 325], ["the SVIP-MP assay", "TEST", 457, 474], ["a panel", "TEST", 489, 496], ["IA virus strains", "PROBLEM", 504, 520], ["AIV strains", "OBSERVATION", 89, 100]]], ["All of the IA virus strains tested were successfully detected, indicating that the assay provided 100% efficiency using the panel of analysed viruses.", [["IA virus", "ORGANISM", 11, 19], ["IA virus", "SPECIES", 11, 19], ["the IA virus strains", "TEST", 7, 27], ["the assay", "TEST", 79, 88], ["the panel", "TEST", 120, 129], ["analysed viruses", "PROBLEM", 133, 149]]], ["Moreover, analysis of the same IA virus strains in different laboratories showed consistent results without discrepancies.Comparison of the SVIP-MP RRT-PCR with the recommended method of the European Community Reference Laboratory for Avian InfluenzaTo demonstrate the real ability of the SVIP-MP assay to detect IA viruses in field specimens, a collection of 3,423 clinical samples was tested.", [["specimens", "ANATOMY", 333, 342], ["samples", "ANATOMY", 375, 382], ["IA virus", "ORGANISM", 31, 39], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 140, 147], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 289, 296], ["samples", "CANCER", 375, 382], ["SVIP", "DNA", 140, 144], ["IA virus", "SPECIES", 31, 39], ["analysis", "TEST", 10, 18], ["the same IA virus strains", "PROBLEM", 22, 47], ["different laboratories", "TEST", 51, 73], ["discrepancies", "PROBLEM", 108, 121], ["the SVIP", "TEST", 136, 144], ["the SVIP-MP assay", "TEST", 285, 302], ["IA viruses in field specimens", "PROBLEM", 313, 342], ["a collection", "TEST", 344, 356], ["consistent results without", "UNCERTAINTY", 81, 107]]], ["The C t cutoff was adjusted to 36.", [["The C t cutoff", "TREATMENT", 0, 14]]], ["The surveillance resulted in the detection of various IA virus subtype combinations: H1N1, H2N2, H3N8, H4N6, H5N1, H5N2, H5N3, H6N5, H7N9, H9N2 and H11N9, and two equine H3N8.Comparison of the SVIP-MP RRT-PCR with the recommended method of the European Community Reference Laboratory for Avian InfluenzaSporadically, non-sigmoidal curve generation appearing at the end of the amplification (C t C 38) was observed, especially in surveillance studies.", [["H5N1, H5N2, H5N3, H6N5, H7N9, H9N2 and H11N9", "DISEASE", 109, 153], ["IA virus", "ORGANISM", 54, 62], ["H3N8", "ORGANISM", 97, 101], ["H4N6, H5N1", "ORGANISM", 103, 113], ["H5N2", "ORGANISM", 115, 119], ["H5N3, H6N5", "ORGANISM", 121, 131], ["H9N2", "ORGANISM", 139, 143], ["SVIP", "DNA", 193, 197], ["H5N1", "SPECIES", 109, 113], ["H5N2", "SPECIES", 115, 119], ["H9N2", "SPECIES", 139, 143], ["equine", "SPECIES", 163, 169], ["H3N8", "SPECIES", 97, 101], ["H4N6", "SPECIES", 103, 107], ["H5N3", "SPECIES", 121, 125], ["H6N5", "SPECIES", 127, 131], ["H7N9", "SPECIES", 133, 137], ["H11N9", "SPECIES", 148, 153], ["H3N8", "SPECIES", 170, 174], ["The surveillance", "TEST", 0, 16], ["various IA virus subtype combinations", "PROBLEM", 46, 83], ["H1N1", "PROBLEM", 85, 89], ["H2N2", "PROBLEM", 91, 95], ["H3N8", "PROBLEM", 97, 101], ["H4N6", "TEST", 103, 107], ["H5N1", "PROBLEM", 109, 113], ["H5N2", "PROBLEM", 115, 119], ["H5N3", "TEST", 121, 125], ["H6N5", "PROBLEM", 127, 131], ["H7N9", "PROBLEM", 133, 137], ["H9N2", "PROBLEM", 139, 143], ["H11N9", "TEST", 148, 153], ["two equine H3N8", "TREATMENT", 159, 174], ["the SVIP", "TEST", 189, 197], ["Avian InfluenzaSporadically", "TREATMENT", 288, 315], ["non-sigmoidal curve generation", "PROBLEM", 317, 347], ["the amplification (C t C", "TREATMENT", 372, 396], ["surveillance studies", "TEST", 429, 449]]], ["However, the anomalous curve shape and weak signal intensity made them clearly distinguishable from the true positive signal.", [["the anomalous curve shape", "PROBLEM", 9, 34], ["weak signal intensity", "PROBLEM", 39, 60], ["anomalous", "OBSERVATION_MODIFIER", 13, 22], ["curve", "OBSERVATION_MODIFIER", 23, 28], ["shape", "OBSERVATION_MODIFIER", 29, 34], ["weak", "OBSERVATION_MODIFIER", 39, 43], ["signal intensity", "OBSERVATION", 44, 60], ["positive signal", "OBSERVATION", 109, 124]]], ["Nevertheless, these artificial curves were irreproducible, and reanalysis, either by the SVIP-MP or the CRL-recommended method, gave negative results.DiscussionThe ongoing evolution of the IA virus, which generates mutations in the viral genome, requires continuous improvements in molecular detection techniques employing RT or RRT-PCR with primers and probes selected from evolutionarily highly conserved regions.", [["SVIP-MP", "GENE_OR_GENE_PRODUCT", 89, 96], ["IA virus", "ORGANISM", 189, 197], ["viral genome", "DNA", 232, 244], ["evolutionarily highly conserved regions", "DNA", 375, 414], ["IA virus", "SPECIES", 189, 197], ["these artificial curves", "TEST", 14, 37], ["the IA virus", "PROBLEM", 185, 197], ["molecular detection techniques", "TEST", 282, 312], ["RRT-PCR", "TREATMENT", 329, 336], ["primers and probes", "TEST", 342, 360], ["viral genome", "OBSERVATION", 232, 244]]], ["There are several assays based on in vitro amplification of the MP fragment of the IA virus genome [3-5, 9, 11, 16, 18, 21] .", [["MP", "GENE_OR_GENE_PRODUCT", 64, 66], ["IA virus", "ORGANISM", 83, 91], ["MP fragment", "DNA", 64, 75], ["IA virus genome", "DNA", 83, 98], ["IA virus", "SPECIES", 83, 91], ["several assays", "TEST", 10, 24], ["several", "OBSERVATION_MODIFIER", 10, 17], ["assays", "OBSERVATION", 18, 24]]], ["Most of them were developed after careful analysis, but some are not completely universal for the detection of all IA virus strains.", [["IA virus", "ORGANISM", 115, 123], ["careful analysis", "TEST", 34, 50], ["the detection", "TEST", 94, 107], ["all IA virus strains", "PROBLEM", 111, 131]]], ["We focused on the development and evaluation of an RRT-PCR assay for universal detection of IA virus that is suitable for detection the virus in various avian, human and other mammal species and attempted to prove the assay's universality, both in a bioinformatic and experimental manner.DiscussionThe primers and the probe were selected on the basis of extensive analysis of variation in the MP segment of the IA virus at the nucleotide level by aligning all of the MP sequences of the ISD database, comprising more than 10,000 sequences.DiscussionThe results revealed considerable genetic variation along the entire MP segment, which supports previous work [8, 20] , but our analysis was based on much broader sequence data.", [["nucleotide", "CHEMICAL", 427, 437], ["IA virus", "ORGANISM", 92, 100], ["human", "ORGANISM", 160, 165], ["IA virus", "ORGANISM", 411, 419], ["MP segment", "DNA", 393, 403], ["MP sequences", "DNA", 467, 479], ["ISD database", "DNA", 487, 499], ["MP segment", "DNA", 618, 628], ["avian", "SPECIES", 153, 158], ["human", "SPECIES", 160, 165], ["IA virus", "SPECIES", 92, 100], ["human", "SPECIES", 160, 165], ["IA virus", "SPECIES", 411, 419], ["evaluation", "TEST", 34, 44], ["an RRT-PCR assay", "TEST", 48, 64], ["universal detection", "TEST", 69, 88], ["IA virus", "PROBLEM", 92, 100], ["the virus", "PROBLEM", 132, 141], ["extensive analysis", "TEST", 354, 372], ["considerable genetic variation", "PROBLEM", 570, 600], ["our analysis", "TEST", 673, 685], ["broader sequence data", "TEST", 704, 725], ["MP segment", "ANATOMY_MODIFIER", 393, 403], ["IA", "ANATOMY", 411, 413], ["virus", "OBSERVATION", 414, 419], ["ISD", "OBSERVATION", 487, 490], ["considerable", "OBSERVATION_MODIFIER", 570, 582], ["genetic variation", "OBSERVATION", 583, 600], ["segment", "ANATOMY_MODIFIER", 621, 628]]], ["Although the primers and the probe were selected independently of the previously published primer and probe sequences, when compared with the published oligonucleotides [3-5, 9, 11, 16, 18, 21] , the SVIP-MP forward and reverse primer motifs were found within the probe sequence used by Spackman and colleagues [16] , and the reverse primer overlapped with the reverse primer sequence described by Ward and colleagues [18] .", [["SVIP-MP", "GENE_OR_GENE_PRODUCT", 200, 207], ["primer and probe sequences", "DNA", 91, 117], ["3-5, 9, 11, 16, 18, 21]", "DNA", 170, 193], ["SVIP-MP forward", "DNA", 200, 215], ["reverse primer motifs", "DNA", 220, 241], ["probe sequence", "DNA", 264, 278], ["reverse primer", "DNA", 326, 340], ["reverse primer sequence", "DNA", 361, 384], ["the primers", "TEST", 9, 20], ["probe sequences", "TEST", 102, 117], ["the published oligonucleotides", "TEST", 138, 168], ["the SVIP", "TEST", 196, 204], ["reverse primer motifs", "PROBLEM", 220, 241]]], ["The probe sequence used in our study was not recognised previously.", [["The probe sequence", "TEST", 0, 18], ["our study", "TEST", 27, 36]]], ["The combination of sequences for both primers and the hybridization probe used in our study was unique.DiscussionTo detect as high a proportion of known MP sequences as possible, the lengths of the oligonucleotides in the present study were noticeably below the primer and probe lengths generally applied in PCR techniques [13] .", [["MP", "GENE_OR_GENE_PRODUCT", 153, 155], ["MP sequences", "DNA", 153, 165], ["both primers", "TREATMENT", 33, 45], ["the hybridization probe", "TREATMENT", 50, 73], ["our study", "TEST", 82, 91], ["the oligonucleotides", "TREATMENT", 194, 214], ["the present study", "TEST", 218, 235], ["PCR techniques", "TEST", 308, 322]]], ["However, this approach ensured over 97% complementarity of MP sequences for the SVIP-MP-F and SVIP-MP-R primers and more than 98.9% for the SVIP-MP-UPL104 probe.", [["MP", "GENE_OR_GENE_PRODUCT", 59, 61], ["MP sequences", "DNA", 59, 71], ["SVIP-MP-F and SVIP-MP-R primers", "DNA", 80, 111], ["SVIP-MP-UPL104 probe", "DNA", 140, 160], ["MP sequences", "TEST", 59, 71], ["the SVIP", "TEST", 76, 84], ["SVIP", "TEST", 94, 98], ["the SVIP", "TEST", 136, 144]]], ["In addition, short oligonucleotides decrease the probability that mutations will appear with their binding sites during the ongoing evolution of the MP segment.DiscussionOn the other hand, the short primers and probe may significantly increase the possibility of anomalous priming, i.e. cross-reactivity, which can result in false positive results.", [["MP", "DISEASE", 149, 151], ["MP", "GENE_OR_GENE_PRODUCT", 149, 151], ["MP segment", "DNA", 149, 159], ["short oligonucleotides", "PROBLEM", 13, 35], ["mutations", "PROBLEM", 66, 75], ["their binding sites", "PROBLEM", 93, 112], ["the short primers", "PROBLEM", 189, 206], ["anomalous priming", "PROBLEM", 263, 280], ["false positive results", "PROBLEM", 325, 347], ["MP segment", "ANATOMY_MODIFIER", 149, 159], ["anomalous", "OBSERVATION", 263, 272]]], ["To minimize these undesirable effects, the annealing/hydrolysis step of the assay was optimised to 60\u00b0C, since the calculated Tm values of the SVIP-MP-F and SVIP-MP-R primers were still high, reaching 69.2 and 67.6\u00b0C. The short LNA-modified octanucleotide probe was originally designed by the manufacturer to anneal at 60\u00b0C.DiscussionThe quality examination of the primers and probe as well as optimization of the SVIP-MP assay confirmed the high sensitivity, specificity, reproducibility and universality of the present diagnostic method.", [["LNA", "CHEMICAL", 228, 231], ["SVIP-MP-F and SVIP-MP-R primers", "DNA", 143, 174], ["octanucleotide probe", "DNA", 241, 261], ["SVIP", "DNA", 414, 418], ["the annealing/hydrolysis step", "TEST", 39, 68], ["the assay", "TEST", 72, 81], ["the calculated Tm values", "TEST", 111, 135], ["the SVIP", "TEST", 139, 147], ["MP", "TEST", 148, 150], ["SVIP", "TEST", 157, 161], ["MP-R primers", "TEST", 162, 174], ["C", "TEST", 215, 216], ["The short LNA", "TEST", 218, 231], ["modified octanucleotide probe", "TREATMENT", 232, 261], ["The quality examination", "TEST", 334, 357], ["the primers", "TEST", 361, 372], ["the SVIP-MP assay", "TEST", 410, 427]]], ["The sensitivity of our assay, estimated using an in vitro-transcribed RNA standard, was comparable with that of RRT-PCR assays developed in other laboratories [4, 16] ; however, virusstrain-, real-time-platform-and laboratory-dependent variations were observed.", [["our assay", "TEST", 19, 28], ["RRT", "TEST", 112, 115], ["PCR assays", "TEST", 116, 126], ["virusstrain", "TEST", 178, 189], ["dependent variations", "OBSERVATION", 226, 246]]], ["Consistently, the best results were obtained on the Rotorgene 6000 instrument, where, in our hands, the SVIP-MP RRT-PCR showed higher sensitivity for the majority of AIV strains in comparison with the recommended method of the European Community Reference Laboratory for Avian Influenza.DiscussionWhen the specificity of the assay was tested using viral and bacterial samples and negative clinical material, the assay detected only IA viruses of different origin with a very low background signal in negative samples.DiscussionTo further evaluate the SVIP-MP RRT-PCR, the inclusivity of the assay was assessed as a measure of universality.", [["samples", "ANATOMY", 368, 375], ["samples", "ANATOMY", 509, 516], ["Avian Influenza", "DISEASE", 271, 286], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 104, 111], ["AIV", "ORGANISM", 166, 169], ["SVIP", "DNA", 104, 108], ["SVIP", "DNA", 551, 555], ["AIV", "SPECIES", 166, 169], ["the SVIP", "TEST", 100, 108], ["MP RRT", "TEST", 109, 115], ["PCR", "TEST", 116, 119], ["AIV strains", "PROBLEM", 166, 177], ["Influenza", "PROBLEM", 277, 286], ["the assay", "TEST", 321, 330], ["viral and bacterial samples", "TEST", 348, 375], ["the assay", "TEST", 408, 417], ["a very low background signal in negative samples", "PROBLEM", 468, 516], ["the SVIP", "TEST", 547, 555], ["PCR", "TEST", 563, 566], ["the assay", "TEST", 587, 596], ["hands", "ANATOMY", 93, 98], ["very", "OBSERVATION_MODIFIER", 470, 474], ["low", "OBSERVATION_MODIFIER", 475, 478], ["negative samples", "OBSERVATION", 500, 516]]], ["We defined the inclusivity as a quantitative expression of the portion of MP segments within the nucleotide sequence collection known to date that can be theoretically detected by the assay.", [["nucleotide", "CHEMICAL", 97, 107], ["nucleotide", "CHEMICAL", 97, 107], ["MP", "GENE_OR_GENE_PRODUCT", 74, 76], ["MP segments", "PROTEIN", 74, 85], ["the nucleotide sequence collection", "PROBLEM", 93, 127], ["the assay", "TEST", 180, 189], ["MP segments", "ANATOMY_MODIFIER", 74, 85]]], ["The bioinformatic analysis predicted that sequences for the forward and reverse primers match over 97% of the over 10,000 IA virus sequences tested.", [["forward and reverse primers", "DNA", 60, 87], ["IA virus sequences", "DNA", 122, 140], ["The bioinformatic analysis", "TEST", 0, 26]]], ["Thus, the sequence complementarity was not absolute, even at the strongly conserved positions.", [["the sequence complementarity", "TEST", 6, 34]]], ["Such IA virus strains were highly suspected of being escape mutants in the SVIP-MP assay.", [["IA virus", "ORGANISM", 5, 13], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 75, 82], ["SVIP", "PROTEIN", 75, 79], ["Such IA virus strains", "PROBLEM", 0, 21], ["escape mutants", "PROBLEM", 53, 67]]], ["To test our assay for universality at the experimental level we used an original approach.", [["test our assay", "TEST", 3, 17], ["an original approach", "TREATMENT", 69, 89]]], ["Due to experimental limitations, mutated primers mimicking the original mutations were synthesized rather than preparing mutated MP sequences.", [["MP", "GENE_OR_GENE_PRODUCT", 129, 131], ["mutated MP sequences", "DNA", 121, 141], ["experimental limitations", "PROBLEM", 7, 31], ["mutated primers", "PROBLEM", 33, 48], ["the original mutations", "PROBLEM", 59, 81], ["mutated MP sequences", "TEST", 121, 141]]], ["The experiments confirmed that all mutated primers amplified the RNA standard successfully, but deviations in C t were observed.", [["all mutated primers", "TREATMENT", 31, 50], ["deviations in C t", "PROBLEM", 96, 113]]], ["These deviations ranged from 3.1, 4.2 and 3.6 C t values for mutated forward and 3, 2.9 and 2.8 for mutated reverse primers, respectively, observed at three dilutions (10 2 , 10 4 and 10 6 copies/ reaction).", [["These deviations", "TEST", 0, 16], ["C t values", "TEST", 46, 56], ["mutated reverse primers", "PROBLEM", 100, 123]]], ["Taken together, we conclude that the primers developed in our study had 100% inclusivity on the basis of retrospective sequence data.DiscussionDetailed analysis of IA virus strains with mutations within the regions of interest indicated sporadic variation without any correlation to the year of isolation, subtype, host species or sampling location.", [["IA virus", "ORGANISM", 164, 172], ["IA virus", "SPECIES", 164, 172], ["the primers", "TEST", 33, 44], ["our study", "TEST", 58, 67], ["retrospective sequence data", "TEST", 105, 132], ["IA virus strains", "PROBLEM", 164, 180], ["mutations", "PROBLEM", 186, 195], ["sporadic variation", "PROBLEM", 237, 255], ["host species", "OBSERVATION", 315, 327]]], ["Nevertheless, the strains carrying mutations within the probe-binding region apparently escaped detection.", [["the strains carrying mutations", "PROBLEM", 14, 44]]], ["Therefore, the inclusivity of the SVIP-MP assay is determined solely via probe complementarity.DiscussionThe universality of the primers and the specificity of the probe were confirmed by experiments on a broad collection of 320 IA virus strains of various reservoirs, geographic origin and collection date.", [["SVIP-MP", "GENE_OR_GENE_PRODUCT", 34, 41], ["SVIP", "PROTEIN", 34, 38], ["the SVIP", "TEST", 30, 38], ["MP assay", "TEST", 39, 47], ["a broad collection", "PROBLEM", 203, 221], ["various", "OBSERVATION_MODIFIER", 249, 256], ["reservoirs", "OBSERVATION_MODIFIER", 257, 267]]], ["Since all of the strains were detected successfully, the predicted inclusivity of the SVIP-MP assay was confirmed.", [["SVIP-MP", "GENE_OR_GENE_PRODUCT", 86, 93], ["SVIP", "PROTEIN", 86, 90], ["the strains", "PROBLEM", 13, 24], ["the SVIP-MP assay", "TEST", 82, 99]]], ["The newly developed assay was successfully integrated into the IA virus surveillance system in the Czech Republic during 2007-2009 and in the investigation of three avian H5N1 outbreak, one avian H7N9 outbreak, and one equine H3N8 outbreak.", [["H5N1", "DISEASE", 171, 175], ["avian H7N9 outbreak", "DISEASE", 190, 209], ["avian H5N1 outbreak", "SPECIES", 165, 184], ["avian", "SPECIES", 190, 195], ["equine", "SPECIES", 219, 225], ["H7N9", "SPECIES", 196, 200], ["H3N8", "SPECIES", 226, 230], ["assay", "TEST", 20, 25], ["H5N1", "OBSERVATION", 171, 175]]], ["Finally, the assay was used for the detection of 30 cases of pandemic influenza A (H1N1) in the Czech Republic.DiscussionIn summary, our study indicates that the SVIP-MP assay based on TaqMan real-time RT-PCR is characterized by excellent parameters and provides a reliable, universal and unambiguous tool for the detection of IA viruses from avian, human and other mammal species.", [["influenza A", "DISEASE", 70, 81], ["influenza A", "ORGANISM", 70, 81], ["SVIP-MP", "GENE_OR_GENE_PRODUCT", 162, 169], ["IA viruses", "ORGANISM", 327, 337], ["human", "ORGANISM", 350, 355], ["SVIP", "DNA", 162, 166], ["pandemic influenza A (H1N1", "SPECIES", 61, 87], ["avian", "SPECIES", 343, 348], ["human", "SPECIES", 350, 355], ["human", "SPECIES", 350, 355], ["the assay", "TEST", 9, 18], ["the detection", "TEST", 32, 45], ["pandemic influenza A", "TREATMENT", 61, 81], ["our study", "TEST", 133, 142], ["the SVIP-MP assay", "TEST", 158, 175], ["TaqMan", "TEST", 185, 191], ["RT-PCR", "TEST", 202, 208], ["IA viruses", "PROBLEM", 327, 337], ["mammal species", "OBSERVATION", 366, 380]]], ["Since the assay was carefully evaluated and is used in surveillance analysis, we believe that it can become a method of choice for surveillance or confirmation purposes in other influenza virus diagnostic laboratories. and Dr. Iva Bernardyova, Dr. Vlastimil Krivda and Dr. Kamil Sedlak from the State Veterinary Institute Prague for providing samples for validation purposes.", [["samples", "ANATOMY", 343, 350], ["the assay", "TEST", 6, 15], ["surveillance analysis", "TEST", 55, 76], ["surveillance or confirmation purposes", "TEST", 131, 168], ["validation purposes", "TEST", 355, 374]]], ["We acknowledge the kind assistance of Dr. Miroslav Zoul and Dr. Dobromila Molinkova in collection of equine field samples.", [["samples", "ANATOMY", 114, 121], ["equine", "ORGANISM", 101, 107], ["equine", "SPECIES", 101, 107]]], ["We also thank Dr. Dagmar Sirova for editorial assistance and all contributors of the GenBank.", [["editorial assistance", "TREATMENT", 36, 56]]], ["In the study were included IA virus strains from the unique collection, founded in 1956, of the National Reference Laboratory for Influenza, National Institute of Public Health, Czech Republic.", [["Influenza", "DISEASE", 130, 139], ["the study", "TEST", 3, 12], ["IA virus strains", "PROBLEM", 27, 43], ["Influenza", "PROBLEM", 130, 139], ["unique", "OBSERVATION_MODIFIER", 53, 59], ["collection", "OBSERVATION", 60, 70]]], ["The collection was created thanks to the lifelong efforts of Dr. Bela Tumova , who was among the first to study the ecology of influenza viruses.", [["influenza viruses", "DISEASE", 127, 144], ["influenza viruses", "ORGANISM", 127, 144], ["influenza viruses", "PROBLEM", 127, 144], ["collection", "OBSERVATION", 4, 14], ["influenza viruses", "OBSERVATION", 127, 144]]]], "6774ccc4c8730e2f8bc03e04ac48f313af55d6eb": [["INTRODUCTIONIntestinal viral pathogens have an enormous social and economic impact worldwide.", [["INTRODUCTIONIntestinal viral pathogens", "PROBLEM", 0, 38], ["enormous", "OBSERVATION_MODIFIER", 47, 55], ["social", "OBSERVATION_MODIFIER", 56, 62]]], ["Gastrointestinal viruses are excreted with the feces and are transmitted by the orofecal route, by direct contact with infected individuals or by contact or consumption of water or contaminated food.", [["Gastrointestinal", "ANATOMY", 0, 16], ["feces", "ANATOMY", 47, 52], ["orofecal", "ANATOMY", 80, 88], ["feces", "ORGANISM_SUBSTANCE", 47, 52], ["Gastrointestinal viruses", "PROBLEM", 0, 24], ["viruses", "OBSERVATION", 17, 24]]], ["Intestinal viral infections coursing with diarrhea are commonly treated by oral or parenteral rehydrating therapies, although alternative treatments such as those based on probiotics are gaining interest for both the treatment and prevention of infectious diarrheas.", [["Intestinal", "ANATOMY", 0, 10], ["oral", "ANATOMY", 75, 79], ["Intestinal viral infections", "DISEASE", 0, 27], ["diarrhea", "DISEASE", 42, 50], ["diarrheas", "DISEASE", 256, 265], ["oral", "ORGANISM_SUBDIVISION", 75, 79], ["Intestinal viral infections", "PROBLEM", 0, 27], ["diarrhea", "PROBLEM", 42, 50], ["oral or parenteral rehydrating therapies", "TREATMENT", 75, 115], ["alternative treatments", "TREATMENT", 126, 148], ["probiotics", "TREATMENT", 172, 182], ["the treatment", "TREATMENT", 213, 226], ["infectious diarrheas", "PROBLEM", 245, 265], ["viral", "OBSERVATION_MODIFIER", 11, 16], ["infections", "OBSERVATION", 17, 27], ["diarrhea", "OBSERVATION", 42, 50], ["infectious", "OBSERVATION_MODIFIER", 245, 255]]], ["Probiotics are live bacteria that generally belong to the lactic acid bacteria group or to the bifidobacteria, but also include some bacilli or yeasts.", [["lactic acid", "CHEMICAL", 58, 69], ["lactic acid", "CHEMICAL", 58, 69], ["lactic acid", "SIMPLE_CHEMICAL", 58, 69], ["bifidobacteria", "SIMPLE_CHEMICAL", 95, 109], ["Probiotics", "TREATMENT", 0, 10], ["live bacteria", "PROBLEM", 15, 28], ["the lactic acid bacteria group", "PROBLEM", 54, 84], ["the bifidobacteria", "PROBLEM", 91, 109], ["some bacilli", "PROBLEM", 128, 140], ["yeasts", "PROBLEM", 144, 150], ["bacilli", "OBSERVATION", 133, 140], ["yeasts", "OBSERVATION", 144, 150]]], ["In general, these microorganisms are common members of the intestinal microbiota but they are also employed in the manufacturing of many fermented foods.", [["intestinal microbiota", "ANATOMY", 59, 80], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 59, 80], ["microorganisms", "OBSERVATION", 18, 32], ["intestinal microbiota", "ANATOMY", 59, 80]]], ["Numerous reports have identified several bacterial probiotic strains as useful tools for the treatment of intestinal disorders and there are many clinical studies indicating that specific probiotic strains, such as Lactobacillus rhamnosus GG (LGG) or Bifidobacterium Bb12, have a positive impact on gastroenteritis.", [["intestinal", "ANATOMY", 106, 116], ["intestinal disorders", "DISEASE", 106, 126], ["Lactobacillus rhamnosus GG", "CHEMICAL", 215, 241], ["LGG", "CHEMICAL", 243, 246], ["Bifidobacterium Bb12", "CHEMICAL", 251, 271], ["gastroenteritis", "DISEASE", 299, 314], ["intestinal", "ORGAN", 106, 116], ["Lactobacillus rhamnosus GG", "ORGANISM", 215, 241], ["LGG", "SIMPLE_CHEMICAL", 243, 246], ["Bifidobacterium Bb12", "ORGANISM", 251, 271], ["Lactobacillus rhamnosus", "SPECIES", 215, 238], ["Lactobacillus rhamnosus", "SPECIES", 215, 238], ["several bacterial probiotic strains", "PROBLEM", 33, 68], ["intestinal disorders", "PROBLEM", 106, 126], ["many clinical studies", "TEST", 141, 162], ["specific probiotic strains", "PROBLEM", 179, 205], ["Lactobacillus rhamnosus GG", "TEST", 215, 241], ["Bifidobacterium Bb12", "TEST", 251, 271], ["gastroenteritis", "PROBLEM", 299, 314], ["several", "OBSERVATION_MODIFIER", 33, 40], ["bacterial probiotic strains", "OBSERVATION", 41, 68], ["intestinal", "ANATOMY", 106, 116], ["positive impact", "OBSERVATION_MODIFIER", 280, 295], ["gastroenteritis", "OBSERVATION", 299, 314]]], ["Several animal and clinical trials with these and other strains have documented a reduced severity and duration of diarrhea after oral intake.", [["oral", "ANATOMY", 130, 134], ["diarrhea", "DISEASE", 115, 123], ["oral", "ORGANISM_SUBDIVISION", 130, 134], ["these and other strains", "PROBLEM", 40, 63], ["a reduced severity", "PROBLEM", 80, 98], ["diarrhea", "PROBLEM", 115, 123], ["reduced", "OBSERVATION_MODIFIER", 82, 89], ["severity", "OBSERVATION_MODIFIER", 90, 98]]], ["Most of the positive effects are believed to be based on immunoregulation, which gives way to enhanced cellular immune responses or higher levels of virusspecific immunoglobulins.", [["cellular", "ANATOMY", 103, 111], ["cellular", "CELL", 103, 111], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 163, 178], ["virusspecific immunoglobulins", "PROTEIN", 149, 178], ["virusspecific immunoglobulins", "TREATMENT", 149, 178], ["positive", "OBSERVATION", 12, 20], ["believed to be", "UNCERTAINTY", 33, 47]]], ["However, other mechanisms exist for explaining the antagonistic effect of probiotics against viral infections, which include a direct interaction of viruses with bacteria and the blocking of specific viral receptors in target cells.INTRODUCTIONEvidence obtained from viruses that do not replicate in the gastrointestinal tract and, more recently, from gastrointestinal viruses, demonstrate that some viruses take advantage of microbiota-triggered processes or microbiota-derived substances for their replication.", [["cells", "ANATOMY", 226, 231], ["gastrointestinal tract", "ANATOMY", 304, 326], ["gastrointestinal", "ANATOMY", 352, 368], ["viral infections", "DISEASE", 93, 109], ["gastrointestinal viruses", "DISEASE", 352, 376], ["cells", "CELL", 226, 231], ["gastrointestinal tract", "ORGAN", 304, 326], ["gastrointestinal viruses", "ORGANISM", 352, 376], ["viral receptors", "PROTEIN", 200, 215], ["target cells", "CELL_TYPE", 219, 231], ["probiotics", "TREATMENT", 74, 84], ["viral infections", "PROBLEM", 93, 109], ["a direct interaction of viruses", "PROBLEM", 125, 156], ["bacteria", "PROBLEM", 162, 170], ["specific viral receptors in target cells", "PROBLEM", 191, 231], ["viruses", "PROBLEM", 267, 274], ["gastrointestinal viruses", "PROBLEM", 352, 376], ["some viruses", "PROBLEM", 395, 407], ["their replication", "TREATMENT", 494, 511], ["target cells", "OBSERVATION", 219, 231], ["viruses", "OBSERVATION", 267, 274], ["gastrointestinal tract", "ANATOMY", 304, 326], ["gastrointestinal", "ANATOMY", 352, 368], ["viruses", "OBSERVATION", 369, 376]]], ["However, in other cases viral infection is inhibited by mechanisms dependent on the presence of the intestinal microbiota.", [["intestinal", "ANATOMY", 100, 110], ["infection", "DISEASE", 30, 39], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 100, 121], ["viral infection", "PROBLEM", 24, 39], ["infection", "OBSERVATION", 30, 39], ["intestinal microbiota", "ANATOMY", 100, 121]]], ["This dual role of the microbiota can be exploited, together with the use of probiotics, for developing new therapeutic strategies to fight against viral infections.GASTROINTESTINAL VIRUSESA great variety of viruses target the gastrointestinal tract, although not all of them cause gastroenteritis.", [["gastrointestinal tract", "ANATOMY", 226, 248], ["viral infections", "DISEASE", 147, 163], ["gastrointestinal tract", "DISEASE", 226, 248], ["gastroenteritis", "DISEASE", 281, 296], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 226, 248], ["probiotics", "TREATMENT", 76, 86], ["viral infections", "PROBLEM", 147, 163], ["gastroenteritis", "PROBLEM", 281, 296], ["infections", "OBSERVATION", 153, 163], ["viruses", "OBSERVATION", 207, 214], ["gastrointestinal tract", "ANATOMY", 226, 248], ["gastroenteritis", "OBSERVATION", 281, 296]]], ["The most important enteric viruses correspond to rotaviruses (RV, Reoviridae family), noroviruses (NoV, Caliciviridae family), enteric adenoviruses (Adenoviridae family), astroviruses (Astroviridae family), and enteroviruses (Picornaviridae family) (Buesa and Rodriguez Diaz, 2006) .", [["enteric adenoviruses", "DISEASE", 127, 147], ["enteroviruses", "DISEASE", 211, 224], ["rotaviruses", "ORGANISM", 49, 60], ["NoV", "ORGANISM", 99, 102], ["Caliciviridae", "GENE_OR_GENE_PRODUCT", 104, 117], ["enteric adenoviruses", "ORGANISM", 127, 147], ["Adenoviridae", "GENE_OR_GENE_PRODUCT", 149, 161], ["astroviruses", "GENE_OR_GENE_PRODUCT", 171, 183], ["Astroviridae", "GENE_OR_GENE_PRODUCT", 185, 197], ["noroviruses", "SPECIES", 86, 97], ["RV", "SPECIES", 62, 64], ["NoV", "SPECIES", 99, 102], ["rotaviruses", "PROBLEM", 49, 60], ["noroviruses", "PROBLEM", 86, 97], ["astroviruses", "PROBLEM", 171, 183], ["viruses", "OBSERVATION", 27, 34], ["rotaviruses", "OBSERVATION", 49, 60]]], ["NoV and RV are by far the most relevant viral groups responsible for gastroenteritis and due to their relevance and to the existence of some clinical trials with probiotics, they will be the focus of this chapter.", [["gastroenteritis", "DISEASE", 69, 84], ["NoV", "ORGANISM", 0, 3], ["RV", "ORGAN", 8, 10], ["NoV", "SPECIES", 0, 3], ["gastroenteritis", "PROBLEM", 69, 84], ["probiotics", "TREATMENT", 162, 172], ["RV", "ANATOMY", 8, 10]]], ["However, at some locations enteric adenoviruses of defined subtypes are the second agents responsible for infantile gastroenteritis and astroviruses may be responsible of up to 9% of the viral diarrhea incidence in developed and developing countries.", [["infantile gastroenteritis", "DISEASE", 106, 131], ["astroviruses", "DISEASE", 136, 148], ["diarrhea", "DISEASE", 193, 201], ["adenoviruses", "ORGANISM", 35, 47], ["the second agents", "TREATMENT", 72, 89], ["infantile gastroenteritis", "PROBLEM", 106, 131], ["astroviruses", "PROBLEM", 136, 148], ["the viral diarrhea", "PROBLEM", 183, 201], ["adenoviruses", "OBSERVATION", 35, 47], ["gastroenteritis", "OBSERVATION", 116, 131], ["astroviruses", "OBSERVATION", 136, 148], ["viral", "OBSERVATION_MODIFIER", 187, 192], ["diarrhea", "OBSERVATION", 193, 201]]], ["One member of the kuboviruses (enteroviruses) is responsible for gastroenteritis outbreaks due to the consumption of contaminated food (Aichi virus).", [["enteroviruses", "DISEASE", 31, 44], ["gastroenteritis", "DISEASE", 65, 80], ["kuboviruses", "GENE_OR_GENE_PRODUCT", 18, 29], ["enteroviruses", "ORGANISM", 31, 44], ["food", "ORGANISM_SUBDIVISION", 130, 134], ["Aichi virus", "ORGANISM", 136, 147], ["Aichi virus", "SPECIES", 136, 147], ["the kuboviruses (enteroviruses", "PROBLEM", 14, 44], ["gastroenteritis outbreaks", "PROBLEM", 65, 90]]], ["Finally, an important representative of enteroviruses, the poliovirus, replicates at the intestine, being primarily asymptomatic, although it finally can target the nervous system resulting in poliomyelitis.", [["intestine", "ANATOMY", 89, 98], ["nervous system", "ANATOMY", 165, 179], ["enteroviruses", "DISEASE", 40, 53], ["poliomyelitis", "DISEASE", 193, 206], ["enteroviruses", "ORGANISM", 40, 53], ["intestine", "ORGAN", 89, 98], ["nervous system", "ANATOMICAL_SYSTEM", 165, 179], ["enteroviruses", "PROBLEM", 40, 53], ["the poliovirus", "PROBLEM", 55, 69], ["poliomyelitis", "PROBLEM", 193, 206], ["enteroviruses", "OBSERVATION", 40, 53], ["poliovirus", "OBSERVATION", 59, 69], ["intestine", "ANATOMY", 89, 98], ["asymptomatic", "OBSERVATION", 116, 128], ["poliomyelitis", "OBSERVATION", 193, 206]]], ["With the exception of poliovirus, data on the interaction of human gastrointestinal viruses different than RV and NoV with the microbiota or are the so-called P-particles.", [["gastrointestinal", "ANATOMY", 67, 83], ["poliovirus", "ORGANISM", 22, 32], ["human", "ORGANISM", 61, 66], ["gastrointestinal viruses", "ORGANISM", 67, 91], ["human", "SPECIES", 61, 66], ["poliovirus", "SPECIES", 22, 32], ["human", "SPECIES", 61, 66], ["RV", "SPECIES", 107, 109], ["NoV", "SPECIES", 114, 117], ["poliovirus", "PROBLEM", 22, 32], ["human gastrointestinal viruses", "PROBLEM", 61, 91], ["poliovirus", "OBSERVATION", 22, 32], ["gastrointestinal", "ANATOMY", 67, 83], ["viruses", "OBSERVATION", 84, 91]]], ["It is known that the C-terminal portion of the VP1 protein, of about 300 amino acids (protruding domain or P domain), is able to form dimers and autoassembles into subviral particles of icosahedric symmetry called P-particles, which are 20 nm in diameter and consist in 12 P-domain dimers.", [["amino acids", "CHEMICAL", 73, 84], ["C", "CHEMICAL", 21, 22], ["amino acids", "CHEMICAL", 73, 84], ["VP1", "GENE_OR_GENE_PRODUCT", 47, 50], ["amino acids", "AMINO_ACID", 73, 84], ["C-terminal portion", "PROTEIN", 21, 39], ["VP1 protein", "PROTEIN", 47, 58], ["protruding domain", "PROTEIN", 86, 103], ["P domain", "PROTEIN", 107, 115], ["P-domain dimers", "PROTEIN", 273, 288], ["the VP1 protein", "TEST", 43, 58], ["amino acids", "TEST", 73, 84], ["protruding domain or P domain)", "PROBLEM", 86, 116], ["terminal", "ANATOMY_MODIFIER", 23, 31], ["VP1 protein", "ANATOMY", 47, 58], ["subviral particles", "OBSERVATION", 164, 182], ["20 nm", "OBSERVATION_MODIFIER", 237, 242]]], ["Noroviral P-particles retain the capacity to bind the receptors, which are specific for each NoV genotype and they are able to induce the production of blocking antibodies.", [["NoV", "ORGANISM", 93, 96], ["blocking antibodies", "PROTEIN", 152, 171], ["Noroviral P-particles", "TREATMENT", 0, 21], ["blocking antibodies", "PROBLEM", 152, 171]]], ["This makes them, together with their easy production in prokaryotic host like Escherichia coli, useful tools for the study of binding specificity and in vaccine development (Tan et al., 2008) .", [["Escherichia coli", "ORGANISM", 78, 94], ["Escherichia coli", "SPECIES", 78, 94], ["Escherichia coli", "SPECIES", 78, 94], ["Escherichia coli", "PROBLEM", 78, 94], ["the study", "TEST", 113, 122], ["binding specificity", "TEST", 126, 145], ["Escherichia coli", "OBSERVATION", 78, 94]]], ["The third model for NoV is constituted by murine NoV (MNoV, genogroup GV) or feline calicivirus.", [["feline calicivirus", "DISEASE", 77, 95], ["NoV", "ORGANISM", 20, 23], ["murine NoV", "ORGANISM", 42, 52], ["MNoV", "GENE_OR_GENE_PRODUCT", 54, 58], ["genogroup GV", "ORGANISM", 60, 72], ["feline calicivirus", "ORGANISM", 77, 95], ["murine", "SPECIES", 42, 48], ["feline calicivirus", "SPECIES", 77, 95], ["NoV", "SPECIES", 20, 23], ["murine NoV", "SPECIES", 42, 52], ["MNoV", "SPECIES", 54, 58], ["feline calicivirus", "SPECIES", 77, 95], ["feline calicivirus", "PROBLEM", 77, 95], ["feline calicivirus", "OBSERVATION", 77, 95]]], ["MNoV are able to in vitro infect B cells and macrophages and produce asymptomatic infections in mice with concomitant viral shedding in feces.", [["B cells", "ANATOMY", 33, 40], ["macrophages", "ANATOMY", 45, 56], ["feces", "ANATOMY", 136, 141], ["infections", "DISEASE", 82, 92], ["MNoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["B cells", "CELL", 33, 40], ["macrophages", "CELL", 45, 56], ["mice", "ORGANISM", 96, 100], ["feces", "ORGANISM_SUBSTANCE", 136, 141], ["MNoV", "PROTEIN", 0, 4], ["B cells", "CELL_TYPE", 33, 40], ["macrophages", "CELL_TYPE", 45, 56], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 96, 100], ["macrophages", "PROBLEM", 45, 56], ["asymptomatic infections in mice", "PROBLEM", 69, 100], ["concomitant viral shedding in feces", "PROBLEM", 106, 141], ["asymptomatic", "OBSERVATION_MODIFIER", 69, 81], ["infections", "OBSERVATION", 82, 92], ["viral shedding", "OBSERVATION", 118, 132]]], ["These kinds of NoV surrogates constitute the almost exclusive alternative (with the exception of the infection in volunteers) for the study of inactivation of NoV after different food treatments.", [["infection", "DISEASE", 101, 110], ["NoV", "ORGANISM", 15, 18], ["volunteers", "ORGANISM", 114, 124], ["NoV", "ORGANISM", 159, 162], ["NoV", "SPECIES", 159, 162], ["NoV surrogates", "TREATMENT", 15, 29], ["the infection", "PROBLEM", 97, 110], ["the study", "TEST", 130, 139], ["different food treatments", "TREATMENT", 169, 194], ["NoV", "OBSERVATION", 15, 18], ["infection", "OBSERVATION", 101, 110]]], ["However, the susceptibility of MNoV to different temperatures, environmental, or food processing conditions is totally different from those of human NoV, which questions the utility of this approach (Richards, 2012) .GASTROINTESTINAL VIRUSESFor cellular attachment, NoV recognize glycoconjugates present at the cell surface that are part of the ABH system of human histo-blood group antigens (HBGA) and Lewis antigens (a, b, x, and y) , which are present in the saliva, gastroduodenal mucosa, and erythrocytes.", [["cellular", "ANATOMY", 245, 253], ["cell surface", "ANATOMY", 311, 323], ["blood", "ANATOMY", 371, 376], ["saliva", "ANATOMY", 462, 468], ["gastroduodenal mucosa", "ANATOMY", 470, 491], ["erythrocytes", "ANATOMY", 497, 509], ["MNoV", "CHEMICAL", 31, 35], ["human", "ORGANISM", 143, 148], ["cellular", "CELL", 245, 253], ["cell surface", "CELLULAR_COMPONENT", 311, 323], ["ABH", "GENE_OR_GENE_PRODUCT", 345, 348], ["human", "ORGANISM", 359, 364], ["histo-blood group antigens", "GENE_OR_GENE_PRODUCT", 365, 391], ["HBGA", "GENE_OR_GENE_PRODUCT", 393, 397], ["Lewis antigens", "GENE_OR_GENE_PRODUCT", 403, 417], ["b", "GENE_OR_GENE_PRODUCT", 422, 423], ["saliva", "ORGANISM_SUBSTANCE", 462, 468], ["gastroduodenal mucosa", "MULTI-TISSUE_STRUCTURE", 470, 491], ["erythrocytes", "CELL", 497, 509], ["human histo-blood group antigens", "PROTEIN", 359, 391], ["HBGA", "PROTEIN", 393, 397], ["Lewis antigens", "PROTEIN", 403, 417], ["erythrocytes", "CELL_TYPE", 497, 509], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 359, 364], ["human NoV", "SPECIES", 143, 152], ["human", "SPECIES", 359, 364], ["blood group antigens", "TEST", 371, 391], ["HBGA", "TEST", 393, 397], ["Lewis antigens", "TEST", 403, 417], ["erythrocytes", "PROBLEM", 497, 509], ["cellular attachment", "OBSERVATION", 245, 264], ["saliva", "ANATOMY", 462, 468], ["gastroduodenal mucosa", "ANATOMY", 470, 491], ["erythrocytes", "ANATOMY", 497, 509]]], ["Differences in the ABH system among individuals have an impact on the susceptibility to infection because each NoV genotype displays a different binding profile (Huang et al., 2005) .", [["infection", "DISEASE", 88, 97], ["ABH", "GENE_OR_GENE_PRODUCT", 19, 22], ["NoV", "ORGANISM", 111, 114], ["the ABH system", "TEST", 15, 29], ["the susceptibility to infection", "PROBLEM", 66, 97], ["infection", "OBSERVATION", 88, 97]]], ["Additionally, the secretor status is also important and individuals with mutations in the FUT-2 gene, which encodes the fucosyltransferase involved in H-antigen synthesis in secretions, lack ABH antigens in saliva and epithelial cells and are less susceptible to NoV infections.", [["secretions", "ANATOMY", 174, 184], ["saliva", "ANATOMY", 207, 213], ["epithelial cells", "ANATOMY", 218, 234], ["infections", "DISEASE", 267, 277], ["secretor", "GENE_OR_GENE_PRODUCT", 18, 26], ["FUT-2", "GENE_OR_GENE_PRODUCT", 90, 95], ["fucosyltransferase", "GENE_OR_GENE_PRODUCT", 120, 138], ["H-antigen", "GENE_OR_GENE_PRODUCT", 151, 160], ["ABH antigens", "GENE_OR_GENE_PRODUCT", 191, 203], ["saliva", "ORGANISM_SUBSTANCE", 207, 213], ["epithelial cells", "CELL", 218, 234], ["NoV", "ORGANISM", 263, 266], ["FUT-2 gene", "DNA", 90, 100], ["fucosyltransferase", "PROTEIN", 120, 138], ["ABH antigens", "PROTEIN", 191, 203], ["epithelial cells", "CELL_TYPE", 218, 234], ["NoV", "SPECIES", 263, 266], ["mutations", "PROBLEM", 73, 82], ["the fucosyltransferase", "TEST", 116, 138], ["secretions", "PROBLEM", 174, 184], ["lack ABH antigens in saliva and epithelial cells", "PROBLEM", 186, 234], ["NoV infections", "PROBLEM", 263, 277], ["epithelial cells", "OBSERVATION", 218, 234], ["infections", "OBSERVATION", 267, 277]]], ["However, NoV cellular tropism is not known and it is not clear whether the binding to HBGA on cell surfaces is only aiding in cellular attachment or if it is also involved in the subsequent infection process.MICROBIOTA OF THE GASTROINTESTINAL TRACT AND VIRUS SUSCEPTIBILITYThe gastrointestinal tract constitutes one of the most complex ecosystems with a huge bacterial population that at some locations can reach up to 10 12 bacteria per gram of content.", [["cellular", "ANATOMY", 13, 21], ["cell surfaces", "ANATOMY", 94, 107], ["cellular", "ANATOMY", 126, 134], ["gastrointestinal tract", "ANATOMY", 277, 299], ["infection", "DISEASE", 190, 199], ["gastrointestinal tract", "DISEASE", 277, 299], ["NoV", "ORGANISM", 9, 12], ["cellular", "CELL", 13, 21], ["HBGA", "GENE_OR_GENE_PRODUCT", 86, 90], ["cell", "CELL", 94, 98], ["cellular", "CELL", 126, 134], ["gastrointestinal tract", "PATHOLOGICAL_FORMATION", 277, 299], ["HBGA", "PROTEIN", 86, 90], ["NoV cellular tropism", "PROBLEM", 9, 29], ["the binding", "PROBLEM", 71, 82], ["cell surfaces", "TREATMENT", 94, 107], ["the subsequent infection process", "PROBLEM", 175, 207], ["a huge bacterial population", "PROBLEM", 352, 379], ["cellular tropism", "OBSERVATION", 13, 29], ["infection", "OBSERVATION", 190, 199], ["GASTROINTESTINAL TRACT", "ANATOMY", 226, 248], ["VIRUS", "OBSERVATION", 253, 258], ["gastrointestinal tract", "ANATOMY", 277, 299], ["most complex", "OBSERVATION_MODIFIER", 323, 335], ["ecosystems", "OBSERVATION", 336, 346], ["huge", "OBSERVATION_MODIFIER", 354, 358], ["bacterial", "OBSERVATION_MODIFIER", 359, 368], ["population", "OBSERVATION", 369, 379]]], ["Despite this complexity, the phylogenetic diversity is limited and most of the bacterial species present belong to the phyla Bacteroidetes and Firmicutes (Blottiere et al., 2013) .", [["the phylogenetic diversity", "PROBLEM", 25, 51], ["the bacterial species", "PROBLEM", 75, 96], ["phylogenetic diversity", "OBSERVATION", 29, 51], ["bacterial species", "OBSERVATION", 79, 96], ["phyla Bacteroidetes", "ANATOMY", 119, 138]]], ["The bacterial composition is dependent on the individual and is affected by many factors such as the genetics, diet, and health status.", [["The bacterial composition", "PROBLEM", 0, 25], ["bacterial composition", "OBSERVATION", 4, 25]]], ["However, a core microbiome is shared between individuals, which probably reflects the important physiological and immune functions attributed to the microbiota.", [["probably reflects", "UNCERTAINTY", 64, 81]]], ["Imbalances in its composition, referred to as dysbiosis, have been linked to a series of pathologies that include inflammatory bowel diseases, obesity, or diabetes, among others (Collado et al., 2009; de Moreno de LeBlanc and LeBlanc, 2014) .", [["bowel", "ANATOMY", 127, 132], ["dysbiosis", "DISEASE", 46, 55], ["inflammatory bowel diseases", "DISEASE", 114, 141], ["obesity", "DISEASE", 143, 150], ["diabetes", "DISEASE", 155, 163], ["bowel", "ORGAN", 127, 132], ["dysbiosis", "PROBLEM", 46, 55], ["pathologies", "PROBLEM", 89, 100], ["inflammatory bowel diseases", "PROBLEM", 114, 141], ["obesity", "PROBLEM", 143, 150], ["diabetes", "PROBLEM", 155, 163], ["inflammatory", "OBSERVATION_MODIFIER", 114, 126], ["bowel", "ANATOMY", 127, 132], ["diseases", "OBSERVATION", 133, 141], ["obesity", "OBSERVATION", 143, 150], ["diabetes", "OBSERVATION", 155, 163]]], ["The intestinal immune system has to remain hyporesponsive to the endogenous microbiota and a complex cross talk is established between the microbiota and epithelium that assures this and, at the same time, prepares the immune system to respond against microbial pathogens.", [["intestinal immune system", "ANATOMY", 4, 28], ["epithelium", "ANATOMY", 154, 164], ["immune system", "ANATOMY", 219, 232], ["intestinal", "ORGAN", 4, 14], ["epithelium", "TISSUE", 154, 164], ["hyporesponsive", "PROBLEM", 43, 57], ["the immune system", "TREATMENT", 215, 232], ["microbial pathogens", "PROBLEM", 252, 271], ["intestinal immune", "ANATOMY", 4, 21], ["hyporesponsive", "OBSERVATION", 43, 57]]], ["The host immune system is able to recognize bacterial-derived products (cell wall components such as peptidoglycan or lipopolysaccharide (LPS) or bacterial DNA) via specialized receptors such as the tolllike receptors (TLR).", [["cell wall", "ANATOMY", 72, 81], ["lipopolysaccharide", "CHEMICAL", 118, 136], ["LPS", "CHEMICAL", 138, 141], ["cell", "CELL", 72, 76], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 118, 136], ["LPS", "SIMPLE_CHEMICAL", 138, 141], ["DNA", "CELLULAR_COMPONENT", 156, 159], ["tolllike receptors", "GENE_OR_GENE_PRODUCT", 199, 217], ["TLR", "GENE_OR_GENE_PRODUCT", 219, 222], ["tolllike receptors", "PROTEIN", 199, 217], ["TLR", "PROTEIN", 219, 222], ["bacterial-derived products (cell wall components", "TREATMENT", 44, 92], ["peptidoglycan or lipopolysaccharide (LPS)", "TREATMENT", 101, 142], ["bacterial DNA", "PROBLEM", 146, 159], ["specialized receptors", "TREATMENT", 165, 186], ["the tolllike receptors", "TREATMENT", 195, 217], ["host immune", "OBSERVATION", 4, 15], ["wall", "ANATOMY_MODIFIER", 77, 81]]], ["This triggers a series of signaling events that end up in the maturation and differentiation of epithelial and immune cells and in the maintenance of the intestinal barrier (Gill and Prasad, 2008) .MICROBIOTA OF THE GASTROINTESTINAL TRACT AND VIRUS SUSCEPTIBILITYViruses that infect the gastrointestinal mucosa have co-evolved with the gut microbial population for which it is not surprising that, as occurred with bacterial pathogens, some aspects of virus infectivity may be modulated by the presence of this microbiota.", [["epithelial", "ANATOMY", 96, 106], ["immune cells", "ANATOMY", 111, 123], ["intestinal barrier", "ANATOMY", 154, 172], ["gastrointestinal mucosa", "ANATOMY", 287, 310], ["epithelial", "CELL", 96, 106], ["immune cells", "CELL", 111, 123], ["intestinal barrier", "MULTI-TISSUE_STRUCTURE", 154, 172], ["gastrointestinal mucosa", "MULTI-TISSUE_STRUCTURE", 287, 310], ["gut", "ORGANISM_SUBDIVISION", 336, 339], ["epithelial and immune cells", "CELL_TYPE", 96, 123], ["signaling events", "PROBLEM", 26, 42], ["epithelial and immune cells", "PROBLEM", 96, 123], ["THE GASTROINTESTINAL TRACT", "PROBLEM", 212, 238], ["VIRUS SUSCEPTIBILITYViruses", "PROBLEM", 243, 270], ["the gut microbial population", "PROBLEM", 332, 360], ["bacterial pathogens", "PROBLEM", 415, 434], ["virus infectivity", "PROBLEM", 452, 469], ["epithelial", "ANATOMY", 96, 106], ["immune cells", "OBSERVATION", 111, 123], ["intestinal barrier", "ANATOMY", 154, 172], ["GASTROINTESTINAL TRACT", "ANATOMY", 216, 238], ["VIRUS SUSCEPTIBILITYViruses", "OBSERVATION", 243, 270], ["gastrointestinal mucosa", "ANATOMY", 287, 310], ["microbial", "OBSERVATION_MODIFIER", 340, 349], ["population", "OBSERVATION", 350, 360], ["virus infectivity", "OBSERVATION", 452, 469]]], ["The first evidence linking the microbiota to viral susceptibility was derived from the use of two models that, with their limitations, have been extensively employed in these studies: germ-free and antibiotic-treated animals (usually mice).", [["germ", "ANATOMY", 184, 188], ["antibiotic", "SIMPLE_CHEMICAL", 198, 208], ["animals", "ORGANISM", 217, 224], ["mice", "ORGANISM", 234, 238], ["mice", "SPECIES", 234, 238], ["mice", "SPECIES", 234, 238], ["viral susceptibility", "PROBLEM", 45, 65], ["these studies", "TEST", 169, 182], ["antibiotic", "TREATMENT", 198, 208]]], ["The first model has the advantage of being completely deprived of microbiota and therefore, the role of intestinal bacteria in viral infectivity can be easily studied.", [["intestinal", "ANATOMY", 104, 114], ["intestinal", "ORGAN", 104, 114], ["intestinal bacteria", "PROBLEM", 104, 123], ["viral infectivity", "PROBLEM", 127, 144], ["intestinal", "ANATOMY", 104, 114], ["bacteria", "OBSERVATION", 115, 123], ["viral infectivity", "OBSERVATION", 127, 144]]], ["Furthermore, the effects of individual bacterial strains (probiotics or commensals) or more complex or defined microbiota can be studied by inoculating and colonizing the germ-free animals.", [["germ", "ANATOMY", 171, 175], ["individual bacterial strains", "PROBLEM", 28, 56]]], ["However, these animals present some disadvantages due to their immature immune system and altered intestinal physiology.", [["immune system", "ANATOMY", 72, 85], ["intestinal", "ANATOMY", 98, 108], ["immune system", "ANATOMICAL_SYSTEM", 72, 85], ["intestinal", "ORGAN", 98, 108], ["their immature immune system", "PROBLEM", 57, 85], ["altered intestinal physiology", "PROBLEM", 90, 119], ["intestinal", "ANATOMY", 98, 108]]], ["The second model, treating animals with antibiotic cocktails, is a more simple and economical way to get rid of the microbiota; however, this approach also has some limitations.", [["antibiotic cocktails", "TREATMENT", 40, 60]]], ["Sensitivity to antibiotics differs between bacteria and even using broad-spectrum antibiotics, a complete depletion of the microbiota cannot be assured.MICROBIOTA OF THE GASTROINTESTINAL TRACT AND VIRUS SUSCEPTIBILITYEarlier evidence of the participation of the intestinal microbiota in viral susceptibility was obtained from animal viruses or viruses that do not target the gastrointestinal tract.", [["intestinal", "ANATOMY", 262, 272], ["gastrointestinal tract", "ANATOMY", 375, 397], ["gastrointestinal tract", "DISEASE", 375, 397], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 262, 283], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 375, 397], ["antibiotics", "TREATMENT", 15, 26], ["bacteria", "PROBLEM", 43, 51], ["broad-spectrum antibiotics", "TREATMENT", 67, 93], ["a complete depletion of the microbiota", "TREATMENT", 95, 133], ["viral susceptibility", "PROBLEM", 287, 307], ["animal viruses", "PROBLEM", 326, 340], ["viruses", "PROBLEM", 344, 351], ["GASTROINTESTINAL TRACT", "ANATOMY", 170, 192], ["VIRUS", "OBSERVATION", 197, 202], ["intestinal microbiota", "ANATOMY", 262, 283], ["viral susceptibility", "OBSERVATION", 287, 307], ["gastrointestinal tract", "ANATOMY", 375, 397]]], ["The replication of dengue virus in its vector, the mosquito Aedes aegypti, is increased in the gut of antibiotic-treated insects.", [["gut", "ANATOMY", 95, 98], ["dengue", "DISEASE", 19, 25], ["dengue virus", "ORGANISM", 19, 31], ["mosquito Aedes aegypti", "ORGANISM", 51, 73], ["gut", "ORGANISM_SUBDIVISION", 95, 98], ["Aedes aegypti", "SPECIES", 60, 73], ["dengue virus", "SPECIES", 19, 31], ["Aedes aegypti", "SPECIES", 60, 73], ["dengue virus", "PROBLEM", 19, 31], ["the mosquito Aedes aegypti", "PROBLEM", 47, 73], ["antibiotic", "TREATMENT", 102, 112], ["dengue virus", "OBSERVATION", 19, 31], ["increased", "OBSERVATION_MODIFIER", 78, 87]]], ["In this system, the microbiota was shown to control the expression of antimicrobial peptides regulated by pathways mediated by TLR signaling (Xi et al., 2008) .", [["TLR", "GENE_OR_GENE_PRODUCT", 127, 130], ["TLR", "PROTEIN", 127, 130], ["antimicrobial peptides", "TREATMENT", 70, 92], ["antimicrobial peptides", "OBSERVATION", 70, 92]]], ["It is hypothesized that the mosquito microbiota enhances the antiviral response by basal stimulation of the immune system.", [["immune system", "ANATOMY", 108, 121], ["antiviral response", "OBSERVATION", 61, 79]]], ["A second example of a role of the microbiota in controlling viral replication is the case of the influenza virus.", [["influenza virus", "DISEASE", 97, 112], ["influenza virus", "ORGANISM", 97, 112], ["influenza virus", "SPECIES", 97, 112], ["influenza virus", "SPECIES", 97, 112], ["viral replication", "TREATMENT", 60, 77], ["the influenza virus", "PROBLEM", 93, 112], ["influenza virus", "OBSERVATION", 97, 112]]], ["Germ-free or antibiotic-treated animals infected with this virus show exacerbated disease symptoms and decreased specific IgG production, for which it is established that the microbiota is needed to develop an adequate antiviral response.", [["antibiotic", "SIMPLE_CHEMICAL", 13, 23], ["animals", "ORGANISM", 32, 39], ["IgG", "GENE_OR_GENE_PRODUCT", 122, 125], ["IgG", "PROTEIN", 122, 125], ["antibiotic", "TREATMENT", 13, 23], ["this virus", "PROBLEM", 54, 64], ["exacerbated disease symptoms", "PROBLEM", 70, 98], ["decreased specific IgG production", "PROBLEM", 103, 136], ["free", "OBSERVATION_MODIFIER", 5, 9], ["exacerbated", "OBSERVATION_MODIFIER", 70, 81], ["disease", "OBSERVATION", 82, 89], ["decreased", "OBSERVATION_MODIFIER", 103, 112], ["IgG production", "OBSERVATION", 122, 136], ["antiviral response", "OBSERVATION", 219, 237]]], ["In this case, an indirect mechanism is proposed by which the microbiota activates the inflammasome and induces the migration of immune cells from the lung to lymph nodes to prime specific T-cell responses (Ichinohe et al., 2011) .MICROBIOTA OF THE GASTROINTESTINAL TRACT AND VIRUS SUSCEPTIBILITYContrary to these two latter cases, microbiota may also participate in processes that result in an enhancement of viral infectivity.", [["immune cells", "ANATOMY", 128, 140], ["lung", "ANATOMY", 150, 154], ["lymph nodes", "ANATOMY", 158, 169], ["T-cell", "ANATOMY", 188, 194], ["immune cells", "CELL", 128, 140], ["lung", "ORGAN", 150, 154], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 158, 169], ["T-cell", "CELL", 188, 194], ["immune cells", "CELL_TYPE", 128, 140], ["an indirect mechanism", "PROBLEM", 14, 35], ["the inflammasome", "PROBLEM", 82, 98], ["immune cells", "PROBLEM", 128, 140], ["viral infectivity", "PROBLEM", 409, 426], ["immune cells", "OBSERVATION", 128, 140], ["lung", "ANATOMY", 150, 154], ["lymph nodes", "OBSERVATION", 158, 169], ["GASTROINTESTINAL TRACT", "ANATOMY", 248, 270], ["VIRUS", "OBSERVATION", 275, 280], ["enhancement", "OBSERVATION_MODIFIER", 394, 405], ["viral infectivity", "OBSERVATION", 409, 426]]], ["Germ-free mice are less susceptible to develop leukemia induced by the murine leukemia virus (Isaak et al., 1988) .", [["leukemia", "ANATOMY", 47, 55], ["leukemia", "DISEASE", 47, 55], ["murine leukemia virus", "DISEASE", 71, 92], ["mice", "ORGANISM", 10, 14], ["leukemia", "CANCER", 47, 55], ["murine leukemia virus", "ORGANISM", 71, 92], ["mice", "SPECIES", 10, 14], ["murine", "SPECIES", 71, 77], ["mice", "SPECIES", 10, 14], ["murine leukemia virus", "SPECIES", 71, 92], ["leukemia", "PROBLEM", 47, 55], ["the murine leukemia virus", "PROBLEM", 67, 92], ["free mice", "OBSERVATION", 5, 14], ["less susceptible", "OBSERVATION_MODIFIER", 19, 35], ["leukemia", "OBSERVATION", 47, 55], ["murine leukemia virus", "OBSERVATION", 71, 92]]], ["It is postulated that this resistance to infection is the result of a diminished population of target immune cells for viral replication in germ-free mice.", [["immune cells", "ANATOMY", 102, 114], ["infection", "DISEASE", 41, 50], ["immune cells", "CELL", 102, 114], ["germ", "ORGANISM_SUBSTANCE", 140, 144], ["mice", "ORGANISM", 150, 154], ["immune cells", "CELL_TYPE", 102, 114], ["mice", "SPECIES", 150, 154], ["mice", "SPECIES", 150, 154], ["this resistance to infection", "PROBLEM", 22, 50], ["a diminished population", "PROBLEM", 68, 91], ["target immune cells", "TREATMENT", 95, 114], ["viral replication", "TREATMENT", 119, 136], ["infection", "OBSERVATION", 41, 50], ["diminished", "OBSERVATION_MODIFIER", 70, 80], ["target immune cells", "OBSERVATION", 95, 114]]], ["In another example, the mouse mammary tumor virus (MMTV), which is transmitted to the offspring through the milk, uses a mechanism based on the microbiota to evade the immune system.", [["mammary tumor", "ANATOMY", 30, 43], ["milk", "ANATOMY", 108, 112], ["immune system", "ANATOMY", 168, 181], ["mammary tumor", "DISEASE", 30, 43], ["mouse", "ORGANISM", 24, 29], ["mammary tumor virus", "ORGANISM", 30, 49], ["MMTV", "ORGANISM", 51, 55], ["milk", "ORGANISM_SUBSTANCE", 108, 112], ["immune system", "ANATOMICAL_SYSTEM", 168, 181], ["mouse", "SPECIES", 24, 29], ["mouse mammary tumor virus", "SPECIES", 24, 49], ["MMTV", "SPECIES", 51, 55], ["the mouse mammary tumor virus", "PROBLEM", 20, 49], ["mammary", "ANATOMY", 30, 37], ["tumor", "OBSERVATION", 38, 43]]], ["MMTV virions are able to trigger TLR4 by means of a bacterial product, LPS.", [["LPS", "CHEMICAL", 71, 74], ["MMTV", "ORGANISM", 0, 4], ["TLR4", "GENE_OR_GENE_PRODUCT", 33, 37], ["LPS", "SIMPLE_CHEMICAL", 71, 74], ["TLR4", "PROTEIN", 33, 37], ["MMTV", "SPECIES", 0, 4], ["MMTV virions", "TREATMENT", 0, 12]]], ["This results in the production of immunosuppressive cytokine IL-10, which blocks the antiviral response (Kane et al., 2011) .", [["IL-10", "GENE_OR_GENE_PRODUCT", 61, 66], ["immunosuppressive cytokine IL-10", "PROTEIN", 34, 66], ["immunosuppressive cytokine IL", "TREATMENT", 34, 63], ["antiviral response", "OBSERVATION", 85, 103]]], ["In this case, MMTV takes advantage of the mechanisms that induce tolerance to the indigenous microbiota to evade the immune response.", [["MMTV", "ORGANISM", 14, 18], ["MMTV", "SPECIES", 14, 18]]], ["As will be discussed later, evidence on the participation of the intestinal microbiota and their derived components in virus infectivity has been finally obtained for human viruses that infect the gastrointestinal tract producing or not gastroenteritis: polioviruses, NoV, and RV.", [["intestinal", "ANATOMY", 65, 75], ["gastrointestinal tract", "ANATOMY", 197, 219], ["gastrointestinal tract", "DISEASE", 197, 219], ["gastroenteritis", "DISEASE", 237, 252], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 65, 86], ["human", "ORGANISM", 167, 172], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 197, 219], ["NoV", "ORGANISM", 268, 271], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["NoV", "SPECIES", 268, 271], ["RV", "SPECIES", 277, 279], ["virus infectivity", "PROBLEM", 119, 136], ["human viruses", "PROBLEM", 167, 180], ["the gastrointestinal tract", "PROBLEM", 193, 219], ["gastroenteritis", "PROBLEM", 237, 252], ["polioviruses", "PROBLEM", 254, 266], ["intestinal microbiota", "ANATOMY", 65, 86], ["gastrointestinal tract", "ANATOMY", 197, 219], ["gastroenteritis", "OBSERVATION", 237, 252], ["polioviruses", "OBSERVATION", 254, 266], ["RV", "ANATOMY", 277, 279]]], ["In these cases, a positive effect of the microbiota in viral infection was found.", [["viral infection", "DISEASE", 55, 70], ["viral infection", "PROBLEM", 55, 70], ["positive", "OBSERVATION_MODIFIER", 18, 26], ["effect", "OBSERVATION_MODIFIER", 27, 33], ["viral", "OBSERVATION_MODIFIER", 55, 60], ["infection", "OBSERVATION", 61, 70]]], ["In principle, this seems contradictory with the protective effects against diarrhea that are usually attributed to probiotics (also members of the microbiota), evidencing that distinct mechanisms initiated by intestinal bacteria modulate the infectivity.SUGGESTED ANTAGONISTIC MECHANISMS OF PROBIOTICS AGAINST INTESTINAL VIRAL PATHOGENSThe antagonistic effect of probiotics has been exhaustively studied for microbial pathogens such as Clostridium, Helicobacter, Salmonella, or enteropathogen E. coli and the inhibitory mechanisms have been elucidated in several cases (Lievin-Le Moal and Servin, 2014) .", [["intestinal", "ANATOMY", 209, 219], ["diarrhea", "DISEASE", 75, 83], ["intestinal bacteria", "ORGANISM", 209, 228], ["Clostridium", "ORGANISM", 436, 447], ["Helicobacter, Salmonella", "ORGANISM", 449, 473], ["enteropathogen E. coli", "ORGANISM", 478, 500], ["E. coli", "SPECIES", 493, 500], ["E. coli", "SPECIES", 493, 500], ["diarrhea", "PROBLEM", 75, 83], ["probiotics", "TREATMENT", 115, 125], ["intestinal bacteria modulate the infectivity", "PROBLEM", 209, 253], ["PROBIOTICS", "TREATMENT", 291, 301], ["INTESTINAL VIRAL PATHOGENSThe antagonistic effect", "TREATMENT", 310, 359], ["probiotics", "TREATMENT", 363, 373], ["microbial pathogens", "PROBLEM", 408, 427], ["Clostridium", "PROBLEM", 436, 447], ["Helicobacter", "PROBLEM", 449, 461], ["Salmonella", "PROBLEM", 463, 473], ["enteropathogen E. coli", "PROBLEM", 478, 500], ["the inhibitory mechanisms", "PROBLEM", 505, 530], ["intestinal", "ANATOMY", 209, 219], ["bacteria", "OBSERVATION", 220, 228], ["infectivity", "OBSERVATION_MODIFIER", 242, 253]]], ["It is believed that most of these mechanisms also apply to the inhibition or viral infection.SUGGESTED ANTAGONISTIC MECHANISMS OF PROBIOTICS AGAINST INTESTINAL VIRAL PATHOGENSProbiotics can interfere with the viral cycle by acting at several steps, interfering with some aspect of viral replication or pathogenesis, or protecting the mucosal barrier function (summarized in Figures 62.1 and 62 .2).", [["mucosal barrier", "ANATOMY", 334, 349], ["viral infection", "DISEASE", 77, 92], ["mucosal barrier", "TISSUE", 334, 349], ["viral infection", "PROBLEM", 77, 92], ["PROBIOTICS", "TREATMENT", 130, 140], ["INTESTINAL VIRAL PATHOGENSProbiotics", "TREATMENT", 149, 185], ["the viral cycle", "TREATMENT", 205, 220], ["viral replication", "TREATMENT", 281, 298], ["pathogenesis", "PROBLEM", 302, 314], ["the mucosal barrier function", "TEST", 330, 358], ["Figures", "TEST", 374, 381], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["infection", "OBSERVATION", 83, 92], ["viral replication", "OBSERVATION", 281, 298]]], ["Also, immunomodulation at the level of innate and adaptive responses has emerged as a major mechanism for antiviral effects.", [["immunomodulation", "TREATMENT", 6, 22], ["antiviral effects", "TREATMENT", 106, 123]]], ["By means of several mechanisms that are still poorly understood, probiotics can modulate specific host pathways and affect the synthesis of The intestinal microbiota can promote or inhibit viral infection through several mechanisms: (i) influencing mucus production or the glycosylation state of surface glycoproteins, which in some cases are the target for viral recognition; (ii) by competitive exclusion or displacement from attachment to viral receptors; and (iii) bacteria can promote virus retention to the cell surface or structural components derived from them are needed for the virus to be infective. many cytokines (e.g., IL-1, IL-2, IL-4, IL-6, IL-10, IL-12, IFN-\u03b3, and TNF-\u03b1).", [["intestinal", "ANATOMY", 144, 154], ["mucus", "ANATOMY", 249, 254], ["surface", "ANATOMY", 296, 303], ["cell surface", "ANATOMY", 513, 525], ["viral infection", "DISEASE", 189, 204], ["intestinal", "ORGAN", 144, 154], ["mucus", "MULTI-TISSUE_STRUCTURE", 249, 254], ["surface glycoproteins", "GENE_OR_GENE_PRODUCT", 296, 317], ["cell surface", "CELLULAR_COMPONENT", 513, 525], ["IL-1", "GENE_OR_GENE_PRODUCT", 633, 637], ["IL-2", "GENE_OR_GENE_PRODUCT", 639, 643], ["IL-4", "GENE_OR_GENE_PRODUCT", 645, 649], ["IL-6", "GENE_OR_GENE_PRODUCT", 651, 655], ["IL-10", "GENE_OR_GENE_PRODUCT", 657, 662], ["IL-12", "GENE_OR_GENE_PRODUCT", 664, 669], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 671, 676], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 682, 687], ["surface glycoproteins", "PROTEIN", 296, 317], ["viral receptors", "PROTEIN", 442, 457], ["cytokines", "PROTEIN", 616, 625], ["IL", "PROTEIN", 664, 666], ["IFN", "PROTEIN", 671, 674], ["\u03b3", "PROTEIN", 675, 676], ["TNF", "PROTEIN", 682, 685], ["probiotics", "TREATMENT", 65, 75], ["viral infection", "PROBLEM", 189, 204], ["influencing mucus production", "PROBLEM", 237, 265], ["surface glycoproteins", "PROBLEM", 296, 317], ["viral recognition", "PROBLEM", 358, 375], ["displacement", "PROBLEM", 410, 422], ["viral receptors", "PROBLEM", 442, 457], ["(iii) bacteria", "PROBLEM", 463, 477], ["virus retention", "PROBLEM", 490, 505], ["structural components", "PROBLEM", 529, 550], ["the virus", "PROBLEM", 584, 593], ["infective", "PROBLEM", 600, 609], ["many cytokines", "TEST", 611, 625], ["IL", "TEST", 633, 635], ["IL", "TEST", 639, 641], ["IL", "TEST", 645, 647], ["IL", "TEST", 651, 653], ["IL", "TEST", 657, 659], ["IL", "TEST", 664, 666], ["IFN", "TEST", 671, 674], ["TNF", "TEST", 682, 685], ["intestinal microbiota", "ANATOMY", 144, 165], ["cell", "OBSERVATION", 513, 517], ["surface", "OBSERVATION_MODIFIER", 518, 525], ["infective", "OBSERVATION", 600, 609], ["cytokines", "OBSERVATION", 616, 625]]], ["This has as a consequence a series of modulatory effects on immune cells: increased cytotoxic and phagocytic capacity of NK cells or macrophages and immune cell (T and B lymphocytes) proliferation and differentiation.", [["immune cells", "ANATOMY", 60, 72], ["NK cells", "ANATOMY", 121, 129], ["macrophages", "ANATOMY", 133, 144], ["immune cell", "ANATOMY", 149, 160], ["T", "ANATOMY", 162, 163], ["B lymphocytes", "ANATOMY", 168, 181], ["immune cells", "CELL", 60, 72], ["NK cells", "CELL", 121, 129], ["macrophages", "CELL", 133, 144], ["immune cell", "CELL", 149, 160], ["T", "CELL", 162, 163], ["B lymphocytes", "CELL", 168, 181], ["immune cells", "CELL_TYPE", 60, 72], ["NK cells", "CELL_TYPE", 121, 129], ["macrophages", "CELL_TYPE", 133, 144], ["T and B lymphocytes", "CELL_TYPE", 162, 181], ["immune cells", "PROBLEM", 60, 72], ["increased cytotoxic and phagocytic capacity of NK cells", "PROBLEM", 74, 129], ["macrophages", "PROBLEM", 133, 144], ["immune cell (T and B lymphocytes) proliferation", "PROBLEM", 149, 196], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["cytotoxic", "OBSERVATION_MODIFIER", 84, 93], ["phagocytic capacity", "OBSERVATION", 98, 117], ["NK cells", "OBSERVATION", 121, 129], ["macrophages", "OBSERVATION_MODIFIER", 133, 144], ["immune cell", "OBSERVATION", 149, 160]]], ["This last effect results in increased antibody responses (Gill and Prasad, 2008) .", [["increased antibody responses", "PROBLEM", 28, 56], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["antibody responses", "OBSERVATION", 38, 56]]], ["Thus, the adjuvant effect of probiotics has been documented for vaccination against several viral pathogens such as hepatitis B, poliovirus, or influenza, giving rise to increased IgG and IgA titers.", [["hepatitis B", "DISEASE", 116, 127], ["influenza", "DISEASE", 144, 153], ["hepatitis B", "ORGANISM", 116, 127], ["poliovirus", "ORGANISM", 129, 139], ["IgG", "GENE_OR_GENE_PRODUCT", 180, 183], ["IgA", "GENE_OR_GENE_PRODUCT", 188, 191], ["IgG", "PROTEIN", 180, 183], ["IgA", "PROTEIN", 188, 191], ["hepatitis B", "SPECIES", 116, 127], ["poliovirus", "SPECIES", 129, 139], ["probiotics", "TREATMENT", 29, 39], ["vaccination", "TREATMENT", 64, 75], ["several viral pathogens", "PROBLEM", 84, 107], ["hepatitis B", "PROBLEM", 116, 127], ["poliovirus", "PROBLEM", 129, 139], ["influenza", "PROBLEM", 144, 153], ["increased IgG", "PROBLEM", 170, 183], ["IgA titers", "PROBLEM", 188, 198], ["increased", "OBSERVATION_MODIFIER", 170, 179], ["IgG", "OBSERVATION", 180, 183], ["IgA titers", "OBSERVATION", 188, 198]]], ["In a similar way, consumption of fermented milk containing LGG was demonstrated to be effective in the promotion of specific IgA secreting cells and increased plasma IgA titers in RV vaccination and during RV infection (Kaila et al., 1992) and the same effect has been evidenced in different animal models.", [["milk", "ANATOMY", 43, 47], ["cells", "ANATOMY", 139, 144], ["plasma", "ANATOMY", 159, 165], ["RV", "ANATOMY", 180, 182], ["RV", "ANATOMY", 206, 208], ["LGG", "CHEMICAL", 59, 62], ["RV infection", "DISEASE", 206, 218], ["milk", "ORGANISM_SUBSTANCE", 43, 47], ["LGG", "SIMPLE_CHEMICAL", 59, 62], ["IgA", "GENE_OR_GENE_PRODUCT", 125, 128], ["cells", "CELL", 139, 144], ["plasma", "ORGANISM_SUBSTANCE", 159, 165], ["IgA", "GENE_OR_GENE_PRODUCT", 166, 169], ["IgA secreting cells", "CELL_TYPE", 125, 144], ["IgA", "PROTEIN", 166, 169], ["RV", "SPECIES", 180, 182], ["RV", "SPECIES", 206, 208], ["fermented milk containing LGG", "TREATMENT", 33, 62], ["specific IgA secreting cells", "PROBLEM", 116, 144], ["increased plasma IgA titers", "PROBLEM", 149, 176], ["RV vaccination", "TREATMENT", 180, 194], ["RV infection", "PROBLEM", 206, 218], ["secreting cells", "OBSERVATION", 129, 144], ["RV", "ANATOMY", 180, 182], ["RV", "ANATOMY", 206, 208], ["infection", "OBSERVATION", 209, 218]]], ["Some studies have suggested that specific probiotics are able to synthesize antiviral substances, although their nature is still unknown (Botic et al., 2007; Seo et al., 2010) .", [["Some studies", "TEST", 0, 12], ["specific probiotics", "TREATMENT", 33, 52]]], ["The many organic acids produced by fermentation of carbohydrates by lactobacilli or bifidobacteria have microbicide activity per se, and it is established through the use of in vitro models that these acids are able to inhibit infectivity for some viruses.", [["organic acids", "CHEMICAL", 9, 22], ["lactobacilli", "CHEMICAL", 68, 80], ["bifidobacteria", "CHEMICAL", 84, 98], ["carbohydrates", "CHEMICAL", 51, 64], ["organic acids", "SIMPLE_CHEMICAL", 9, 22], ["carbohydrates", "SIMPLE_CHEMICAL", 51, 64], ["lactobacilli", "SIMPLE_CHEMICAL", 68, 80], ["bifidobacteria", "SIMPLE_CHEMICAL", 84, 98], ["The many organic acids", "TREATMENT", 0, 22], ["carbohydrates", "TREATMENT", 51, 64], ["lactobacilli", "TREATMENT", 68, 80], ["bifidobacteria", "TREATMENT", 84, 98], ["these acids", "TREATMENT", 195, 206], ["some viruses", "PROBLEM", 243, 255], ["organic acids", "OBSERVATION", 9, 22]]], ["This suggests that the acid environment may reduce viral infection.", [["viral infection", "DISEASE", 51, 66], ["the acid environment", "PROBLEM", 19, 39], ["viral infection", "PROBLEM", 51, 66], ["acid environment", "OBSERVATION", 23, 39], ["viral", "OBSERVATION_MODIFIER", 51, 56], ["infection", "OBSERVATION", 57, 66]]], ["However, the fact that enteric viruses have evolved to replicate in the gastrointestinal niche and are therefore adapted to thrive in this environment may limit this effect.", [["gastrointestinal niche", "ANATOMY", 72, 94], ["enteric viruses", "ORGANISM", 23, 38], ["gastrointestinal", "ORGAN", 72, 88], ["enteric viruses", "PROBLEM", 23, 38], ["enteric", "OBSERVATION_MODIFIER", 23, 30], ["viruses", "OBSERVATION", 31, 38], ["gastrointestinal niche", "ANATOMY", 72, 94]]], ["Production of virucide substances can also be induced in the host cells by probiotics.", [["cells", "ANATOMY", 66, 71], ["virucide substances", "SIMPLE_CHEMICAL", 14, 33], ["host cells", "CELL", 61, 71], ["host cells", "CELL_TYPE", 61, 71], ["Production of virucide substances", "PROBLEM", 0, 33], ["probiotics", "TREATMENT", 75, 85]]], ["Reactive oxygen species production such as H 2 O 2 or are NOwere increased by LGG and Lactobacillus casei Shirota and strains of Lactobacillus pentosus, Lactobacillus plantarum, and Lactobacillus fermentum up to 50% depending on the combination of strain and cell line.", [["cell line", "ANATOMY", 259, 268], ["oxygen", "CHEMICAL", 9, 15], ["LGG", "CHEMICAL", 78, 81], ["Lactobacillus pentosus, Lactobacillus plantarum", "CHEMICAL", 129, 176], ["Lactobacillus fermentum", "CHEMICAL", 182, 205], ["oxygen", "CHEMICAL", 9, 15], ["H 2 O 2", "CHEMICAL", 43, 50], ["Reactive oxygen species", "SIMPLE_CHEMICAL", 0, 23], ["H 2 O 2", "GENE_OR_GENE_PRODUCT", 43, 50], ["NOwere", "SIMPLE_CHEMICAL", 58, 64], ["LGG", "SIMPLE_CHEMICAL", 78, 81], ["Lactobacillus casei Shirota", "ORGANISM", 86, 113], ["Lactobacillus pentosus", "ORGANISM", 129, 151], ["Lactobacillus plantarum", "ORGANISM", 153, 176], ["Lactobacillus fermentum", "ORGANISM", 182, 205], ["cell line", "CELL", 259, 268], ["cell line", "CELL_LINE", 259, 268], ["Lactobacillus casei", "SPECIES", 86, 105], ["Lactobacillus pentosus", "SPECIES", 129, 151], ["Lactobacillus plantarum", "SPECIES", 153, 176], ["Lactobacillus fermentum", "SPECIES", 182, 205], ["Lactobacillus casei", "SPECIES", 86, 105], ["Lactobacillus pentosus", "SPECIES", 129, 151], ["Lactobacillus plantarum", "SPECIES", 153, 176], ["Lactobacillus fermentum", "SPECIES", 182, 205], ["Reactive oxygen species production", "PROBLEM", 0, 34], ["LGG", "TEST", 78, 81], ["Lactobacillus casei", "TREATMENT", 86, 105], ["Lactobacillus pentosus", "PROBLEM", 129, 151], ["Lactobacillus plantarum", "TREATMENT", 153, 176], ["Lactobacillus fermentum", "TREATMENT", 182, 205], ["strain", "PROBLEM", 248, 254], ["cell line", "TREATMENT", 259, 268], ["oxygen species", "OBSERVATION", 9, 23], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["Lactobacillus pentosus", "ANATOMY", 129, 151], ["Lactobacillus plantarum", "ANATOMY", 153, 176], ["cell line", "OBSERVATION", 259, 268]]], ["This results in diminished or complete abolishment of the disruption of in vitro culture monolayers by RV infection (Maragkoudakis et al., 2010) .", [["monolayers", "ANATOMY", 89, 99], ["RV infection", "DISEASE", 103, 115], ["monolayers", "CELL", 89, 99], ["RV", "ORGAN", 103, 105], ["in vitro culture monolayers", "CELL_LINE", 72, 99], ["the disruption", "PROBLEM", 54, 68], ["vitro culture monolayers", "TEST", 75, 99], ["RV infection", "PROBLEM", 103, 115], ["diminished", "OBSERVATION_MODIFIER", 16, 26], ["RV", "ANATOMY", 103, 105], ["infection", "OBSERVATION", 106, 115]]], ["Infection by RV in cultured cells promotes chloride excretion linked to an increase in reactive oxygen species and mediated by the viral enterotoxin NSP4.", [["cells", "ANATOMY", 28, 33], ["chloride", "CHEMICAL", 43, 51], ["oxygen", "CHEMICAL", 96, 102], ["chloride", "CHEMICAL", 43, 51], ["oxygen", "CHEMICAL", 96, 102], ["cells", "CELL", 28, 33], ["chloride", "SIMPLE_CHEMICAL", 43, 51], ["reactive oxygen species", "SIMPLE_CHEMICAL", 87, 110], ["NSP4", "GENE_OR_GENE_PRODUCT", 149, 153], ["cultured cells", "CELL_LINE", 19, 33], ["viral enterotoxin NSP4", "PROTEIN", 131, 153], ["Infection", "PROBLEM", 0, 9], ["RV in cultured cells", "TEST", 13, 33], ["chloride excretion", "PROBLEM", 43, 61], ["reactive oxygen species", "PROBLEM", 87, 110], ["the viral enterotoxin NSP4", "TREATMENT", 127, 153], ["RV", "ANATOMY", 13, 15], ["increase", "OBSERVATION_MODIFIER", 75, 83], ["reactive oxygen species", "OBSERVATION", 87, 110], ["viral enterotoxin NSP4", "OBSERVATION", 131, 153]]], ["This effect can be inhibited by supernatants of the probiotic yeasts Saccharomyces boulardii, which prevents RV-induced oxidative stress (Buccigrossi et al., 2014) .", [["supernatants", "ANATOMY", 32, 44], ["Saccharomyces boulardii", "ORGANISM", 69, 92], ["Saccharomyces boulardii", "SPECIES", 69, 92], ["Saccharomyces boulardii", "SPECIES", 69, 92], ["the probiotic yeasts Saccharomyces boulardii", "TREATMENT", 48, 92], ["yeasts Saccharomyces boulardii", "OBSERVATION", 62, 92], ["RV", "ANATOMY", 109, 111], ["oxidative stress", "OBSERVATION", 120, 136]]], ["As this probiotic yeast has proven beneficial effects on RV diarrhea, these results provide new clues on the anti-RV effects of probiotics.", [["anti-RV", "ANATOMY", 109, 116], ["RV diarrhea", "DISEASE", 57, 68], ["anti-RV", "CANCER", 109, 116], ["yeast", "SPECIES", 18, 23], ["yeast", "SPECIES", 18, 23], ["RV", "SPECIES", 57, 59], ["this probiotic yeast", "TREATMENT", 3, 23], ["RV diarrhea", "PROBLEM", 57, 68], ["the anti-RV effects of probiotics", "TREATMENT", 105, 138], ["RV", "ANATOMY", 57, 59], ["diarrhea", "OBSERVATION", 60, 68]]], ["Other antiviral molecules whose production is induced in response to the microbiota are defensins.", [["antiviral molecules", "PROTEIN", 6, 25], ["Other antiviral molecules", "PROBLEM", 0, 25], ["antiviral molecules", "OBSERVATION", 6, 25]]], ["These peptides have a strong antibacterial activity, but it has been described that alpha-defensin binds to human adenovirus limiting viral replication in vitro by preventing virus uncoating in the cell entry process.", [["cell", "ANATOMY", 198, 202], ["alpha-defensin", "CHEMICAL", 84, 98], ["alpha-defensin", "GENE_OR_GENE_PRODUCT", 84, 98], ["human", "ORGANISM", 108, 113], ["adenovirus", "ORGANISM", 114, 124], ["cell", "CELL", 198, 202], ["alpha-defensin", "PROTEIN", 84, 98], ["human", "SPECIES", 108, 113], ["human adenovirus", "SPECIES", 108, 124], ["a strong antibacterial activity", "PROBLEM", 20, 51], ["alpha-defensin binds", "PROBLEM", 84, 104], ["human adenovirus", "PROBLEM", 108, 124], ["viral replication", "TREATMENT", 134, 151], ["virus", "PROBLEM", 175, 180], ["strong", "OBSERVATION_MODIFIER", 22, 28], ["antibacterial activity", "OBSERVATION", 29, 51], ["cell entry process", "OBSERVATION", 198, 216]]], ["However, the relevance of this phenomenon in vivo has to be established (Wilson et al., 2013) .SUGGESTED ANTAGONISTIC MECHANISMS OF PROBIOTICS AGAINST INTESTINAL VIRAL PATHOGENSThe relationship between probiotics and mucus synthesis has been proven in some cases.SUGGESTED ANTAGONISTIC MECHANISMS OF PROBIOTICS AGAINST INTESTINAL VIRAL PATHOGENSLGG and L. plantarum 299v are able to increase mucin secretion in cultured cells by upregulating the expression of MUC-2 and MUC-3 genes.", [["mucus", "ANATOMY", 217, 222], ["cells", "ANATOMY", 420, 425], ["mucus", "MULTI-TISSUE_STRUCTURE", 217, 222], ["L. plantarum 299v", "ORGANISM", 353, 370], ["mucin", "GENE_OR_GENE_PRODUCT", 392, 397], ["cells", "CELL", 420, 425], ["MUC-2", "GENE_OR_GENE_PRODUCT", 460, 465], ["MUC-3", "GENE_OR_GENE_PRODUCT", 470, 475], ["cultured cells", "CELL_LINE", 411, 425], ["MUC-2 and MUC-3 genes", "DNA", 460, 481], ["L. plantarum", "SPECIES", 353, 365], ["L. plantarum 299v", "SPECIES", 353, 370], ["PROBIOTICS", "TREATMENT", 132, 142], ["probiotics", "TREATMENT", 202, 212], ["mucus synthesis", "TREATMENT", 217, 232], ["PROBIOTICS", "TREATMENT", 300, 310], ["L. plantarum", "TREATMENT", 353, 365], ["mucin secretion in cultured cells", "PROBLEM", 392, 425], ["MUC", "TEST", 460, 463], ["L. plantarum", "ANATOMY", 353, 365]]], ["The thick mucus layer (compared to the width of the epithelial layer) represents a first line of defense against infection and it is composed of mucins and other glycoproteins that interact with the microbiota and in some cases represents a first anchor site and a source of nutrients for many enteric bacteria.", [["mucus layer", "ANATOMY", 10, 21], ["epithelial layer", "ANATOMY", 52, 68], ["infection", "DISEASE", 113, 122], ["mucus layer", "TISSUE", 10, 21], ["epithelial layer", "TISSUE", 52, 68], ["mucins", "GENE_OR_GENE_PRODUCT", 145, 151], ["The thick mucus layer", "PROBLEM", 0, 21], ["infection", "PROBLEM", 113, 122], ["mucins and other glycoproteins", "PROBLEM", 145, 175], ["a first anchor site", "PROBLEM", 239, 258], ["many enteric bacteria", "PROBLEM", 289, 310], ["thick", "OBSERVATION_MODIFIER", 4, 9], ["mucus", "OBSERVATION_MODIFIER", 10, 15], ["layer", "OBSERVATION_MODIFIER", 16, 21], ["epithelial", "ANATOMY_MODIFIER", 52, 62], ["layer", "ANATOMY_MODIFIER", 63, 68], ["first line", "OBSERVATION_MODIFIER", 83, 93], ["infection", "OBSERVATION", 113, 122], ["bacteria", "OBSERVATION", 302, 310]]], ["At the same time, its dynamic renewal and the movements linked to the transit through the gastrointestinal tract means that it constitutes, besides a physical barrier limiting access to epithelial cells, a way to entrap and exclude viral particles promoting their elimination in the feces.", [["gastrointestinal tract", "ANATOMY", 90, 112], ["epithelial cells", "ANATOMY", 186, 202], ["feces", "ANATOMY", 283, 288], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 90, 112], ["epithelial cells", "CELL", 186, 202], ["feces", "ORGANISM_SUBDIVISION", 283, 288], ["epithelial cells", "CELL_TYPE", 186, 202], ["epithelial cells", "PROBLEM", 186, 202], ["viral particles", "PROBLEM", 232, 247], ["gastrointestinal tract", "ANATOMY", 90, 112], ["epithelial cells", "OBSERVATION", 186, 202], ["viral particles", "OBSERVATION", 232, 247], ["feces", "ANATOMY", 283, 288]]], ["Lactobacilli and bifidobacteria also possess surface factors that promote their binding to intestinal mucus or components of the extracellular matrix.", [["surface", "ANATOMY", 45, 52], ["intestinal mucus", "ANATOMY", 91, 107], ["extracellular matrix", "ANATOMY", 129, 149], ["Lactobacilli", "CHEMICAL", 0, 12], ["Lactobacilli", "SIMPLE_CHEMICAL", 0, 12], ["bifidobacteria", "SIMPLE_CHEMICAL", 17, 31], ["intestinal mucus", "MULTI-TISSUE_STRUCTURE", 91, 107], ["extracellular matrix", "CELLULAR_COMPONENT", 129, 149], ["surface factors", "PROTEIN", 45, 60], ["Lactobacilli", "TREATMENT", 0, 12], ["bifidobacteria", "TREATMENT", 17, 31], ["surface factors", "PROBLEM", 45, 60], ["the extracellular matrix", "PROBLEM", 125, 149], ["intestinal", "ANATOMY", 91, 101], ["mucus", "OBSERVATION", 102, 107], ["extracellular matrix", "OBSERVATION", 129, 149]]], ["Some of these proteins are extracellular factors, such as the surface layer proteins (SlpA) or specialized proteins for mucosal binding: the mucus binding pili structures that are found in some lactobacilli (e.g., LGG and some bifidobacteria).", [["extracellular", "ANATOMY", 27, 40], ["surface layer", "ANATOMY", 62, 75], ["mucosal", "ANATOMY", 120, 127], ["mucus", "ANATOMY", 141, 146], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 27, 40], ["surface layer proteins", "GENE_OR_GENE_PRODUCT", 62, 84], ["SlpA", "GENE_OR_GENE_PRODUCT", 86, 90], ["mucosal", "MULTI-TISSUE_STRUCTURE", 120, 127], ["mucus", "GENE_OR_GENE_PRODUCT", 141, 146], ["pili", "GENE_OR_GENE_PRODUCT", 155, 159], ["lactobacilli", "SIMPLE_CHEMICAL", 194, 206], ["extracellular factors", "PROTEIN", 27, 48], ["surface layer proteins", "PROTEIN", 62, 84], ["SlpA", "PROTEIN", 86, 90], ["specialized proteins", "PROTEIN", 95, 115], ["extracellular factors", "PROBLEM", 27, 48], ["the surface layer proteins", "PROBLEM", 58, 84], ["mucosal binding", "PROBLEM", 120, 135], ["the mucus binding pili structures", "PROBLEM", 137, 170], ["some lactobacilli", "PROBLEM", 189, 206], ["LGG", "PROBLEM", 214, 217], ["proteins", "OBSERVATION", 14, 22], ["extracellular factors", "OBSERVATION", 27, 48], ["some lactobacilli", "ANATOMY", 189, 206]]], ["In other occasions, adhesion factors consist of \"moonlighting proteins,\" which are generally cytoplasmic proteins that are targeted to the surface by still unclear export mechanisms (chaperones, glycolytic enzymes, etc.) and that in some cases mediate in the interaction with the mucosal surface in strains of L. plantarum, L. casei, Lactobacillus reuteri, or Lactobacillus johnsonii.", [["cytoplasmic", "ANATOMY", 93, 104], ["surface", "ANATOMY", 139, 146], ["mucosal surface", "ANATOMY", 280, 295], ["Lactobacillus reuteri", "CHEMICAL", 334, 355], ["Lactobacillus johnsonii", "CHEMICAL", 360, 383], ["cytoplasmic", "ORGANISM_SUBSTANCE", 93, 104], ["surface", "CELLULAR_COMPONENT", 139, 146], ["glycolytic enzymes", "GENE_OR_GENE_PRODUCT", 195, 213], ["mucosal surface", "CELLULAR_COMPONENT", 280, 295], ["L. plantarum", "ORGANISM", 310, 322], ["L. casei", "ORGANISM", 324, 332], ["Lactobacillus reuteri", "ORGANISM", 334, 355], ["Lactobacillus johnsonii", "ORGANISM", 360, 383], ["adhesion factors", "PROTEIN", 20, 36], ["moonlighting proteins", "PROTEIN", 49, 70], ["cytoplasmic proteins", "PROTEIN", 93, 113], ["chaperones", "PROTEIN", 183, 193], ["glycolytic enzymes", "PROTEIN", 195, 213], ["L. plantarum", "SPECIES", 310, 322], ["L. casei", "SPECIES", 324, 332], ["Lactobacillus reuteri", "SPECIES", 334, 355], ["Lactobacillus johnsonii", "SPECIES", 360, 383], ["L. plantarum", "SPECIES", 310, 322], ["L. casei", "SPECIES", 324, 332], ["Lactobacillus reuteri", "SPECIES", 334, 355], ["Lactobacillus johnsonii", "SPECIES", 360, 383], ["adhesion factors", "PROBLEM", 20, 36], ["\"moonlighting proteins", "PROBLEM", 48, 70], ["generally cytoplasmic proteins", "PROBLEM", 83, 113], ["glycolytic enzymes", "TEST", 195, 213], ["L. casei", "TREATMENT", 324, 332], ["Lactobacillus reuteri", "TREATMENT", 334, 355], ["Lactobacillus johnsonii", "TREATMENT", 360, 383], ["mucosal surface", "ANATOMY", 280, 295], ["L. plantarum", "ANATOMY", 310, 322], ["L. casei", "ANATOMY", 324, 332], ["Lactobacillus johnsonii", "OBSERVATION", 360, 383]]], ["These adhesion factors possess lectin-like activity, help in the colonization process of these bacteria, and may participate in the competitive exclusion and displacement of virus from target cells.", [["cells", "ANATOMY", 192, 197], ["lectin", "GENE_OR_GENE_PRODUCT", 31, 37], ["cells", "CELL", 192, 197], ["adhesion factors", "PROTEIN", 6, 22], ["lectin", "PROTEIN", 31, 37], ["target cells", "CELL_TYPE", 185, 197], ["These adhesion factors", "PROBLEM", 0, 22], ["lectin-like activity", "PROBLEM", 31, 51], ["these bacteria", "PROBLEM", 89, 103], ["displacement of virus from target cells", "PROBLEM", 158, 197], ["lectin", "OBSERVATION_MODIFIER", 31, 37], ["bacteria", "OBSERVATION", 95, 103]]], ["Apart from this, probiotic strains have been shown to directly bind viruses.", [["probiotic strains", "PROBLEM", 17, 34], ["viruses", "OBSERVATION", 68, 75]]], ["Thus, LGG or Bifidobacterium lactis Bb12, the two strains in which efficacy on viral diarrheas has been better documented, display a remarkable binding ability to RV (Salminen et al., 2010) .", [["LGG", "CHEMICAL", 6, 9], ["viral diarrheas", "DISEASE", 79, 94], ["LGG", "SIMPLE_CHEMICAL", 6, 9], ["Bifidobacterium lactis Bb12", "ORGANISM", 13, 40], ["Bifidobacterium lactis", "SPECIES", 13, 35], ["Bifidobacterium lactis", "SPECIES", 13, 35], ["LGG", "PROBLEM", 6, 9], ["Bifidobacterium lactis Bb12", "TREATMENT", 13, 40], ["the two strains", "PROBLEM", 42, 57], ["viral diarrheas", "PROBLEM", 79, 94]]], ["Other probiotics such as L. casei BL23 or E. coli Nissle 1917 are able to bind viral particles (Rubio-del-Campo et al., 2014) .", [["L. casei BL23", "ORGANISM", 25, 38], ["E. coli", "ORGANISM", 42, 49], ["Nissle 1917", "ORGANISM", 50, 61], ["L. casei", "SPECIES", 25, 33], ["E. coli", "SPECIES", 42, 49], ["L. casei BL23", "SPECIES", 25, 38], ["E. coli", "SPECIES", 42, 49], ["Other probiotics", "TREATMENT", 0, 16], ["L. casei BL23", "TREATMENT", 25, 38], ["E. coli Nissle", "TREATMENT", 42, 56]]], ["Many virus receptors consist of glycosylated proteins present at the cell surfaces.", [["cell surfaces", "ANATOMY", 69, 82], ["cell surfaces", "CELLULAR_COMPONENT", 69, 82], ["virus receptors", "PROTEIN", 5, 20], ["glycosylated proteins", "PROTEIN", 32, 53], ["Many virus receptors", "PROBLEM", 0, 20], ["glycosylated proteins", "PROBLEM", 32, 53], ["virus", "OBSERVATION", 5, 10], ["glycosylated proteins", "OBSERVATION", 32, 53], ["cell surfaces", "OBSERVATION", 69, 82]]], ["It is thus anticipated that these probiotic strains express on their surfaces glycosylated proteins or other polymeric substances of carbohydrate nature that can be mimicking viral receptors.", [["carbohydrate", "CHEMICAL", 133, 145], ["glycosylated proteins", "PROTEIN", 78, 99], ["viral receptors", "PROTEIN", 175, 190], ["these probiotic strains", "TREATMENT", 28, 51]]], ["As will be discussed later, this already has been reported for other enteric strains, which possess sugar structures at the surface resembling HBGA and are able to interact with NoV VLP.SUGGESTED ANTAGONISTIC MECHANISMS OF PROBIOTICS AGAINST INTESTINAL VIRAL PATHOGENSProbiotics may contribute to the maintenance of the integrity of the intestinal epithelial barrier that is compromised during intestinal viral infections.", [["surface", "ANATOMY", 124, 131], ["intestinal epithelial barrier", "ANATOMY", 337, 366], ["intestinal", "ANATOMY", 394, 404], ["viral infections", "DISEASE", 405, 421], ["sugar", "CHEMICAL", 100, 105], ["sugar", "SIMPLE_CHEMICAL", 100, 105], ["surface", "CELLULAR_COMPONENT", 124, 131], ["HBGA", "SIMPLE_CHEMICAL", 143, 147], ["NoV VLP", "ORGANISM", 178, 185], ["intestinal epithelial barrier", "TISSUE", 337, 366], ["intestinal", "ORGAN", 394, 404], ["HBGA", "PROTEIN", 143, 147], ["NoV VLP", "PROTEIN", 178, 185], ["other enteric strains", "PROBLEM", 63, 84], ["PROBIOTICS", "TREATMENT", 223, 233], ["INTESTINAL VIRAL PATHOGENSProbiotics", "TREATMENT", 242, 278], ["the intestinal epithelial barrier", "TREATMENT", 333, 366], ["intestinal viral infections", "PROBLEM", 394, 421], ["intestinal", "ANATOMY", 337, 347], ["epithelial barrier", "OBSERVATION", 348, 366], ["intestinal", "ANATOMY", 394, 404], ["viral infections", "OBSERVATION", 405, 421]]], ["Viral diarrheas comprise several mechanisms that result in an increase of secretion of water and electrolytes and in the paracellular epithelial permeability.", [["paracellular epithelial", "ANATOMY", 121, 144], ["Viral diarrheas", "DISEASE", 0, 15], ["water", "SIMPLE_CHEMICAL", 87, 92], ["electrolytes", "SIMPLE_CHEMICAL", 97, 109], ["paracellular epithelial", "TISSUE", 121, 144], ["Viral diarrheas", "PROBLEM", 0, 15], ["an increase of secretion of water and electrolytes", "PROBLEM", 59, 109], ["the paracellular epithelial permeability", "TEST", 117, 157], ["diarrheas", "OBSERVATION", 6, 15], ["increase", "OBSERVATION_MODIFIER", 62, 70], ["paracellular", "ANATOMY_MODIFIER", 121, 133], ["epithelial permeability", "OBSERVATION", 134, 157]]], ["In addition, epithelial damage and apoptosis occur.", [["epithelial", "ANATOMY", 13, 23], ["epithelial", "TISSUE", 13, 23], ["epithelial damage", "PROBLEM", 13, 30], ["apoptosis", "PROBLEM", 35, 44], ["epithelial damage", "OBSERVATION", 13, 30], ["apoptosis", "OBSERVATION", 35, 44]]], ["Several probiotic strains have demonstrated their capacity to counteract these effects via distinct mechanisms Therefore, through the maintenance of intestinal homeostasis probiotics may help to keep the intestinal barrier integrity.", [["intestinal", "ANATOMY", 149, 159], ["intestinal barrier", "ANATOMY", 204, 222], ["intestinal", "ORGAN", 149, 159], ["intestinal barrier", "TISSUE", 204, 222], ["Several probiotic strains", "PROBLEM", 0, 25], ["their capacity", "PROBLEM", 44, 58], ["intestinal homeostasis probiotics", "TREATMENT", 149, 182], ["the intestinal barrier integrity", "TREATMENT", 200, 232], ["intestinal", "ANATOMY", 149, 159], ["intestinal", "ANATOMY", 204, 214]]], ["LGG secrete soluble factors to the culture medium that are protein members of the machinery for cell wall biosynthesis and turnover (endolysins p40 and p75).", [["cell wall", "ANATOMY", 96, 105], ["LGG", "CHEMICAL", 0, 3], ["LGG", "SIMPLE_CHEMICAL", 0, 3], ["cell wall", "CELLULAR_COMPONENT", 96, 105], ["endolysins p40", "GENE_OR_GENE_PRODUCT", 133, 147], ["p75", "GENE_OR_GENE_PRODUCT", 152, 155], ["soluble factors", "PROTEIN", 12, 27], ["p40", "PROTEIN", 144, 147], ["p75", "PROTEIN", 152, 155], ["LGG secrete soluble factors", "PROBLEM", 0, 27], ["the culture medium", "TEST", 31, 49], ["cell wall biosynthesis", "TEST", 96, 118], ["turnover (endolysins p40", "TREATMENT", 123, 147]]], ["These proteins have been shown to act on the Akt and PI3-K signaling pathways through activation of the epidermal growth factor receptor .", [["Akt", "GENE_OR_GENE_PRODUCT", 45, 48], ["PI3-K", "GENE_OR_GENE_PRODUCT", 53, 58], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 104, 136], ["Akt", "PROTEIN", 45, 48], ["PI3", "PROTEIN", 53, 56], ["epidermal growth factor receptor", "PROTEIN", 104, 136], ["the Akt", "TEST", 41, 48], ["PI3", "TEST", 53, 56], ["the epidermal growth factor receptor", "PROBLEM", 100, 136]]], ["This results in protection of the epithelium both in vitro and in vivo from apoptosis triggered by inflammatory cytokines like TNF-\u03b1 or IFN-\u03b3, oxidative damage, or chemically induced inflammation.", [["epithelium", "ANATOMY", 34, 44], ["inflammation", "DISEASE", 183, 195], ["epithelium", "TISSUE", 34, 44], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 127, 132], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 136, 141], ["inflammatory cytokines", "PROTEIN", 99, 121], ["TNF", "PROTEIN", 127, 130], ["IFN", "PROTEIN", 136, 139], ["the epithelium", "PROBLEM", 30, 44], ["vitro", "TREATMENT", 53, 58], ["apoptosis", "PROBLEM", 76, 85], ["inflammatory cytokines", "TEST", 99, 121], ["TNF", "TEST", 127, 130], ["\u03b1", "PROBLEM", 131, 132], ["IFN", "PROBLEM", 136, 139], ["\u03b3", "PROBLEM", 140, 141], ["oxidative damage", "PROBLEM", 143, 159], ["chemically induced inflammation", "PROBLEM", 164, 195], ["inflammatory", "OBSERVATION_MODIFIER", 99, 111], ["oxidative damage", "OBSERVATION", 143, 159], ["chemically induced", "OBSERVATION_MODIFIER", 164, 182], ["inflammation", "OBSERVATION", 183, 195]]], ["Also, low-molecular-weight peptides released by LGG induce cytoprotective heat-shock proteins (HSP25 and HSP72).", [["LGG", "CHEMICAL", 48, 51], ["LGG", "SIMPLE_CHEMICAL", 48, 51], ["heat-shock proteins", "GENE_OR_GENE_PRODUCT", 74, 93], ["HSP25", "GENE_OR_GENE_PRODUCT", 95, 100], ["HSP72", "GENE_OR_GENE_PRODUCT", 105, 110], ["cytoprotective heat-shock proteins", "PROTEIN", 59, 93], ["HSP25", "PROTEIN", 95, 100], ["HSP72", "PROTEIN", 105, 110], ["weight peptides", "PROBLEM", 20, 35], ["cytoprotective heat", "TEST", 59, 78], ["shock proteins", "PROBLEM", 79, 93], ["HSP25", "TEST", 95, 100], ["HSP72", "TEST", 105, 110], ["low", "OBSERVATION_MODIFIER", 6, 9]]], ["All this results in apoptosis resistance and maintenance of the epithelial structure by increasing the expression of proteins of the tight junctions, such as zonula occludens-1, occludin, or claudin (Seth et al., 2008) .", [["epithelial structure", "ANATOMY", 64, 84], ["tight junctions", "ANATOMY", 133, 148], ["epithelial structure", "TISSUE", 64, 84], ["tight junctions", "CELLULAR_COMPONENT", 133, 148], ["zonula occludens-1", "GENE_OR_GENE_PRODUCT", 158, 176], ["occludin", "GENE_OR_GENE_PRODUCT", 178, 186], ["claudin", "GENE_OR_GENE_PRODUCT", 191, 198], ["zonula occludens-1", "PROTEIN", 158, 176], ["occludin", "PROTEIN", 178, 186], ["claudin", "PROTEIN", 191, 198], ["apoptosis resistance", "PROBLEM", 20, 40], ["zonula occludens", "TREATMENT", 158, 174], ["apoptosis resistance", "OBSERVATION", 20, 40], ["epithelial structure", "OBSERVATION", 64, 84], ["increasing", "OBSERVATION_MODIFIER", 88, 98], ["tight junctions", "OBSERVATION", 133, 148], ["zonula occludens", "OBSERVATION", 158, 174]]], ["LGG p40 also increases MUC-2 expression in mice in vivo, leading to an increased mucus production and thickening of the intestinal mucus layer, which as described before may protect against infection .", [["mucus", "ANATOMY", 81, 86], ["intestinal mucus layer", "ANATOMY", 120, 142], ["infection", "DISEASE", 190, 199], ["LGG p40", "GENE_OR_GENE_PRODUCT", 0, 7], ["MUC-2", "GENE_OR_GENE_PRODUCT", 23, 28], ["mice", "ORGANISM", 43, 47], ["mucus", "ORGANISM_SUBSTANCE", 81, 86], ["intestinal mucus layer", "TISSUE", 120, 142], ["p40", "PROTEIN", 4, 7], ["MUC", "PROTEIN", 23, 26], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["LGG p40", "TEST", 0, 7], ["an increased mucus production", "PROBLEM", 68, 97], ["thickening of the intestinal mucus layer", "PROBLEM", 102, 142], ["infection", "PROBLEM", 190, 199], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["mucus production", "OBSERVATION", 81, 97], ["thickening", "OBSERVATION", 102, 112], ["intestinal mucus", "ANATOMY", 120, 136], ["layer", "OBSERVATION_MODIFIER", 137, 142], ["may protect against", "UNCERTAINTY", 170, 189], ["infection", "OBSERVATION", 190, 199]]], ["Other characterized proteic factors may contribute to maintain the intestinal homeostasis by playing a role in the host-bacterium cross talk.", [["intestinal", "ANATOMY", 67, 77], ["proteic factors", "GENE_OR_GENE_PRODUCT", 20, 35], ["intestinal", "ORGAN", 67, 77], ["proteic factors", "PROTEIN", 20, 35], ["Other characterized proteic factors", "PROBLEM", 0, 35], ["the intestinal homeostasis", "PROBLEM", 63, 89], ["proteic factors", "OBSERVATION", 20, 35], ["intestinal", "ANATOMY", 67, 77], ["homeostasis", "OBSERVATION", 78, 89]]], ["The cell wall-anchored proteinase from L. casei, PrtP, an enzyme required for milk casein degradation, has proven to play a role in intestinal homeostasis by selective degradation of proinflammatory cytokines (von Schillde et al., 2012) .", [["cell wall", "ANATOMY", 4, 13], ["intestinal", "ANATOMY", 132, 142], ["cell", "CELL", 4, 8], ["L. casei", "ORGANISM", 39, 47], ["PrtP", "GENE_OR_GENE_PRODUCT", 49, 53], ["milk casein", "GENE_OR_GENE_PRODUCT", 78, 89], ["intestinal", "ORGAN", 132, 142], ["cell wall-anchored proteinase", "PROTEIN", 4, 33], ["PrtP", "PROTEIN", 49, 53], ["proinflammatory cytokines", "PROTEIN", 183, 208], ["L. casei", "SPECIES", 39, 47], ["L. casei", "SPECIES", 39, 47], ["The cell wall", "TEST", 0, 13], ["L. casei", "TREATMENT", 39, 47], ["an enzyme", "TEST", 55, 64], ["milk casein degradation", "TREATMENT", 78, 101], ["intestinal homeostasis", "TREATMENT", 132, 154], ["cell", "OBSERVATION", 4, 8], ["wall", "ANATOMY_MODIFIER", 9, 13], ["intestinal", "ANATOMY", 132, 142]]], ["The serpin homologues secreted by bifidobacterial species, which are specific inhibitors of proteases such as the human neutrophil elastase, are susceptible to reduce tissue damage at sites of intestinal inflammation (Ivanov et al., 2006) .ROTAVIRUSES, NOROVIRUSES, AND THE INTESTINAL MICROBIOTADue to the lack of simple models for the study of the interactions between RV, NoV, and the intestinal microbiota/probiotics, very few studies exist on this matter.", [["neutrophil", "ANATOMY", 120, 130], ["tissue", "ANATOMY", 167, 173], ["intestinal", "ANATOMY", 193, 203], ["intestinal", "ANATOMY", 387, 397], ["inflammation", "DISEASE", 204, 216], ["serpin", "GENE_OR_GENE_PRODUCT", 4, 10], ["bifidobacterial species", "ORGANISM", 34, 57], ["human", "ORGANISM", 114, 119], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 120, 139], ["tissue", "TISSUE", 167, 173], ["intestinal", "ORGAN", 193, 203], ["RV", "MULTI-TISSUE_STRUCTURE", 370, 372], ["intestinal", "ORGAN", 387, 397], ["serpin homologues", "PROTEIN", 4, 21], ["proteases", "PROTEIN", 92, 101], ["human neutrophil elastase", "PROTEIN", 114, 139], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 114, 119], ["bifidobacterial species", "PROBLEM", 34, 57], ["proteases", "TREATMENT", 92, 101], ["the human neutrophil elastase", "TREATMENT", 110, 139], ["tissue damage", "PROBLEM", 167, 180], ["intestinal inflammation", "PROBLEM", 193, 216], ["ROTAVIRUSES", "PROBLEM", 240, 251], ["the study", "TEST", 332, 341], ["probiotics", "TREATMENT", 409, 419], ["bifidobacterial species", "OBSERVATION", 34, 57], ["neutrophil elastase", "OBSERVATION", 120, 139], ["intestinal", "ANATOMY", 193, 203], ["inflammation", "OBSERVATION", 204, 216], ["NOROVIRUSES", "OBSERVATION", 253, 264], ["INTESTINAL", "ANATOMY", 274, 284], ["intestinal microbiota", "ANATOMY", 387, 408]]], ["Different strains of lactobacilli have been shown to bind on their surfaces P-particles of human NoV from genotypes GI.1 and GII.4.", [["lactobacilli", "CHEMICAL", 21, 33], ["lactobacilli", "SIMPLE_CHEMICAL", 21, 33], ["human", "ORGANISM", 91, 96], ["NoV", "ORGANISM", 97, 100], ["human", "SPECIES", 91, 96], ["human NoV", "SPECIES", 91, 100], ["Different strains of lactobacilli", "TREATMENT", 0, 33]]], ["Competitive experiments using lactobacilli and GII.4 P-particles showed that the presence of the bacteria inhibited the binding of the subviral particles to intestinal epithelial HT-29 cells (Rubio-del-Campo et al., 2014) .", [["intestinal epithelial HT-29 cells", "ANATOMY", 157, 190], ["lactobacilli", "SIMPLE_CHEMICAL", 30, 42], ["intestinal epithelial HT-29 cells", "CELL", 157, 190], ["intestinal epithelial HT-29 cells", "CELL_LINE", 157, 190], ["lactobacilli", "TREATMENT", 30, 42], ["GII.4 P-particles", "TEST", 47, 64], ["the bacteria", "PROBLEM", 93, 105], ["intestinal epithelial HT", "TEST", 157, 181], ["bacteria", "OBSERVATION", 97, 105], ["subviral particles", "OBSERVATION", 135, 153], ["intestinal epithelial", "ANATOMY", 157, 178]]], ["These observations also would be in agreement with previous reports showing that specific strains of Lactobacillus brevis, Lactobacillus gasseri, Lactobacillus salivarius, and Lactobacillus acidophilus isolated from feces display on their surfaces lectin-like activities that reside in their S-layer proteins and are able to bind types A, B, and H HBGAs.", [["feces", "ANATOMY", 216, 221], ["Lactobacillus brevis", "CHEMICAL", 101, 121], ["Lactobacillus gasseri", "CHEMICAL", 123, 144], ["Lactobacillus brevis", "ORGANISM", 101, 121], ["Lactobacillus gasseri", "ORGANISM", 123, 144], ["Lactobacillus salivarius", "ORGANISM", 146, 170], ["Lactobacillus acidophilus", "ORGANISM", 176, 201], ["feces", "ORGANISM_SUBSTANCE", 216, 221], ["lectin", "GENE_OR_GENE_PRODUCT", 248, 254], ["B", "GENE_OR_GENE_PRODUCT", 339, 340], ["H HBGAs", "SIMPLE_CHEMICAL", 346, 353], ["lectin", "PROTEIN", 248, 254], ["S-layer proteins", "PROTEIN", 292, 308], ["B", "PROTEIN", 339, 340], ["Lactobacillus brevis", "SPECIES", 101, 121], ["Lactobacillus gasseri", "SPECIES", 123, 144], ["Lactobacillus salivarius", "SPECIES", 146, 170], ["Lactobacillus acidophilus", "SPECIES", 176, 201], ["Lactobacillus brevis", "SPECIES", 101, 121], ["Lactobacillus gasseri", "SPECIES", 123, 144], ["Lactobacillus salivarius", "SPECIES", 146, 170], ["Lactobacillus acidophilus", "SPECIES", 176, 201], ["Lactobacillus brevis", "PROBLEM", 101, 121], ["Lactobacillus gasseri", "TREATMENT", 123, 144], ["Lactobacillus salivarius", "TREATMENT", 146, 170], ["Lactobacillus acidophilus", "TREATMENT", 176, 201], ["Lactobacillus brevis", "ANATOMY", 101, 121]]], ["These data suggest two types of mechanisms by which probiotics may interfere with binding of NoV to their target cells.", [["cells", "ANATOMY", 113, 118], ["NoV", "ORGANISM", 93, 96], ["cells", "CELL", 113, 118], ["target cells", "CELL_TYPE", 106, 118], ["probiotics", "TREATMENT", 52, 62], ["two types", "OBSERVATION_MODIFIER", 19, 28]]], ["First, probiotics may inhibit viral binding by competitive exclusion by blocking viral receptors and second, they can bind viruses on the surface promoting their elimination in feces and limiting viral access to target cells.ROTAVIRUSES, NOROVIRUSES, AND THE INTESTINAL MICROBIOTAAn intestinal isolate of Enterobacter sp. presents on its surface polymeric substances resembling A-type HBGA and it is able to bind NoV VLP of the GI.1 and GII.6 genotypes, which have binding capacity to this HBGA (Miura et al., 2013) .", [["surface", "ANATOMY", 138, 145], ["feces", "ANATOMY", 177, 182], ["cells", "ANATOMY", 219, 224], ["surface", "ANATOMY", 338, 345], ["surface", "CELLULAR_COMPONENT", 138, 145], ["feces", "ORGANISM_SUBDIVISION", 177, 182], ["cells", "CELL", 219, 224], ["intestinal", "ORGAN", 283, 293], ["Enterobacter sp", "ORGANISM", 305, 320], ["viral receptors", "PROTEIN", 81, 96], ["target cells", "CELL_TYPE", 212, 224], ["NoV VLP", "PROTEIN", 413, 420], ["GII", "PROTEIN", 437, 440], ["probiotics", "TREATMENT", 7, 17], ["viral binding", "PROBLEM", 30, 43], ["ROTAVIRUSES", "PROBLEM", 225, 236], ["NOROVIRUSES", "PROBLEM", 238, 249], ["Enterobacter sp", "PROBLEM", 305, 320], ["A-type HBGA", "PROBLEM", 378, 389], ["NOROVIRUSES", "OBSERVATION", 238, 249], ["INTESTINAL", "ANATOMY", 259, 269], ["intestinal", "ANATOMY", 283, 293], ["Enterobacter", "OBSERVATION", 305, 317], ["A-type", "OBSERVATION_MODIFIER", 378, 384]]], ["The presence of very close serological relationships to A, B, and H HBGA is present in about 10% of Gram-negative enterobacteria belonging to E. coli, Salmonella, Citrobacter, Proteus, Klebsiella, Pseudomonas, and Serratia, which explains the presence of immunoglobulins against nonself HBGA in humans.", [["HBGA", "CHEMICAL", 287, 291], ["B", "GENE_OR_GENE_PRODUCT", 59, 60], ["H HBGA", "ORGANISM", 66, 72], ["Gram", "GENE_OR_GENE_PRODUCT", 100, 104], ["E. coli", "ORGANISM", 142, 149], ["Salmonella", "ORGANISM", 151, 161], ["Citrobacter", "ORGANISM", 163, 174], ["Proteus, Klebsiella", "ORGANISM", 176, 195], ["Pseudomonas", "ORGANISM", 197, 208], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 255, 270], ["nonself HBGA", "SIMPLE_CHEMICAL", 279, 291], ["humans", "ORGANISM", 295, 301], ["immunoglobulins", "PROTEIN", 255, 270], ["E. coli", "SPECIES", 142, 149], ["humans", "SPECIES", 295, 301], ["E. coli", "SPECIES", 142, 149], ["humans", "SPECIES", 295, 301], ["H HBGA", "TEST", 66, 72], ["Gram", "TEST", 100, 104], ["enterobacteria", "PROBLEM", 114, 128], ["E. coli", "PROBLEM", 142, 149], ["Salmonella", "PROBLEM", 151, 161], ["Citrobacter", "PROBLEM", 163, 174], ["Proteus", "PROBLEM", 176, 183], ["Klebsiella", "PROBLEM", 185, 195], ["Pseudomonas", "PROBLEM", 197, 208], ["Serratia", "PROBLEM", 214, 222], ["immunoglobulins", "PROBLEM", 255, 270], ["nonself HBGA in humans", "PROBLEM", 279, 301], ["very", "OBSERVATION_MODIFIER", 16, 20], ["Klebsiella", "OBSERVATION_MODIFIER", 185, 195], ["Serratia", "OBSERVATION", 214, 222]]], ["The existence of this HBGA activity in bacteria is generally dependent on the expression of different glycosyltransferases that are encoded in O-antigen synthesis gene clusters and that are responsible for the incorporation of the polysaccharide moieties in LPS of Gram-negative bacteria.ROTAVIRUSES, NOROVIRUSES, AND THE INTESTINAL MICROBIOTAA recent breakthrough on NoV research is represented by the finding that, similar to murine NoV, human NoV can infect lymphocytes .", [["lymphocytes", "ANATOMY", 461, 472], ["LPS", "CHEMICAL", 258, 261], ["HBGA", "GENE_OR_GENE_PRODUCT", 22, 26], ["O-antigen", "GENE_OR_GENE_PRODUCT", 143, 152], ["LPS", "SIMPLE_CHEMICAL", 258, 261], ["Gram", "GENE_OR_GENE_PRODUCT", 265, 269], ["NoV", "ORGANISM", 368, 371], ["murine", "ORGANISM", 428, 434], ["NoV", "ORGANISM", 435, 438], ["human", "ORGANISM", 440, 445], ["NoV", "ORGANISM", 446, 449], ["lymphocytes", "CELL", 461, 472], ["HBGA", "PROTEIN", 22, 26], ["glycosyltransferases", "PROTEIN", 102, 122], ["O-antigen synthesis gene clusters", "DNA", 143, 176], ["lymphocytes", "CELL_TYPE", 461, 472], ["murine", "SPECIES", 428, 434], ["human", "SPECIES", 440, 445], ["NoV", "SPECIES", 435, 438], ["human", "SPECIES", 440, 445], ["this HBGA activity in bacteria", "PROBLEM", 17, 47], ["different glycosyltransferases", "PROBLEM", 92, 122], ["the polysaccharide moieties", "PROBLEM", 227, 254], ["Gram-negative bacteria", "PROBLEM", 265, 287], ["ROTAVIRUSES", "PROBLEM", 288, 299], ["NOROVIRUSES", "PROBLEM", 301, 312], ["activity", "OBSERVATION_MODIFIER", 27, 35], ["bacteria", "OBSERVATION", 39, 47], ["generally", "OBSERVATION_MODIFIER", 51, 60], ["dependent", "OBSERVATION_MODIFIER", 61, 70], ["negative bacteria", "OBSERVATION", 270, 287], ["NOROVIRUSES", "OBSERVATION", 301, 312], ["INTESTINAL", "ANATOMY", 322, 332]]], ["Since the discovery of human NoV 40 years ago, multiple attempts to reproduce infection in in vitro cell culture systems or adequate small animal models failed.", [["cell culture", "ANATOMY", 100, 112], ["infection", "DISEASE", 78, 87], ["human", "ORGANISM", 23, 28], ["cell", "CELL", 100, 104], ["human", "SPECIES", 23, 28], ["human NoV", "SPECIES", 23, 32], ["infection", "PROBLEM", 78, 87], ["vitro cell culture systems", "TEST", 94, 120], ["infection", "OBSERVATION", 78, 87], ["small", "OBSERVATION_MODIFIER", 133, 138]]], ["Recently, it has been demonstrated that human NoV infection can take place in vitro by using B cells as hosts and that this infectivity is linked to the intestinal microbiota .", [["B cells", "ANATOMY", 93, 100], ["intestinal", "ANATOMY", 153, 163], ["NoV infection", "DISEASE", 46, 59], ["human", "ORGANISM", 40, 45], ["NoV", "ORGANISM", 46, 49], ["B cells", "CELL", 93, 100], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 153, 174], ["B cells", "CELL_TYPE", 93, 100], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["human NoV infection", "PROBLEM", 40, 59], ["B cells", "TREATMENT", 93, 100], ["this infectivity", "PROBLEM", 119, 135], ["infection", "OBSERVATION", 50, 59], ["intestinal microbiota", "ANATOMY", 153, 174]]], ["Stocks of NoV isolated from feces and filtered (devoid of any accompanying bacteria) are much less infective than unfiltered NoV preparations.", [["feces", "ANATOMY", 28, 33], ["NoV", "ORGANISM", 10, 13], ["feces", "ORGANISM_SUBSTANCE", 28, 33], ["NoV", "SPECIES", 10, 13], ["NoV", "SPECIES", 125, 128], ["NoV", "PROBLEM", 10, 13], ["any accompanying bacteria", "PROBLEM", 58, 83], ["NoV", "OBSERVATION", 10, 13], ["bacteria", "OBSERVATION", 75, 83]]], ["It was also shown that enteric bacteria, such as Enterobacter cloacae, that express H-type HBGA on its surface, enhances GII.4 NoV attachment and infection in target cells in a dose-dependent manner .", [["surface", "ANATOMY", 103, 110], ["cells", "ANATOMY", 166, 171], ["infection", "DISEASE", 146, 155], ["Enterobacter cloacae", "ORGANISM", 49, 69], ["H-type HBGA", "GENE_OR_GENE_PRODUCT", 84, 95], ["surface", "CELLULAR_COMPONENT", 103, 110], ["GII.4 NoV", "ORGANISM", 121, 130], ["cells", "CELL", 166, 171], ["H-type HBGA", "PROTEIN", 84, 95], ["target cells", "CELL_TYPE", 159, 171], ["Enterobacter cloacae", "SPECIES", 49, 69], ["Enterobacter cloacae", "SPECIES", 49, 69], ["GII.4 NoV", "SPECIES", 121, 130], ["enteric bacteria", "PROBLEM", 23, 39], ["Enterobacter cloacae", "PROBLEM", 49, 69], ["H-type HBGA", "PROBLEM", 84, 95], ["infection in target cells", "PROBLEM", 146, 171], ["enteric", "OBSERVATION_MODIFIER", 23, 30], ["bacteria", "OBSERVATION", 31, 39], ["Enterobacter cloacae", "OBSERVATION", 49, 69], ["H-type", "OBSERVATION_MODIFIER", 84, 90], ["surface", "OBSERVATION_MODIFIER", 103, 110], ["GII.4 NoV", "OBSERVATION", 121, 130], ["infection", "OBSERVATION", 146, 155], ["target cells", "OBSERVATION", 159, 171]]], ["However, an E. coli strain lacking HBGA activity or its LPS does not show any effect.", [["LPS", "CHEMICAL", 56, 59], ["E. coli", "ORGANISM", 12, 19], ["strain", "ORGANISM", 20, 26], ["HBGA", "GENE_OR_GENE_PRODUCT", 35, 39], ["LPS", "SIMPLE_CHEMICAL", 56, 59], ["HBGA", "PROTEIN", 35, 39], ["E. coli", "SPECIES", 12, 19], ["E. coli", "SPECIES", 12, 19], ["an E. coli strain", "TEST", 9, 26], ["its LPS", "TEST", 52, 59], ["coli strain", "OBSERVATION", 15, 26]]], ["In agreement with these findings, MNoV infection in antibiotictreated mice is reduced compared to mice with normal intestinal microbiota.", [["intestinal", "ANATOMY", 115, 125], ["MNoV", "CHEMICAL", 34, 38], ["infection", "DISEASE", 39, 48], ["MNoV", "GENE_OR_GENE_PRODUCT", 34, 38], ["mice", "ORGANISM", 70, 74], ["mice", "ORGANISM", 98, 102], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 115, 136], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 98, 102], ["these findings", "TEST", 18, 32], ["MNoV infection in antibiotictreated mice", "PROBLEM", 34, 74], ["infection", "OBSERVATION", 39, 48], ["intestinal microbiota", "ANATOMY", 115, 136]]], ["Microbiota ablation with antibiotics also prevented persistent MNoV infection in mice.", [["MNoV", "CHEMICAL", 63, 67], ["infection", "DISEASE", 68, 77], ["MNoV", "GENE_OR_GENE_PRODUCT", 63, 67], ["mice", "ORGANISM", 81, 85], ["mice", "SPECIES", 81, 85], ["MNoV", "SPECIES", 63, 67], ["mice", "SPECIES", 81, 85], ["Microbiota ablation", "TREATMENT", 0, 19], ["antibiotics", "TREATMENT", 25, 36], ["persistent MNoV infection", "PROBLEM", 52, 77], ["ablation", "OBSERVATION", 11, 19], ["persistent", "OBSERVATION_MODIFIER", 52, 62], ["MNoV", "OBSERVATION_MODIFIER", 63, 67], ["infection", "OBSERVATION", 68, 77]]], ["This effect was dependent on the IFN-\u03b3 receptor (Baldridge et al., 2015) , which again suggests that intestinal microbiota promotes MNoV persistence and that components of the innate immune system counteract it.", [["intestinal microbiota", "ANATOMY", 101, 122], ["MNoV", "ANATOMY", 132, 136], ["IFN-\u03b3 receptor", "GENE_OR_GENE_PRODUCT", 33, 47], ["intestinal", "ORGAN", 101, 111], ["MNoV", "GENE_OR_GENE_PRODUCT", 132, 136], ["IFN", "PROTEIN", 33, 36], ["\u03b3 receptor", "PROTEIN", 37, 47], ["intestinal microbiota", "PROBLEM", 101, 122], ["the innate immune system", "TREATMENT", 172, 196], ["intestinal microbiota", "ANATOMY", 101, 122]]], ["Although additional mechanisms derived from the microbiota cannot be excluded, the interaction of NoV with the intestinal bacteria seems a crucial factor for a productive attachment of the virus to target cells.", [["intestinal", "ANATOMY", 111, 121], ["cells", "ANATOMY", 205, 210], ["NoV", "ORGANISM", 98, 101], ["intestinal", "ORGAN", 111, 121], ["cells", "CELL", 205, 210], ["target cells", "CELL_TYPE", 198, 210], ["the intestinal bacteria", "PROBLEM", 107, 130], ["a crucial factor", "PROBLEM", 137, 153], ["a productive attachment of the virus", "PROBLEM", 158, 194], ["intestinal", "ANATOMY", 111, 121]]], ["Biopsies analysis of individuals infected with NoV and infections using tissue explants pointed to intestinal epithelial cells as targets for human NoV replication, but it is now evident that these viruses may present different cellular tropisms.", [["Biopsies", "ANATOMY", 0, 8], ["tissue explants", "ANATOMY", 72, 87], ["intestinal epithelial cells", "ANATOMY", 99, 126], ["cellular", "ANATOMY", 228, 236], ["infections", "DISEASE", 55, 65], ["individuals", "ORGANISM", 21, 32], ["NoV", "ORGANISM", 47, 50], ["tissue explants", "TISSUE", 72, 87], ["intestinal epithelial cells", "CELL", 99, 126], ["human", "ORGANISM", 142, 147], ["cellular", "CELL", 228, 236], ["intestinal epithelial cells", "CELL_TYPE", 99, 126], ["human", "SPECIES", 142, 147], ["NoV", "SPECIES", 47, 50], ["human NoV", "SPECIES", 142, 151], ["Biopsies analysis", "TEST", 0, 17], ["individuals infected", "PROBLEM", 21, 41], ["NoV", "PROBLEM", 47, 50], ["infections", "PROBLEM", 55, 65], ["tissue explants", "TREATMENT", 72, 87], ["intestinal epithelial cells", "PROBLEM", 99, 126], ["human NoV replication", "TREATMENT", 142, 163], ["these viruses", "PROBLEM", 192, 205], ["different cellular tropisms", "PROBLEM", 218, 245], ["intestinal epithelial cells", "OBSERVATION", 99, 126], ["viruses", "OBSERVATION", 198, 205], ["cellular tropisms", "OBSERVATION", 228, 245]]], ["Similarly, it has been shown that in vivo infection by MNoV in mice targets B lymphocytes from intestinal Peyer's patches.", [["B lymphocytes", "ANATOMY", 76, 89], ["infection", "DISEASE", 42, 51], ["MNoV", "CHEMICAL", 55, 59], ["MNoV", "GENE_OR_GENE_PRODUCT", 55, 59], ["mice", "ORGANISM", 63, 67], ["B lymphocytes", "CELL", 76, 89], ["MNoV", "PROTEIN", 55, 59], ["B lymphocytes", "CELL_TYPE", 76, 89], ["mice", "SPECIES", 63, 67], ["MNoV", "SPECIES", 55, 59], ["mice", "SPECIES", 63, 67], ["vivo infection", "PROBLEM", 37, 51], ["intestinal Peyer's patches", "TREATMENT", 95, 121], ["vivo", "OBSERVATION_MODIFIER", 37, 41], ["infection", "OBSERVATION", 42, 51], ["intestinal", "ANATOMY", 95, 105]]], ["Whether these results, which have been obtained with the GII.4 genotype, could be extended to other NoV genotypes needs to be explored.", [["NoV", "ORGANISM", 100, 103]]], ["In any case, these new findings open the door to a kind of research on NoV biology that has been elusive in past years.", [["NoV", "ORGANISM", 71, 74]]], ["The mechanism on how NoV use HBGA molecules derived from the microbiota for infectivity is not known.", [["NoV", "ORGANISM", 21, 24], ["HBGA molecules", "GENE_OR_GENE_PRODUCT", 29, 43], ["HBGA molecules", "PROTEIN", 29, 43], ["HBGA molecules", "PROBLEM", 29, 43], ["infectivity", "PROBLEM", 76, 87]]], ["Earlier studies evidenced that the in vitro binding of NoV VLPs to several HBGA was promoted by uncharacterized stool components and the participation of antibodies or proteins in this process was discarded, as the effects were not sensitive to temperature (Harrington et al., 2004) .", [["HBGA", "CHEMICAL", 75, 79], ["NoV VLPs", "ORGANISM", 55, 63], ["HBGA", "GENE_OR_GENE_PRODUCT", 75, 79], ["NoV VLPs", "PROTEIN", 55, 63], ["HBGA", "PROTEIN", 75, 79], ["antibodies", "PROTEIN", 154, 164], ["NoV", "SPECIES", 55, 58], ["Earlier studies", "TEST", 0, 15], ["NoV VLPs", "PROBLEM", 55, 63], ["uncharacterized stool components", "PROBLEM", 96, 128], ["antibodies or proteins", "PROBLEM", 154, 176], ["stool", "OBSERVATION", 112, 117]]], ["This raised the hypothesis that the microbiota or lipidic or polysaccharide substances derived from it are participating in the process.", [["lipidic", "SIMPLE_CHEMICAL", 50, 57], ["polysaccharide substances", "PROBLEM", 61, 86]]], ["Similar to human NoV and MNoV, it has been demonstrated that antibiotic treatment in mice or the use of germ-free mice reduced RV infection in more than 40% (Uchiyama et al., 2014) .", [["RV", "ANATOMY", 127, 129], ["RV infection", "DISEASE", 127, 139], ["human", "ORGANISM", 11, 16], ["NoV", "ORGANISM", 17, 20], ["MNoV", "CELL", 25, 29], ["mice", "ORGANISM", 85, 89], ["germ-free", "ORGANISM", 104, 113], ["mice", "ORGANISM", 114, 118], ["RV", "ORGAN", 127, 129], ["human", "SPECIES", 11, 16], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 114, 118], ["human", "SPECIES", 11, 16], ["NoV", "SPECIES", 17, 20], ["MNoV", "SPECIES", 25, 29], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 114, 118], ["RV", "SPECIES", 127, 129], ["antibiotic treatment", "TREATMENT", 61, 81], ["free mice reduced RV infection", "PROBLEM", 109, 139], ["RV", "ANATOMY", 127, 129], ["infection", "OBSERVATION", 130, 139]]], ["A more persistent anti-RV response in terms of specific IgA secreting cells, linked to a reduced severity and diarrhea duration, is also found in animals with depleted microbiota.", [["anti-RV", "ANATOMY", 18, 25], ["cells", "ANATOMY", 70, 75], ["diarrhea", "DISEASE", 110, 118], ["anti-RV", "CANCER", 18, 25], ["IgA", "GENE_OR_GENE_PRODUCT", 56, 59], ["cells", "CELL", 70, 75], ["IgA secreting cells", "CELL_TYPE", 56, 75], ["A more persistent anti-RV response", "PROBLEM", 0, 34], ["specific IgA secreting cells", "PROBLEM", 47, 75], ["a reduced severity", "PROBLEM", 87, 105], ["diarrhea duration", "PROBLEM", 110, 127], ["persistent", "OBSERVATION_MODIFIER", 7, 17], ["anti-RV response", "OBSERVATION", 18, 34], ["IgA secreting cells", "OBSERVATION", 56, 75], ["reduced", "OBSERVATION_MODIFIER", 89, 96], ["severity", "OBSERVATION_MODIFIER", 97, 105], ["diarrhea", "OBSERVATION", 110, 118], ["depleted microbiota", "OBSERVATION", 159, 178]]], ["Therefore, the two virus groups responsible for the majority of gastroenteritis rely on the intestinal microbiota for infectivity.ROTAVIRUSES, NOROVIRUSES, AND THE INTESTINAL MICROBIOTAAnother research study on the participation of the intestinal microbiota in the infectivity of enteric viruses has revealed that other microbial-derived products are also important for viral pathogenesis.", [["intestinal", "ANATOMY", 92, 102], ["intestinal", "ANATOMY", 236, 246], ["gastroenteritis", "DISEASE", 64, 79], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 92, 113], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 236, 257], ["the two virus groups", "TREATMENT", 11, 31], ["gastroenteritis", "PROBLEM", 64, 79], ["infectivity", "PROBLEM", 118, 129], ["ROTAVIRUSES", "PROBLEM", 130, 141], ["THE INTESTINAL MICROBIOTAAnother research study", "TEST", 160, 207], ["the intestinal microbiota", "TREATMENT", 232, 257], ["enteric viruses", "PROBLEM", 280, 295], ["viral pathogenesis", "PROBLEM", 370, 388], ["gastroenteritis", "OBSERVATION", 64, 79], ["intestinal microbiota", "ANATOMY", 92, 113], ["NOROVIRUSES", "OBSERVATION", 143, 154], ["INTESTINAL", "ANATOMY", 164, 174], ["intestinal microbiota", "ANATOMY", 236, 257]]], ["Human polioviruses can infect transgenic mice that express the poliovirus receptor (PVR).", [["Human", "ORGANISM", 0, 5], ["polioviruses", "ORGANISM", 6, 18], ["mice", "ORGANISM", 41, 45], ["poliovirus receptor", "GENE_OR_GENE_PRODUCT", 63, 82], ["PVR", "GENE_OR_GENE_PRODUCT", 84, 87], ["poliovirus receptor", "PROTEIN", 63, 82], ["PVR", "PROTEIN", 84, 87], ["Human", "SPECIES", 0, 5], ["mice", "SPECIES", 41, 45], ["Human polioviruses", "SPECIES", 0, 18], ["mice", "SPECIES", 41, 45], ["Human polioviruses", "PROBLEM", 0, 18]]], ["In this model, ablation of the intestinal microbiota by antibiotic treatment or the use of germ-free mice resulted in reduced viral infectivity.", [["intestinal", "ANATOMY", 31, 41], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 31, 52], ["mice", "ORGANISM", 101, 105], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 101, 105], ["ablation", "TREATMENT", 15, 23], ["the intestinal microbiota", "TREATMENT", 27, 52], ["antibiotic treatment", "TREATMENT", 56, 76], ["germ-free mice", "TREATMENT", 91, 105], ["reduced viral infectivity", "PROBLEM", 118, 143], ["ablation", "OBSERVATION", 15, 23], ["intestinal microbiota", "ANATOMY", 31, 52], ["reduced", "OBSERVATION_MODIFIER", 118, 125], ["viral infectivity", "OBSERVATION", 126, 143]]], ["It has been demonstrated that the presence of bacterial strains enhanced viral binding to PVR and infectivity and that the bacterial component LPS was responsible for this (Kuss et al., 2011) .", [["LPS", "CHEMICAL", 143, 146], ["PVR", "GENE_OR_GENE_PRODUCT", 90, 93], ["LPS", "SIMPLE_CHEMICAL", 143, 146], ["bacterial strains enhanced viral binding", "PROBLEM", 46, 86], ["PVR and infectivity", "PROBLEM", 90, 109], ["the bacterial component LPS", "PROBLEM", 119, 146], ["bacterial strains", "OBSERVATION", 46, 63], ["viral binding", "OBSERVATION", 73, 86]]], ["The VP1 capsid protein of the poliovirus virion binds LPS and this binding stabilizes the virion making it more heat-stable and bleach-resistant (Robinson et al., 2014) .", [["LPS", "CHEMICAL", 54, 57], ["VP1", "GENE_OR_GENE_PRODUCT", 4, 7], ["poliovirus virion", "ORGANISM", 30, 47], ["LPS", "GENE_OR_GENE_PRODUCT", 54, 57], ["virion", "CELLULAR_COMPONENT", 90, 96], ["VP1 capsid protein", "PROTEIN", 4, 22], ["poliovirus", "SPECIES", 30, 40], ["The VP1 capsid protein", "TEST", 0, 22], ["the poliovirus virion binds LPS", "TREATMENT", 26, 57], ["this binding", "PROBLEM", 62, 74], ["the virion", "TREATMENT", 86, 96], ["VP1", "OBSERVATION_MODIFIER", 4, 7], ["capsid protein", "OBSERVATION", 8, 22], ["poliovirus virion", "OBSERVATION", 30, 47], ["stable", "OBSERVATION_MODIFIER", 117, 123]]], ["A specific point mutation has been characterized in poliovirus VP1 (T99K) that presents a reduced interaction with LPS and rendered less infective viruses.", [["LPS", "CHEMICAL", 115, 118], ["poliovirus VP1", "ORGANISM", 52, 66], ["LPS", "SIMPLE_CHEMICAL", 115, 118], ["poliovirus VP1", "PROTEIN", 52, 66], ["A specific point mutation", "PROBLEM", 0, 25], ["poliovirus VP1", "TEST", 52, 66], ["a reduced interaction with LPS", "PROBLEM", 88, 118], ["less infective viruses", "PROBLEM", 132, 154], ["infective viruses", "OBSERVATION", 137, 154]]], ["Therefore, two different mechanisms mediated by the microbiota are involved in the enhancement of poliovirus infectivity: virion stability and cell attachment, but attachment requires significantly less LPS than stabilization (Robinson et al., 2014) .", [["cell", "ANATOMY", 143, 147], ["LPS", "CHEMICAL", 203, 206], ["poliovirus", "ORGANISM", 98, 108], ["cell", "CELL", 143, 147], ["LPS", "SIMPLE_CHEMICAL", 203, 206], ["poliovirus", "SPECIES", 98, 108], ["poliovirus infectivity", "PROBLEM", 98, 120], ["virion stability", "TREATMENT", 122, 138], ["cell attachment", "PROBLEM", 143, 158], ["poliovirus infectivity", "OBSERVATION", 98, 120], ["virion stability", "OBSERVATION", 122, 138], ["cell attachment", "OBSERVATION", 143, 158]]], ["Only the polysaccharide moiety of LPS is needed for this, as detoxified LPS in which the lipid A portion is removed retains the stabilization ability to poliovirus.", [["LPS", "CHEMICAL", 34, 37], ["LPS", "CHEMICAL", 72, 75], ["LPS", "SIMPLE_CHEMICAL", 34, 37], ["LPS", "SIMPLE_CHEMICAL", 72, 75], ["poliovirus", "ORGANISM", 153, 163], ["LPS", "TREATMENT", 34, 37], ["detoxified LPS", "TREATMENT", 61, 75], ["poliovirus", "PROBLEM", 153, 163], ["stabilization", "OBSERVATION", 128, 141]]], ["The polysaccharide chitin (long polymer of N-acetylglucosamine, GlcNAc) and the peptidoglycan component of the bacterial cell wall (a polymer carrying GlcNAc) have similar stabilizing characteristics.", [["cell wall", "ANATOMY", 121, 130], ["chitin", "CHEMICAL", 19, 25], ["N-acetylglucosamine", "CHEMICAL", 43, 62], ["N-acetylglucosamine", "CHEMICAL", 43, 62], ["GlcNAc", "CHEMICAL", 64, 70], ["GlcNAc", "CHEMICAL", 151, 157], ["polysaccharide chitin", "SIMPLE_CHEMICAL", 4, 25], ["N-acetylglucosamine", "SIMPLE_CHEMICAL", 43, 62], ["GlcNAc", "SIMPLE_CHEMICAL", 64, 70], ["cell wall", "TISSUE", 121, 130], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 151, 157], ["The polysaccharide chitin", "TREATMENT", 0, 25], ["N-acetylglucosamine, GlcNAc", "TREATMENT", 43, 70], ["the peptidoglycan component", "TREATMENT", 76, 103], ["the bacterial cell wall", "PROBLEM", 107, 130], ["a polymer carrying GlcNAc", "TREATMENT", 132, 157], ["polysaccharide", "OBSERVATION_MODIFIER", 4, 18], ["chitin", "OBSERVATION_MODIFIER", 19, 25], ["bacterial cell", "OBSERVATION", 111, 125], ["wall", "ANATOMY_MODIFIER", 126, 130], ["stabilizing characteristics", "OBSERVATION", 172, 199]]], ["In contrast, monomeric GlcNAc or chitohexaose (six GlcNAc residues) lack this effect, for which it is postulated that polysaccharides with more than six GlcNAc residues are required (Robinson et al., 2014) .ROTAVIRUSES, NOROVIRUSES, AND THE INTESTINAL MICROBIOTAThe relevant role of the microbiota in viral infectivity can be viewed as a \"double-edged sword,\" and it can have important implications in the use of probiotics.", [["chitohexaose", "CHEMICAL", 33, 45], ["GlcNAc", "CHEMICAL", 23, 29], ["chitohexaose", "CHEMICAL", 33, 45], ["GlcNAc", "CHEMICAL", 51, 57], ["GlcNAc", "CHEMICAL", 153, 159], ["monomeric GlcNAc", "GENE_OR_GENE_PRODUCT", 13, 29], ["chitohexaose", "SIMPLE_CHEMICAL", 33, 45], ["polysaccharides", "SIMPLE_CHEMICAL", 118, 133], ["monomeric GlcNAc", "TREATMENT", 13, 29], ["chitohexaose (six GlcNAc residues", "TREATMENT", 33, 66], ["polysaccharides", "TREATMENT", 118, 133], ["six GlcNAc residues", "TREATMENT", 149, 168], ["ROTAVIRUSES", "PROBLEM", 207, 218], ["viral infectivity", "PROBLEM", 301, 318], ["probiotics", "TREATMENT", 413, 423], ["NOROVIRUSES", "OBSERVATION", 220, 231], ["INTESTINAL MICROBIOTA", "ANATOMY", 241, 262]]], ["Some in vitro experiments have revealed that specific probiotic strains may impact bacterial pathogen adhesion.", [["Some in vitro experiments", "PROBLEM", 0, 25], ["specific probiotic strains", "PROBLEM", 45, 71], ["bacterial pathogen adhesion", "PROBLEM", 83, 110], ["bacterial", "OBSERVATION_MODIFIER", 83, 92], ["pathogen adhesion", "OBSERVATION", 93, 110]]], ["Thus, LGG enhanced adhesion of E. coli serotype O157 to human intestinal mucus by 50% (Lee et al., 2003) and other L. rhamnosus strains have similar effects (300% increment in adhesion) of Salmonella typhimurium (Tuomola et al., 1999) .", [["intestinal mucus", "ANATOMY", 62, 78], ["LGG", "CHEMICAL", 6, 9], ["LGG", "SIMPLE_CHEMICAL", 6, 9], ["E. coli", "ORGANISM", 31, 38], ["serotype O157", "ORGANISM", 39, 52], ["human", "ORGANISM", 56, 61], ["intestinal mucus", "MULTI-TISSUE_STRUCTURE", 62, 78], ["L. rhamnosus strains", "ORGANISM", 115, 135], ["Salmonella typhimurium", "ORGANISM", 189, 211], ["E. coli serotype O157", "SPECIES", 31, 52], ["human", "SPECIES", 56, 61], ["L. rhamnosus", "SPECIES", 115, 127], ["Salmonella typhimurium", "SPECIES", 189, 211], ["E. coli", "SPECIES", 31, 38], ["O157", "SPECIES", 48, 52], ["human", "SPECIES", 56, 61], ["L. rhamnosus", "SPECIES", 115, 127], ["Salmonella typhimurium", "SPECIES", 189, 211], ["E. coli serotype O157", "PROBLEM", 31, 52], ["other L. rhamnosus strains", "PROBLEM", 109, 135], ["Salmonella typhimurium", "PROBLEM", 189, 211], ["adhesion", "OBSERVATION_MODIFIER", 19, 27], ["E. coli", "OBSERVATION_MODIFIER", 31, 38], ["intestinal mucus", "ANATOMY", 62, 78]]], ["Also, Enterococcus faecium strains of veterinary use improved the adhesion of Campylobacter jejuni by 200% (Rinkinen et al., 2003) .", [["Campylobacter jejuni", "DISEASE", 78, 98], ["Enterococcus faecium", "ORGANISM", 6, 26], ["Campylobacter jejuni", "ORGANISM", 78, 98], ["Enterococcus faecium", "SPECIES", 6, 26], ["Campylobacter jejuni", "SPECIES", 78, 98], ["Enterococcus faecium", "SPECIES", 6, 26], ["Campylobacter jejuni", "SPECIES", 78, 98], ["Enterococcus faecium strains", "PROBLEM", 6, 34], ["Campylobacter jejuni", "PROBLEM", 78, 98], ["Enterococcus faecium", "OBSERVATION", 6, 26], ["adhesion", "OBSERVATION_MODIFIER", 66, 74], ["Campylobacter jejuni", "OBSERVATION", 78, 98]]], ["Therefore, it seems that specific combinations of probioticpathogen may represent a potential risk by increasing the interaction of the pathogen with the mucosa.", [["mucosa", "ANATOMY", 154, 160], ["probioticpathogen", "CHEMICAL", 50, 67], ["probioticpathogen", "SIMPLE_CHEMICAL", 50, 67], ["mucosa", "MULTI-TISSUE_STRUCTURE", 154, 160], ["probioticpathogen", "TREATMENT", 50, 67], ["increasing", "OBSERVATION_MODIFIER", 102, 112], ["mucosa", "ANATOMY", 154, 160]]], ["The same situation was observed when L. casei BL23 and E. coli Nissle 1917 were assayed for inhibition of GII.4 P-particles binding to HT-29 cells (Rubio-del-Campo et al., 2014) .", [["HT-29 cells", "ANATOMY", 135, 146], ["L. casei BL23", "ORGANISM", 37, 50], ["E. coli", "ORGANISM", 55, 62], ["Nissle 1917", "ORGANISM", 63, 74], ["HT-29 cells", "CELL", 135, 146], ["HT-29 cells", "CELL_LINE", 135, 146], ["L. casei", "SPECIES", 37, 45], ["E. coli", "SPECIES", 55, 62], ["L. casei BL23", "SPECIES", 37, 50], ["E. coli", "SPECIES", 55, 62], ["L. casei BL23", "TEST", 37, 50], ["E. coli Nissle", "TREATMENT", 55, 69], ["GII", "TEST", 106, 109], ["HT", "TEST", 135, 137], ["Rubio", "TEST", 148, 153]]], ["Exclusion and displacement experiments show that bacteria enhance the retention of the subviral particles to the cell surface, suggesting the possibility that in some specific cases viruses can take advantage of the intestinal microbiota or particular bacteria to reach the target cells.", [["cell surface", "ANATOMY", 113, 125], ["intestinal", "ANATOMY", 216, 226], ["cells", "ANATOMY", 281, 286], ["cell surface", "CELLULAR_COMPONENT", 113, 125], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 216, 237], ["cells", "CELL", 281, 286], ["target cells", "CELL_TYPE", 274, 286], ["displacement experiments", "TEST", 14, 38], ["bacteria", "PROBLEM", 49, 57], ["some specific cases viruses", "PROBLEM", 162, 189], ["the intestinal microbiota", "PROBLEM", 212, 237], ["particular bacteria", "PROBLEM", 241, 260], ["displacement", "OBSERVATION_MODIFIER", 14, 26], ["bacteria", "OBSERVATION_MODIFIER", 49, 57], ["retention", "OBSERVATION_MODIFIER", 70, 79], ["subviral particles", "OBSERVATION", 87, 105], ["cell surface", "OBSERVATION", 113, 125], ["suggesting the possibility", "UNCERTAINTY", 127, 153], ["intestinal", "ANATOMY", 216, 226], ["target cells", "OBSERVATION", 274, 286]]], ["According to the results of infectivity of human GII.4 NoV in B cells , this situation is probably also encountered in vivo.", [["B cells", "ANATOMY", 62, 69], ["human", "ORGANISM", 43, 48], ["GII.4 NoV", "ORGANISM", 49, 58], ["B cells", "CELL", 62, 69], ["B cells", "CELL_TYPE", 62, 69], ["human", "SPECIES", 43, 48], ["human GII.4 NoV", "SPECIES", 43, 58]]], ["Whether specific probiotics can block viral attachment or, conversely, they contribute to its cellular surface binding needs to be explored.ROTAVIRUSES, NOROVIRUSES, AND THE INTESTINAL MICROBIOTARV and NoV use oligosaccharides from glycoconjugates on cellular surfaces as receptors for attachment and entry.", [["cellular surface", "ANATOMY", 94, 110], ["cellular surfaces", "ANATOMY", 251, 268], ["cellular", "CELL", 94, 102], ["cellular", "CELL", 251, 259], ["block viral attachment", "PROBLEM", 32, 54], ["its cellular surface binding", "PROBLEM", 90, 118], ["ROTAVIRUSES", "PROBLEM", 140, 151], ["NOROVIRUSES", "PROBLEM", 153, 164], ["THE INTESTINAL MICROBIOTARV", "TREATMENT", 170, 197], ["cellular surfaces", "TREATMENT", 251, 268], ["NOROVIRUSES", "OBSERVATION", 153, 164], ["INTESTINAL", "ANATOMY", 174, 184]]], ["RV recognize sialic acid (N-acetyl-neuraminic acid) residues as a first step for cellular entry.", [["cellular", "ANATOMY", 81, 89], ["sialic acid", "CHEMICAL", 13, 24], ["N-acetyl-neuraminic acid", "CHEMICAL", 26, 50], ["sialic acid", "CHEMICAL", 13, 24], ["N-acetyl-neuraminic acid", "CHEMICAL", 26, 50], ["sialic acid", "SIMPLE_CHEMICAL", 13, 24], ["N-acetyl-neuraminic acid", "SIMPLE_CHEMICAL", 26, 50], ["cellular", "CELL", 81, 89], ["RV", "TEST", 0, 2], ["sialic acid", "TEST", 13, 24], ["N-acetyl-neuraminic acid)", "TREATMENT", 26, 51], ["sialic acid", "OBSERVATION", 13, 24]]], ["As already mentioned, NoV display binding specificities toward \u03b11,2-fucosylated carbohydrates and \u03b12,3-sialylated carbohydrates, which form part of HBGA expressed at mucosal surfaces.", [["mucosal surfaces", "ANATOMY", 166, 182], ["carbohydrates", "CHEMICAL", 80, 93], ["carbohydrates", "CHEMICAL", 114, 127], ["NoV", "ORGANISM", 22, 25], ["\u03b11,2-fucosylated carbohydrates", "SIMPLE_CHEMICAL", 63, 93], ["\u03b12,3-sialylated carbohydrates", "SIMPLE_CHEMICAL", 98, 127], ["HBGA", "SIMPLE_CHEMICAL", 148, 152], ["mucosal surfaces", "MULTI-TISSUE_STRUCTURE", 166, 182], ["HBGA", "PROTEIN", 148, 152], ["binding specificities", "TEST", 34, 55], ["fucosylated carbohydrates", "TREATMENT", 68, 93], ["sialylated carbohydrates", "TREATMENT", 103, 127], ["mucosal surfaces", "ANATOMY", 166, 182]]], ["Many bacterial species also bind to glycosylated surface proteins via their adhesins or can take advantage of glycoconjugates present in the mucosa as a carbon source.", [["surface", "ANATOMY", 49, 56], ["mucosa", "ANATOMY", 141, 147], ["carbon", "CHEMICAL", 153, 159], ["mucosa", "MULTI-TISSUE_STRUCTURE", 141, 147], ["glycosylated surface proteins", "PROTEIN", 36, 65], ["adhesins", "PROTEIN", 76, 84], ["Many bacterial species", "PROBLEM", 0, 22], ["glycosylated surface proteins", "TREATMENT", 36, 65], ["glycoconjugates", "TREATMENT", 110, 125], ["bacterial species", "OBSERVATION", 5, 22], ["mucosa", "ANATOMY", 141, 147], ["carbon source", "OBSERVATION", 153, 166]]], ["Susceptibility to NoV infections has been related to HBGA types but the individual secretor status, determined by the presence of the H antigen in secretions and epithelia and linked to the FUT-2 gene, is of special relevance.", [["secretions", "ANATOMY", 147, 157], ["epithelia", "ANATOMY", 162, 171], ["NoV infections", "DISEASE", 18, 32], ["NoV", "ORGANISM", 18, 21], ["HBGA", "GENE_OR_GENE_PRODUCT", 53, 57], ["H antigen", "GENE_OR_GENE_PRODUCT", 134, 143], ["epithelia", "TISSUE", 162, 171], ["FUT-2", "GENE_OR_GENE_PRODUCT", 190, 195], ["H antigen", "PROTEIN", 134, 143], ["FUT-2 gene", "DNA", 190, 200], ["NoV", "SPECIES", 18, 21], ["NoV infections", "PROBLEM", 18, 32], ["HBGA types", "PROBLEM", 53, 63], ["the H antigen in secretions", "PROBLEM", 130, 157], ["epithelia", "PROBLEM", 162, 171], ["infections", "OBSERVATION", 22, 32]]], ["It has been shown that the antibody prevalence and titer to NoV was dependent on the secretor status rather than the blood group (Larsson et al., 2006) .", [["blood", "ANATOMY", 117, 122], ["NoV", "ORGANISM", 60, 63], ["blood", "ORGANISM_SUBSTANCE", 117, 122], ["NoV", "SPECIES", 60, 63], ["the antibody prevalence", "TEST", 23, 46]]], ["Thus, NoV infection depends on the gut microbiota and the secretor status, but could it be possible that the gut microbiota was also dependent on the secretor status?", [["gut", "ANATOMY", 35, 38], ["gut microbiota", "ANATOMY", 109, 123], ["infection", "DISEASE", 10, 19], ["NoV", "ORGANISM", 6, 9], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 35, 49], ["secretor", "GENE_OR_GENE_PRODUCT", 58, 66], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 109, 123], ["NoV", "SPECIES", 6, 9], ["NoV infection", "PROBLEM", 6, 19], ["infection", "OBSERVATION", 10, 19]]], ["Recent studies have shown exactly this (Wacklin et al., 2011 (Wacklin et al., , 2014 : human gut microbiota (HGM) composition varies depending on the FUT-2 genotype.", [["human", "ORGANISM", 87, 92], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 93, 107], ["FUT-2", "GENE_OR_GENE_PRODUCT", 150, 155], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["Recent studies", "TEST", 0, 14], ["the FUT", "TEST", 146, 153]]], ["Individuals defective in FUT-2 are less susceptible to NoV infections and at the same time have less diverse intestinal microbiota and presented marked diminished numbers of Bifidobacterium bifidum, Bifidobacterium adolescentis, and Bifidobacterium catenulatum/pseudocatenulatum (Wacklin et al., 2011) .", [["intestinal", "ANATOMY", 109, 119], ["infections", "DISEASE", 59, 69], ["Bifidobacterium bifidum", "CHEMICAL", 174, 197], ["FUT-2", "GENE_OR_GENE_PRODUCT", 25, 30], ["NoV", "ORGANISM", 55, 58], ["intestinal microbiota", "PATHOLOGICAL_FORMATION", 109, 130], ["Bifidobacterium bifidum", "ORGANISM", 174, 197], ["Bifidobacterium adolescentis", "ORGANISM", 199, 227], ["Bifidobacterium catenulatum", "ORGANISM", 233, 260], ["pseudocatenulatum", "ORGANISM", 261, 278], ["FUT", "PROTEIN", 25, 28], ["Bifidobacterium bifidum", "SPECIES", 174, 197], ["Bifidobacterium adolescentis", "SPECIES", 199, 227], ["Bifidobacterium catenulatum", "SPECIES", 233, 260], ["pseudocatenulatum", "SPECIES", 261, 278], ["NoV", "SPECIES", 55, 58], ["Bifidobacterium bifidum", "SPECIES", 174, 197], ["Bifidobacterium adolescentis", "SPECIES", 199, 227], ["Bifidobacterium catenulatum/pseudocatenulatum", "SPECIES", 233, 278], ["Individuals defective in FUT", "PROBLEM", 0, 28], ["NoV infections", "PROBLEM", 55, 69], ["marked diminished numbers of Bifidobacterium bifidum", "PROBLEM", 145, 197], ["Bifidobacterium adolescentis", "PROBLEM", 199, 227], ["Bifidobacterium catenulatum/pseudocatenulatum", "PROBLEM", 233, 278], ["infections", "OBSERVATION", 59, 69], ["intestinal microbiota", "ANATOMY", 109, 130], ["marked", "OBSERVATION_MODIFIER", 145, 151], ["diminished", "OBSERVATION_MODIFIER", 152, 162], ["Bifidobacterium bifidum", "ANATOMY", 174, 197], ["Bifidobacterium", "ANATOMY", 233, 248]]], ["Interestingly, specific members of the microbiota such as Bacteroides thetaiotaomicron can modulate the fucosylation state of surface glycans of enterocytes by regulating the host fucosylation pathways (Bry et al., 1996) .", [["surface glycans", "ANATOMY", 126, 141], ["enterocytes", "ANATOMY", 145, 156], ["Bacteroides thetaiotaomicron", "ORGANISM", 58, 86], ["enterocytes", "MULTI-TISSUE_STRUCTURE", 145, 156], ["enterocytes", "CELL_TYPE", 145, 156], ["Bacteroides thetaiotaomicron", "SPECIES", 58, 86], ["Bacteroides thetaiotaomicron", "SPECIES", 58, 86], ["Bacteroides thetaiotaomicron", "TREATMENT", 58, 86], ["enterocytes", "ANATOMY", 145, 156]]], ["This species and a strain of L. casei secrete soluble factors to the culture supernatant that increase the surface galactose content in enterocyte cells, limiting RV infection (Varyukhina et al., 2011) .", [["supernatant", "ANATOMY", 77, 88], ["surface", "ANATOMY", 107, 114], ["enterocyte cells", "ANATOMY", 136, 152], ["RV", "ANATOMY", 163, 165], ["galactose", "CHEMICAL", 115, 124], ["RV infection", "DISEASE", 163, 175], ["galactose", "CHEMICAL", 115, 124], ["L. casei", "ORGANISM", 29, 37], ["galactose", "SIMPLE_CHEMICAL", 115, 124], ["enterocyte cells", "CELL", 136, 152], ["RV", "ORGAN", 163, 165], ["soluble factors", "PROTEIN", 46, 61], ["enterocyte cells", "CELL_TYPE", 136, 152], ["L. casei", "SPECIES", 29, 37], ["L. casei", "SPECIES", 29, 37], ["This species", "PROBLEM", 0, 12], ["L. casei secrete soluble factors", "TREATMENT", 29, 61], ["the culture supernatant", "TEST", 65, 88], ["the surface galactose content", "TEST", 103, 132], ["enterocyte cells", "PROBLEM", 136, 152], ["RV infection", "PROBLEM", 163, 175], ["surface", "OBSERVATION_MODIFIER", 107, 114], ["galactose content", "OBSERVATION", 115, 132], ["enterocyte cells", "OBSERVATION", 136, 152], ["RV", "ANATOMY", 163, 165], ["infection", "OBSERVATION", 166, 175]]], ["Thus, in the complex gut ecosystem, viral infectivity studies have to consider many aspects that include host genetic background, glycobiology, and gut microbiota.EFFICACY OF PROBIOTICS AGAINST ENTERIC VIRUSES IN IN VITRO MODELS, ANIMAL, AND CLINICAL TRIALSWe recently reviewed the scientific data describing evidence of protection conferred by probiotics against intestinal viral infections in vitro, in laboratory animal studies, and in clinical trials (Rodriguez-Diaz and Monedero, 2012) .", [["gut ecosystem", "ANATOMY", 21, 34], ["gut microbiota", "ANATOMY", 148, 162], ["intestinal", "ANATOMY", 364, 374], ["intestinal viral infections", "DISEASE", 364, 391], ["gut", "ORGANISM_SUBDIVISION", 21, 24], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 148, 162], ["intestinal viral", "ORGANISM", 364, 380], ["viral infectivity studies", "TEST", 36, 61], ["PROBIOTICS", "TREATMENT", 175, 185], ["probiotics", "TREATMENT", 345, 355], ["intestinal viral infections", "PROBLEM", 364, 391], ["laboratory animal studies", "TEST", 405, 430], ["viral infectivity", "OBSERVATION", 36, 53], ["gut microbiota", "ANATOMY", 148, 162], ["VIRUSES", "OBSERVATION", 202, 209], ["intestinal", "ANATOMY", 364, 374], ["viral", "OBSERVATION", 375, 380]]], ["In the present section, we intend to update that data to track the new evidence published since 2011.EFFICACY OF PROBIOTICS AGAINST ENTERIC VIRUSES IN IN VITRO MODELS, ANIMAL, AND CLINICAL TRIALSDue to their importance and to the existence of proper in vitro and in vivo models, most of the evidence of the effectiveness of probiotics has been obtained with RV as the viral model.", [["PROBIOTICS", "TREATMENT", 113, 123], ["probiotics", "TREATMENT", 324, 334], ["VIRUSES", "OBSERVATION", 140, 147], ["viral model", "OBSERVATION", 368, 379]]], ["In the same way, RV was the selected pathogen in most of the clinical trials where the efficacy of probiotics on viral pathogens has been investigated.", [["the selected pathogen", "PROBLEM", 24, 45], ["probiotics", "TREATMENT", 99, 109], ["viral pathogens", "PROBLEM", 113, 128], ["RV", "ANATOMY", 17, 19]]], ["This is due to the great prevalence of these viruses in the infantile population, even after the introduction of RV vaccines, and to the existence of diagnostic tools for their detection.", [["infantile", "DISEASE", 60, 69], ["these viruses", "PROBLEM", 39, 52], ["RV vaccines", "TREATMENT", 113, 124], ["diagnostic tools", "TEST", 150, 166], ["their detection", "TEST", 171, 186], ["viruses", "OBSERVATION", 45, 52]]], ["Fortunately, new research on probiotics and NoV, the other viruses responsible for the great majority of gastroenteritis, is being published with the use of NoV surrogates in vitro, and at least in one clinical trial in humans.", [["gastroenteritis", "DISEASE", 105, 120], ["NoV", "ORGANISM", 44, 47], ["NoV", "ORGANISM", 157, 160], ["humans", "ORGANISM", 220, 226], ["humans", "SPECIES", 220, 226], ["NoV", "SPECIES", 44, 47], ["NoV", "SPECIES", 157, 160], ["humans", "SPECIES", 220, 226], ["probiotics", "TREATMENT", 29, 39], ["the other viruses", "PROBLEM", 49, 66], ["gastroenteritis", "PROBLEM", 105, 120], ["new", "OBSERVATION_MODIFIER", 13, 16], ["gastroenteritis", "OBSERVATION", 105, 120]]], ["New data has also been presented with respect to other viruses from the intestinal tract, as the transmissible gastroenteritis coronavirus (TGC).", [["intestinal tract", "ANATOMY", 72, 88], ["gastroenteritis coronavirus", "DISEASE", 111, 138], ["intestinal tract", "ORGAN", 72, 88], ["gastroenteritis coronavirus", "ORGANISM", 111, 138], ["transmissible gastroenteritis coronavirus", "SPECIES", 97, 138], ["other viruses from the intestinal tract", "PROBLEM", 49, 88], ["the transmissible gastroenteritis coronavirus", "PROBLEM", 93, 138], ["viruses", "OBSERVATION", 55, 62], ["intestinal tract", "ANATOMY", 72, 88], ["transmissible", "OBSERVATION_MODIFIER", 97, 110], ["gastroenteritis coronavirus", "OBSERVATION", 111, 138]]], ["Probiotics have also proved to be effective against other viruses, including respiratory viruses (Al Kassaa et al., 2014) , but they will not be discussed in this chapter.Efficacy of Probiotics: In Vitro DataThe in vitro models are of special interest to study not only the ability of probiotics to block viral infection but also to unravel the mechanisms of such inhibition at the cellular level.", [["cellular", "ANATOMY", 382, 390], ["respiratory viruses", "DISEASE", 77, 96], ["viral infection", "DISEASE", 305, 320], ["cellular", "CELL", 382, 390], ["Probiotics", "TREATMENT", 0, 10], ["other viruses", "PROBLEM", 52, 65], ["respiratory viruses", "PROBLEM", 77, 96], ["Probiotics", "TREATMENT", 183, 193], ["probiotics", "TREATMENT", 285, 295], ["block viral infection", "PROBLEM", 299, 320], ["such inhibition at the cellular level", "PROBLEM", 359, 396], ["viruses", "OBSERVATION", 58, 65], ["infection", "OBSERVATION", 311, 320]]], ["It is now well established that RV (as well as NoV) utilize oligosaccharides in the surface of the cells in the first steps of viral infection as receptors and co-receptors.Efficacy of Probiotics: In Vitro DataVaryukhina and collaborators have shown that glycan-modifying bacteria such as the probiotic bacteria L. casei DN114001 and the commensal bacteria Bacteroides thetaiotaomicron are able to inhibit RV infection in the mucus secretor human cell line HT-29-MTX through the modification of the glycan surface of the cells.", [["surface", "ANATOMY", 84, 91], ["cells", "ANATOMY", 99, 104], ["RV", "ANATOMY", 406, 408], ["mucus", "ANATOMY", 426, 431], ["cell line", "ANATOMY", 447, 456], ["surface", "ANATOMY", 506, 513], ["cells", "ANATOMY", 521, 526], ["viral infection", "DISEASE", 127, 142], ["L. casei DN114001", "CHEMICAL", 312, 329], ["RV infection", "DISEASE", 406, 418], ["HT-29-MTX", "CHEMICAL", 457, 466], ["MTX", "CHEMICAL", 463, 466], ["surface", "CELLULAR_COMPONENT", 84, 91], ["cells", "CELL", 99, 104], ["L. casei DN114001", "ORGANISM", 312, 329], ["commensal bacteria Bacteroides thetaiotaomicron", "ORGANISM", 338, 385], ["RV", "CELL", 406, 408], ["mucus secretor", "CELL", 426, 440], ["human", "ORGANISM", 441, 446], ["cell line HT-29-MTX", "CELL", 447, 466], ["surface", "CELLULAR_COMPONENT", 506, 513], ["cells", "CELL", 521, 526], ["co-receptors", "PROTEIN", 160, 172], ["mucus secretor human cell line", "CELL_LINE", 426, 456], ["L. casei", "SPECIES", 312, 320], ["Bacteroides thetaiotaomicron", "SPECIES", 357, 385], ["human", "SPECIES", 441, 446], ["L. casei DN114001", "SPECIES", 312, 329], ["Bacteroides thetaiotaomicron", "SPECIES", 357, 385], ["RV", "SPECIES", 406, 408], ["human", "SPECIES", 441, 446], ["oligosaccharides", "TREATMENT", 60, 76], ["viral infection", "PROBLEM", 127, 142], ["Probiotics", "TREATMENT", 185, 195], ["glycan", "TEST", 255, 261], ["modifying bacteria", "PROBLEM", 262, 280], ["the probiotic bacteria L. casei DN", "TREATMENT", 289, 323], ["the commensal bacteria Bacteroides thetaiotaomicron", "TREATMENT", 334, 385], ["RV infection", "PROBLEM", 406, 418], ["HT", "TEST", 457, 459], ["MTX", "TREATMENT", 463, 466], ["viral infection", "OBSERVATION", 127, 142], ["RV", "ANATOMY", 406, 408], ["infection", "OBSERVATION", 409, 418], ["cell line", "OBSERVATION", 447, 456], ["glycan", "ANATOMY_MODIFIER", 499, 505], ["surface", "ANATOMY_MODIFIER", 506, 513], ["cells", "ANATOMY", 521, 526]]], ["This modification was made through a secreted soluble factor of the bacteria that proved to have the same effect as the utilization of a galactosyltransferase from bovine milk (Varyukhina et al., 2011) .", [["milk", "ANATOMY", 171, 175], ["galactosyltransferase", "GENE_OR_GENE_PRODUCT", 137, 158], ["bovine", "ORGANISM", 164, 170], ["milk", "ORGANISM_SUBSTANCE", 171, 175], ["secreted soluble factor", "PROTEIN", 37, 60], ["galactosyltransferase", "PROTEIN", 137, 158], ["bovine", "SPECIES", 164, 170], ["bovine", "SPECIES", 164, 170], ["the bacteria", "PROBLEM", 64, 76], ["a galactosyltransferase from bovine milk", "TREATMENT", 135, 175]]], ["A novel mechanism for anti-RV activity has been recently described for the probiotic yeast S. boulardii.", [["anti-RV", "ANATOMY", 22, 29], ["anti-RV", "CANCER", 22, 29], ["yeast S. boulardii", "ORGANISM", 85, 103], ["anti-RV", "PROTEIN", 22, 29], ["yeast", "SPECIES", 85, 90], ["S. boulardii", "SPECIES", 91, 103], ["yeast", "SPECIES", 85, 90], ["S. boulardii", "SPECIES", 91, 103], ["anti-RV activity", "PROBLEM", 22, 38]]], ["The authors of the work investigated the role of oxidative stress (reactive oxygen species and oxidized and reduced glutathione) in the chloride secretion induced by RV and its toxin NSP4 in human epithelial cells.", [["epithelial cells", "ANATOMY", 197, 213], ["oxygen", "CHEMICAL", 76, 82], ["glutathione", "CHEMICAL", 116, 127], ["chloride", "CHEMICAL", 136, 144], ["oxygen", "CHEMICAL", 76, 82], ["oxidized and reduced glutathione", "CHEMICAL", 95, 127], ["chloride", "CHEMICAL", 136, 144], ["reactive oxygen species", "SIMPLE_CHEMICAL", 67, 90], ["oxidized", "SIMPLE_CHEMICAL", 95, 103], ["glutathione", "SIMPLE_CHEMICAL", 116, 127], ["chloride", "SIMPLE_CHEMICAL", 136, 144], ["NSP4", "GENE_OR_GENE_PRODUCT", 183, 187], ["human", "ORGANISM", 191, 196], ["epithelial cells", "CELL", 197, 213], ["toxin NSP4", "PROTEIN", 177, 187], ["human epithelial cells", "CELL_TYPE", 191, 213], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 191, 196], ["oxidative stress", "PROBLEM", 49, 65], ["reactive oxygen species", "TREATMENT", 67, 90], ["reduced glutathione)", "PROBLEM", 108, 128], ["the chloride secretion", "PROBLEM", 132, 154], ["RV", "TEST", 166, 168], ["its toxin NSP4 in human epithelial cells", "PROBLEM", 173, 213], ["reactive", "OBSERVATION_MODIFIER", 67, 75], ["oxygen species", "OBSERVATION", 76, 90], ["RV", "ANATOMY", 166, 168], ["human epithelial cells", "OBSERVATION", 191, 213]]], ["Both the antioxidant N-acetylcysteine and the supernatants of S. boulardii cultures were able to prevent RV and NSP4 chloride secretion via reduction of the oxidative stress.", [["supernatants", "ANATOMY", 46, 58], ["N-acetylcysteine", "CHEMICAL", 21, 37], ["chloride", "CHEMICAL", 117, 125], ["N-acetylcysteine", "CHEMICAL", 21, 37], ["chloride", "CHEMICAL", 117, 125], ["antioxidant N-acetylcysteine", "SIMPLE_CHEMICAL", 9, 37], ["S. boulardii", "ORGANISM", 62, 74], ["NSP4", "GENE_OR_GENE_PRODUCT", 112, 116], ["chloride", "SIMPLE_CHEMICAL", 117, 125], ["S. boulardii", "SPECIES", 62, 74], ["S. boulardii", "SPECIES", 62, 74], ["RV", "SPECIES", 105, 107], ["the antioxidant N-acetylcysteine", "TREATMENT", 5, 37], ["the supernatants", "TREATMENT", 42, 58], ["S. boulardii cultures", "TEST", 62, 83], ["RV", "TEST", 105, 107], ["NSP4 chloride secretion", "PROBLEM", 112, 135], ["the oxidative stress", "PROBLEM", 153, 173], ["oxidative stress", "OBSERVATION", 157, 173]]], ["The proposed mechanism of action then will be the production of unidentified soluble metabolites by S. boulardii that prevent oxidative stress (Buccigrossi et al., 2014) .", [["S. boulardii", "ORGANISM", 100, 112], ["S. boulardii", "SPECIES", 100, 112], ["S. boulardii", "SPECIES", 100, 112], ["unidentified soluble metabolites", "TREATMENT", 64, 96], ["oxidative stress", "PROBLEM", 126, 142]]], ["In vitro studies have also been utilized recently to evaluate novel probiotic strains, while these efforts are of interest to characterize the potential as probiotics of new bacterial isolates, few clues are reported on how probiotics exert their function.", [["vitro studies", "TEST", 3, 16], ["novel probiotic strains", "PROBLEM", 62, 85], ["new bacterial isolates", "PROBLEM", 170, 192]]], ["A new probiotic bacterium, Bifidobacterium longum subsp. infantis CECT7210, showed anti-RV activity in HT-29 and MA-104 cells (Munoz et al., 2011) .", [["anti-RV", "ANATOMY", 83, 90], ["HT-29", "ANATOMY", 103, 108], ["MA-104 cells", "ANATOMY", 113, 125], ["CECT7210", "CHEMICAL", 66, 74], ["Bifidobacterium longum", "ORGANISM", 27, 49], ["subsp", "ORGANISM", 50, 55], ["infantis", "ORGANISM", 57, 65], ["CECT7210", "SIMPLE_CHEMICAL", 66, 74], ["anti-RV", "CANCER", 83, 90], ["HT-29", "CELL", 103, 108], ["MA-104 cells", "CELL", 113, 125], ["anti-RV", "PROTEIN", 83, 90], ["HT-29", "CELL_LINE", 103, 108], ["MA-104 cells", "CELL_LINE", 113, 125], ["Bifidobacterium longum subsp", "SPECIES", 27, 55], ["infantis", "SPECIES", 57, 65], ["Bifidobacterium longum subsp", "SPECIES", 27, 55], ["infantis", "SPECIES", 57, 65], ["A new probiotic bacterium", "PROBLEM", 0, 25], ["Bifidobacterium longum subsp", "PROBLEM", 27, 55], ["anti-RV activity", "TEST", 83, 99], ["HT", "TEST", 103, 105], ["MA", "TEST", 113, 115], ["new", "OBSERVATION_MODIFIER", 2, 5], ["probiotic bacterium", "OBSERVATION_MODIFIER", 6, 25], ["Bifidobacterium longum", "ANATOMY", 27, 49]]], ["Similarly, three new bacteria isolated from feces of breast-fed infants (Lactobacillus paracasei CNCM I-4034, B. breve CNCM I-4035, and L. rhamnosus CNCM I-4036) were analyzed for their anti-RV activity in HT-29 cells.", [["feces", "ANATOMY", 44, 49], ["breast", "ANATOMY", 53, 59], ["anti-RV", "ANATOMY", 186, 193], ["HT-29 cells", "ANATOMY", 206, 217], ["Lactobacillus paracasei CNCM I-4034, B. breve CNCM I-4035", "CHEMICAL", 73, 130], ["CNCM I-4036", "CHEMICAL", 149, 160], ["feces", "ORGANISM_SUBDIVISION", 44, 49], ["breast", "ORGANISM_SUBDIVISION", 53, 59], ["infants", "ORGANISM", 64, 71], ["Lactobacillus paracasei CNCM I-4034", "ORGANISM", 73, 108], ["B. breve CNCM I-4035", "ORGANISM", 110, 130], ["L. rhamnosus CNCM I-4036", "CELL", 136, 160], ["HT-29 cells", "CELL", 206, 217], ["HT-29 cells", "CELL_LINE", 206, 217], ["infants", "SPECIES", 64, 71], ["Lactobacillus paracasei", "SPECIES", 73, 96], ["B. breve CNCM", "SPECIES", 110, 123], ["L. rhamnosus", "SPECIES", 136, 148], ["Lactobacillus paracasei CNCM I-4034", "SPECIES", 73, 108], ["B. breve CNCM I-4035", "SPECIES", 110, 130], ["L. rhamnosus CNCM I-4036", "SPECIES", 136, 160], ["three new bacteria", "PROBLEM", 11, 29], ["Lactobacillus paracasei", "TEST", 73, 96], ["L. rhamnosus", "TEST", 136, 148], ["new", "OBSERVATION_MODIFIER", 17, 20], ["bacteria", "OBSERVATION", 21, 29], ["breast", "ANATOMY", 53, 59]]], ["The supernatants from L. rhamnosus CNCM I-4036 and L. paracasei CNCM I-4034 proved to have straindependent antiviral activity, while B. breve CNCM I-4035 did not have any anti-RV activity (Munoz-Quezada et al., 2013) .Efficacy of Probiotics: In Vitro DataDespite their great importance for health, human NoV have been difficult to cultivate in an in vitro cell culture system, which impaired their study, including the investigation of potential probiotics against them.", [["supernatants", "ANATOMY", 4, 16], ["cell", "ANATOMY", 356, 360], ["L. rhamnosus CNCM I-4036", "CHEMICAL", 22, 46], ["CNCM I-4034", "CHEMICAL", 64, 75], ["CNCM I-4035", "CHEMICAL", 142, 153], ["L. rhamnosus CNCM I-4036", "ORGANISM", 22, 46], ["L. paracasei", "ORGANISM", 51, 63], ["CNCM I-4034", "ORGANISM", 64, 75], ["B. breve CNCM", "ORGANISM", 133, 146], ["anti-RV", "CANCER", 171, 178], ["human", "ORGANISM", 298, 303], ["NoV", "ORGANISM", 304, 307], ["cell", "CELL", 356, 360], ["L. rhamnosus CNCM", "SPECIES", 22, 39], ["L. paracasei", "SPECIES", 51, 63], ["B. breve", "SPECIES", 133, 141], ["human", "SPECIES", 298, 303], ["L. rhamnosus CNCM I-4036", "SPECIES", 22, 46], ["L. paracasei CNCM I-4034", "SPECIES", 51, 75], ["B. breve CNCM I-4035", "SPECIES", 133, 153], ["human", "SPECIES", 298, 303], ["straindependent antiviral activity", "TREATMENT", 91, 125], ["Probiotics", "TREATMENT", 230, 240], ["their study", "TEST", 392, 403], ["potential probiotics", "TREATMENT", 436, 456], ["L.", "OBSERVATION_MODIFIER", 22, 24], ["rhamnosus", "OBSERVATION", 25, 34]]], ["Recently, different NoV surrogates have been utilized to study the anti-NV activity of different bacterial strains.", [["NoV", "ORGANISM", 20, 23], ["anti-NV", "GENE_OR_GENE_PRODUCT", 67, 74], ["different bacterial strains", "PROBLEM", 87, 114], ["bacterial strains", "OBSERVATION", 97, 114]]], ["Lee and collaborators reported the inactivation of feline calicivirus and murine NoV during the fermentation of Dongchimi, a Korean vegetal fermented product.", [["feline calicivirus", "DISEASE", 51, 69], ["Dongchimi", "CHEMICAL", 112, 121], ["feline calicivirus", "ORGANISM", 51, 69], ["murine", "ORGANISM", 74, 80], ["NoV", "ORGANISM", 81, 84], ["Dongchimi", "SIMPLE_CHEMICAL", 112, 121], ["feline calicivirus", "SPECIES", 51, 69], ["murine", "SPECIES", 74, 80], ["feline calicivirus", "SPECIES", 51, 69], ["NoV", "SPECIES", 81, 84], ["Dongchimi", "TREATMENT", 112, 121], ["a Korean vegetal fermented product", "TREATMENT", 123, 157]]], ["In this case, no evidence of the mode of action or the bacteria responsible of the effect was obtained, but this represents the first report shedding some light on NoV inactivation by fermented products (Lee et al., 2012) .", [["NoV", "ORGANISM", 164, 167], ["the bacteria", "PROBLEM", 51, 63], ["no evidence of", "UNCERTAINTY", 14, 28]]], ["More recently, the feline calicivirus was also utilized as a human NoV surrogate to study the antiviral activity of the probiotic strain Lactococcus lactis subsp. lactis LM0230.", [["feline calicivirus", "DISEASE", 19, 37], ["LM0230", "CHEMICAL", 170, 176], ["feline calicivirus", "ORGANISM", 19, 37], ["human", "ORGANISM", 61, 66], ["NoV", "ORGANISM", 67, 70], ["Lactococcus lactis", "ORGANISM", 137, 155], ["subsp", "ORGANISM", 156, 161], ["lactis LM0230", "ORGANISM", 163, 176], ["feline calicivirus", "SPECIES", 19, 37], ["human", "SPECIES", 61, 66], ["Lactococcus lactis subsp", "SPECIES", 137, 161], ["lactis", "SPECIES", 163, 169], ["feline calicivirus", "SPECIES", 19, 37], ["human", "SPECIES", 61, 66], ["Lactococcus lactis subsp", "SPECIES", 137, 161], ["lactis", "SPECIES", 163, 169], ["the feline calicivirus", "PROBLEM", 15, 37], ["a human NoV surrogate", "TREATMENT", 59, 80], ["lactis", "TEST", 163, 169]]], ["The authors show that the preincubation of the virus with the bacterial cells as well as with the filtrated culture media reduced the viral infection (Aboubakr et al., 2014) .", [["cells", "ANATOMY", 72, 77], ["viral infection", "DISEASE", 134, 149], ["bacterial cells", "CELL", 62, 77], ["bacterial cells", "CELL_TYPE", 62, 77], ["the virus", "PROBLEM", 43, 52], ["the bacterial cells", "PROBLEM", 58, 77], ["the filtrated culture media", "TEST", 94, 121], ["the viral infection", "PROBLEM", 130, 149], ["bacterial cells", "OBSERVATION", 62, 77], ["viral infection", "OBSERVATION", 134, 149]]], ["Perhaps the most utilized human NoV surrogates for structural, functional, and antigenic studies have been the NoV VLP and NoV P-particles.", [["human", "ORGANISM", 26, 31], ["NoV VLP", "ORGANISM", 111, 118], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["antigenic studies", "TEST", 79, 96]]], ["These last surrogates were utilized to assay the ability of several probiotic and nonprobiotic bacteria from intestinal or food origin to bind human NoV and to study whether that binding produced any impairment in the NoV-host interaction.", [["intestinal", "ANATOMY", 109, 119], ["intestinal", "ORGAN", 109, 119], ["human", "ORGANISM", 143, 148], ["NoV", "ORGANISM", 149, 152], ["human", "SPECIES", 143, 148], ["human NoV", "SPECIES", 143, 152], ["nonprobiotic bacteria", "PROBLEM", 82, 103], ["any impairment", "PROBLEM", 196, 210], ["intestinal", "ANATOMY", 109, 119]]], ["Interestingly, only when the bacteria (L. casei BL23 or E. coli Nissle 1917) and NoV P-particles (GI.1 genotype) were coadministered to HT-29 cells, a reduction of NoV P-particles binding to cells was found.", [["HT-29 cells", "ANATOMY", 136, 147], ["cells", "ANATOMY", 191, 196], ["HT", "DISEASE", 136, 138], ["L. casei BL23", "ORGANISM", 39, 52], ["E. coli", "ORGANISM", 56, 63], ["Nissle 1917", "ORGANISM", 64, 75], ["HT-29 cells", "CELL", 136, 147], ["cells", "CELL", 191, 196], ["HT-29 cells", "CELL_LINE", 136, 147], ["L. casei", "SPECIES", 39, 47], ["E. coli", "SPECIES", 56, 63], ["L. casei", "SPECIES", 39, 47], ["E. coli", "SPECIES", 56, 63], ["the bacteria", "TEST", 25, 37], ["L. casei BL23", "TEST", 39, 52], ["E. coli Nissle", "TREATMENT", 56, 70], ["NoV P-particles (GI.1 genotype)", "TREATMENT", 81, 112], ["HT", "TEST", 136, 138]]], ["When either NoV P-particles or probiotic bacteria were preincubated with the cells, an increase in the NoV particles binding to HT-29 was observed (Rubio-del-Campo et al., 2014).", [["cells", "ANATOMY", 77, 82], ["HT-29", "CHEMICAL", 128, 133], ["cells", "CELL", 77, 82], ["probiotic bacteria", "PROBLEM", 31, 49], ["the cells", "PROBLEM", 73, 82], ["HT", "TEST", 128, 130], ["increase", "OBSERVATION_MODIFIER", 87, 95]]], ["As already discussed, this surprising enhancement effect of probiotics on NoV attachment has been recently corroborated by the establishment of a human NoV cell culture system with the participation of gut microbiota .Efficacy of Probiotics: In Vitro DataThe TGC is a virus of great importance on pig farms as it produces acute diarrhea in pigs and can cause a high mortality in newborn piglets.", [["cell", "ANATOMY", 156, 160], ["gut microbiota", "ANATOMY", 202, 216], ["diarrhea", "DISEASE", 328, 336], ["NoV", "ORGANISM", 74, 77], ["human", "ORGANISM", 146, 151], ["NoV cell", "CELL", 152, 160], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 202, 216], ["pig", "ORGANISM", 297, 300], ["pigs", "ORGANISM", 340, 344], ["piglets", "ORGANISM", 387, 394], ["human", "SPECIES", 146, 151], ["pig", "SPECIES", 297, 300], ["pigs", "SPECIES", 340, 344], ["piglets", "SPECIES", 387, 394], ["NoV", "SPECIES", 74, 77], ["human", "SPECIES", 146, 151], ["pig", "SPECIES", 297, 300], ["pigs", "SPECIES", 340, 344], ["NoV attachment", "PROBLEM", 74, 88], ["a human NoV cell culture system", "TREATMENT", 144, 175], ["pig farms", "TREATMENT", 297, 306], ["acute diarrhea", "PROBLEM", 322, 336], ["a high mortality in newborn piglets", "PROBLEM", 359, 394], ["acute", "OBSERVATION_MODIFIER", 322, 327], ["diarrhea", "OBSERVATION", 328, 336], ["high", "OBSERVATION_MODIFIER", 361, 365], ["mortality", "OBSERVATION", 366, 375], ["newborn piglets", "OBSERVATION", 379, 394]]], ["Putative probiotic bacteria Lactobacillus spp. (probio 37 and probio 38) isolated from porcine gastrointestinal tract was shown to have anti-TGC activity in vitro.", [["gastrointestinal tract", "ANATOMY", 95, 117], ["Lactobacillus spp.", "CHEMICAL", 28, 46], ["probio 37 and probio 38", "CHEMICAL", 48, 71], ["Lactobacillus spp.", "ORGANISM", 28, 46], ["probio 37", "ORGANISM", 48, 57], ["probio 38", "ORGANISM", 62, 71], ["porcine", "ORGANISM", 87, 94], ["gastrointestinal tract", "ORGAN", 95, 117], ["anti-TGC", "GENE_OR_GENE_PRODUCT", 136, 144], ["anti-TGC", "PROTEIN", 136, 144], ["Lactobacillus spp.", "SPECIES", 28, 46], ["porcine", "SPECIES", 87, 94], ["Lactobacillus spp.", "SPECIES", 28, 46], ["porcine", "SPECIES", 87, 94], ["Putative probiotic bacteria Lactobacillus spp.", "PROBLEM", 0, 46], ["probio", "TEST", 48, 54], ["probio", "TEST", 62, 68], ["bacteria", "OBSERVATION_MODIFIER", 19, 27], ["Lactobacillus spp.", "OBSERVATION", 28, 46], ["gastrointestinal tract", "ANATOMY", 95, 117]]], ["The filtrated supernatants of both isolates were able to reduce TGC infectivity in ST cells (Kumar et al., 2010) .", [["supernatants", "ANATOMY", 14, 26], ["ST cells", "ANATOMY", 83, 91], ["TGC", "SIMPLE_CHEMICAL", 64, 67], ["ST cells", "CELL", 83, 91], ["ST cells", "CELL_TYPE", 83, 91], ["The filtrated supernatants of both isolates", "TREATMENT", 0, 43], ["TGC infectivity in ST cells", "PROBLEM", 64, 91]]], ["Similarly, the probiotic E. faecium NCIMB 10415 strain was able to inhibit TGC virus infection and to increase ST cells viability.", [["ST cells", "ANATOMY", 111, 119], ["NCIMB 10415", "CHEMICAL", 36, 47], ["infection", "DISEASE", 85, 94], ["E. faecium NCIMB 10415", "ORGANISM", 25, 47], ["TGC virus", "ORGANISM", 75, 84], ["ST cells", "CELL", 111, 119], ["ST cells", "CELL_TYPE", 111, 119], ["E. faecium", "SPECIES", 25, 35], ["E. faecium NCIMB 10415 strain", "SPECIES", 25, 54], ["the probiotic E. faecium NCIMB", "TEST", 11, 41], ["strain", "PROBLEM", 48, 54], ["TGC virus infection", "PROBLEM", 75, 94], ["increase ST cells viability", "PROBLEM", 102, 129]]], ["In this case, four protocols were studied, including pretreatment of cells, competition, postinfection treatment, and cell-free preincubation.", [["cells", "ANATOMY", 69, 74], ["cell", "ANATOMY", 118, 122], ["cells", "CELL", 69, 74], ["cell", "CELL", 118, 122], ["postinfection treatment", "TREATMENT", 89, 112], ["cell-free preincubation", "TREATMENT", 118, 141]]], ["In all four cases, an antiviral dose-response effect was observed (Chai et al., 2013) .Animal ModelsSimilar to the in vitro studies, the animal models have been utilized not only to study the efficacy of probiotics but mostly to obtain mechanistic information on the conferred protection.", [["an antiviral dose", "TREATMENT", 19, 36], ["vitro studies", "TEST", 118, 131], ["probiotics", "TREATMENT", 204, 214], ["the conferred protection", "TREATMENT", 263, 287]]], ["In this case, all the new data has been obtained for RV in three different animal models including rats, mice, and pigs.", [["rats", "ORGANISM", 99, 103], ["mice", "ORGANISM", 105, 109], ["pigs", "ORGANISM", 115, 119], ["rats", "SPECIES", 99, 103], ["mice", "SPECIES", 105, 109], ["pigs", "SPECIES", 115, 119], ["mice", "SPECIES", 105, 109], ["pigs", "SPECIES", 115, 119], ["RV", "TREATMENT", 53, 55]]], ["On top of the study of single probiotic strains and pathogenic RV, the effect of HGM transplantation and the use of vaccine strains of RV have also been addressed recently.", [["HGM", "CHEMICAL", 81, 84], ["RV", "MULTI-TISSUE_STRUCTURE", 135, 137], ["RV", "SPECIES", 135, 137], ["the study", "TEST", 10, 19], ["single probiotic strains", "TREATMENT", 23, 47], ["pathogenic RV", "PROBLEM", 52, 65], ["HGM transplantation", "TREATMENT", 81, 100], ["vaccine strains of RV", "TREATMENT", 116, 137], ["RV", "ANATOMY", 63, 65], ["HGM transplantation", "OBSERVATION", 81, 100], ["RV", "ANATOMY", 135, 137]]], ["Most of the results point to the modulation of the host immune system as the main mechanism of how probiotics help the organisms to fight against RV diarrhea.Animal ModelsVentola and collaborators utilized the newborn rat model to study the effectiveness of live or dead LGG against simian RV SA11 strain.", [["RV diarrhea", "DISEASE", 146, 157], ["LGG", "CHEMICAL", 271, 274], ["rat", "ORGANISM", 218, 221], ["LGG", "SIMPLE_CHEMICAL", 271, 274], ["simian RV SA11", "ORGANISM", 283, 297], ["rat", "SPECIES", 218, 221], ["simian", "SPECIES", 283, 289], ["RV", "SPECIES", 146, 148], ["simian RV SA11", "SPECIES", 283, 297], ["RV diarrhea", "PROBLEM", 146, 157], ["simian RV SA11 strain", "PROBLEM", 283, 304], ["diarrhea", "OBSERVATION", 149, 157]]], ["While a reduction of diarrhea was not observed, the authors found that both live and dead probiotics possessed beneficial effects for the rat pups in terms of prevention of the reduction of body weight losses and prevention of colon swelling compared to the infected control group (Ventola et al., 2012) .", [["body", "ANATOMY", 190, 194], ["colon", "ANATOMY", 227, 232], ["diarrhea", "DISEASE", 21, 29], ["weight losses", "DISEASE", 195, 208], ["colon swelling", "DISEASE", 227, 241], ["rat", "ORGANISM", 138, 141], ["pups", "ORGANISM_SUBDIVISION", 142, 146], ["body", "ORGANISM_SUBDIVISION", 190, 194], ["colon", "ORGAN", 227, 232], ["rat", "SPECIES", 138, 141], ["rat", "SPECIES", 138, 141], ["diarrhea", "PROBLEM", 21, 29], ["dead probiotics", "TREATMENT", 85, 100], ["the rat pups", "TREATMENT", 134, 146], ["body weight losses", "PROBLEM", 190, 208], ["colon swelling", "PROBLEM", 227, 241], ["reduction", "OBSERVATION_MODIFIER", 8, 17], ["diarrhea", "OBSERVATION", 21, 29], ["colon", "ANATOMY", 227, 232], ["swelling", "OBSERVATION", 233, 241]]], ["The adult mice model was utilized to confirm the anti-RV properties of the probiotic bacterial strain B. longum subsp. infantis CECT7210.", [["anti-RV", "ANATOMY", 49, 56], ["CECT7210", "CHEMICAL", 128, 136], ["mice", "ORGANISM", 10, 14], ["B. longum", "ORGANISM", 102, 111], ["subsp", "ORGANISM", 112, 117], ["mice", "SPECIES", 10, 14], ["B. longum subsp", "SPECIES", 102, 117], ["infantis", "SPECIES", 119, 127], ["mice", "SPECIES", 10, 14], ["B. longum subsp", "SPECIES", 102, 117], ["infantis", "SPECIES", 119, 127], ["the probiotic bacterial strain B. longum subsp", "PROBLEM", 71, 117]]], ["The authors found a delay of rotavirus shedding at 48 h postinfection and a lower antigen concentration at 7 days from infection, thus confirming their previous in vitro results (Munoz et al., 2011) .", [["infection", "DISEASE", 119, 128], ["rotavirus", "ORGANISM", 29, 38], ["rotavirus", "SPECIES", 29, 38], ["rotavirus shedding", "PROBLEM", 29, 47], ["a lower antigen concentration", "TREATMENT", 74, 103], ["infection", "PROBLEM", 119, 128], ["infection", "OBSERVATION", 119, 128]]], ["More interesting are the results obtained with the newborn mice model where reduction of diarrhea can result in a better understanding of the anti-RV effect of probiotics.", [["anti-RV", "ANATOMY", 142, 149], ["diarrhea", "DISEASE", 89, 97], ["mice", "ORGANISM", 59, 63], ["anti-RV", "CANCER", 142, 149], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 59, 63], ["the newborn mice model", "TREATMENT", 47, 69], ["diarrhea", "PROBLEM", 89, 97], ["the anti-RV effect of probiotics", "TREATMENT", 138, 170]]], ["The probiotic strain L. gasseri SBT2055 was heat inactivated and utilized to feed fertilized adult female mice.", [["L. gasseri", "CHEMICAL", 21, 31], ["SBT2055", "CHEMICAL", 32, 39], ["L. gasseri", "ORGANISM", 21, 31], ["SBT2055", "ORGANISM", 32, 39], ["mice", "ORGANISM", 106, 110], ["L. gasseri", "SPECIES", 21, 31], ["mice", "SPECIES", 106, 110], ["L. gasseri", "SPECIES", 21, 31], ["mice", "SPECIES", 106, 110]]], ["The dams were subsequently orally immunized with RV SA11 strain.", [["dams", "ORGANISM", 4, 8], ["RV", "SPECIES", 49, 51], ["RV SA11 strain", "PROBLEM", 49, 63]]], ["After birth, the pups of immunized females were challenged with RV and the diarrhea and IgA recorded.", [["diarrhea", "DISEASE", 75, 83], ["pups", "ORGANISM", 17, 21], ["IgA", "GENE_OR_GENE_PRODUCT", 88, 91], ["IgA", "PROTEIN", 88, 91], ["RV", "SPECIES", 64, 66], ["RV", "PROBLEM", 64, 66], ["the diarrhea", "PROBLEM", 71, 83], ["IgA", "TEST", 88, 91], ["RV", "ANATOMY", 64, 66], ["diarrhea", "OBSERVATION", 75, 83]]], ["This study showed a reduction in diarrhea in the pups from the group of mice that had been fed with STB2055 associated to a higher production of IgA in the immunized dams that also received the probiotic (Kadooka et al., 2012) .", [["diarrhea", "DISEASE", 33, 41], ["STB2055", "CHEMICAL", 100, 107], ["STB2055", "CHEMICAL", 100, 107], ["pups", "ORGANISM", 49, 53], ["mice", "ORGANISM", 72, 76], ["STB2055", "SIMPLE_CHEMICAL", 100, 107], ["IgA", "GENE_OR_GENE_PRODUCT", 145, 148], ["dams", "ORGANISM", 166, 170], ["IgA", "PROTEIN", 145, 148], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["This study", "TEST", 0, 10], ["a reduction in diarrhea in the pups", "PROBLEM", 18, 53], ["a higher production of IgA", "PROBLEM", 122, 148], ["reduction", "OBSERVATION_MODIFIER", 20, 29], ["diarrhea", "OBSERVATION", 33, 41]]], ["Two different strains of L. reuteri (DSM 17938 and ATCC PTA 6475) were also utilized in a neonatal mice model.", [["DSM 17938", "CHEMICAL", 37, 46], ["PTA 6475", "CHEMICAL", 56, 64], ["L. reuteri", "ORGANISM", 25, 35], ["DSM 17938", "CELL", 37, 46], ["ATCC PTA 6475", "CELL", 51, 64], ["mice", "ORGANISM", 99, 103], ["L. reuteri", "SPECIES", 25, 35], ["mice", "SPECIES", 99, 103], ["L. reuteri (DSM 17938 and ATCC PTA 6475", "SPECIES", 25, 64], ["mice", "SPECIES", 99, 103], ["a neonatal mice model", "TREATMENT", 88, 109], ["different", "OBSERVATION_MODIFIER", 4, 13], ["strains", "OBSERVATION_MODIFIER", 14, 21], ["L.", "OBSERVATION_MODIFIER", 25, 27], ["reuteri", "OBSERVATION_MODIFIER", 28, 35]]], ["Newborn mice were infected with homologous RV murine strain EC and subsequently treated or not with probiotics.", [["EC", "ANATOMY", 60, 62], ["mice", "ORGANISM", 8, 12], ["murine", "ORGANISM", 46, 52], ["EC", "CELL", 60, 62], ["RV murine strain EC", "CELL_LINE", 43, 62], ["mice", "SPECIES", 8, 12], ["murine", "SPECIES", 46, 52], ["mice", "SPECIES", 8, 12], ["homologous RV murine strain EC", "TREATMENT", 32, 62], ["probiotics", "TREATMENT", 100, 110]]], ["Both strains were able to reduce the duration of diarrhea.", [["diarrhea", "DISEASE", 49, 57], ["Both strains", "PROBLEM", 0, 12], ["diarrhea", "PROBLEM", 49, 57]]], ["The authors could explain the beneficial effect of probiotics through various mechanisms, which included a suppression of proinflammatory molecules such as macrophage inflammatory protein-1\u03b1 and IL-1\u03b2, but also a reduction in IL-7, IL-10, IL-12, and IFN-\u03b3 was observed, together with increased anti-RV specific antibodies.", [["macrophage inflammatory protein-1\u03b1", "GENE_OR_GENE_PRODUCT", 156, 190], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 195, 200], ["IL-7", "GENE_OR_GENE_PRODUCT", 226, 230], ["IL-10", "GENE_OR_GENE_PRODUCT", 232, 237], ["IL-12", "GENE_OR_GENE_PRODUCT", 239, 244], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 250, 255], ["anti-RV", "SIMPLE_CHEMICAL", 294, 301], ["proinflammatory molecules", "PROTEIN", 122, 147], ["macrophage inflammatory protein-1\u03b1 and IL-1\u03b2", "PROTEIN", 156, 200], ["IFN-\u03b3", "PROTEIN", 250, 255], ["anti-RV specific antibodies", "PROTEIN", 294, 321], ["probiotics", "TREATMENT", 51, 61], ["proinflammatory molecules", "PROBLEM", 122, 147], ["macrophage inflammatory protein", "TEST", 156, 187], ["IL", "TEST", 195, 197], ["IL", "TEST", 226, 228], ["IL", "TEST", 232, 234], ["IL", "TEST", 239, 241], ["IFN", "TEST", 250, 253], ["increased anti-RV specific antibodies", "PROBLEM", 284, 321], ["proinflammatory molecules", "OBSERVATION", 122, 147], ["reduction", "OBSERVATION_MODIFIER", 213, 222]]], ["The administration of probiotics also improved intestinal histopathology and enhanced intestinal microbiome richness and phylogenetic diversity (Preidis et al., 2012) .", [["intestinal", "ANATOMY", 47, 57], ["intestinal", "ANATOMY", 86, 96], ["intestinal", "ORGAN", 47, 57], ["intestinal", "ORGAN", 86, 96], ["probiotics", "TREATMENT", 22, 32], ["intestinal", "ANATOMY", 47, 57], ["histopathology", "OBSERVATION", 58, 72], ["intestinal", "ANATOMY", 86, 96], ["microbiome richness", "OBSERVATION", 97, 116], ["phylogenetic diversity", "OBSERVATION", 121, 143]]], ["Different doses and times of administration of LGG were assayed also in newborn mice to evaluate different interventions with these probiotic bacteria.", [["LGG", "CHEMICAL", 47, 50], ["LGG", "SIMPLE_CHEMICAL", 47, 50], ["mice", "ORGANISM", 80, 84], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84], ["administration of LGG", "TREATMENT", 29, 50], ["different interventions", "TREATMENT", 97, 120], ["these probiotic bacteria", "PROBLEM", 126, 150]]], ["The authors found that the most efficient intervention was the pretreating of the pups with the higher doses of bacteria.", [["pups", "ORGANISM", 82, 86], ["bacteria", "PROBLEM", 112, 120]]], ["The shortening in diarrhea and reduction of epithelium vacuolation in the jejunum could be explained by an increase of anti-RV IgA and IFN-\u03b3 .Animal ModelsThe gnotobiotic (gn) piglet model has been utilized in several studies in recent years to study how modulation of immune responses by probiotics can help in fighting rotavirus infections.", [["epithelium", "ANATOMY", 44, 54], ["jejunum", "ANATOMY", 74, 81], ["diarrhea", "DISEASE", 18, 26], ["rotavirus infections", "DISEASE", 321, 341], ["epithelium", "TISSUE", 44, 54], ["jejunum", "ORGAN", 74, 81], ["anti-RV IgA", "GENE_OR_GENE_PRODUCT", 119, 130], ["IFN", "GENE_OR_GENE_PRODUCT", 135, 138], ["piglet", "ORGANISM", 176, 182], ["rotavirus", "ORGANISM", 321, 330], ["anti-RV IgA", "PROTEIN", 119, 130], ["IFN", "PROTEIN", 135, 138], ["rotavirus", "SPECIES", 321, 330], ["The shortening in diarrhea", "PROBLEM", 0, 26], ["epithelium vacuolation in the jejunum", "PROBLEM", 44, 81], ["an increase of anti-RV IgA", "PROBLEM", 104, 130], ["The gnotobiotic (gn) piglet model", "PROBLEM", 155, 188], ["immune responses", "TREATMENT", 269, 285], ["probiotics", "TREATMENT", 289, 299], ["fighting rotavirus infections", "PROBLEM", 312, 341], ["shortening", "OBSERVATION_MODIFIER", 4, 14], ["diarrhea", "OBSERVATION", 18, 26], ["reduction", "OBSERVATION_MODIFIER", 31, 40], ["epithelium vacuolation", "OBSERVATION", 44, 66], ["jejunum", "ANATOMY", 74, 81], ["could be explained", "UNCERTAINTY", 82, 100], ["increase", "OBSERVATION_MODIFIER", 107, 115]]], ["In this sense, Azevedo and coworkers showed that a combination of L. acidophilus and L. reuteri can modulate cytokine responses in gn pigs infected with human RV, suggesting a regulatory role of lactic acid bacteria in maintaining gut homeostasis (Azevedo et al., 2012) .", [["gut", "ANATOMY", 231, 234], ["lactic acid", "CHEMICAL", 195, 206], ["lactic acid", "CHEMICAL", 195, 206], ["L. acidophilus", "ORGANISM", 66, 80], ["L. reuteri", "ORGANISM", 85, 95], ["gn pigs", "ORGANISM", 131, 138], ["human", "ORGANISM", 153, 158], ["RV", "ORGANISM", 159, 161], ["lactic acid", "SIMPLE_CHEMICAL", 195, 206], ["gut", "ORGANISM_SUBDIVISION", 231, 234], ["cytokine", "PROTEIN", 109, 117], ["L. acidophilus", "SPECIES", 66, 80], ["L. reuteri", "SPECIES", 85, 95], ["pigs", "SPECIES", 134, 138], ["human", "SPECIES", 153, 158], ["L. acidophilus", "SPECIES", 66, 80], ["L. reuteri", "SPECIES", 85, 95], ["pigs", "SPECIES", 134, 138], ["human", "SPECIES", 153, 158], ["L. acidophilus", "TREATMENT", 66, 80], ["L. reuteri", "TREATMENT", 85, 95], ["human RV", "TREATMENT", 153, 161], ["lactic acid bacteria", "PROBLEM", 195, 215], ["lactic acid", "OBSERVATION", 195, 206]]], ["The gn piglet model also has been utilized to study the effect of different dosages of the proinflammatory L. acidophilus NCFM used as an adjuvant of human RV vaccine.", [["NCFM", "CHEMICAL", 122, 126], ["L. acidophilus NCFM", "ORGANISM", 107, 126], ["human", "ORGANISM", 150, 155], ["RV vaccine", "ORGANISM", 156, 166], ["L. acidophilus", "SPECIES", 107, 121], ["human", "SPECIES", 150, 155], ["L. acidophilus", "SPECIES", 107, 121], ["human", "SPECIES", 150, 155], ["The gn piglet model", "TREATMENT", 0, 19], ["different dosages", "TREATMENT", 66, 83], ["the proinflammatory L. acidophilus NCFM", "TREATMENT", 87, 126], ["an adjuvant of human RV vaccine", "TREATMENT", 135, 166], ["gn", "OBSERVATION", 4, 6]]], ["Interestingly, a low dose of NCFM increased IFN-\u03b3 T-cell response and downregulated TGF-\u03b2 and IL-10 production compared to a high dose.", [["T-cell", "ANATOMY", 50, 56], ["NCFM", "CHEMICAL", 29, 33], ["NCFM", "SIMPLE_CHEMICAL", 29, 33], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 44, 49], ["T-cell", "CELL", 50, 56], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 84, 89], ["IL-10", "GENE_OR_GENE_PRODUCT", 94, 99], ["IFN", "PROTEIN", 44, 47], ["TGF-\u03b2", "PROTEIN", 84, 89], ["a low dose of NCFM", "TREATMENT", 15, 33], ["T", "TEST", 50, 51], ["downregulated TGF", "TEST", 70, 87], ["IL", "TEST", 94, 96], ["cell response", "OBSERVATION", 52, 65], ["downregulated", "OBSERVATION_MODIFIER", 70, 83], ["TGF", "OBSERVATION_MODIFIER", 84, 87]]], ["These results are highly relevant because the same probiotic bacteria at different dosages can have opposite effects and either promote or suppress IFN-\u03b3 producing T cell or Treg cell immune responses Wen et al., 2012) .", [["T cell", "ANATOMY", 164, 170], ["Treg cell", "ANATOMY", 174, 183], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 148, 153], ["T cell", "CELL", 164, 170], ["Treg cell", "CELL", 174, 183], ["IFN", "PROTEIN", 148, 151], ["the same probiotic bacteria", "PROBLEM", 42, 69], ["IFN", "TEST", 148, 151], ["T cell", "PROBLEM", 164, 170]]], ["A combination of two probiotics (LGG and B. lactis Bb12) were utilized in combination or not with milk colostrum (col/milk) and the immune response to a human RV attenuated vaccine (AttHRV) studied.", [["milk", "ANATOMY", 118, 122], ["LGG", "CHEMICAL", 33, 36], ["LGG", "SIMPLE_CHEMICAL", 33, 36], ["B. lactis Bb12", "ORGANISM", 41, 55], ["milk", "ORGANISM", 98, 102], ["colostrum", "ORGANISM_SUBSTANCE", 103, 112], ["milk", "ORGANISM_SUBSTANCE", 118, 122], ["human", "ORGANISM", 153, 158], ["B. lactis", "SPECIES", 41, 50], ["milk", "SPECIES", 98, 102], ["human", "SPECIES", 153, 158], ["B. lactis", "SPECIES", 41, 50], ["human", "SPECIES", 153, 158], ["AttHRV", "SPECIES", 182, 188], ["two probiotics", "TREATMENT", 17, 31], ["LGG and B. lactis Bb12)", "TREATMENT", 33, 56], ["milk colostrum (col/milk", "TREATMENT", 98, 122], ["a human RV attenuated vaccine", "TREATMENT", 151, 180]]], ["The complexity of the study design makes it difficult to draw conclusions other than in words of the authors: \"col/milk components (soluble mediators) affect initial probiotic colonization, and together, they modulate neonatal antibody responses to oral AttHRV vaccine in complex ways\" .", [["oral", "ANATOMY", 249, 253], ["AttHRV", "CHEMICAL", 254, 260], ["oral", "ORGANISM_SUBDIVISION", 249, 253], ["col", "PROTEIN", 111, 114], ["soluble mediators", "PROTEIN", 132, 149], ["the study", "TEST", 18, 27], ["col/milk components (soluble mediators", "TREATMENT", 111, 149], ["initial probiotic colonization", "PROBLEM", 158, 188], ["neonatal antibody responses", "PROBLEM", 218, 245], ["oral AttHRV vaccine", "TREATMENT", 249, 268]]], ["In a subsequent study, the authors evaluated the same probiotics in the gn piglet model in response to the AttHRV and to a virulent human RV strain.", [["piglet", "ORGANISM", 75, 81], ["AttHRV", "GENE_OR_GENE_PRODUCT", 107, 113], ["human", "ORGANISM", 132, 137], ["RV strain", "ORGANISM", 138, 147], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["a subsequent study", "TEST", 3, 21], ["the gn piglet model", "TREATMENT", 68, 87], ["a virulent human RV strain", "PROBLEM", 121, 147], ["RV strain", "OBSERVATION", 138, 147]]], ["Similar to what was observed with different doses of probiotics, the modulation of immunological responses mediated by LGG-and Bb12-colonized gn piglets to the virulent RV differed from the responses to the vaccine strain (Chattha et al., 2014) .", [["RV", "ANATOMY", 169, 171], ["LGG", "SIMPLE_CHEMICAL", 119, 122], ["Bb12", "GENE_OR_GENE_PRODUCT", 127, 131], ["gn piglets", "ORGANISM", 142, 152], ["RV", "ORGAN", 169, 171], ["piglets", "SPECIES", 145, 152], ["probiotics", "TREATMENT", 53, 63], ["LGG", "TEST", 119, 122], ["Bb12", "TEST", 127, 131], ["gn", "OBSERVATION", 142, 144], ["virulent RV", "OBSERVATION_MODIFIER", 160, 171]]], ["The combination of LGG and Bb12 also modulated the innate immune response to RV in the gn piglet model.", [["LGG", "CHEMICAL", 19, 22], ["Bb12", "CHEMICAL", 27, 31], ["LGG", "SIMPLE_CHEMICAL", 19, 22], ["Bb12", "SIMPLE_CHEMICAL", 27, 31], ["piglet", "ORGAN", 90, 96], ["LGG and Bb12", "TREATMENT", 19, 31], ["the gn piglet model", "TREATMENT", 83, 102], ["LGG", "OBSERVATION", 19, 22], ["RV", "ANATOMY", 77, 79], ["gn piglet model", "OBSERVATION", 87, 102]]], ["The authors showed that the combination of vaccination and colonization by LGG and Bb12 completely abolished diarrhea after virulent RV challenge through immunomaturation as reflected by increased frequencies of CD4, SWC3a, CD11R1, and MHCII expressing mononuclear cells (MNCs) and conventional dendritic cells in intestinal tissues and blood postchallenge .", [["mononuclear cells", "ANATOMY", 253, 270], ["MNCs", "ANATOMY", 272, 276], ["dendritic cells", "ANATOMY", 295, 310], ["intestinal tissues", "ANATOMY", 314, 332], ["blood", "ANATOMY", 337, 342], ["LGG", "CHEMICAL", 75, 78], ["Bb12", "CHEMICAL", 83, 87], ["diarrhea", "DISEASE", 109, 117], ["LGG", "SIMPLE_CHEMICAL", 75, 78], ["Bb12", "SIMPLE_CHEMICAL", 83, 87], ["CD4", "GENE_OR_GENE_PRODUCT", 212, 215], ["SWC3a", "GENE_OR_GENE_PRODUCT", 217, 222], ["CD11R1", "GENE_OR_GENE_PRODUCT", 224, 230], ["MHCII", "GENE_OR_GENE_PRODUCT", 236, 241], ["mononuclear cells", "CELL", 253, 270], ["MNCs", "CELL", 272, 276], ["conventional dendritic cells", "CELL", 282, 310], ["intestinal tissues", "TISSUE", 314, 332], ["blood", "ORGANISM_SUBSTANCE", 337, 342], ["CD4", "PROTEIN", 212, 215], ["SWC3a", "PROTEIN", 217, 222], ["CD11R1", "PROTEIN", 224, 230], ["MHCII expressing mononuclear cells", "CELL_TYPE", 236, 270], ["MNCs", "CELL_TYPE", 272, 276], ["dendritic cells", "CELL_TYPE", 295, 310], ["RV", "SPECIES", 133, 135], ["vaccination", "TREATMENT", 43, 54], ["colonization", "PROBLEM", 59, 71], ["LGG", "PROBLEM", 75, 78], ["diarrhea", "PROBLEM", 109, 117], ["virulent RV challenge", "TREATMENT", 124, 145], ["immunomaturation", "TREATMENT", 154, 170], ["CD4", "TEST", 212, 215], ["MNCs", "TEST", 272, 276], ["conventional dendritic cells in intestinal tissues", "PROBLEM", 282, 332], ["blood postchallenge", "TEST", 337, 356], ["increased", "OBSERVATION_MODIFIER", 187, 196], ["mononuclear cells", "OBSERVATION", 253, 270], ["dendritic cells", "OBSERVATION", 295, 310], ["intestinal tissues", "ANATOMY", 314, 332]]], ["Gn pigs were also utilized to study the mechanism of LGG protection conferred to RV.", [["RV", "ANATOMY", 81, 83], ["LGG", "CHEMICAL", 53, 56], ["Gn pigs", "ORGANISM", 0, 7], ["LGG", "SIMPLE_CHEMICAL", 53, 56], ["Gn pigs", "SPECIES", 0, 7], ["Gn pigs", "TREATMENT", 0, 7], ["LGG protection", "TREATMENT", 53, 67], ["RV", "ANATOMY", 81, 83]]], ["The authors show that LGG is able to protect ileal epithelium from virulent human rotavirus injuries.", [["ileal epithelium", "ANATOMY", 45, 61], ["LGG", "CHEMICAL", 22, 25], ["rotavirus injuries", "DISEASE", 82, 100], ["LGG", "SIMPLE_CHEMICAL", 22, 25], ["ileal epithelium", "TISSUE", 45, 61], ["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["LGG", "PROBLEM", 22, 25], ["ileal epithelium", "PROBLEM", 45, 61], ["virulent human rotavirus injuries", "PROBLEM", 67, 100], ["ileal epithelium", "ANATOMY", 45, 61], ["virulent human", "OBSERVATION", 67, 81], ["rotavirus injuries", "OBSERVATION", 82, 100]]], ["Oral treatment with this strain increased the integrity of epithelium through the compensatory expression of \u03b1-catenin and \u03b2-catenin; tight junction proteins occludin, claudin-3, and claudin-4; and leak protein claudin-2.Animal ModelsLGG also increased mucin production and maintained the serum levels of the proinflammatory cytokine TGF-\u03b2 .", [["Oral", "ANATOMY", 0, 4], ["epithelium", "ANATOMY", 59, 69], ["tight junction", "ANATOMY", 134, 148], ["serum", "ANATOMY", 289, 294], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["epithelium", "TISSUE", 59, 69], ["\u03b1-catenin", "GENE_OR_GENE_PRODUCT", 109, 118], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 123, 132], ["tight junction", "GENE_OR_GENE_PRODUCT", 134, 148], ["occludin", "GENE_OR_GENE_PRODUCT", 158, 166], ["claudin-3", "GENE_OR_GENE_PRODUCT", 168, 177], ["claudin-4", "GENE_OR_GENE_PRODUCT", 183, 192], ["claudin-2", "GENE_OR_GENE_PRODUCT", 211, 220], ["mucin", "GENE_OR_GENE_PRODUCT", 253, 258], ["serum", "ORGANISM_SUBSTANCE", 289, 294], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 334, 339], ["\u03b1-catenin", "PROTEIN", 109, 118], ["\u03b2-catenin", "PROTEIN", 123, 132], ["tight junction proteins", "PROTEIN", 134, 157], ["occludin", "PROTEIN", 158, 166], ["claudin-3", "PROTEIN", 168, 177], ["claudin-4", "PROTEIN", 183, 192], ["leak protein claudin-2", "PROTEIN", 198, 220], ["proinflammatory cytokine", "PROTEIN", 309, 333], ["TGF-\u03b2", "PROTEIN", 334, 339], ["Oral treatment", "TREATMENT", 0, 14], ["this strain", "PROBLEM", 20, 31], ["\u03b1-catenin and \u03b2-catenin", "TREATMENT", 109, 132], ["tight junction proteins occludin", "TREATMENT", 134, 166], ["claudin", "TEST", 168, 175], ["claudin", "TEST", 183, 190], ["leak protein claudin", "TEST", 198, 218], ["increased mucin production", "PROBLEM", 243, 269], ["the serum levels", "TEST", 285, 301], ["the proinflammatory cytokine TGF", "TEST", 305, 337], ["compensatory expression", "OBSERVATION", 82, 105], ["increased", "OBSERVATION_MODIFIER", 243, 252], ["mucin production", "OBSERVATION", 253, 269]]], ["LGG has also been shown to protect against RV challenge in the gn piglet model through a novel mechanism reducing the autophagy induced by RV induction, as the treatment with LGG reduced the autophagy markers ATG16L1 and Beclin-1 and autophagy regulator mTOR preventing virus-induced tissue damage (Wu et al., 2014) .Animal ModelsInteresting results have been obtained in models in which transplantation of HGM to the gn pigs has been carried out.", [["RV", "ANATOMY", 43, 45], ["RV", "ANATOMY", 139, 141], ["tissue", "ANATOMY", 284, 290], ["LGG", "CHEMICAL", 0, 3], ["LGG", "CHEMICAL", 175, 178], ["tissue damage", "DISEASE", 284, 297], ["LGG", "SIMPLE_CHEMICAL", 0, 3], ["RV", "ORGAN", 43, 45], ["piglet", "ORGAN", 66, 72], ["LGG", "SIMPLE_CHEMICAL", 175, 178], ["ATG16L1", "GENE_OR_GENE_PRODUCT", 209, 216], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 221, 229], ["mTOR", "GENE_OR_GENE_PRODUCT", 254, 258], ["tissue", "TISSUE", 284, 290], ["HGM", "CANCER", 407, 410], ["pigs", "ORGANISM", 421, 425], ["autophagy markers", "PROTEIN", 191, 208], ["ATG16L1", "PROTEIN", 209, 216], ["Beclin-1", "PROTEIN", 221, 229], ["autophagy regulator", "PROTEIN", 234, 253], ["mTOR", "PROTEIN", 254, 258], ["pigs", "SPECIES", 421, 425], ["RV challenge", "TREATMENT", 43, 55], ["the gn piglet model", "TREATMENT", 59, 78], ["the autophagy", "PROBLEM", 114, 127], ["RV induction", "TREATMENT", 139, 151], ["the treatment", "TREATMENT", 156, 169], ["LGG", "TREATMENT", 175, 178], ["ATG16L1", "TEST", 209, 216], ["Beclin", "TEST", 221, 227], ["autophagy regulator mTOR", "TREATMENT", 234, 258], ["virus", "PROBLEM", 270, 275], ["tissue damage", "PROBLEM", 284, 297], ["transplantation of HGM", "TREATMENT", 388, 410], ["the gn pigs", "TREATMENT", 414, 425], ["gn piglet", "OBSERVATION", 63, 72]]], ["It can be argued that the lack of microbiota in the gn piglet model may interfere with the obtained results, especially if the same probiotic strains are to be used in humans that are obviously not depleted of their microbiota.", [["piglet", "ORGANISM", 55, 61], ["humans", "ORGANISM", 168, 174], ["humans", "SPECIES", 168, 174], ["humans", "SPECIES", 168, 174], ["the gn piglet model", "TREATMENT", 48, 67], ["the same probiotic strains", "PROBLEM", 123, 149]]], ["Two recent investigations address this issue with the use of transplantation models of HGM into gn piglets.", [["HGM", "CANCER", 87, 90], ["piglets", "ORGANISM", 99, 106], ["piglets", "SPECIES", 99, 106], ["transplantation models of HGM", "TREATMENT", 61, 90]]], ["The very well-characterized LGG strain was utilized in both gn pigs and HGM transplanted gn pigs.", [["pigs", "ORGANISM", 63, 67], ["pigs", "ORGANISM", 92, 96], ["pigs", "SPECIES", 63, 67], ["pigs", "SPECIES", 92, 96], ["pigs", "SPECIES", 63, 67], ["LGG strain", "PROBLEM", 28, 38], ["gn pigs", "OBSERVATION", 89, 96]]], ["As expected, the HGM group differed from the gn pigs in their response to LGG treatment.", [["LGG", "CHEMICAL", 74, 77], ["HGM", "CANCER", 17, 20], ["pigs", "ORGANISM", 48, 52], ["LGG", "SIMPLE_CHEMICAL", 74, 77], ["pigs", "SPECIES", 48, 52], ["the gn pigs", "TREATMENT", 41, 52], ["LGG treatment", "TREATMENT", 74, 87]]], ["The HGM group had an enhanced Th1 cellular immunity, but LGG treatment did not affect antibody responses in comparison to gn piglets that also responded with increased antibody response to RV.Animal ModelsThe authors argued that a higher dose of LGG might be needed to overtake the influence of the transplanted microbiota to achieve the immunostimulatory effect in the HGM pigs .", [["cellular", "ANATOMY", 34, 42], ["LGG", "CHEMICAL", 57, 60], ["LGG", "CHEMICAL", 246, 249], ["HGM", "CANCER", 4, 7], ["Th1 cellular", "CELL", 30, 42], ["LGG", "SIMPLE_CHEMICAL", 57, 60], ["piglets", "ORGANISM", 125, 132], ["LGG", "SIMPLE_CHEMICAL", 246, 249], ["HGM pigs", "ORGANISM", 370, 378], ["piglets", "SPECIES", 125, 132], ["pigs", "SPECIES", 374, 378], ["LGG treatment", "TREATMENT", 57, 70], ["antibody responses", "TEST", 86, 104], ["gn piglets", "TREATMENT", 122, 132], ["increased antibody response", "PROBLEM", 158, 185], ["a higher dose of LGG", "TREATMENT", 229, 249], ["the transplanted microbiota", "TREATMENT", 295, 322], ["Th1 cellular immunity", "OBSERVATION", 30, 51], ["antibody response", "OBSERVATION", 168, 185], ["RV", "ANATOMY", 189, 191]]], ["In their effort to validate the transplanted HGM gn piglet model, the same research group showed that both LGG and virulent human RV modulate the transplanted HGM similarly to what happens in human natural gut microbiota, suggesting that the HGM pig model is valuable for testing the response of microbiota to probiotic interventions .Clinical TrialsWhile the in vitro studies and animal models are very valuable tools for the characterization of new putative probiotics and for the elucidation of their underlying mechanisms of action, none of them can substitute for clinical trials to study the safety and efficacy of a probiotic intervention in humans.", [["HGM", "ANATOMY", 159, 162], ["gut microbiota", "ANATOMY", 206, 220], ["LGG", "CHEMICAL", 107, 110], ["piglet", "ORGANISM", 52, 58], ["LGG", "SIMPLE_CHEMICAL", 107, 110], ["human", "ORGANISM", 124, 129], ["RV", "CELL", 130, 132], ["HGM", "CANCER", 159, 162], ["human", "ORGANISM", 192, 197], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 206, 220], ["HGM pig", "ORGANISM", 242, 249], ["humans", "ORGANISM", 649, 655], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 192, 197], ["pig", "SPECIES", 246, 249], ["humans", "SPECIES", 649, 655], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 192, 197], ["pig", "SPECIES", 246, 249], ["humans", "SPECIES", 649, 655], ["the HGM pig model", "TREATMENT", 238, 255], ["probiotic interventions", "TREATMENT", 310, 333], ["Clinical Trials", "TEST", 335, 350], ["the in vitro studies", "TEST", 356, 376], ["new putative probiotics", "TREATMENT", 447, 470], ["a probiotic intervention", "TREATMENT", 621, 645], ["virulent", "OBSERVATION_MODIFIER", 115, 123], ["human RV", "ANATOMY", 124, 132], ["transplanted HGM", "OBSERVATION", 146, 162]]], ["Since our last revision, a variety of clinical trials have been published with different probiotics and results.", [["our last revision", "TREATMENT", 6, 23], ["clinical trials", "TREATMENT", 38, 53], ["different probiotics", "TREATMENT", 79, 99], ["revision", "OBSERVATION", 15, 23]]], ["Again, the variability in administration protocols and study designs makes it difficult to obtain general conclusions.", [["administration protocols", "TREATMENT", 26, 50], ["study", "TEST", 55, 60]]], ["While all the published interventions have not detected any safety issues related to the administered probiotics, some of them were shown to be inefficient for the treatment of RV-induced diarrhea.", [["diarrhea", "DISEASE", 188, 196], ["the administered probiotics", "TREATMENT", 85, 112], ["RV-induced diarrhea", "PROBLEM", 177, 196], ["RV", "ANATOMY", 177, 179], ["diarrhea", "OBSERVATION", 188, 196]]], ["Also, for the first time the use of probiotics has been addressed to NoV-induced diarrhea in humans.", [["diarrhea", "DISEASE", 81, 89], ["NoV", "ORGANISM", 69, 72], ["humans", "ORGANISM", 93, 99], ["humans", "SPECIES", 93, 99], ["humans", "SPECIES", 93, 99], ["probiotics", "TREATMENT", 36, 46], ["diarrhea", "PROBLEM", 81, 89]]], ["An open-case controlled study was conducted to assay the efficacy of L. casei Shirota against NoV in the elderly.", [["Shirota", "CHEMICAL", 78, 85], ["L. casei Shirota", "ORGANISM", 69, 85], ["NoV", "ORGANISM", 94, 97], ["L. casei", "SPECIES", 69, 77], ["L. casei", "SPECIES", 69, 77], ["NoV", "SPECIES", 94, 97], ["An open-case controlled study", "TEST", 0, 29]]], ["The study enrolled 77 adults with an average age of 84 years.", [["adults", "ORGANISM", 22, 28], ["The study", "TEST", 0, 9]]], ["The authors found that while daily consumption of milk fermented with the probiotic did not prevent the diarrhea produced by NoV, a reduction in the mean duration of fever was observed (Nagata et al., 2011) .", [["diarrhea", "DISEASE", 104, 112], ["fever", "DISEASE", 166, 171], ["milk", "ORGANISM_SUBSTANCE", 50, 54], ["NoV", "SPECIES", 125, 128], ["milk fermented", "TREATMENT", 50, 64], ["the probiotic", "TREATMENT", 70, 83], ["the diarrhea", "PROBLEM", 100, 112], ["a reduction", "TREATMENT", 130, 141], ["fever", "PROBLEM", 166, 171]]], ["Several clinical trials have been performed in the last few years studying the effect of several probiotics against RV in the infant population.", [["infant", "SPECIES", 126, 132], ["RV", "SPECIES", 116, 118], ["several probiotics", "TREATMENT", 89, 107]]], ["S. boulardii was shown to be efficient against RV diarrhea in infants in a double-blinded, placebo-controlled study in Brazil.", [["RV", "ANATOMY", 47, 49], ["RV diarrhea", "DISEASE", 47, 58], ["S. boulardii", "ORGANISM", 0, 12], ["infants", "ORGANISM", 62, 69], ["S. boulardii", "SPECIES", 0, 12], ["infants", "SPECIES", 62, 69], ["S. boulardii", "SPECIES", 0, 12], ["RV", "SPECIES", 47, 49], ["S. boulardii", "TREATMENT", 0, 12], ["RV diarrhea", "PROBLEM", 47, 58], ["placebo", "TREATMENT", 91, 98], ["diarrhea", "OBSERVATION", 50, 58]]], ["The study included 182 infants and 57% were confirmed to be positive for rotavirus by commercial ELISA tests.", [["infants", "ORGANISM", 23, 30], ["rotavirus", "ORGANISM", 73, 82], ["infants", "SPECIES", 23, 30], ["rotavirus", "SPECIES", 73, 82], ["The study", "TEST", 0, 9], ["rotavirus", "PROBLEM", 73, 82], ["commercial ELISA tests", "TEST", 86, 108]]], ["The infants that received the probiotic yeast (200 mg/day for 5 days) after the onset of diarrhea had reduced diarrhea duration, thus proving its efficiency (Correa et al., 2011) .", [["diarrhea", "DISEASE", 89, 97], ["diarrhea", "DISEASE", 110, 118], ["infants", "ORGANISM", 4, 11], ["infants", "SPECIES", 4, 11], ["yeast", "SPECIES", 40, 45], ["yeast", "SPECIES", 40, 45], ["the probiotic yeast", "TREATMENT", 26, 45], ["diarrhea", "PROBLEM", 89, 97], ["reduced diarrhea duration", "PROBLEM", 102, 127]]], ["Another randomized double-blind, placebo-controlled clinical trial was performed to study the effectiveness of Bacillus coagulans against RV diarrhea in children in Kolkata, India.", [["RV", "ANATOMY", 138, 140], ["RV diarrhea", "DISEASE", 138, 149], ["Bacillus coagulans", "ORGANISM", 111, 129], ["RV diarrhea", "ORGANISM", 138, 149], ["children", "ORGANISM", 153, 161], ["Bacillus coagulans", "SPECIES", 111, 129], ["children", "SPECIES", 153, 161], ["Bacillus coagulans", "SPECIES", 111, 129], ["placebo", "TREATMENT", 33, 40], ["Bacillus coagulans", "PROBLEM", 111, 129], ["RV diarrhea", "PROBLEM", 138, 149], ["diarrhea", "OBSERVATION", 141, 149]]], ["Also, a randomized double-blind, placebo-controlled clinical trial involving 106 infants (6-48 months of age) using L. reuteri DSM 17938 as the probiotic strain did not show any beneficial effect in RV-produced diarrhea (Wanke and Szajewska, 2012) .", [["L. reuteri DSM 17938", "CHEMICAL", 116, 136], ["diarrhea", "DISEASE", 211, 219], ["infants", "ORGANISM", 81, 88], ["L. reuteri DSM 17938", "ORGANISM", 116, 136], ["infants", "SPECIES", 81, 88], ["L. reuteri", "SPECIES", 116, 126], ["L. reuteri DSM 17938", "SPECIES", 116, 136], ["a randomized double-blind", "TREATMENT", 6, 31], ["placebo", "TREATMENT", 33, 40], ["L. reuteri DSM", "TEST", 116, 130], ["the probiotic strain", "TEST", 140, 160], ["diarrhea", "PROBLEM", 211, 219], ["RV", "ANATOMY", 199, 201], ["diarrhea", "OBSERVATION", 211, 219]]], ["The efficacy against RV of B. lactis and S. boulardii was assayed in a prospective randomized clinical trial with 75 children.", [["B. lactis", "ORGANISM", 27, 36], ["S. boulardii", "ORGANISM", 41, 53], ["children", "ORGANISM", 117, 125], ["B. lactis", "SPECIES", 27, 36], ["S. boulardii", "SPECIES", 41, 53], ["children", "SPECIES", 117, 125], ["RV", "SPECIES", 21, 23], ["B. lactis", "SPECIES", 27, 36], ["S. boulardii", "SPECIES", 41, 53], ["S. boulardii", "TREATMENT", 41, 53]]], ["Both treatments resulted in a shortened diarrhea duration compared to the nonprobiotic group (Erdogan et al., 2012) .", [["diarrhea", "DISEASE", 40, 48], ["a shortened diarrhea duration", "PROBLEM", 28, 57]]], ["A novel probiotic combination called BIO-THREE, composed of three different bacteria (strains of Enterococcus faecalis, Clostridium butyricum, and Bacillus mesentericus), was tested against RV-and Salmonellaproduced diarrhea in a single center open-label controlled clinical trial.", [["BIO-THREE", "CHEMICAL", 37, 46], ["diarrhea", "DISEASE", 216, 224], ["BIO-THREE", "SIMPLE_CHEMICAL", 37, 46], ["Enterococcus faecalis", "ORGANISM", 97, 118], ["Clostridium butyricum", "ORGANISM", 120, 141], ["Bacillus mesentericus", "ORGANISM", 147, 168], ["Enterococcus faecalis", "SPECIES", 97, 118], ["Clostridium butyricum", "SPECIES", 120, 141], ["Bacillus mesentericus", "SPECIES", 147, 168], ["Enterococcus faecalis", "SPECIES", 97, 118], ["Clostridium butyricum", "SPECIES", 120, 141], ["Bacillus mesentericus", "SPECIES", 147, 168], ["RV", "SPECIES", 190, 192], ["three different bacteria", "PROBLEM", 60, 84], ["Enterococcus faecalis", "PROBLEM", 97, 118], ["Clostridium butyricum", "PROBLEM", 120, 141], ["Bacillus mesentericus)", "PROBLEM", 147, 169], ["RV", "TEST", 190, 192], ["Salmonellaproduced diarrhea", "PROBLEM", 197, 224], ["Enterococcus faecalis", "OBSERVATION", 97, 118]]], ["The trial involved 159 patients from 3 months to 14 years of age (42 confirmed to be RV positive).", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31]]], ["The results showed a reduction in diarrhea duration while there was no effect in diarrhea severity .", [["diarrhea", "DISEASE", 34, 42], ["diarrhea", "DISEASE", 81, 89], ["a reduction in diarrhea duration", "PROBLEM", 19, 51], ["diarrhea severity", "PROBLEM", 81, 98], ["reduction", "OBSERVATION_MODIFIER", 21, 30], ["diarrhea", "OBSERVATION", 34, 42], ["no", "UNCERTAINTY", 68, 70], ["effect", "OBSERVATION_MODIFIER", 71, 77]]], ["LGG is one of the better-characterized probiotics in vitro, in vivo, and in clinical trials.", [["LGG", "CHEMICAL", 0, 3], ["LGG", "SIMPLE_CHEMICAL", 0, 3]]], ["In 2014, Aggarwal and collaborators showed the efficacy of LGG in the reduction of the duration of diarrhea in an open-case controlled study in India enrolling 200 children with RV and non-RV diarrhea (Aggarwal et al., 2014) .", [["LGG", "CHEMICAL", 59, 62], ["diarrhea", "DISEASE", 99, 107], ["diarrhea", "DISEASE", 192, 200], ["LGG", "SIMPLE_CHEMICAL", 59, 62], ["children", "ORGANISM", 164, 172], ["children", "SPECIES", 164, 172], ["LGG", "PROBLEM", 59, 62], ["diarrhea", "PROBLEM", 99, 107], ["RV and non-RV diarrhea", "PROBLEM", 178, 200], ["reduction", "OBSERVATION_MODIFIER", 70, 79], ["RV", "ANATOMY", 178, 180]]], ["More interestingly, Sindhu and collaborators performed a randomized double-blinded, placebo-controlled trial in children (n = 124) infected with RV and Cryptosporidium, a protozoan parasite.", [["protozoan parasite", "DISEASE", 171, 189], ["children", "ORGANISM", 112, 120], ["Cryptosporidium", "ORGANISM", 152, 167], ["children", "SPECIES", 112, 120], ["RV", "SPECIES", 145, 147], ["placebo", "TREATMENT", 84, 91], ["RV", "PROBLEM", 145, 147], ["Cryptosporidium", "PROBLEM", 152, 167], ["a protozoan parasite", "PROBLEM", 169, 189], ["RV", "ANATOMY", 145, 147], ["Cryptosporidium", "OBSERVATION", 152, 167], ["protozoan parasite", "OBSERVATION", 171, 189]]], ["Children infected with RV that also received LGG exhibited fewer repeated diarrheal episodes and impaired intestinal function after the intervention.", [["intestinal", "ANATOMY", 106, 116], ["LGG", "CHEMICAL", 45, 48], ["diarrheal episodes", "DISEASE", 74, 92], ["impaired intestinal function", "DISEASE", 97, 125], ["Children", "ORGANISM", 0, 8], ["intestinal", "ORGAN", 106, 116], ["Children", "SPECIES", 0, 8], ["RV", "SPECIES", 23, 25], ["LGG", "TREATMENT", 45, 48], ["fewer repeated diarrheal episodes", "PROBLEM", 59, 92], ["impaired intestinal function", "PROBLEM", 97, 125], ["the intervention", "TREATMENT", 132, 148], ["RV", "ANATOMY", 23, 25], ["diarrheal episodes", "OBSERVATION", 74, 92], ["impaired", "OBSERVATION_MODIFIER", 97, 105], ["intestinal function", "OBSERVATION", 106, 125]]], ["This group also had significant increased IgG levels postintervention (Sindhu et al., 2014) .", [["IgG", "GENE_OR_GENE_PRODUCT", 42, 45], ["IgG", "PROTEIN", 42, 45], ["significant increased IgG levels postintervention", "PROBLEM", 20, 69], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["IgG levels", "OBSERVATION", 42, 52]]], ["This is one of the few studies in humans that provides a mechanistic explanation of probiotics mechanism of action against viral diarrhea.Clinical TrialsUnfortunately, a unification of study designs with the different tested probiotics does not exist to date.", [["viral diarrhea", "DISEASE", 123, 137], ["humans", "ORGANISM", 34, 40], ["humans", "SPECIES", 34, 40], ["humans", "SPECIES", 34, 40], ["probiotics mechanism", "TREATMENT", 84, 104], ["viral diarrhea", "PROBLEM", 123, 137], ["study designs", "TEST", 185, 198], ["the different tested probiotics", "TREATMENT", 204, 235]]], ["Furthermore, all the studies were conducted in a single center and with a relatively small number of patients.", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["all the studies", "TEST", 13, 28], ["small", "OBSERVATION_MODIFIER", 85, 90]]], ["The European Society for Pediatric Gastroenterology, Hepatology and Nutrition and the European Society for Pediatric Infectious Diseases have recently published their \"Evidence-Based Guidelines for the Management of Acute Gastroenteritis in Children in Europe.\"", [["Infectious Diseases", "DISEASE", 117, 136], ["Gastroenteritis", "DISEASE", 222, 237], ["Children", "SPECIES", 241, 249], ["Acute Gastroenteritis", "PROBLEM", 216, 237], ["Acute", "OBSERVATION_MODIFIER", 216, 221], ["Gastroenteritis", "OBSERVATION", 222, 237]]], ["In this guide, only two probiotic strains (LGG and S. boulardii) are strongly recommended, always in combination with oral rehydration.", [["oral", "ANATOMY", 118, 122], ["LGG", "CHEMICAL", 43, 46], ["LGG", "SIMPLE_CHEMICAL", 43, 46], ["S. boulardii", "ORGANISM", 51, 63], ["oral", "ORGANISM_SUBDIVISION", 118, 122], ["S. boulardii", "SPECIES", 51, 63], ["S. boulardii", "SPECIES", 51, 63], ["two probiotic strains", "TREATMENT", 20, 41], ["LGG and S. boulardii", "TREATMENT", 43, 63], ["oral rehydration", "TREATMENT", 118, 134]]], ["Interestingly, the recommendation is accompanied with \"moderate to low quality of evidence\" in the reduction of the duration and intensity of the symptoms , indicating that more scientific evidence is needed to warranty the beneficial activity of probiotics to fight viral diarrhea in humans.CONCLUSIONSImmunomodulation has emerged as the most plausible mechanism by which probiotics exert their antiviral effects in the gastrointestinal tract.", [["gastrointestinal tract", "ANATOMY", 421, 443], ["viral diarrhea", "DISEASE", 267, 281], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 421, 443], ["the symptoms", "PROBLEM", 142, 154], ["probiotics", "TREATMENT", 247, 257], ["viral diarrhea in humans.CONCLUSIONSImmunomodulation", "PROBLEM", 267, 319], ["their antiviral effects in the gastrointestinal tract", "PROBLEM", 390, 443], ["reduction", "OBSERVATION_MODIFIER", 99, 108], ["antiviral effects", "OBSERVATION", 396, 413], ["gastrointestinal tract", "ANATOMY", 421, 443]]], ["The scientific data about mechanisms are still scarce but clinical trials support the use of specific strains to alleviate diarrhea symptoms and reduce its duration, mostly in children.", [["diarrhea", "DISEASE", 123, 131], ["children", "ORGANISM", 176, 184], ["children", "SPECIES", 176, 184], ["specific strains", "PROBLEM", 93, 109], ["diarrhea symptoms", "PROBLEM", 123, 140]]], ["However, standardized treatment protocols (strains, doses, and frequencies) are still needed.", [["standardized treatment protocols", "TREATMENT", 9, 41]]], ["The dual role of microbiota in the susceptibility to viral infections (viral pathogens can benefit from the microbiota for infection or they can be inhibited) may constitute the basis for new antiviral therapies.", [["viral infections", "DISEASE", 53, 69], ["infection", "DISEASE", 123, 132], ["viral infections (viral pathogens", "PROBLEM", 53, 86], ["infection", "PROBLEM", 123, 132], ["new antiviral therapies", "TREATMENT", 188, 211], ["viral", "OBSERVATION_MODIFIER", 53, 58], ["infections", "OBSERVATION", 59, 69]]], ["The knowledge about the virus/host/microbiota interactions should be extended and provide new information on what specific bacteria are playing a role and what are the interactions exploited by the viruses.", [["the virus/host/microbiota interactions", "TREATMENT", 20, 58]]], ["It is known that probiotics can modulate the composition of the microbiota.", [["probiotics", "TREATMENT", 17, 27]]], ["Consequently, it can be envisaged that the levels of different bacteria could be manipulated or the interaction mechanisms disturbed by the use of probiotics or other dietary interventions.", [["different bacteria", "PROBLEM", 53, 71], ["probiotics", "TREATMENT", 147, 157], ["other dietary interventions", "TREATMENT", 161, 188]]]], "PMC7526632": [["IntroductionCOVID-19 (Corona Virus Disease-2019) has emerged as a pandemic factor that has infected more than 26.5 million people, 3.5 million being actively sick, since the first case appeared (1).", [["Corona Virus Disease", "DISEASE", 22, 42], ["Corona Virus Disease-2019", "ORGANISM", 22, 47], ["people", "ORGANISM", 123, 129], ["people", "SPECIES", 123, 129], ["Corona Virus Disease-2019", "SPECIES", 22, 47], ["IntroductionCOVID", "TEST", 0, 17], ["Corona Virus Disease", "PROBLEM", 22, 42], ["a pandemic factor", "PROBLEM", 64, 81]]], ["It caused by Sars-Cov-2 (Severe Acute Respiratory Syndrome Coronavirus 2) virus.", [["Acute Respiratory Syndrome Coronavirus", "DISEASE", 32, 70], ["Sars-Cov-2 (", "ORGANISM", 13, 25], ["Severe Acute Respiratory Syndrome Coronavirus", "ORGANISM", 25, 70], ["Sars-Cov-2 (Severe Acute Respiratory Syndrome Coronavirus 2) virus", "SPECIES", 13, 79], ["Sars", "TEST", 13, 17], ["Cov", "TEST", 18, 21], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 25, 70], ["virus", "PROBLEM", 74, 79], ["Sars", "OBSERVATION", 13, 17], ["Severe", "OBSERVATION_MODIFIER", 25, 31], ["Acute", "OBSERVATION_MODIFIER", 32, 37], ["Respiratory Syndrome", "OBSERVATION", 38, 58]]], ["The fatality rate is highest in patients aged \u226565 years or those with certain comorbidities ([2], [3], [4]).", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["certain comorbidities", "PROBLEM", 70, 91]]], ["The population of patients with hypertension, chronic respiratory and cardiac diseases, diabetes mellitus, renal failure and malignancy are defined as the most severely affected group (5).IntroductionIn the studies where the incubation period of the virus is performed, the median reaches from 4 days to 14 days.", [["respiratory", "ANATOMY", 54, 65], ["cardiac", "ANATOMY", 70, 77], ["renal", "ANATOMY", 107, 112], ["hypertension", "DISEASE", 32, 44], ["chronic respiratory and cardiac diseases", "DISEASE", 46, 86], ["diabetes mellitus", "DISEASE", 88, 105], ["renal failure", "DISEASE", 107, 120], ["malignancy", "DISEASE", 125, 135], ["patients", "ORGANISM", 18, 26], ["cardiac", "ORGAN", 70, 77], ["renal", "ORGAN", 107, 112], ["patients", "SPECIES", 18, 26], ["hypertension", "PROBLEM", 32, 44], ["chronic respiratory and cardiac diseases", "PROBLEM", 46, 86], ["diabetes mellitus", "PROBLEM", 88, 105], ["renal failure", "PROBLEM", 107, 120], ["malignancy", "PROBLEM", 125, 135], ["the studies", "TEST", 203, 214], ["the virus", "PROBLEM", 246, 255], ["hypertension", "OBSERVATION", 32, 44], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["respiratory", "ANATOMY", 54, 65], ["cardiac", "ANATOMY", 70, 77], ["diseases", "OBSERVATION", 78, 86], ["diabetes mellitus", "OBSERVATION", 88, 105], ["renal", "ANATOMY", 107, 112], ["failure", "OBSERVATION", 113, 120], ["malignancy", "OBSERVATION", 125, 135], ["most severely", "OBSERVATION_MODIFIER", 155, 168]]], ["([4], [5], [6]).", [["[5], [6]", "SIMPLE_CHEMICAL", 6, 14]]], ["Although there are clinical findings on a wide scale ranging from mild respiratory symptoms to severe respiratory failure, it is possible to say that severe cases are around 4-5% ([7], [8]).", [["respiratory", "ANATOMY", 71, 82], ["respiratory", "ANATOMY", 102, 113], ["respiratory symptoms", "DISEASE", 71, 91], ["respiratory failure", "DISEASE", 102, 121], ["a wide scale", "TEST", 40, 52], ["mild respiratory symptoms", "PROBLEM", 66, 91], ["severe respiratory failure", "PROBLEM", 95, 121], ["severe cases", "PROBLEM", 150, 162], ["mild", "OBSERVATION_MODIFIER", 66, 70], ["respiratory symptoms", "OBSERVATION", 71, 91], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["respiratory failure", "OBSERVATION", 102, 121], ["severe", "OBSERVATION_MODIFIER", 150, 156]]], ["It is evident that early diagnosis, treatment and optimal isolation of the patient and his/her environment are vital at the point of treatment due to the spread of the disease.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["treatment", "TREATMENT", 36, 45], ["treatment", "TREATMENT", 133, 142], ["the disease", "PROBLEM", 164, 175], ["early", "OBSERVATION_MODIFIER", 19, 24], ["disease", "OBSERVATION", 168, 175]]], ["In the literature, we see that there are many publications on the diagnosis of the disease.", [["the disease", "PROBLEM", 79, 90], ["many", "OBSERVATION_MODIFIER", 41, 45], ["publications", "OBSERVATION", 46, 58], ["disease", "OBSERVATION", 83, 90]]], ["The analysis of various samples based on real-time polymerase chain reaction (RT-PCR), which was used as the gold standard diagnostic method, cannot achieve sufficient speed and sensitivity in the diagnosis of the disease.", [["samples", "ANATOMY", 24, 31], ["The analysis", "TEST", 0, 12], ["various samples", "TEST", 16, 31], ["RT-PCR", "TEST", 78, 84], ["the disease", "PROBLEM", 210, 221], ["disease", "OBSERVATION", 214, 221]]], ["This, in particular, delays the isolation of patients and accelerates disease spread.IntroductionThere are differences in the sensitivity of the PCR samples studied with various samples.", [["samples", "ANATOMY", 178, 185], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["accelerates disease spread", "PROBLEM", 58, 84], ["the PCR samples", "TEST", 141, 156], ["various samples", "TEST", 170, 185]]], ["In the most recent study of Wenling Wang et al. (9), the sensitivity order was as follows: Bronchoalveolar lavage 93%, throat culture 72%, nasal sample 63%, fibrobronchoscopic brush biopsy 46%, pharyngeal sample 32%, faeces 29%, blood% 1 and urine 0%.", [["Bronchoalveolar lavage", "ANATOMY", 91, 113], ["throat", "ANATOMY", 119, 125], ["nasal sample", "ANATOMY", 139, 151], ["brush", "ANATOMY", 176, 181], ["pharyngeal sample", "ANATOMY", 194, 211], ["blood", "ANATOMY", 229, 234], ["urine", "ANATOMY", 242, 247], ["brush biopsy", "MULTI-TISSUE_STRUCTURE", 176, 188], ["pharyngeal", "ORGAN", 194, 204], ["blood", "ORGANISM_SUBSTANCE", 229, 234], ["urine", "ORGANISM_SUBSTANCE", 242, 247], ["Bronchoalveolar lavage", "TEST", 91, 113], ["throat culture", "TEST", 119, 133], ["nasal sample", "TEST", 139, 151], ["fibrobronchoscopic brush biopsy", "TEST", 157, 188], ["pharyngeal sample", "TEST", 194, 211], ["faeces", "TEST", 217, 223], ["blood", "TEST", 229, 234], ["urine", "TEST", 242, 247], ["pharyngeal", "ANATOMY", 194, 204]]], ["Evaluation with bronchoalveolar lavage is quite difficult in emergency conditions and it does not seem possible due to the high risk of transmission.", [["bronchoalveolar lavage", "ANATOMY", 16, 38], ["Evaluation", "TEST", 0, 10], ["bronchoalveolar lavage", "TEST", 16, 38], ["bronchoalveolar lavage", "OBSERVATION", 16, 38]]], ["Therefore, negative results in potential cases lead to different opinions about the approach to patients.IntroductionPCR comparison with diagnostic methods based on thorax computed tomography (CT) has also been studied in the literature and the sensitivity appears to be high in favor of CT.", [["patients", "ORGANISM", 96, 104], ["thorax", "ORGAN", 165, 171], ["patients", "SPECIES", 96, 104], ["diagnostic methods", "TEST", 137, 155], ["thorax computed tomography", "TEST", 165, 191], ["CT", "TEST", 193, 195], ["the sensitivity", "TEST", 241, 256], ["CT", "TEST", 288, 290], ["thorax", "ANATOMY", 165, 171], ["high", "OBSERVATION", 271, 275]]], ["(10) In our study, the data from 2217 patients who were admitted to the emergency room of our hospital between March 2020 and June 2020; diagnosed as COVID-19 and hospitalized or discharged with home isolation were retrospectively analyzed.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["our study", "TEST", 8, 17], ["home isolation", "TREATMENT", 195, 209]]], ["Clinical features, treatments, laboratory and imaging results and mortality data of this patient group were retrospectively examined.", [["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96], ["treatments", "TREATMENT", 19, 29], ["imaging", "TEST", 46, 53], ["mortality data", "TEST", 66, 80]]], ["Based on the hypothesis that it could present a new diagnostic method in terms of the early diagnosis and early isolation, it was aimed at providing early diagnosis for especially those patients with typical radiological involvement and clinical findings through the Lactate Dehydrogenase/ Lymphocyte (LDH/Lymphocyte) ratio.IntroductionThe basis of our study and the starting point of our hypothesis is the other clinical studies based on LDH, which is an important indicator in the early diagnosis of pneumocystis carinii clinic-laboratory, which is an important factor of atypical pneumonia ([11], [12], [13]).", [["Lymphocyte", "ANATOMY", 306, 316], ["Lactate", "CHEMICAL", 267, 274], ["pneumocystis carinii", "DISEASE", 502, 522], ["pneumonia", "DISEASE", 583, 592], ["Lactate", "CHEMICAL", 267, 274], ["patients", "ORGANISM", 186, 194], ["Lactate Dehydrogenase", "GENE_OR_GENE_PRODUCT", 267, 288], ["Lymphocyte", "CELL", 290, 300], ["LDH", "GENE_OR_GENE_PRODUCT", 302, 305], ["Lymphocyte", "CELL", 306, 316], ["LDH", "GENE_OR_GENE_PRODUCT", 439, 442], ["pneumocystis carinii", "ORGANISM", 502, 522], ["Lactate Dehydrogenase", "PROTEIN", 267, 288], ["LDH", "PROTEIN", 302, 305], ["patients", "SPECIES", 186, 194], ["pneumocystis carinii", "SPECIES", 502, 522], ["pneumocystis carinii", "SPECIES", 502, 522], ["typical radiological involvement", "PROBLEM", 200, 232], ["the Lactate Dehydrogenase", "TEST", 263, 288], ["Lymphocyte (LDH/Lymphocyte) ratio", "TEST", 290, 323], ["our study", "TEST", 349, 358], ["clinical studies", "TEST", 413, 429], ["LDH", "TEST", 439, 442], ["atypical pneumonia", "PROBLEM", 574, 592], ["new", "OBSERVATION_MODIFIER", 48, 51], ["Lymphocyte", "ANATOMY", 290, 300], ["Lymphocyte", "ANATOMY", 306, 316], ["pneumocystis carinii", "OBSERVATION", 502, 522], ["atypical", "OBSERVATION_MODIFIER", 574, 582], ["pneumonia", "OBSERVATION", 583, 592]]], ["Although LDH is an enzyme originating from many organs and systems, it increases significantly especially in patients with lung involvement.", [["organs", "ANATOMY", 48, 54], ["lung", "ANATOMY", 123, 127], ["LDH", "GENE_OR_GENE_PRODUCT", 9, 12], ["organs", "ORGAN", 48, 54], ["patients", "ORGANISM", 109, 117], ["lung", "ORGAN", 123, 127], ["LDH", "PROTEIN", 9, 12], ["patients", "SPECIES", 109, 117], ["LDH", "TEST", 9, 12], ["an enzyme", "TEST", 16, 25], ["lung involvement", "PROBLEM", 123, 139], ["lung", "ANATOMY", 123, 127], ["involvement", "OBSERVATION", 128, 139]]], ["In addition, we see that lymphopenia, which will occur secondary to viral infections, is also present in COVID-19 cases.", [["lymphopenia", "DISEASE", 25, 36], ["viral infections", "DISEASE", 68, 84], ["lymphopenia", "PROBLEM", 25, 36], ["viral infections", "PROBLEM", 68, 84], ["COVID", "TEST", 105, 110], ["lymphopenia", "OBSERVATION", 25, 36], ["viral", "OBSERVATION_MODIFIER", 68, 73], ["infections", "OBSERVATION", 74, 84]]], ["The study was conducted with the hypothesis that the combination of these laboratory values \u200b\u200bwould yield a more sensitive result in early diagnosis.Statistical Analysis ::: Material and MethodsThe analysis of the data was carried out using SPSS 25 and Medcalc package programs.", [["The study", "TEST", 0, 9], ["these laboratory values", "TEST", 68, 91], ["the data", "TEST", 210, 218], ["SPSS", "TEST", 241, 245], ["Medcalc package programs", "TREATMENT", 253, 277]]], ["Descriptive statistics are presented by giving frequency and percentage tables for categorical variables and arithmetic mean, standard deviation, median, minimum and maximum values \u200b\u200bfor quantitative variables.", [["categorical variables", "TEST", 83, 104], ["arithmetic mean", "TEST", 109, 124]]], ["Chi-square test was used for comparisons between two categorical variables, and independent sample t-test was used for comparison of categorical variables and quantitative variables since the categorical variable contains two categories.", [["Chi-square test", "TEST", 0, 15], ["independent sample t-test", "TEST", 80, 105], ["categorical variables", "TEST", 133, 154]]], ["The logistic regression analysis was carried out by including the factors determined to have an impact on survival conditions as a result of binary comparisons.", [["The logistic regression analysis", "TEST", 0, 32], ["survival conditions", "TREATMENT", 106, 125]]], ["ROC analysis was applied to test the acceptability of LDH / Lymphocyte ratio as diagnostic test and to determine the predictive values \u200b\u200bin mortality.Demographic Datas, Comorbidities, Initial PCR and CT Results, Last Status and Follow Up Subtypes ::: ResultsThe data of 2217 patients in total were examined.", [["Lymphocyte", "ANATOMY", 60, 70], ["LDH", "GENE_OR_GENE_PRODUCT", 54, 57], ["Lymphocyte", "CELL", 60, 70], ["patients", "ORGANISM", 275, 283], ["LDH", "PROTEIN", 54, 57], ["patients", "SPECIES", 275, 283], ["ROC analysis", "TEST", 0, 12], ["LDH", "TEST", 54, 57], ["Lymphocyte ratio", "TEST", 60, 76], ["diagnostic test", "TEST", 80, 95], ["Initial PCR", "TEST", 184, 195], ["CT Results", "TEST", 200, 210], ["The data", "TEST", 258, 266]]], ["53% of the patients were male (n: 1175); 47% were female (n: 1042).", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["The mean age was 47.66 \u00b1 17.23.", [["The mean age", "TEST", 0, 12]]], ["60.2% (n: 1334) of the them received inpatient treatment; 39.8% (n: 883) received outpatient treatment.", [["inpatient treatment", "TREATMENT", 37, 56], ["outpatient treatment", "TREATMENT", 82, 102]]], ["The mortality rate of the patients was determined as 3.1% (n: 68).", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["The mortality rate", "TEST", 0, 18]]], ["The most common comorbidity of the patients was hypertension with 20.6% (n: 456).", [["hypertension", "DISEASE", 48, 60], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["hypertension", "PROBLEM", 48, 60], ["hypertension", "OBSERVATION", 48, 60]]], ["Hypertension was followed by diabetes mellitus with 16.2% (n: 360).", [["Hypertension", "DISEASE", 0, 12], ["diabetes mellitus", "DISEASE", 29, 46], ["Hypertension", "PROBLEM", 0, 12], ["diabetes mellitus", "PROBLEM", 29, 46]]], ["The positivity rate of the 1 st PCR results of the patients was 69.5% (n = 1541).", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["The positivity rate", "TEST", 0, 19], ["the 1 st PCR", "TEST", 23, 35]]], ["PCR result is negative, but 2.", [["PCR", "TEST", 0, 3], ["negative", "OBSERVATION", 14, 22]]], ["PCR result positive patient rate was 4.74% (n = 105).", [["patient", "ORGANISM", 20, 27], ["patient", "SPECIES", 20, 27], ["PCR", "TEST", 0, 3], ["patient rate", "TEST", 20, 32]]], ["First two negative but the third positive was 1.17 (n = 38) of them.", [["negative", "OBSERVATION", 10, 18]]], ["9.61 % (n = 213) of patients have 3 negative PCR results.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["Initially, typical COVID-19 involvement was detected with CT in 71.9% (n: 1594); while 1387 of them were bilateral; 207 of them were unilateral involvement (Table 1).Drug Usage for COVID-19 Treatment ::: ResultsHydroxychloroquine was used in 82.3% of the patients (n: 1824); this was followed by azithromycin with 44.5% (n: 987).", [["Hydroxychloroquine", "CHEMICAL", 211, 229], ["azithromycin", "CHEMICAL", 296, 308], ["COVID-19", "CHEMICAL", 181, 189], ["Hydroxychloroquine", "CHEMICAL", 211, 229], ["azithromycin", "CHEMICAL", 296, 308], ["COVID-19", "CANCER", 19, 27], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 211, 229], ["patients", "ORGANISM", 255, 263], ["azithromycin", "SIMPLE_CHEMICAL", 296, 308], ["patients", "SPECIES", 255, 263], ["CT", "TEST", 58, 60], ["unilateral involvement", "PROBLEM", 133, 155], ["COVID", "TEST", 181, 186], ["Hydroxychloroquine", "TREATMENT", 211, 229], ["azithromycin", "TREATMENT", 296, 308], ["bilateral", "ANATOMY_MODIFIER", 105, 114]]], ["Additional antibiotherapy was needed in 14.6% of patients (n: 324).", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["Additional antibiotherapy", "TREATMENT", 0, 25], ["antibiotherapy", "OBSERVATION", 11, 25]]], ["2.7% (n: 60) of patients were receiving favipiravir (Table 2).Laboratory Results ::: ResultsMean absolute lymphocyte count was 1809.66 \u00b1 5146.25; mean LDH 268.56 \u00b1 140.39 and mean LDH / Lymphocyte ratio was 0.17 \u00b1 0.31 (Table 3).Comorbidity and Drug Usage - Survival Analysis ::: ResultsCOPD, CHF, CAD, HT, DM, CKD and malignancy were found to have a significant statistical relationship with survival (p < 0.001).", [["lymphocyte", "ANATOMY", 106, 116], ["Lymphocyte", "ANATOMY", 186, 196], ["favipiravir", "CHEMICAL", 40, 51], ["CHF", "DISEASE", 293, 296], ["CAD", "DISEASE", 298, 301], ["HT", "DISEASE", 303, 305], ["DM", "DISEASE", 307, 309], ["CKD", "DISEASE", 311, 314], ["malignancy", "DISEASE", 319, 329], ["favipiravir", "CHEMICAL", 40, 51], ["patients", "ORGANISM", 16, 24], ["favipiravir", "SIMPLE_CHEMICAL", 40, 51], ["lymphocyte", "CELL", 106, 116], ["LDH", "GENE_OR_GENE_PRODUCT", 151, 154], ["Lymphocyte", "CELL", 186, 196], ["LDH", "PROTEIN", 151, 154], ["LDH", "PROTEIN", 180, 183], ["patients", "SPECIES", 16, 24], ["favipiravir", "TREATMENT", 40, 51], ["Mean absolute lymphocyte count", "TEST", 92, 122], ["mean LDH", "TEST", 146, 154], ["mean LDH", "TEST", 175, 183], ["Lymphocyte ratio", "TEST", 186, 202], ["Comorbidity", "PROBLEM", 229, 240], ["ResultsCOPD", "PROBLEM", 280, 291], ["CHF", "PROBLEM", 293, 296], ["CAD", "PROBLEM", 298, 301], ["HT", "PROBLEM", 303, 305], ["DM", "PROBLEM", 307, 309], ["CKD", "PROBLEM", 311, 314], ["malignancy", "PROBLEM", 319, 329], ["CHF", "OBSERVATION", 293, 296], ["CAD", "OBSERVATION", 298, 301], ["CKD", "OBSERVATION", 311, 314], ["malignancy", "OBSERVATION", 319, 329], ["significant", "OBSERVATION_MODIFIER", 351, 362]]], ["Those with any comorbidity had high mortality than those without comorbidity (p < 0.001) (Table 4).Comorbidity and Drug Usage - Survival Analysis ::: ResultsWhen the relationship between drug usage and survival was examined, no statistically significant relationship was found for hydroxychloroquine and azithromycin (p = 0.616, p = 0.095).", [["hydroxychloroquine", "CHEMICAL", 281, 299], ["azithromycin", "CHEMICAL", 304, 316], ["hydroxychloroquine", "CHEMICAL", 281, 299], ["azithromycin", "CHEMICAL", 304, 316], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 281, 299], ["azithromycin", "SIMPLE_CHEMICAL", 304, 316], ["any comorbidity", "PROBLEM", 11, 26], ["high mortality", "PROBLEM", 31, 45], ["comorbidity", "PROBLEM", 65, 76], ["Comorbidity", "PROBLEM", 99, 110], ["hydroxychloroquine", "TREATMENT", 281, 299], ["azithromycin", "TREATMENT", 304, 316]]], ["Significantly more deaths were observed in patients using oseltamivir (p = 0.031), lopinavir / ritonavir (p = 0.022), supplemental antibiotherapy (p < 0.001) and favipiravir (p < 0.001) (Table 5).Follow Up Subtype, CT Findings, 1\u2009st PCR and Presence of Involvement in CT and Survival Analysis ::: ResultsWhen the effects of involvement subtypes on survival in CT are examined, it was revealed that patients with bilateral CT involvement showed significantly high mortality (p < 0.001).", [["deaths", "DISEASE", 19, 25], ["oseltamivir", "CHEMICAL", 58, 69], ["lopinavir / ritonavir", "CHEMICAL", 83, 104], ["favipiravir", "CHEMICAL", 162, 173], ["oseltamivir", "CHEMICAL", 58, 69], ["lopinavir", "CHEMICAL", 83, 92], ["ritonavir", "CHEMICAL", 95, 104], ["favipiravir", "CHEMICAL", 162, 173], ["patients", "ORGANISM", 43, 51], ["oseltamivir", "SIMPLE_CHEMICAL", 58, 69], ["lopinavir", "SIMPLE_CHEMICAL", 83, 92], ["ritonavir", "SIMPLE_CHEMICAL", 95, 104], ["favipiravir", "SIMPLE_CHEMICAL", 162, 173], ["patients", "ORGANISM", 398, 406], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 398, 406], ["oseltamivir", "TREATMENT", 58, 69], ["lopinavir", "TREATMENT", 83, 92], ["ritonavir", "TREATMENT", 95, 104], ["supplemental antibiotherapy", "TREATMENT", 118, 145], ["favipiravir", "TREATMENT", 162, 173], ["CT Findings", "TEST", 215, 226], ["1\u2009st PCR", "TEST", 228, 236], ["CT", "TEST", 268, 270], ["CT", "TEST", 360, 362], ["bilateral CT involvement", "TEST", 412, 436], ["significantly high mortality", "PROBLEM", 444, 472]]], ["In patients with CT involvement, there was more statistically deaths than those without CT involvement (p = 0.014) (Table 6).Laboratory Results, LDH/Lymphocyte Ratio and Age and Survival Analysis ::: ResultsWhen the relationship between laboratory data and survival is examined, high LDH / lymphocyte ratio (p = 0.001), high leukocyte (p = 0.001), high neutrophil (p < 0.001), low hemoglobin (p = 0.001), high LDH (p < 0.001), high CRP (p < 0.001), high D-Dimer (p = 0.025), high urea (p < 0.001), high AST (p = 0.003) and low albumin (p = 0.003) were found to have statistically significant high mortality (Table 7).Logistic Regression Analysis of Datas ::: ResultsThe p values \u200b\u200bfor step, block and model were less than 0.001 and p = 0.718 at the end of the Hosmer and Lemeshow test.", [["lymphocyte", "ANATOMY", 290, 300], ["high leukocyte", "ANATOMY", 320, 334], ["neutrophil", "ANATOMY", 353, 363], ["deaths", "DISEASE", 62, 68], ["urea", "CHEMICAL", 480, 484], ["urea", "CHEMICAL", 480, 484], ["patients", "ORGANISM", 3, 11], ["Lymphocyte", "CELL", 149, 159], ["LDH", "GENE_OR_GENE_PRODUCT", 284, 287], ["lymphocyte", "CELL", 290, 300], ["leukocyte", "CELL", 325, 334], ["neutrophil", "CELL", 353, 363], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 381, 391], ["LDH", "GENE_OR_GENE_PRODUCT", 410, 413], ["CRP", "GENE_OR_GENE_PRODUCT", 432, 435], ["D-Dimer", "SIMPLE_CHEMICAL", 454, 461], ["urea", "SIMPLE_CHEMICAL", 480, 484], ["AST", "SIMPLE_CHEMICAL", 503, 506], ["albumin", "GENE_OR_GENE_PRODUCT", 527, 534], ["LDH", "PROTEIN", 145, 148], ["LDH", "PROTEIN", 284, 287], ["neutrophil", "CELL_TYPE", 353, 363], ["hemoglobin", "PROTEIN", 381, 391], ["LDH", "PROTEIN", 410, 413], ["CRP", "PROTEIN", 432, 435], ["AST", "PROTEIN", 503, 506], ["patients", "SPECIES", 3, 11], ["CT involvement", "TEST", 17, 31], ["CT involvement", "TEST", 88, 102], ["Laboratory Results", "TEST", 125, 143], ["LDH", "TEST", 145, 148], ["Lymphocyte Ratio", "TEST", 149, 165], ["Survival Analysis", "TEST", 178, 195], ["laboratory data", "TEST", 237, 252], ["survival", "TEST", 257, 265], ["high LDH / lymphocyte ratio", "PROBLEM", 279, 306], ["p", "TEST", 308, 309], ["high leukocyte", "PROBLEM", 320, 334], ["high neutrophil", "PROBLEM", 348, 363], ["low hemoglobin", "PROBLEM", 377, 391], ["high LDH", "PROBLEM", 405, 413], ["high CRP", "PROBLEM", 427, 435], ["high D-Dimer", "PROBLEM", 449, 461], ["high urea", "PROBLEM", 475, 484], ["high AST", "PROBLEM", 498, 506], ["low albumin", "PROBLEM", 523, 534], ["The p values", "TEST", 666, 678], ["p", "TEST", 732, 733], ["Lemeshow test", "TEST", 771, 784], ["high leukocyte", "ANATOMY", 320, 334], ["significant", "OBSERVATION_MODIFIER", 580, 591], ["high", "OBSERVATION_MODIFIER", 592, 596]]], ["The model was found to be feasible and analyses continued.", [["analyses", "TEST", 39, 47]]], ["As a result of logistic regression analysis; 1 unit increase in age was found to increase the mortality risk by 1.034 times, while 1 unit increase in CRP was found to increase the risk 1.007 times (Table 8).ROC Analysis: LDH/Lymphocyte Ratio for Diagnosis and Survival ::: ResultsIn order to test the usability of the LDH / Lymphocyte ratio in diagnosis for COVID-19 disease, individuals who showed unilateral and bilateral specific CT involvement were considered positive due to less false negativity of CT compared to PCR and evaluations were performed by accepting the CT results as a gold standard.", [["Lymphocyte", "ANATOMY", 225, 235], ["Lymphocyte", "ANATOMY", 324, 334], ["CRP", "GENE_OR_GENE_PRODUCT", 150, 153], ["Lymphocyte", "CELL", 225, 235], ["LDH", "GENE_OR_GENE_PRODUCT", 318, 321], ["Lymphocyte", "CELL", 324, 334], ["individuals", "ORGANISM", 376, 387], ["CRP", "PROTEIN", 150, 153], ["LDH", "PROTEIN", 221, 224], ["LDH", "PROTEIN", 318, 321], ["COVID-19", "SPECIES", 358, 366], ["logistic regression analysis", "TEST", 15, 43], ["CRP", "TEST", 150, 153], ["ROC Analysis", "TEST", 207, 219], ["LDH", "TEST", 221, 224], ["the LDH / Lymphocyte ratio", "TEST", 314, 340], ["COVID-19 disease", "PROBLEM", 358, 374], ["unilateral", "PROBLEM", 399, 409], ["bilateral specific CT involvement", "PROBLEM", 414, 447], ["CT", "TEST", 505, 507], ["PCR", "TEST", 520, 523], ["evaluations", "TEST", 528, 539], ["the CT", "TEST", 568, 574], ["LDH", "ANATOMY", 318, 321], ["Lymphocyte", "ANATOMY", 324, 334], ["bilateral", "ANATOMY_MODIFIER", 414, 423]]], ["As a result of ROC analysis; the area under the curve (AUC) was found to be 0.706 (p < 0.001; cut-off> 0.06) and it was concluded that the LDH / Lymphocyte ratio was diagnostic for COVID-19.", [["Lymphocyte", "ANATOMY", 145, 155], ["LDH", "GENE_OR_GENE_PRODUCT", 139, 142], ["Lymphocyte", "CELL", 145, 155], ["LDH", "PROTEIN", 139, 142], ["ROC analysis", "TEST", 15, 27], ["the curve", "TEST", 44, 53], ["AUC", "TEST", 55, 58], ["cut-off", "TEST", 94, 101], ["the LDH / Lymphocyte ratio", "TEST", 135, 161], ["COVID", "TEST", 181, 186], ["Lymphocyte", "ANATOMY", 145, 155]]], ["The sensitivity at the cut-off point is 76.4 and specificity is 59.60 (Table 9).ROC Analysis: LDH/Lymphocyte Ratio for Diagnosis and Survival ::: ResultsROC analysis was performed to evaluate the LDH / Lymphocyte ratio in terms of survival conditions and the area under the curve (AUC) was found to be 0.749 (p < 0.001; cut-off> 0.21).", [["Lymphocyte", "ANATOMY", 98, 108], ["Lymphocyte", "ANATOMY", 202, 212], ["Lymphocyte", "CELL", 98, 108], ["Lymphocyte", "CELL", 202, 212], ["LDH", "PROTEIN", 94, 97], ["LDH", "PROTEIN", 196, 199], ["The sensitivity", "TEST", 0, 15], ["specificity", "TEST", 49, 60], ["ROC Analysis", "TEST", 80, 92], ["LDH", "TEST", 94, 97], ["ResultsROC analysis", "TEST", 146, 165], ["the LDH", "TEST", 192, 199], ["Lymphocyte ratio", "TEST", 202, 218], ["survival conditions", "TREATMENT", 231, 250], ["the curve", "TEST", 270, 279], ["AUC", "TEST", 281, 284], ["cut-", "TEST", 320, 324], ["Lymphocyte", "ANATOMY", 202, 212]]], ["The sensitivity at cut-off point is 70.59 and specificity is 73.88 (Table 10).DiscussionOur study contains 3-months data of COVID-19 and has single center homogenization.", [["COVID-19", "CHEMICAL", 124, 132], ["The sensitivity", "TEST", 0, 15], ["specificity", "TEST", 46, 57], ["DiscussionOur study", "TEST", 78, 97], ["COVID", "TEST", 124, 129]]], ["It is clear that it will make a significant contribution to the literature not only in terms of revealing the data or determining the survival relationship, but also in terms of the new alternative it offers at the point of diagnosis.DiscussionIt is possible to say that most of the patients who applied for emergency services were isolated by hospitalization.", [["patients", "ORGANISM", 283, 291], ["patients", "SPECIES", 283, 291], ["emergency services", "TREATMENT", 308, 326], ["clear", "OBSERVATION", 6, 11]]], ["This not only provided an advantage in terms of isolation, but also facilitated clinical follow-up and data transfer.", [["isolation", "TREATMENT", 48, 57]]], ["All deaths were among inpatients.", [["deaths", "DISEASE", 4, 10]]], ["Our hospital\u2019s mortality rate was 3.1% with 68 patients, which is in line with the literature data.DiscussionThe positive rate of PCR result was 69.5%.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["mortality rate", "TEST", 15, 29], ["PCR", "TEST", 130, 133]]], ["It should be emphasized that all PCR negative cases have CT involvement.", [["all PCR", "TEST", 29, 36], ["CT involvement", "TEST", 57, 71]]], ["This is in line with the discussions carried out in the literature before.", [["line", "OBSERVATION_MODIFIER", 11, 15]]], ["Studies based on radiological findings have demonstrated higher CT involvement and sensitivity (14,15).", [["radiological findings", "TEST", 17, 38], ["higher CT involvement", "PROBLEM", 57, 78], ["sensitivity", "TEST", 83, 94]]], ["In our study, typical COVID-19 involvement was found in 71.9% of patients with baseline CT (n: 1594); 1387 of them are bilateral; 207 of them consisted of unilateral involvement.", [["COVID-19", "CANCER", 22, 30], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["our study", "TEST", 3, 12], ["typical COVID", "TEST", 14, 27], ["baseline CT", "TEST", 79, 90], ["unilateral involvement", "PROBLEM", 155, 177], ["bilateral", "ANATOMY_MODIFIER", 119, 128], ["unilateral", "OBSERVATION_MODIFIER", 155, 165], ["involvement", "OBSERVATION", 166, 177]]], ["This data is the first in the literature.DiscussionSignificant statistical relationship between LDH / Lymphocyte ratio and survival, which form the basis of our study, has been shown.", [["Lymphocyte", "ANATOMY", 102, 112], ["LDH", "GENE_OR_GENE_PRODUCT", 96, 99], ["Lymphocyte", "CELL", 102, 112], ["LDH", "PROTEIN", 96, 99], ["LDH / Lymphocyte ratio", "TEST", 96, 118], ["our study", "TEST", 157, 166], ["Lymphocyte", "ANATOMY", 102, 112]]], ["In order to test the usability of the LDH / Lymphocyte ratio in diagnosis for COVID-19, the patients with unilateral and bilateral specific CT involvement were considered positive due to less false negativity than PCR and the evaluations were performed by accepting the CT results as the gold standard.", [["Lymphocyte", "ANATOMY", 44, 54], ["LDH", "GENE_OR_GENE_PRODUCT", 38, 41], ["Lymphocyte", "CELL", 44, 54], ["patients", "ORGANISM", 92, 100], ["LDH", "PROTEIN", 38, 41], ["patients", "SPECIES", 92, 100], ["the LDH / Lymphocyte ratio", "TEST", 34, 60], ["COVID", "TEST", 78, 83], ["unilateral and bilateral specific CT involvement", "PROBLEM", 106, 154], ["less false negativity than PCR", "PROBLEM", 187, 217], ["the evaluations", "TEST", 222, 237], ["the CT", "TEST", 266, 272], ["LDH", "ANATOMY", 38, 41], ["Lymphocyte", "ANATOMY", 44, 54], ["bilateral", "ANATOMY_MODIFIER", 121, 130]]], ["As a result of ROC analysis; the area under the curve (AUC) was found to be 0.706 (p < 0.001; cut-off> 0.06) and it was concluded that the LDH / Lymphocyte ratio was diagnostic for COVID-19.", [["Lymphocyte", "ANATOMY", 145, 155], ["LDH", "GENE_OR_GENE_PRODUCT", 139, 142], ["Lymphocyte", "CELL", 145, 155], ["LDH", "PROTEIN", 139, 142], ["ROC analysis", "TEST", 15, 27], ["the curve", "TEST", 44, 53], ["AUC", "TEST", 55, 58], ["cut-off", "TEST", 94, 101], ["the LDH / Lymphocyte ratio", "TEST", 135, 161], ["COVID", "TEST", 181, 186], ["Lymphocyte", "ANATOMY", 145, 155]]], ["The sensitivity at cut-off point is 76.4 and specificity is 59.60.", [["The sensitivity", "TEST", 0, 15], ["specificity", "TEST", 45, 56]]], ["ROC analysis was performed to evaluate the LDH / Lymphocyte ratio for survival and the area under the curve (AUC) was found to be 0.749 (p < 0.001; cut-off> 0.21).", [["Lymphocyte", "ANATOMY", 49, 59], ["Lymphocyte", "CELL", 49, 59], ["LDH", "PROTEIN", 43, 46], ["ROC analysis", "TEST", 0, 12], ["the LDH", "TEST", 39, 46], ["Lymphocyte ratio", "TEST", 49, 65], ["the curve", "TEST", 98, 107], ["AUC", "TEST", 109, 112], ["cut-", "TEST", 148, 152], ["LDH", "ANATOMY", 43, 46], ["Lymphocyte", "ANATOMY", 49, 59]]], ["The sensitivity at cut-off point is 70.59 and specificity is 73.88.", [["The sensitivity", "TEST", 0, 15], ["specificity", "TEST", 46, 57]]], ["Our LDH/Lymphocyte ratio is usable in terms of mortality and putting cut-off in terms of diagnosis and mortality, they have been a big contribution of our study to the literature.", [["Lymphocyte", "ANATOMY", 8, 18], ["LDH", "GENE_OR_GENE_PRODUCT", 4, 7], ["Lymphocyte", "CELL", 8, 18], ["LDH", "PROTEIN", 4, 7], ["Our LDH/Lymphocyte ratio", "TEST", 0, 24], ["our study", "TEST", 151, 160], ["Lymphocyte ratio", "OBSERVATION", 8, 24]]], ["Our ratio is very impressive in early diagnosis and mortality prediction due to its easy application, especially since COVID-19 has no specific treatment yet and the importance of early isolation is unquestionable.DiscussionThe most frequently used treatment is hydroxychloroquine, which is an expected finding.", [["COVID-19", "CHEMICAL", 119, 127], ["hydroxychloroquine", "CHEMICAL", 262, 280], ["hydroxychloroquine", "CHEMICAL", 262, 280], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 262, 280], ["Our ratio", "TEST", 0, 9], ["COVID", "TEST", 119, 124], ["specific treatment", "TREATMENT", 135, 153], ["treatment", "TREATMENT", 249, 258], ["hydroxychloroquine", "TREATMENT", 262, 280], ["very", "OBSERVATION_MODIFIER", 13, 17], ["impressive", "OBSERVATION_MODIFIER", 18, 28]]], ["At this point, when examining the use of favipiravir specifically; we see that it was used for 2.7% of patients.", [["favipiravir", "CHEMICAL", 41, 52], ["favipiravir", "CHEMICAL", 41, 52], ["favipiravir", "SIMPLE_CHEMICAL", 41, 52], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["favipiravir", "TREATMENT", 41, 52]]], ["Due to the rapid increase in case numbers all around the world and the limited and contradictory data from the initial cases, the permission to use favipiravir is subjected to the regulations of Ministry of Health.", [["favipiravir", "CHEMICAL", 148, 159], ["favipiravir", "CHEMICAL", 148, 159], ["favipiravir", "SIMPLE_CHEMICAL", 148, 159], ["the rapid increase in case numbers", "PROBLEM", 7, 41], ["favipiravir", "TREATMENT", 148, 159], ["rapid", "OBSERVATION_MODIFIER", 11, 16], ["increase", "OBSERVATION_MODIFIER", 17, 25]]], ["With the increasing experience in dealing with cases, its scope of usage has broadened.", [["increasing", "OBSERVATION_MODIFIER", 9, 19]]], ["While it was initially only being used in the intensive care unit, lately its application has been extended to other patients.DiscussionLooking at the survival data; in parallel with the literature, the relationship between comorbidities such as COPD, HT, DM, CHF, CAD and presence of malignancy and survival has been revealed.", [["COPD", "DISEASE", 246, 250], ["HT", "DISEASE", 252, 254], ["DM", "DISEASE", 256, 258], ["CHF", "DISEASE", 260, 263], ["CAD", "DISEASE", 265, 268], ["malignancy", "DISEASE", 285, 295], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["COPD", "PROBLEM", 246, 250], ["HT", "PROBLEM", 252, 254], ["DM", "PROBLEM", 256, 258], ["CHF", "PROBLEM", 260, 263], ["CAD", "PROBLEM", 265, 268], ["malignancy", "PROBLEM", 285, 295], ["COPD", "OBSERVATION", 246, 250], ["CHF", "OBSERVATION", 260, 263], ["malignancy", "OBSERVATION", 285, 295]]], ["Similarly, statistical significance between any presence of comorbidity and no comorbidity was also shown in our study ([16], [17], [18], [19], [20]).", [["comorbidity", "PROBLEM", 60, 71], ["comorbidity", "PROBLEM", 79, 90], ["our study", "TEST", 109, 118], ["comorbidity", "OBSERVATION", 60, 71]]], ["In the data between drug usage and survival, there was no significant relationship between hydroxychloroquine and azithromycin and survival.", [["hydroxychloroquine", "CHEMICAL", 91, 109], ["azithromycin", "CHEMICAL", 114, 126], ["hydroxychloroquine", "CHEMICAL", 91, 109], ["azithromycin", "CHEMICAL", 114, 126], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 91, 109], ["azithromycin", "SIMPLE_CHEMICAL", 114, 126], ["survival", "TREATMENT", 35, 43], ["hydroxychloroquine", "TREATMENT", 91, 109], ["azithromycin", "TREATMENT", 114, 126], ["survival", "TREATMENT", 131, 139]]], ["Contrary to expectations, a survival relationship was found in the use of oseltamivir, additional antibiotherapy and favipiravir.", [["oseltamivir", "CHEMICAL", 74, 85], ["favipiravir", "CHEMICAL", 117, 128], ["oseltamivir", "CHEMICAL", 74, 85], ["favipiravir", "CHEMICAL", 117, 128], ["oseltamivir", "SIMPLE_CHEMICAL", 74, 85], ["favipiravir", "SIMPLE_CHEMICAL", 117, 128], ["oseltamivir", "TREATMENT", 74, 85], ["additional antibiotherapy", "TREATMENT", 87, 112], ["favipiravir", "TREATMENT", 117, 128]]], ["It should be taken into consideration that all patients requiring additional antibiotherapy or those who have to use favipiravir are fragile patients in intensive care conditions who require hospitalisation and close follow-up.", [["favipiravir", "CHEMICAL", 117, 128], ["favipiravir", "CHEMICAL", 117, 128], ["patients", "ORGANISM", 47, 55], ["favipiravir", "SIMPLE_CHEMICAL", 117, 128], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 141, 149], ["additional antibiotherapy", "TREATMENT", 66, 91], ["favipiravir", "TREATMENT", 117, 128]]], ["The mortality rate is higher in this patient group as expected.", [["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44], ["The mortality rate", "TEST", 0, 18], ["higher", "OBSERVATION_MODIFIER", 22, 28]]], ["Further data requirements are obvious in terms of favipiravir and treatment responses.", [["favipiravir", "CHEMICAL", 50, 61], ["favipiravir", "CHEMICAL", 50, 61], ["favipiravir", "SIMPLE_CHEMICAL", 50, 61], ["Further data requirements", "TEST", 0, 25], ["favipiravir and treatment responses", "TREATMENT", 50, 85]]], ["(21, 22) Again, the majority of this patient group consists of critical patients that are in line with the National Institutes of Health (NIH) guidelines.", [["patient", "ORGANISM", 37, 44], ["patients", "ORGANISM", 72, 80], ["patient", "SPECIES", 37, 44], ["patients", "SPECIES", 72, 80]]], ["It is worth noting that clinical pictures such as ARDS (acute respiratory distress syndrome), septic shock, cardiac dysfunction, multiorgan failure are common in this patient population (23,24).DiscussionWhen it is examined in terms of CT involvement and survival, new data were obtained.", [["respiratory", "ANATOMY", 62, 73], ["cardiac", "ANATOMY", 108, 115], ["multiorgan", "ANATOMY", 129, 139], ["ARDS", "DISEASE", 50, 54], ["acute respiratory distress syndrome", "DISEASE", 56, 91], ["septic shock", "DISEASE", 94, 106], ["cardiac dysfunction", "DISEASE", 108, 127], ["multiorgan failure", "DISEASE", 129, 147], ["cardiac", "ORGAN", 108, 115], ["multiorgan", "ORGAN", 129, 139], ["patient", "ORGANISM", 167, 174], ["patient", "SPECIES", 167, 174], ["clinical pictures", "PROBLEM", 24, 41], ["ARDS", "PROBLEM", 50, 54], ["acute respiratory distress syndrome", "PROBLEM", 56, 91], ["septic shock", "PROBLEM", 94, 106], ["cardiac dysfunction", "PROBLEM", 108, 127], ["multiorgan failure", "PROBLEM", 129, 147], ["CT involvement", "TEST", 236, 250], ["new data", "TEST", 265, 273], ["ARDS", "OBSERVATION", 50, 54], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["respiratory distress", "OBSERVATION", 62, 82], ["septic shock", "OBSERVATION", 94, 106], ["cardiac", "ANATOMY", 108, 115], ["dysfunction", "OBSERVATION", 116, 127], ["multiorgan failure", "OBSERVATION", 129, 147]]], ["Especially it is important to find a significant relationship between bilateral involvement and survival.", [["bilateral", "ANATOMY_MODIFIER", 70, 79], ["involvement", "OBSERVATION", 80, 91]]], ["It should be said that it can be used more easily than the specific findings described in the previous literature data especially regarding the pandemic patient density (25).", [["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["the previous literature data", "TEST", 90, 118]]], ["It should be noted that the relationship between laboratory data and survival is parallel to the literature.", [["laboratory data", "TEST", 49, 64]]], ["As a result of logistic regression analysis; 1 unit increase in age was found to increase the mortality risk by 1.034 times, while 1 unit increase in CRP was found to increase the risk 1.007 times.", [["CRP", "GENE_OR_GENE_PRODUCT", 150, 153], ["CRP", "PROTEIN", 150, 153], ["logistic regression analysis", "TEST", 15, 43], ["CRP", "TEST", 150, 153]]], ["These findings seem to be a potentially original contribution to the existing literature (26, 27).LimitationsOur study has some limitations.", [["Our study", "TEST", 109, 118], ["seem to be", "UNCERTAINTY", 15, 25]]], ["The potential relationship between the LDH/Lymphocyte ratio and other infectious diseases is unknown.", [["Lymphocyte", "ANATOMY", 43, 53], ["infectious diseases", "DISEASE", 70, 89], ["LDH", "GENE_OR_GENE_PRODUCT", 39, 42], ["Lymphocyte", "CELL", 43, 53], ["LDH", "PROTEIN", 39, 42], ["the LDH/Lymphocyte ratio", "TEST", 35, 59], ["other infectious diseases", "PROBLEM", 64, 89], ["LDH", "ANATOMY", 39, 42], ["Lymphocyte", "ANATOMY", 43, 53], ["infectious", "OBSERVATION", 70, 80]]], ["For this reason, the relationship between this ratio and mixed infection or other viral pneumonias can lead to confusion as it is not clear.", [["infection", "DISEASE", 63, 72], ["pneumonias", "DISEASE", 88, 98], ["confusion", "DISEASE", 111, 120], ["this ratio", "PROBLEM", 42, 52], ["mixed infection", "PROBLEM", 57, 72], ["other viral pneumonias", "PROBLEM", 76, 98], ["confusion", "PROBLEM", 111, 120], ["mixed", "OBSERVATION_MODIFIER", 57, 62], ["infection", "OBSERVATION", 63, 72], ["viral", "OBSERVATION_MODIFIER", 82, 87], ["pneumonias", "OBSERVATION", 88, 98], ["clear", "OBSERVATION", 134, 139]]], ["Another important limitation point is that new treatment options were not available for the patients included in the study and they were included in the study mostly at the beginning of the pandemic.", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["new treatment options", "TREATMENT", 43, 64], ["the study", "TEST", 113, 122], ["the study", "TEST", 149, 158], ["new", "OBSERVATION_MODIFIER", 43, 46]]], ["Therefore, it should be noted that our current treatment approach and guidelines are different.ConclusionAs a result, in our study, we revealed a single center data and examined the LDH / Lymphocyte ratio.", [["Lymphocyte", "ANATOMY", 188, 198], ["LDH", "GENE_OR_GENE_PRODUCT", 182, 185], ["Lymphocyte", "CELL", 188, 198], ["LDH", "PROTEIN", 182, 185], ["our current treatment approach", "TREATMENT", 35, 65], ["our study", "TEST", 121, 130], ["the LDH / Lymphocyte ratio", "TEST", 178, 204], ["LDH", "ANATOMY", 182, 185], ["Lymphocyte", "ANATOMY", 188, 198]]], ["LDH / Lymphocyte ratio was analyzed in terms of diagnosis and mortality with using specific CT involvement as the gold standard method which was found to be a more sensitive method due to PCR false negativity; 0.06 and 0.21 \u200b\u200bwere obtained as cut off values for diagnosis and mortality.Ethics StatementThe study protocol has been approved by Istanbul Training and Research Hospital Ethics Committee and Ministry of Health.", [["Lymphocyte", "ANATOMY", 6, 16], ["LDH", "GENE_OR_GENE_PRODUCT", 0, 3], ["Lymphocyte", "CELL", 6, 16], ["LDH", "PROTEIN", 0, 3], ["LDH", "TEST", 0, 3], ["Lymphocyte ratio", "TEST", 6, 22], ["specific CT involvement", "TEST", 83, 106], ["PCR false negativity", "PROBLEM", 188, 208], ["mortality", "PROBLEM", 276, 285], ["Lymphocyte ratio", "OBSERVATION", 6, 22]]], ["None of the authors have disclosures relevant to this manuscript.Conflict of InterestNone to declare.Author ContributionsAll authors contributed to the collection of patients data.", [["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["patients data", "TEST", 166, 179]]], ["IS wrote the manuscript and made tables.Data AvailabilityThe authors declare that data supporting the findings of this study are available within the article.", [["this study", "TEST", 114, 124]]]], "9d3a3e66c47a288c1ae7048c853a583c4eabf721": [["S evere acute respiratory syndrome (SARS) is a newly emerged disease, caused by a previously unknown coronavirus.", [["acute respiratory syndrome", "DISEASE", 8, 34], ["SARS", "DISEASE", 36, 40], ["coronavirus", "DISEASE", 101, 112], ["coronavirus", "ORGANISM", 101, 112], ["S evere acute respiratory syndrome (SARS)", "SPECIES", 0, 41], ["S evere acute respiratory syndrome", "PROBLEM", 0, 34], ["SARS", "PROBLEM", 36, 40], ["a newly emerged disease", "PROBLEM", 45, 68], ["a previously unknown coronavirus", "PROBLEM", 80, 112], ["acute", "OBSERVATION_MODIFIER", 8, 13], ["respiratory syndrome", "OBSERVATION", 14, 34], ["coronavirus", "OBSERVATION", 101, 112]]], ["During late February 2003, a physician who was incubating SARS traveled from Guangzhou, the provincial capital, to Hong Kong, Special Administrative Region of China, and stayed at a hotel.", [["SARS", "DISEASE", 58, 62]]], ["There, the virus was transmitted from him to local residents and to travelers, who became ill and transmitted disease to others when they returned to Vietnam, Singapore, Canada, and Taiwan, Province of China (1) .", [["ill and transmitted disease", "DISEASE", 90, 117], ["the virus", "PROBLEM", 7, 16], ["ill", "PROBLEM", 90, 93], ["transmitted disease", "PROBLEM", 98, 117], ["virus", "OBSERVATION", 11, 16]]], ["SARS has now occurred in >8,450 people with >800 deaths worldwide.", [["SARS", "DISEASE", 0, 4], ["deaths", "DISEASE", 49, 55], ["people", "ORGANISM", 32, 38], ["people", "SPECIES", 32, 38], ["SARS", "PROBLEM", 0, 4]]]], "495400387b9de21dad1e43542bdb526236169011": [["ACE2 -das missbrauchte MultitalentIn seinem 20.", [["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TEST", 0, 4], ["MultitalentIn seinem", "TREATMENT", 23, 43]]], ["Geburtsjahr hat ACE2 (\"angiotensin-converting enzyme 2\") traurige Ber\u00fchmtheit erlangt.", [["angiotensin", "CHEMICAL", 23, 34], ["ACE2", "GENE_OR_GENE_PRODUCT", 16, 20], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 23, 54], ["ACE2", "PROTEIN", 16, 20], ["Geburtsjahr hat ACE2 (\"angiotensin", "TREATMENT", 0, 34]]], ["Der Grund ist seine Ausbeutung als Rezeptor durch SARS(\"severe acute respiratory syndrome\")-CoV(\"coronavirus\")-2, den Erreger der COVID-19(\"coronavirus disease 2019\")-Pandemie.", [["SARS", "DISEASE", 50, 54], ["acute respiratory syndrome", "DISEASE", 63, 89], ["coronavirus disease", "DISEASE", 140, 159], ["Der Grund ist seine Ausbeutung als Rezeptor durch SARS(\"severe acute respiratory syndrome\")-CoV", "SPECIES", 0, 95], ["den Erreger der COVID-19", "SPECIES", 114, 138], ["durch SARS", "PROBLEM", 44, 54], ["severe acute respiratory syndrome\"", "PROBLEM", 56, 90], ["CoV(\"coronavirus\"", "PROBLEM", 92, 109], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["respiratory syndrome", "OBSERVATION", 69, 89]]], ["ACE2 wurde im Jahr 2000 von zwei Gruppen unabh\u00e4ngig voneinander als Homolog von ACE entdeckt [1, 8] .", [["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE2", "PROTEIN", 0, 4], ["ACE2 wurde im Jahr 2000 von zwei Gruppen unabh\u00e4ngig voneinander als Homolog von ACE entdeckt", "SPECIES", 0, 92], ["ACE2 wurde im Jahr", "TREATMENT", 0, 18], ["Gruppen unabh\u00e4ngig voneinander als Homolog von ACE entdeckt", "TREATMENT", 33, 92]]], ["W\u00e4hrend ACE zwei proteolytisch aktive Zentren mit je einem gebundenen Zinkatom aufweist, hat ACE2 nur eines (.", [["ACE2", "PROTEIN", 93, 97], ["W\u00e4hrend ACE zwei proteolytisch aktive Zentren mit je einem gebundenen Zinkatom aufweist, hat ACE2 nur eines", "SPECIES", 0, 107], ["ACE zwei proteolytisch", "TREATMENT", 8, 30], ["Zentren", "TREATMENT", 38, 45]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["Allerdings ist auch nur eine H\u00e4lfte von ACE2 homolog zu ACE, die andere H\u00e4lfte ist homolog zu Collectrin, was auf eine Genfusion in der Evolution von ACE2 hindeutet.", [["ACE2", "GENE_OR_GENE_PRODUCT", 150, 154], ["ACE2", "PROTEIN", 150, 154], ["auch nur eine H\u00e4lfte von ACE2 homolog zu ACE, die andere H\u00e4lfte ist homolog zu Collectrin", "SPECIES", 15, 104], ["Allerdings ist auch nur eine H\u00e4lfte von ACE2 homolog zu ACE", "TREATMENT", 0, 59], ["H\u00e4lfte ist homolog zu Collectrin", "TREATMENT", 72, 104], ["auf eine Genfusion", "TREATMENT", 110, 128]]], ["Die Collectrindom\u00e4ne bringt ACE2 eine weitere von der Proteasefunktion unabh\u00e4ngige Eigenschaft ein, auf die weiter unten eingegangen wird.ACE2 als ProteaseACE2 tr\u00e4gt seinen Namen insofern zurecht, als es, wie ACE, Angiotensin(Ang)-Peptide umsetzt (.", [["Angiotensin", "CHEMICAL", 214, 225], ["Ang", "CHEMICAL", 226, 229], ["ACE2", "GENE_OR_GENE_PRODUCT", 138, 142], ["Angiotensin(Ang)-Peptide umsetzt", "GENE_OR_GENE_PRODUCT", 214, 246], ["ACE2", "PROTEIN", 138, 142], ["ACE2 als ProteaseACE2 tr\u00e4gt", "TREATMENT", 138, 165], ["insofern zurecht", "TREATMENT", 179, 195], ["wie ACE", "TREATMENT", 205, 212], ["Angiotensin(Ang)", "TREATMENT", 214, 230], ["Peptide umsetzt", "TREATMENT", 231, 246]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["Wie bei ACE ist Ang I ein Substrat, ACE2 erzeugt aber nicht Ang II wie ACE sondern Ang(1-9), denn es ist eine Monocarboxypeptidase, die nur eine C-terminale Aminos\u00e4ure von Peptiden abspaltet, im Gegensatz zu ACE, das als Dicarboxypeptidase zwei abspaltet [1, 8, 9] .", [["Ang", "CHEMICAL", 16, 19], ["Ang", "CHEMICAL", 83, 86], ["1-9", "CHEMICAL", 87, 90], ["nur eine C-terminale Aminos\u00e4ure von Peptiden abspaltet, im Gegensatz zu ACE, das als Dicarboxypeptidase zwei abspaltet", "SPECIES", 136, 254], ["Wie bei ACE ist Ang I ein Substrat", "TREATMENT", 0, 34], ["ACE2 erzeugt", "TREATMENT", 36, 48], ["Ang II wie ACE sondern Ang", "TREATMENT", 60, 86], ["terminale Aminos\u00e4ure von Peptiden abspaltet", "TREATMENT", 147, 190], ["im Gegensatz zu ACE", "TREATMENT", 192, 211]]], ["Die f\u00fcr das Renin-Angiotensin-Aldosteron-System (RAAS) wichtigere Aktivit\u00e4t von ACE2 ist allerdings die Verk\u00fcrzung von Ang II zu Ang(1-7).", [["Angiotensin", "CHEMICAL", 18, 29], ["Ang", "CHEMICAL", 119, 122], ["Ang", "CHEMICAL", 129, 132], ["Angiotensin", "TREATMENT", 18, 29], ["Aldosteron-System (RAAS)", "TREATMENT", 30, 54], ["Aktivit\u00e4t von ACE2 ist allerdings", "TREATMENT", 66, 99], ["Verk\u00fcrzung von Ang II zu Ang", "TREATMENT", 104, 132]]], ["Mit dieser Reaktion wird ACE2 zu einem entscheidenden Stellglied des RAAS, da das vasokonstriktive und gewebesch\u00e4digende Ang II zum vasodilatatorischen und gewebesch\u00fctzenden Ang(1-7) umgebaut wird [6] .", [["Ang", "CHEMICAL", 121, 124], ["Ang", "CHEMICAL", 174, 177], ["Mit dieser Reaktion", "TREATMENT", 0, 19], ["Ang II zum vasodilatatorischen und gewebesch\u00fctzenden Ang", "TREATMENT", 121, 177]]], ["Die Bildung von Ang(1-7) geschieht lokal im Gewebe, wo das Peptid dann mit seinem Rezeptor Mas interagiert und oft gegens\u00e4tzliche Wirkungen zu Ang II an seinem AT1-Rezeptor (Angiotensin-II-Rezeptor Subtyp 1) hervorruft.", [["Ang", "CHEMICAL", 16, 19], ["Ang", "CHEMICAL", 143, 146], ["Angiotensin-II", "CHEMICAL", 174, 188], ["Angiotensin-II", "GENE_OR_GENE_PRODUCT", 174, 188], ["Die Bildung von Ang(1-7) geschieht lokal im Gewebe, wo das Peptid dann mit seinem Rezeptor Mas interagiert und oft gegens\u00e4tzliche Wirkungen zu Ang II an seinem AT1-Rezeptor (Angiotensin-II-Rezeptor Subtyp 1", "SPECIES", 0, 206], ["Peptid", "TEST", 59, 65], ["Mas", "TEST", 91, 94], ["gegens\u00e4tzliche", "TEST", 115, 129], ["Wirkungen", "TEST", 130, 139], ["an seinem AT1", "TREATMENT", 150, 163], ["Rezeptor (Angiotensin-II-Rezeptor Subtyp", "TREATMENT", 164, 204]]], ["Die unterschiedlichen enzymatischen Eigenschaften von ACE und ACE2 f\u00fchren auch dazu, dass ACE-Inhibitoren keinen Effekt auf die Aktivit\u00e4t von ACE2 haben.", [["ACE2", "GENE_OR_GENE_PRODUCT", 142, 146], ["ACE2", "PROTEIN", 142, 146], ["Die unterschiedlichen enzymatischen Eigenschaften von ACE und ACE2 f\u00fchren auch dazu, dass ACE-Inhibitoren keinen Effekt auf die Aktivit\u00e4t von ACE2 haben", "SPECIES", 0, 152], ["Die", "PROBLEM", 0, 3], ["Eigenschaften von ACE und ACE2 f\u00fchren", "TREATMENT", 36, 73], ["dass ACE", "TREATMENT", 85, 93], ["Inhibitoren keinen", "TREATMENT", 94, 112]]], ["Die pharmakologische Beeinflussung von ACE2 zielt im Gegensatz zu ACE auf dessen Aktivierung ab, da das Enzym ja Ang II abbaut.", [["Ang", "CHEMICAL", 113, 116], ["Die pharmakologische Beeinflussung von ACE2 zielt im Gegensatz zu ACE auf dessen Aktivierung ab, da das Enzym ja Ang II abbaut", "SPECIES", 0, 126], ["Die", "PROBLEM", 0, 3]]], ["Allerdings sind bisher nur sehr unspezifische Aktivatoren bekannt, und nur rekombinant hergestelltes ACE2 wurde klinisch getestet, um die Aktivit\u00e4t bei Lungenerkrankungen zu steigern [5] .ACE2 als ProteaseEs wird, wohl wegen des Namens, sehr oft vergessen, dass ACE2 neben Angiotensinen auch andere aktive Peptide umsetzt, wie Apelin-13 und desArg 9 -Bradykinin [9] .", [["desArg 9 -Bradykinin", "CHEMICAL", 341, 361], ["Arg 9 -Bradykinin", "CHEMICAL", 344, 361], ["ACE2", "GENE_OR_GENE_PRODUCT", 188, 192], ["ACE2", "GENE_OR_GENE_PRODUCT", 262, 266], ["ACE2", "PROTEIN", 188, 192], ["ACE2 als ProteaseEs wird", "TREATMENT", 188, 212], ["Apelin", "TEST", 327, 333]]], ["Apeline sind in der Herzentwicklung und f\u00fcr die Regulation des Gef\u00e4\u00dftonus von gro\u00dfer Bedeutung, und desArg 9 -Bradykinin aktiviert den inflammatorischen Arm des Kallikrein-Kinin-Systems, sodass anzunehmen ist, dass ACE2 auch \u00fcber die Inaktivierung dieser Peptide eine relevante Rolle bei Herz-Kreislauf-und anderen Erkrankungen spielt.Funktion von ACE2 in der NiereZahlreiche Ver\u00f6ffentlichungen unterst\u00fctzen eine wichtige Rolle der ACE2/ Ang(1-7)/Mas-Achse f\u00fcr die Nierenfunktion [6] .", [["desArg 9 -Bradykinin", "CHEMICAL", 100, 120], ["Ang", "CHEMICAL", 438, 441], ["der Herzentwicklung und f\u00fcr die Regulation des Gef\u00e4\u00dftonus von gro\u00dfer Bedeutung, und desArg 9 -Bradykinin aktiviert den inflammatorischen Arm des Kallikrein-Kinin-Systems, sodass anzunehmen ist, dass ACE2 auch \u00fcber die Inaktivierung dieser Peptide eine relevante Rolle bei Herz-Kreislauf-und anderen Erkrankungen spielt", "SPECIES", 16, 334], ["Bradykinin aktiviert", "TREATMENT", 110, 130], ["Arm des Kallikrein", "TREATMENT", 153, 171], ["Kinin-Systems", "TREATMENT", 172, 185], ["sodass anzunehmen ist", "TREATMENT", 187, 208], ["dass ACE2", "TREATMENT", 210, 219], ["Rolle", "TEST", 278, 283], ["Kreislauf", "TEST", 293, 302]]], ["ACE2 wird entlang des proximalen Tubulus in der Nierenrinde gefunden, ist aber wohl nicht das einzige Enzym, das in der Niere Ang(1-7) generieren kann; die neutrale Endopeptidase (auch Neprilysin [NEP]) genannt), die durch die neue Medikamentenklasse der ARNI (Angiotensin-Rezeptor-Neprilysin-Inhibitoren; Kombination aus AT1-Rezeptor-und NEP-Inhibitor) geblockt wird, ist in diesem Organ auch aktiv (.", [["Ang", "CHEMICAL", 126, 129], ["Angiotensin", "CHEMICAL", 261, 272], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE2", "PROTEIN", 0, 4], ["durch die neue Medikamentenklasse der ARNI (Angiotensin-Rezeptor-Neprilysin-Inhibitoren; Kombination aus AT1-Rezeptor-und NEP-Inhibitor) geblockt wird", "SPECIES", 217, 367], ["ACE2 wird entlang des", "TREATMENT", 0, 21], ["generieren kann", "TREATMENT", 135, 150], ["Endopeptidase (auch Neprilysin [NEP]) genannt)", "TREATMENT", 165, 211], ["Angiotensin", "TREATMENT", 261, 272], ["Rezeptor", "TREATMENT", 273, 281], ["Neprilysin", "TREATMENT", 282, 292], ["Inhibitoren", "TREATMENT", 293, 304], ["Kombination aus AT1", "TREATMENT", 306, 325], ["Rezeptor", "TREATMENT", 326, 334], ["und NEP-Inhibitor", "TREATMENT", 335, 352], ["geblockt wird", "TREATMENT", 354, 367]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["Die ACE2/Ang(1-7)/Mas-Achse spielt bei Nierenerkrankungen eine protektive Rolle.", [["Ang", "CHEMICAL", 9, 12], ["ACE2", "GENE_OR_GENE_PRODUCT", 4, 8], ["ACE2", "PROTEIN", 4, 8]]], ["ACE2-defiziente M\u00e4use entwickeln im Alter spontan eine Glomerulosklerose.", [["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TEST", 0, 4]]], ["Dar\u00fcber hinaus sind diese Tiere anf\u00e4lliger f\u00fcr isch\u00e4mie-, reperfusions-und diabetesbedingte Nephropathie.", [["Nephropathie", "DISEASE", 92, 104], ["reperfusions", "PROBLEM", 58, 70], ["Nephropathie", "PROBLEM", 92, 104]]], ["Infusion von rekombinantem ACE2 in M\u00e4usen verhindert diese Sch\u00e4den.", [["Infusion von rekombinantem ACE2", "TREATMENT", 0, 31]]], ["Eine chronische Hemmung von ACE2 mit dem spezifischen Inhibitor MLN-4760 f\u00fchrt sowohl bei gesunden als auch bei diabetischen M\u00e4usen zu glomerul\u00e4ren Sch\u00e4den und Albuminurie.Funktion von ACE2 in der NiereAufgrund des Mangels an zugelassenen spezifisch wirkenden Arzneimitteln gibt es noch keine interventionellen Studien zu Nierenerkrankungen beim Menschen, die die Effekte der ACE2/Ang(1-7)/Mas-Achse klinisch belegen k\u00f6nnten.", [["Ang", "CHEMICAL", 381, 384], ["Eine chronische Hemmung von ACE2 mit dem spezifischen Inhibitor MLN-4760 f\u00fchrt sowohl bei gesunden als auch bei diabetischen M\u00e4usen zu glomerul\u00e4ren Sch\u00e4den und Albuminurie", "SPECIES", 0, 171], ["zugelassenen spezifisch wirkenden Arzneimitteln gibt es noch keine interventionellen Studien zu Nierenerkrankungen beim Menschen, die die Effekte der ACE2/Ang(1-7)/Mas-Achse klinisch belegen k\u00f6nnten", "SPECIES", 226, 424], ["Eine chronische Hemmung von ACE2 mit dem spezifischen Inhibitor", "TREATMENT", 0, 63], ["Funktion von ACE2 in der NiereAufgrund des", "TREATMENT", 172, 214], ["an zugelassenen spezifisch", "TREATMENT", 223, 249], ["Arzneimitteln gibt", "TREATMENT", 260, 278]]], ["Da ACE2 in Plasma und Urin von Patienten mit chronischen Nierenerkrankungen unterschiedlicher Genese erh\u00f6ht ist, scheint diese Achse aber auch bei Patienten -wahrscheinlich kompensatorisch -aktiv zu sein.", [["ACE2", "GENE_OR_GENE_PRODUCT", 3, 7], ["Plasma", "ORGANISM_SUBSTANCE", 11, 17], ["ACE2", "PROTEIN", 3, 7], ["Patienten mit chronischen Nierenerkrankungen unterschiedlicher Genese erh\u00f6ht ist, scheint diese Achse aber auch bei Patienten -wahrscheinlich kompensatorisch -aktiv zu sein", "SPECIES", 31, 203], ["Plasma und Urin", "TEST", 11, 26]]], ["Die neuen Studien zeigten, dass ACE2 als Dimer auf der Zelloberfl\u00e4che vorliegt [10] .", [["dass ACE2 als Dimer auf der Zelloberfl\u00e4che vorliegt", "TREATMENT", 27, 78]]], ["Es w\u00e4re also denkbar, dass die Spaltung durch TMPRSS2 nur eines der beiden Monomere trifft und der Komplex aus ACE2 und dem Virus \u00fcber das zweite Monomer weiter in der Membran verankert bleibt, eine Konformations\u00e4nderung durchmacht und dadurch erst dem Virus die Fusion mit der Zelle erlaubt, aber das ist bisher Spekulation.", [["Spaltung durch TMPRSS2 nur eines der beiden Monomere trifft und der Komplex aus ACE2 und dem Virus \u00fcber das zweite Monomer weiter in der Membran verankert bleibt, eine Konformations\u00e4nderung durchmacht und dadurch erst dem Virus die Fusion mit der Zelle erlaubt, aber das ist bisher Spekulation", "SPECIES", 31, 324]]], ["Generell verdanken wir COVID-19 einen gro\u00dfen Wissenszuwachs \u00fcber ACE2, z.", [["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["ACE2", "PROTEIN", 65, 69], ["Generell verdanken wir COVID", "TREATMENT", 0, 28]]], ["B. einen \u00dcberblick \u00fcber seine Expression in verschiedensten menschlichen Zelltypen.", [["B. einen", "SPECIES", 0, 8], ["verschiedensten menschlichen Zelltypen", "TREATMENT", 44, 82]]], ["Der wichtigste Zelltyp f\u00fcr die Infektion mit SARS-CoV-2 ist die alveol\u00e4re Typ-2-Zelle im Lungenepithel, dessen Befall die schweren Verl\u00e4ufe der Erkrankung bedingt.", [["Der wichtigste Zelltyp f\u00fcr die Infektion mit SARS-CoV-2 ist die alveol\u00e4re Typ-2-Zelle im Lungenepithel, dessen Befall die schweren Verl\u00e4ufe der Erkrankung bedingt", "SPECIES", 0, 162], ["mit SARS", "PROBLEM", 41, 49], ["CoV", "TEST", 50, 53], ["Typ", "TEST", 74, 77], ["Zelle im Lungenepithel", "TREATMENT", 80, 102]]], ["Eine direkte SARS-CoV-2-Infektion der Niere ist trotz ACE2-Expression in diesem Organ noch nicht sicher nachgewiesen worden, was wahrscheinlich darauf zur\u00fcckzuf\u00fchren ist, dass bisher auch noch keine infekti\u00f6sen Viren im Blut gefunden wurden.", [["CoV", "TEST", 18, 21], ["Infektion", "PROBLEM", 24, 33]]], ["Die bei COVID-19-Patienten beschriebenen Nierensch\u00e4den sind wahrscheinlich sekund\u00e4r und durch die Entgleisung des Immun-und des Gerinnungssystems bei der Erkrankung ausgel\u00f6st.Funktion von ACE2 in der NiereDie Rolle des RAAS bei COVID-19 wird seit Beginn der Pandemie diskutiert.", [["Die bei COVID-19-Patienten beschriebenen Nierensch\u00e4den sind wahrscheinlich sekund\u00e4r und durch die Entgleisung des Immun-und des Gerinnungssystems bei der Erkrankung ausgel\u00f6st", "SPECIES", 0, 174], ["der NiereDie Rolle des RAAS bei COVID-19 wird seit Beginn der Pandemie diskutiert", "SPECIES", 196, 277], ["COVID", "TEST", 8, 13], ["Funktion von ACE2 in der NiereDie Rolle des RAAS bei COVID", "TREATMENT", 175, 233]]], ["Insbesondere wurde erwogen, RAAS-Blocker-Behandlungen bei Patienten auszusetzen, weil publiziert worden war, Deshalb empfehlen auch alle relevanten Fachgesellschaften, RAAS-Blocker bei COVID-19 nicht abzusetzen.", [["Insbesondere wurde erwogen, RAAS-Blocker-Behandlungen bei Patienten auszusetzen, weil publiziert worden war, Deshalb empfehlen auch alle relevanten Fachgesellschaften, RAAS-Blocker bei COVID-19 nicht abzusetzen", "SPECIES", 0, 210], ["RAAS-Blocker", "TREATMENT", 28, 40], ["Behandlungen", "TREATMENT", 41, 53], ["RAAS-Blocker bei COVID", "TREATMENT", 168, 190]]], ["Die protektive Wirkung der RAAS-Blocker k\u00f6nnte darauf hinweisen, dass es bei CO-VID-19 zu einer verst\u00e4rkten Wirkung von Ang II kommt, weil das abbauende Enzym ACE2 zumindest in der Lunge durch Zerst\u00f6rung der exprimierenden Zellen verschwindet.", [["Ang", "CHEMICAL", 120, 123], ["Die protektive Wirkung der RAAS-Blocker k\u00f6nnte darauf hinweisen, dass es bei CO-VID-19 zu einer verst\u00e4rkten Wirkung von Ang II kommt", "SPECIES", 0, 132], ["Blocker", "TREATMENT", 32, 39], ["VID", "TEST", 80, 83], ["ACE2 zumindest", "TREATMENT", 159, 173]]], ["Deshalb laufen zurzeit klinische Studien mit rekombinantem ACE2 an COVID-19-Patienten, zum einen um die verlorene Ang-IImetabolisierende Aktivit\u00e4t zu ersetzen, aber auch um das Virus vor der Bindung an die Zelle abzufangen -ein Konzept, das zumindest in kultivierten menschlichen Organoiden erfolgreich getestet wurde [5] .", [["Ang", "CHEMICAL", 114, 117], ["Deshalb laufen zurzeit klinische Studien mit rekombinantem ACE2 an COVID-19-Patienten, zum einen um die verlorene Ang-IImetabolisierende Aktivit\u00e4t zu ersetzen, aber auch um das Virus vor der Bindung an die Zelle abzufangen -ein Konzept, das zumindest in kultivierten menschlichen Organoiden erfolgreich getestet wurde", "SPECIES", 0, 317], ["Deshalb laufen zurzeit klinische", "TREATMENT", 0, 32], ["an COVID", "TREATMENT", 64, 72], ["verlorene Ang", "TREATMENT", 104, 117], ["IImetabolisierende Aktivit\u00e4t zu ersetzen", "TREATMENT", 118, 158]]], ["Dar\u00fcber hinaus wird gerade weltweit versucht, mit Antik\u00f6rpern, Peptiden, Aptameren und Kleinmolek\u00fclen die Bindung des SARS-CoV-2-S-Proteins an ACE2 und damit die Infektion zu blockieren.", [["Dar\u00fcber hinaus wird gerade weltweit versucht, mit Antik\u00f6rpern, Peptiden, Aptameren und Kleinmolek\u00fclen die Bindung des SARS-CoV-2-S-Proteins an ACE2 und damit die Infektion zu blockieren", "SPECIES", 0, 185], ["Peptiden", "TREATMENT", 63, 71], ["Aptameren", "TREATMENT", 73, 82], ["CoV", "TEST", 123, 126]]], ["Ein Mangel an Patienten k\u00f6nnte dann klinische Studien unm\u00f6glich machen, sodass wir erst bei der n\u00e4chsten Pandemie, die durch Coronaviren ausgel\u00f6st wird, welche wieder ACE2 als Rezeptor nutzen, die Entwicklung der Medikamente zu Ende f\u00fchren k\u00f6nnen.", [["sodass wir erst bei der n\u00e4chsten Pandemie, die durch Coronaviren ausgel\u00f6st wird, welche wieder ACE2 als Rezeptor nutzen, die Entwicklung der Medikamente zu Ende f\u00fchren k\u00f6nnen", "SPECIES", 72, 246]]]], "PMC7491405": [["At the time of writing, the severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2) pandemic continues globally, with nearly 15 milliondocumented cases and more than 600,000 deaths worldwide (1).", [["SARS-CoV-2) pandemic", "DISEASE", 76, 96], ["deaths", "DISEASE", 178, 184], ["SARS-CoV-2", "ORGANISM", 76, 86], ["SARS-CoV-2", "SPECIES", 76, 86], ["the severe acute respiratory syndromecoronavirus", "PROBLEM", 24, 72], ["SARS", "TEST", 76, 80], ["CoV", "TEST", 81, 84], ["pandemic", "PROBLEM", 88, 96], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["respiratory syndromecoronavirus", "OBSERVATION", 41, 72]]], ["Many countries have recently seen falls in the number ofconfirmed cases and are beginning to cautiously reopen following lockdown measures,whereas others are experiencing a continued increase, \u201csecond waves\u201d ofinfection, or localized outbreaks following an initial reduction in cases (2, 3).", [["lockdown measures", "TREATMENT", 121, 138], ["a continued increase, \u201csecond waves\u201d ofinfection", "PROBLEM", 171, 219], ["an initial reduction", "TREATMENT", 254, 274], ["increase", "OBSERVATION_MODIFIER", 183, 191], ["reduction", "OBSERVATION_MODIFIER", 265, 274]]]], "PMC7172674": [["IntroductionThe endoplasmic reticulum (ER) is a multi-functional organelle that distinguishes itself from other organelles by its size and the plethora of functions associated with it.", [["endoplasmic reticulum", "ANATOMY", 16, 37], ["ER", "ANATOMY", 39, 41], ["organelle", "ANATOMY", 65, 74], ["organelles", "ANATOMY", 112, 122], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 16, 37], ["ER", "GENE_OR_GENE_PRODUCT", 39, 41], ["organelle", "CELLULAR_COMPONENT", 65, 74], ["organelles", "CELLULAR_COMPONENT", 112, 122], ["ER", "PROTEIN", 39, 41], ["endoplasmic reticulum", "OBSERVATION", 16, 37], ["size", "OBSERVATION_MODIFIER", 130, 134], ["plethora", "OBSERVATION_MODIFIER", 143, 151]]], ["The size of this organelle and the potential array of targeting mechanisms required to build this little intracellular city were first recognized almost 20 years ago [1].", [["organelle", "ANATOMY", 17, 26], ["intracellular", "ANATOMY", 105, 118], ["organelle", "CELLULAR_COMPONENT", 17, 26], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 105, 118], ["this organelle", "PROBLEM", 12, 26], ["targeting mechanisms", "PROBLEM", 54, 74], ["size", "OBSERVATION_MODIFIER", 4, 8]]], ["Initial studies on the ER were done at the beginning of the 20th century by Santiago Ramon y Cajal in neurons [2].", [["neurons", "ANATOMY", 102, 109], ["ER", "GENE_OR_GENE_PRODUCT", 23, 25], ["neurons", "CELL", 102, 109], ["ER", "PROTEIN", 23, 25], ["Initial studies", "TEST", 0, 15]]], ["Following its proper discovery in 1945 by Keith Porter and co-workers on electron micrographs [3] and its designation in 1952 [4], microscopic and biochemical observations led to the identification of two distinct domains of the ER: the rough ER, characterized by the presence of ribosomes, and the smooth ER that is devoid of ribosomes [5], [6].", [["ER", "ANATOMY", 229, 231], ["ER", "ANATOMY", 243, 245], ["ribosomes", "ANATOMY", 280, 289], ["smooth ER", "ANATOMY", 299, 308], ["ER", "GENE_OR_GENE_PRODUCT", 229, 231], ["ER", "GENE_OR_GENE_PRODUCT", 243, 245], ["ribosomes", "CELLULAR_COMPONENT", 280, 289], ["ER", "GENE_OR_GENE_PRODUCT", 306, 308], ["ribosomes", "CELLULAR_COMPONENT", 327, 336], ["ER", "PROTEIN", 229, 231], ["ER", "PROTEIN", 243, 245], ["ribosomes", "PROTEIN", 280, 289], ["smooth ER", "PROTEIN", 299, 308], ["ribosomes", "OBSERVATION", 280, 289], ["smooth", "OBSERVATION_MODIFIER", 299, 305]]], ["Both are found in biochemical preparations first generated in the early 1940s and termed microsomes by Albert Claude [7].", [["microsomes", "ANATOMY", 89, 99], ["microsomes", "TISSUE", 89, 99]]], ["Quite early, it became also clear that the nuclear envelope is another domain of the ER [8].", [["nuclear", "ANATOMY", 43, 50], ["nuclear", "CELLULAR_COMPONENT", 43, 50], ["ER", "GENE_OR_GENE_PRODUCT", 85, 87], ["ER", "PROTEIN", 85, 87]]], ["Recent progress has highlighted how the same set of proteins that shape rough and smooth ER tubules also determine the formation of the nuclear pore complex, a decisive event in the biogenesis of the nucleus [9].IntroductionThe presence of ribosomes and mRNA on rough ER preparations suggested that this domain of the ER mediates the synthesis of secretory and membrane proteins [5].", [["smooth ER tubules", "ANATOMY", 82, 99], ["nuclear pore", "ANATOMY", 136, 148], ["nucleus", "ANATOMY", 200, 207], ["ER", "ANATOMY", 318, 320], ["membrane", "ANATOMY", 361, 369], ["ER", "GENE_OR_GENE_PRODUCT", 89, 91], ["tubules", "TISSUE", 92, 99], ["nuclear pore", "CELLULAR_COMPONENT", 136, 148], ["nucleus", "CELLULAR_COMPONENT", 200, 207], ["ribosomes", "CELLULAR_COMPONENT", 240, 249], ["ER", "GENE_OR_GENE_PRODUCT", 268, 270], ["ER", "GENE_OR_GENE_PRODUCT", 318, 320], ["membrane", "CELLULAR_COMPONENT", 361, 369], ["nuclear pore complex", "PROTEIN", 136, 156], ["ribosomes", "RNA", 240, 249], ["mRNA", "RNA", 254, 258], ["ER", "PROTEIN", 268, 270], ["ER", "PROTEIN", 318, 320], ["secretory and membrane proteins", "PROTEIN", 347, 378], ["secretory and membrane proteins", "PROBLEM", 347, 378], ["nucleus", "ANATOMY", 200, 207]]], ["Consistent with this hypothesis, the machineries responsible for the translocation of proteins into the ER [10], [11], [12], [13] and their glycosylation were found on the rough ER [14].", [["ER", "GENE_OR_GENE_PRODUCT", 104, 106], ["[11]", "SIMPLE_CHEMICAL", 113, 117], ["[12]", "SIMPLE_CHEMICAL", 119, 123], ["[13]", "SIMPLE_CHEMICAL", 125, 129], ["ER", "GENE_OR_GENE_PRODUCT", 178, 180], ["ER", "PROTEIN", 104, 106], ["ER", "PROTEIN", 178, 180], ["this hypothesis", "PROBLEM", 16, 31], ["their glycosylation", "TEST", 134, 153]]], ["Sorting to this domain of the ER is thought to involve preferential targeting of rough ER proteins to sheet-like, low curvature domains of the ER that are decorated with ribosomes [15].", [["ER", "ANATOMY", 30, 32], ["ER", "ANATOMY", 143, 145], ["ER", "GENE_OR_GENE_PRODUCT", 30, 32], ["ER", "GENE_OR_GENE_PRODUCT", 87, 89], ["ER", "GENE_OR_GENE_PRODUCT", 143, 145], ["ER", "PROTEIN", 30, 32], ["ER proteins", "PROTEIN", 87, 98], ["low curvature domains", "PROTEIN", 114, 135], ["ER", "PROTEIN", 143, 145], ["sheet", "TEST", 102, 107], ["low curvature domains of the ER", "PROBLEM", 114, 145], ["low curvature", "OBSERVATION_MODIFIER", 114, 127]]], ["However, the functions of the rough ER may not be restricted to secretory protein production, since recent studies have shown that autophagosome formation involves membranes of the rough ER [16], [17], suggesting that this domain of the ER may exhibit heterogeneity under certain circumstances.IntroductionContrary to these numerous breakthroughs in the understanding of the functions of the rough ER, progress on the smooth ER has been slower.", [["ER", "ANATOMY", 36, 38], ["autophagosome", "ANATOMY", 131, 144], ["membranes", "ANATOMY", 164, 173], ["ER", "ANATOMY", 237, 239], ["ER", "ANATOMY", 398, 400], ["smooth ER", "ANATOMY", 418, 427], ["ER", "GENE_OR_GENE_PRODUCT", 36, 38], ["autophagosome", "CELLULAR_COMPONENT", 131, 144], ["membranes", "CELLULAR_COMPONENT", 164, 173], ["ER", "GENE_OR_GENE_PRODUCT", 187, 189], ["ER", "GENE_OR_GENE_PRODUCT", 237, 239], ["ER", "GENE_OR_GENE_PRODUCT", 398, 400], ["ER", "GENE_OR_GENE_PRODUCT", 425, 427], ["ER", "PROTEIN", 36, 38], ["ER", "PROTEIN", 187, 189], ["ER", "PROTEIN", 237, 239], ["ER", "PROTEIN", 398, 400], ["ER", "PROTEIN", 425, 427], ["secretory protein production", "PROBLEM", 64, 92], ["recent studies", "TEST", 100, 114], ["autophagosome formation", "PROBLEM", 131, 154], ["Introduction", "TREATMENT", 294, 306], ["may not be", "UNCERTAINTY", 39, 49], ["autophagosome formation", "OBSERVATION", 131, 154], ["heterogeneity", "OBSERVATION", 252, 265], ["numerous", "OBSERVATION_MODIFIER", 324, 332], ["breakthroughs", "OBSERVATION", 333, 346], ["slower", "OBSERVATION_MODIFIER", 437, 443]]], ["Initially, this portion of the ER was identified by the absence of ribosomes on its surface [6].", [["ER", "ANATOMY", 31, 33], ["ribosomes", "ANATOMY", 67, 76], ["surface", "ANATOMY", 84, 91], ["ER", "GENE_OR_GENE_PRODUCT", 31, 33], ["ribosomes", "CELLULAR_COMPONENT", 67, 76], ["surface", "CELLULAR_COMPONENT", 84, 91], ["ER", "PROTEIN", 31, 33], ["ribosomes", "OBSERVATION_MODIFIER", 67, 76]]], ["The past two decades have seen the identification and characterization of subdomains of the smooth ER, including ER exit sites (ERES), the cortical ER (also known as peripheral ER or plasma membrane-associated ER, PAM), the mitochondria-associated membrane (MAM), and the ER quality control compartment (ERQC).", [["smooth ER", "ANATOMY", 92, 101], ["ER exit sites", "ANATOMY", 113, 126], ["cortical ER", "ANATOMY", 139, 150], ["peripheral ER", "ANATOMY", 166, 179], ["plasma membrane", "ANATOMY", 183, 198], ["ER", "ANATOMY", 210, 212], ["mitochondria", "ANATOMY", 224, 236], ["membrane", "ANATOMY", 248, 256], ["ER", "ANATOMY", 272, 274], ["ER", "GENE_OR_GENE_PRODUCT", 99, 101], ["ER", "GENE_OR_GENE_PRODUCT", 113, 115], ["cortical ER", "GENE_OR_GENE_PRODUCT", 139, 150], ["ER", "GENE_OR_GENE_PRODUCT", 177, 179], ["plasma membrane", "CELLULAR_COMPONENT", 183, 198], ["ER", "GENE_OR_GENE_PRODUCT", 210, 212], ["PAM", "GENE_OR_GENE_PRODUCT", 214, 217], ["mitochondria", "CELLULAR_COMPONENT", 224, 236], ["membrane", "CELLULAR_COMPONENT", 248, 256], ["MAM", "CELLULAR_COMPONENT", 258, 261], ["ER", "GENE_OR_GENE_PRODUCT", 272, 274], ["smooth ER", "PROTEIN", 92, 101], ["ER exit sites", "PROTEIN", 113, 126], ["ERES", "PROTEIN", 128, 132], ["cortical ER", "PROTEIN", 139, 150], ["peripheral ER", "PROTEIN", 166, 179], ["plasma membrane-associated ER", "PROTEIN", 183, 212], ["PAM", "PROTEIN", 214, 217], ["ER", "PROTEIN", 272, 274], ["the identification", "TEST", 31, 49], ["smooth", "OBSERVATION_MODIFIER", 92, 98], ["cortical", "ANATOMY_MODIFIER", 139, 147]]], ["Our image of the smooth ER as the lesser cousin of the rough ER is therefore changing quickly and the smooth ER emerges as a heterogeneous mix of highly specialized subdomains.", [["smooth ER", "ANATOMY", 17, 26], ["ER", "ANATOMY", 61, 63], ["smooth ER", "ANATOMY", 102, 111], ["ER", "GENE_OR_GENE_PRODUCT", 24, 26], ["ER", "GENE_OR_GENE_PRODUCT", 61, 63], ["ER", "GENE_OR_GENE_PRODUCT", 109, 111], ["smooth ER", "PROTEIN", 17, 26], ["ER", "PROTEIN", 61, 63], ["ER", "PROTEIN", 109, 111], ["lesser", "OBSERVATION_MODIFIER", 34, 40], ["smooth", "OBSERVATION_MODIFIER", 102, 108], ["heterogeneous", "OBSERVATION_MODIFIER", 125, 138], ["mix", "OBSERVATION_MODIFIER", 139, 142], ["highly", "OBSERVATION_MODIFIER", 146, 152], ["specialized", "OBSERVATION_MODIFIER", 153, 164], ["subdomains", "OBSERVATION_MODIFIER", 165, 175]]], ["Moreover, the existence of these membrane domains within the smooth ER supports the hypothesis that smooth ER proteins are actively sorted away from rough ER proteins [15], but the deciphering of such putative mechanisms is not yet very advanced.IntroductionBiochemical characterizations of the smooth ER determined that this domain is rich in enzymes involved in drug detoxification such as NADPH cytochrome c reductase [18] and epoxide hydrolase [19].", [["membrane", "ANATOMY", 33, 41], ["smooth ER", "ANATOMY", 61, 70], ["smooth ER", "ANATOMY", 100, 109], ["smooth ER", "ANATOMY", 295, 304], ["NADPH", "CHEMICAL", 392, 397], ["NADPH", "CHEMICAL", 392, 397], ["epoxide", "CHEMICAL", 430, 437], ["membrane", "CELLULAR_COMPONENT", 33, 41], ["ER", "GENE_OR_GENE_PRODUCT", 68, 70], ["ER", "GENE_OR_GENE_PRODUCT", 107, 109], ["ER", "GENE_OR_GENE_PRODUCT", 155, 157], ["ER", "GENE_OR_GENE_PRODUCT", 302, 304], ["NADPH cytochrome c reductase", "GENE_OR_GENE_PRODUCT", 392, 420], ["epoxide hydrolase", "GENE_OR_GENE_PRODUCT", 430, 447], ["membrane domains", "PROTEIN", 33, 49], ["smooth ER", "PROTEIN", 61, 70], ["smooth ER proteins", "PROTEIN", 100, 118], ["ER proteins", "PROTEIN", 155, 166], ["smooth ER", "PROTEIN", 295, 304], ["enzymes", "PROTEIN", 344, 351], ["NADPH cytochrome c reductase", "PROTEIN", 392, 420], ["epoxide hydrolase", "PROTEIN", 430, 447], ["these membrane domains", "PROBLEM", 27, 49], ["smooth ER proteins", "PROBLEM", 100, 118], ["drug detoxification", "TREATMENT", 364, 383], ["NADPH cytochrome c reductase [18] and epoxide hydrolase", "TREATMENT", 392, 447], ["membrane", "OBSERVATION", 33, 41], ["smooth", "OBSERVATION_MODIFIER", 61, 67], ["smooth", "OBSERVATION_MODIFIER", 100, 106]]], ["In the presence of high amounts of toxins such as ethanol, the smooth ER increases in size [20], [21], concomitant with an increased production of smooth ER-associated detoxifying enzymes such as cytochrome P450 2E1 [22].", [["smooth ER", "ANATOMY", 63, 72], ["ethanol", "CHEMICAL", 50, 57], ["ethanol", "CHEMICAL", 50, 57], ["ethanol", "SIMPLE_CHEMICAL", 50, 57], ["ER", "GENE_OR_GENE_PRODUCT", 70, 72], ["ER", "GENE_OR_GENE_PRODUCT", 154, 156], ["cytochrome P450 2E1", "GENE_OR_GENE_PRODUCT", 196, 215], ["ER", "PROTEIN", 70, 72], ["ER", "PROTEIN", 154, 156], ["detoxifying enzymes", "PROTEIN", 168, 187], ["cytochrome P450 2E1", "PROTEIN", 196, 215], ["high amounts of toxins", "PROBLEM", 19, 41], ["an increased production of smooth ER", "PROBLEM", 120, 156], ["detoxifying enzymes", "PROBLEM", 168, 187], ["cytochrome P450 2E1", "TEST", 196, 215], ["high amounts", "OBSERVATION_MODIFIER", 19, 31], ["smooth", "OBSERVATION_MODIFIER", 63, 69], ["increases", "OBSERVATION_MODIFIER", 73, 82], ["size", "OBSERVATION_MODIFIER", 86, 90], ["increased", "OBSERVATION_MODIFIER", 123, 132], ["production", "OBSERVATION_MODIFIER", 133, 143], ["smooth", "OBSERVATION_MODIFIER", 147, 153]]], ["Similar expansion of the rough ER is observed when protein secretion increases, for example, during the differentiation of B cells into plasma cells, coinciding with an increase of proteins involved in the production of secretory proteins [23].", [["ER", "ANATOMY", 31, 33], ["B cells", "ANATOMY", 123, 130], ["plasma cells", "ANATOMY", 136, 148], ["ER", "GENE_OR_GENE_PRODUCT", 31, 33], ["B cells", "CELL", 123, 130], ["plasma cells", "CELL", 136, 148], ["ER", "PROTEIN", 31, 33], ["B cells", "CELL_TYPE", 123, 130], ["plasma cells", "CELL_TYPE", 136, 148], ["secretory proteins", "PROTEIN", 220, 238], ["protein secretion", "PROBLEM", 51, 68], ["B cells into plasma cells", "PROBLEM", 123, 148], ["an increase of proteins", "PROBLEM", 166, 189], ["secretory proteins", "PROBLEM", 220, 238], ["expansion", "OBSERVATION_MODIFIER", 8, 17], ["rough", "OBSERVATION_MODIFIER", 25, 30], ["increases", "OBSERVATION_MODIFIER", 69, 78], ["plasma cells", "OBSERVATION", 136, 148], ["increase", "OBSERVATION_MODIFIER", 169, 177]]], ["Together, these findings demonstrate not only the existence of rough and smooth ER-specific transcriptional responses, but also the ability of the cell to specifically expand either ER membrane system, including mechanisms that keep rough and smooth ER separate in a state of ER expansion.", [["smooth ER", "ANATOMY", 73, 82], ["cell", "ANATOMY", 147, 151], ["ER membrane system", "ANATOMY", 182, 200], ["smooth ER", "ANATOMY", 243, 252], ["ER", "ANATOMY", 276, 278], ["ER", "GENE_OR_GENE_PRODUCT", 80, 82], ["cell", "CELL", 147, 151], ["ER", "GENE_OR_GENE_PRODUCT", 182, 184], ["ER", "GENE_OR_GENE_PRODUCT", 250, 252], ["ER", "GENE_OR_GENE_PRODUCT", 276, 278], ["ER", "PROTEIN", 80, 82], ["ER", "PROTEIN", 182, 184], ["ER", "PROTEIN", 250, 252], ["ER", "PROTEIN", 276, 278], ["smooth", "OBSERVATION_MODIFIER", 73, 79], ["smooth", "OBSERVATION_MODIFIER", 243, 249]]], ["Interestingly, the site of lipid synthesis during ER expansion is the smooth ER [24], suggesting that ER expansion may first result in naked, smooth ER that can later be decorated with ribosomes [25].IntroductionResearch during the past decade has shown that both rough and smooth ER enzymes rely on the precision of intra-ER targeting mechanisms.", [["ER", "ANATOMY", 50, 52], ["ER", "ANATOMY", 102, 104], ["smooth ER", "ANATOMY", 142, 151], ["lipid", "SIMPLE_CHEMICAL", 27, 32], ["ER", "GENE_OR_GENE_PRODUCT", 50, 52], ["ER", "GENE_OR_GENE_PRODUCT", 77, 79], ["ER", "GENE_OR_GENE_PRODUCT", 102, 104], ["ER", "GENE_OR_GENE_PRODUCT", 149, 151], ["ER", "GENE_OR_GENE_PRODUCT", 281, 283], ["intra-ER", "GENE_OR_GENE_PRODUCT", 317, 325], ["ER", "PROTEIN", 50, 52], ["ER", "PROTEIN", 102, 104], ["ER", "PROTEIN", 149, 151], ["ER enzymes", "PROTEIN", 281, 291], ["intra-ER", "PROTEIN", 317, 325], ["lipid synthesis", "PROBLEM", 27, 42], ["ER expansion", "TEST", 50, 62], ["ER expansion", "PROBLEM", 102, 114], ["smooth ER enzymes", "TEST", 274, 291], ["lipid synthesis", "OBSERVATION", 27, 42], ["expansion", "OBSERVATION_MODIFIER", 53, 62], ["smooth", "OBSERVATION_MODIFIER", 70, 76]]], ["For example, triacylglycerol hydrolase becomes inefficient in the mobilization of lipids when its ER localization motif is mutated from a histidine-isoleucine-aspartic acid-leucine (HIEL) to a classical lysine-glutamic acid-aspartic acid-leucine (KDEL) sequence.", [["triacylglycerol", "CHEMICAL", 13, 28], ["histidine-isoleucine-aspartic acid-leucine", "CHEMICAL", 138, 180], ["HIEL", "CHEMICAL", 182, 186], ["lysine", "CHEMICAL", 203, 209], ["triacylglycerol", "CHEMICAL", 13, 28], ["histidine", "CHEMICAL", 138, 147], ["isoleucine", "CHEMICAL", 148, 158], ["aspartic acid-leucine", "CHEMICAL", 159, 180], ["HIEL", "CHEMICAL", 182, 186], ["lysine", "CHEMICAL", 203, 209], ["glutamic acid-aspartic acid-leucine", "CHEMICAL", 210, 245], ["KDEL", "CHEMICAL", 247, 251], ["triacylglycerol hydrolase", "GENE_OR_GENE_PRODUCT", 13, 38], ["lipids", "SIMPLE_CHEMICAL", 82, 88], ["ER", "GENE_OR_GENE_PRODUCT", 98, 100], ["histidine-isoleucine-aspartic acid-leucine", "SIMPLE_CHEMICAL", 138, 180], ["glutamic acid-aspartic acid-leucine", "SIMPLE_CHEMICAL", 210, 245], ["KDEL", "AMINO_ACID", 247, 251], ["triacylglycerol hydrolase", "PROTEIN", 13, 38], ["ER localization motif", "PROTEIN", 98, 119], ["histidine-isoleucine-aspartic acid-leucine", "PROTEIN", 138, 180], ["HIEL", "PROTEIN", 182, 186], ["classical lysine-glutamic acid-aspartic acid-leucine (KDEL) sequence", "PROTEIN", 193, 261], ["triacylglycerol hydrolase", "PROBLEM", 13, 38], ["the mobilization of lipids", "TREATMENT", 62, 88], ["a histidine-isoleucine", "TEST", 136, 158], ["a classical lysine", "TEST", 191, 209]]], ["Although both motifs allow the interaction with the KDEL receptor, only the HIEL motif leads to proper targeting of triacylglycerol hydrolase to the peripheral smooth ER [26].", [["peripheral smooth ER", "ANATOMY", 149, 169], ["triacylglycerol", "CHEMICAL", 116, 131], ["KDEL", "GENE_OR_GENE_PRODUCT", 52, 56], ["triacylglycerol hydrolase", "GENE_OR_GENE_PRODUCT", 116, 141], ["ER", "GENE_OR_GENE_PRODUCT", 167, 169], ["KDEL receptor", "PROTEIN", 52, 65], ["HIEL motif", "DNA", 76, 86], ["triacylglycerol hydrolase", "PROTEIN", 116, 141], ["the KDEL receptor", "TREATMENT", 48, 65], ["the HIEL motif", "TREATMENT", 72, 86], ["triacylglycerol hydrolase", "TREATMENT", 116, 141], ["peripheral smooth", "ANATOMY", 149, 166]]], ["Intra-ER targeting is also relevant for the study of the ER using fluorescent proteins in vivo.", [["ER", "ANATOMY", 57, 59], ["Intra-ER", "GENE_OR_GENE_PRODUCT", 0, 8], ["ER", "GENE_OR_GENE_PRODUCT", 57, 59], ["ER", "PROTEIN", 6, 8], ["ER", "PROTEIN", 57, 59], ["fluorescent proteins", "PROTEIN", 66, 86], ["the study", "TEST", 40, 49], ["fluorescent proteins", "TREATMENT", 66, 86]]], ["Studies had initially indicated that ER-targeted green fluorescent protein (GFP) is freely diffusible within the ER lumen, albeit at a slower speed than in aqueous solutions and three- to sixfold slower than in the cytoplasm [27].", [["ER lumen", "ANATOMY", 113, 121], ["cytoplasm", "ANATOMY", 215, 224], ["ER", "GENE_OR_GENE_PRODUCT", 37, 39], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 49, 74], ["GFP", "GENE_OR_GENE_PRODUCT", 76, 79], ["ER", "GENE_OR_GENE_PRODUCT", 113, 115], ["cytoplasm", "ORGANISM_SUBSTANCE", 215, 224], ["ER", "PROTEIN", 37, 39], ["green fluorescent protein", "PROTEIN", 49, 74], ["GFP", "PROTEIN", 76, 79], ["Studies", "TEST", 0, 7], ["green fluorescent protein (GFP", "TEST", 49, 79], ["lumen", "ANATOMY_MODIFIER", 116, 121]]], ["However, red and green fluorescent proteins (RFP/GFP) when fused to the KDEL motif do not co-localize within the ER of neuronal cells [28].", [["ER", "ANATOMY", 113, 115], ["neuronal cells", "ANATOMY", 119, 133], ["green fluorescent proteins", "GENE_OR_GENE_PRODUCT", 17, 43], ["RFP", "GENE_OR_GENE_PRODUCT", 45, 48], ["GFP", "GENE_OR_GENE_PRODUCT", 49, 52], ["KDEL", "GENE_OR_GENE_PRODUCT", 72, 76], ["ER", "GENE_OR_GENE_PRODUCT", 113, 115], ["neuronal cells", "CELL", 119, 133], ["red and green fluorescent proteins", "PROTEIN", 9, 43], ["RFP", "PROTEIN", 45, 48], ["GFP", "PROTEIN", 49, 52], ["KDEL motif", "PROTEIN", 72, 82], ["ER", "PROTEIN", 113, 115], ["neuronal cells", "CELL_TYPE", 119, 133], ["red and green fluorescent proteins", "PROBLEM", 9, 43], ["RFP/GFP", "TEST", 45, 52], ["the KDEL motif", "TEST", 68, 82]]], ["This finding corroborates that intra-ER sorting is distinct from ER retention.", [["ER", "ANATOMY", 65, 67], ["intra-ER", "GENE_OR_GENE_PRODUCT", 31, 39], ["ER", "GENE_OR_GENE_PRODUCT", 65, 67], ["intra-ER", "PROTEIN", 31, 39], ["ER", "PROTEIN", 65, 67], ["intra-ER sorting", "PROBLEM", 31, 47], ["ER retention", "PROBLEM", 65, 77], ["distinct", "OBSERVATION_MODIFIER", 51, 59], ["retention", "OBSERVATION_MODIFIER", 68, 77]]], ["Similarly, GFP fusions with presumed ER proteins have led to spurious results, such as in the case of the oxidoreductase ERp44, which targets to the rough ER when fused to GFP, although its endogenous form is found close to ER exit sites and the Golgi [29], [30].", [["ER", "ANATOMY", 155, 157], ["Golgi", "ANATOMY", 246, 251], ["GFP", "GENE_OR_GENE_PRODUCT", 11, 14], ["ER", "GENE_OR_GENE_PRODUCT", 37, 39], ["ERp44", "GENE_OR_GENE_PRODUCT", 121, 126], ["ER", "GENE_OR_GENE_PRODUCT", 155, 157], ["GFP", "GENE_OR_GENE_PRODUCT", 172, 175], ["ER", "GENE_OR_GENE_PRODUCT", 224, 226], ["Golgi", "CELLULAR_COMPONENT", 246, 251], ["GFP fusions", "DNA", 11, 22], ["ER proteins", "PROTEIN", 37, 48], ["oxidoreductase ERp44", "PROTEIN", 106, 126], ["ER", "PROTEIN", 155, 157], ["GFP", "PROTEIN", 172, 175], ["ER exit sites", "PROTEIN", 224, 237], ["GFP fusions", "TEST", 11, 22], ["ER proteins", "PROBLEM", 37, 48], ["the oxidoreductase ERp44", "TREATMENT", 102, 126], ["GFP", "TEST", 172, 175], ["GFP fusions", "OBSERVATION", 11, 22]]], ["Another example is GFP-tagged Sec61\u03b2 that loses its specific targeting to the rough ER seen for the endogenous protein [31].", [["ER", "ANATOMY", 84, 86], ["GFP", "GENE_OR_GENE_PRODUCT", 19, 22], ["Sec61\u03b2", "GENE_OR_GENE_PRODUCT", 30, 36], ["ER", "GENE_OR_GENE_PRODUCT", 84, 86], ["GFP", "PROTEIN", 19, 22], ["Sec61\u03b2", "PROTEIN", 30, 36], ["ER", "PROTEIN", 84, 86], ["GFP", "TEST", 19, 22], ["the endogenous protein", "TEST", 96, 118]]], ["This review aims to outline what is known about the composition of individual domains of the ER and the intracellular sorting mechanisms that give rise to the unique architecture of the ER.", [["ER", "ANATOMY", 93, 95], ["intracellular", "ANATOMY", 104, 117], ["ER", "ANATOMY", 186, 188], ["ER", "GENE_OR_GENE_PRODUCT", 93, 95], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 104, 117], ["ER", "GENE_OR_GENE_PRODUCT", 186, 188], ["ER", "PROTEIN", 93, 95], ["ER", "PROTEIN", 186, 188]]], ["We will usually refer to what is known about ER domain enrichment in mammalian cells, unless noted otherwise.", [["cells", "ANATOMY", 79, 84], ["ER", "GENE_OR_GENE_PRODUCT", 45, 47], ["mammalian cells", "CELL", 69, 84], ["ER", "PROTEIN", 45, 47], ["mammalian cells", "CELL_TYPE", 69, 84], ["ER domain enrichment in mammalian cells", "PROBLEM", 45, 84], ["mammalian cells", "OBSERVATION", 69, 84]]], ["Individual domains discussed in the text and known bona fide markers are summarized in Fig. 1.Targeting to rough ER domainsThe distinctive feature of the rough ER is the presence of ribosomes and protein translocation channels, also called translocons.", [["ER", "ANATOMY", 160, 162], ["ribosomes", "ANATOMY", 182, 191], ["ER", "GENE_OR_GENE_PRODUCT", 113, 115], ["ER", "GENE_OR_GENE_PRODUCT", 160, 162], ["ribosomes", "CELLULAR_COMPONENT", 182, 191], ["bona fide markers", "PROTEIN", 51, 68], ["ER domains", "PROTEIN", 113, 123], ["ER", "PROTEIN", 160, 162], ["ribosomes", "PROTEIN", 182, 191], ["protein translocation channels", "PROTEIN", 196, 226], ["translocons", "PROTEIN", 240, 251], ["ribosomes and protein translocation channels", "PROBLEM", 182, 226], ["fide markers", "OBSERVATION", 56, 68], ["distinctive", "OBSERVATION_MODIFIER", 127, 138], ["rough", "OBSERVATION_MODIFIER", 154, 159], ["ribosomes", "OBSERVATION", 182, 191], ["protein translocation channels", "OBSERVATION", 196, 226]]], ["Together, these proteins mediate the production of secretory proteins and proteins to be inserted into the membranes of the secretory pathway.", [["membranes", "ANATOMY", 107, 116], ["membranes", "CELLULAR_COMPONENT", 107, 116], ["secretory proteins", "PROTEIN", 51, 69], ["secretory proteins", "PROBLEM", 51, 69], ["proteins", "TREATMENT", 74, 82], ["membranes", "ANATOMY_MODIFIER", 107, 116], ["secretory pathway", "OBSERVATION", 124, 141]]], ["Translocons are made up of more than 20 polypeptides that span the membrane individually multiple times [32]; associated with them are the translocon-associated protein (TRAP) complex, translocating chain-associated membrane protein (TRAM), oligosaccharyltransferases (OST), signal peptidase, the signal recognition particle (SRP) receptor and accessory proteins [33], [34].", [["membrane", "ANATOMY", 67, 75], ["membrane", "CELLULAR_COMPONENT", 67, 75], ["translocon-associated protein (TRAP) complex, translocating chain-associated membrane protein", "GENE_OR_GENE_PRODUCT", 139, 232], ["TRAM", "GENE_OR_GENE_PRODUCT", 234, 238], ["oligosaccharyltransferases", "GENE_OR_GENE_PRODUCT", 241, 267], ["OST", "GENE_OR_GENE_PRODUCT", 269, 272], ["signal peptidase", "GENE_OR_GENE_PRODUCT", 275, 291], ["signal recognition particle (SRP) receptor", "GENE_OR_GENE_PRODUCT", 297, 339], ["translocon-associated protein (TRAP) complex", "PROTEIN", 139, 183], ["translocating chain-associated membrane protein", "PROTEIN", 185, 232], ["TRAM", "PROTEIN", 234, 238], ["oligosaccharyltransferases", "PROTEIN", 241, 267], ["OST", "PROTEIN", 269, 272], ["signal peptidase", "PROTEIN", 275, 291], ["signal recognition particle (SRP) receptor", "PROTEIN", 297, 339], ["accessory proteins", "PROTEIN", 344, 362], ["translocating chain", "TEST", 185, 204], ["signal peptidase", "TEST", 275, 291], ["accessory proteins", "TEST", 344, 362], ["membrane protein", "OBSERVATION", 216, 232]]], ["Within the translocons, the Sec61 \u03b1, \u03b2, and \u03b3 proteins are thought to capture and bind ribosomes [32], [35], [36] that are also associated with translation initiation factors and mRNAs [37], [38].", [["Sec61 \u03b1", "GENE_OR_GENE_PRODUCT", 28, 35], ["\u03b2", "GENE_OR_GENE_PRODUCT", 37, 38], ["\u03b3", "GENE_OR_GENE_PRODUCT", 44, 45], ["translocons", "PROTEIN", 11, 22], ["Sec61 \u03b1, \u03b2, and \u03b3 proteins", "PROTEIN", 28, 54], ["translation initiation factors", "PROTEIN", 144, 174], ["mRNAs", "RNA", 179, 184], ["the Sec61", "TEST", 24, 33], ["bind ribosomes", "TEST", 82, 96], ["mRNAs", "TEST", 179, 184]]], ["Formation of these interactions is thus a critical determinant of rough ER formation.", [["ER", "ANATOMY", 72, 74], ["ER", "GENE_OR_GENE_PRODUCT", 72, 74], ["ER", "PROTEIN", 72, 74]]], ["Moreover, the interaction between the Sec61 proteins and ribosomes depends on the formation of a complex between the ER-associated signal receptor and the SRP that recognizes mRNAs giving rise to signal peptides [39], [40].", [["Sec61", "GENE_OR_GENE_PRODUCT", 38, 43], ["ribosomes", "CELLULAR_COMPONENT", 57, 66], ["ER", "GENE_OR_GENE_PRODUCT", 117, 119], ["SRP", "CELLULAR_COMPONENT", 155, 158], ["Sec61 proteins", "PROTEIN", 38, 52], ["ER-associated signal receptor", "PROTEIN", 117, 146], ["SRP", "PROTEIN", 155, 158], ["mRNAs", "RNA", 175, 180], ["the Sec61 proteins", "TEST", 34, 52], ["signal peptides", "TEST", 196, 211]]], ["However, secretory protein mRNA localization to the ER does not require the presence of SRPs, suggesting these mRNAs are additionally equipped with so far unknown targeting information [41], [42].", [["ER", "ANATOMY", 52, 54], ["ER", "GENE_OR_GENE_PRODUCT", 52, 54], ["SRPs", "GENE_OR_GENE_PRODUCT", 88, 92], ["ER", "PROTEIN", 52, 54], ["SRPs", "PROTEIN", 88, 92], ["mRNAs", "RNA", 111, 116], ["secretory protein mRNA localization", "TEST", 9, 44], ["SRPs", "PROBLEM", 88, 92]]], ["A special case of ER targeting of mRNAs is observed with the mRNA for the yeast transcription factor Hac1, the substrate of the ER-stress activated endonuclease Ire1p.", [["ER", "GENE_OR_GENE_PRODUCT", 18, 20], ["Hac1", "GENE_OR_GENE_PRODUCT", 101, 105], ["ER", "GENE_OR_GENE_PRODUCT", 128, 130], ["Ire1p", "GENE_OR_GENE_PRODUCT", 161, 166], ["ER", "PROTEIN", 18, 20], ["mRNAs", "RNA", 34, 39], ["mRNA", "RNA", 61, 65], ["yeast transcription factor", "PROTEIN", 74, 100], ["Hac1", "PROTEIN", 101, 105], ["ER", "PROTEIN", 128, 130], ["stress activated endonuclease", "PROTEIN", 131, 160], ["Ire1p", "PROTEIN", 161, 166], ["yeast", "SPECIES", 74, 79], ["yeast", "SPECIES", 74, 79], ["stress activated endonuclease Ire1p", "TREATMENT", 131, 166]]], ["Here, the 3\u2032 untranslated region element is sufficient for the targeting to localized accumulation of Ire1 activity [43].Targeting to rough ER domainsOverall, association with the translocon depends frequently on direct protein\u2013protein interactions with translocon and ribosome components.", [["translocon", "ANATOMY", 180, 190], ["translocon", "ANATOMY", 254, 264], ["ribosome", "ANATOMY", 269, 277], ["Ire1", "GENE_OR_GENE_PRODUCT", 102, 106], ["ER", "GENE_OR_GENE_PRODUCT", 140, 142], ["3\u2032 untranslated region element", "DNA", 10, 40], ["Ire1", "PROTEIN", 102, 106], ["ER domains", "PROTEIN", 140, 150], ["translocon and ribosome components", "PROTEIN", 254, 288], ["the 3\u2032 untranslated region element", "TREATMENT", 6, 40], ["direct protein\u2013protein interactions", "TREATMENT", 213, 248], ["translocon and ribosome components", "TREATMENT", 254, 288], ["Ire1 activity", "OBSERVATION", 102, 115], ["ribosome components", "OBSERVATION", 269, 288]]], ["This mechanism is utilized in particular by the OST complex [44], composed of ribophorin I and II, OST48, STT3A, STT3B, and DAD1 in mammals [45], [46], which can bind to the translocon in a ribosome-dependent or -independent manner [46], [47].", [["translocon", "ANATOMY", 174, 184], ["ribophorin I", "GENE_OR_GENE_PRODUCT", 78, 90], ["II", "GENE_OR_GENE_PRODUCT", 95, 97], ["OST48", "GENE_OR_GENE_PRODUCT", 99, 104], ["STT3A", "GENE_OR_GENE_PRODUCT", 106, 111], ["STT3B", "GENE_OR_GENE_PRODUCT", 113, 118], ["DAD1", "GENE_OR_GENE_PRODUCT", 124, 128], ["[46]", "SIMPLE_CHEMICAL", 146, 150], ["OST complex", "PROTEIN", 48, 59], ["ribophorin I and II", "PROTEIN", 78, 97], ["OST48", "PROTEIN", 99, 104], ["STT3A", "PROTEIN", 106, 111], ["STT3B", "PROTEIN", 113, 118], ["DAD1", "PROTEIN", 124, 128], ["translocon", "PROTEIN", 174, 184], ["OST48", "TEST", 99, 104], ["STT3A", "TEST", 106, 111], ["STT3B", "TEST", 113, 118]]], ["These divergent OST targeting mechanisms stem from the sequence of events in the glycosylation process, which comprises ribosome-requiring cotranslational N-glycosylation, but also posttranslational N-glycosylation of newly synthesized proteins [48].", [["N", "CHEMICAL", 155, 156], ["N", "CHEMICAL", 199, 200], ["ribosome", "CELLULAR_COMPONENT", 120, 128], ["These divergent OST targeting mechanisms stem", "PROBLEM", 0, 45], ["the glycosylation process", "PROBLEM", 77, 102], ["cotranslational N-glycosylation", "TREATMENT", 139, 170], ["newly synthesized proteins", "PROBLEM", 218, 244]]], ["For some subunits of the OST complex, specific targeting information has been described: ribophorin I requires luminal domains for its retention within the ER, whereas cytosolic and transmembrane sequences are needed in the case of ribophorin II [49], [50].", [["luminal", "ANATOMY", 111, 118], ["ER", "ANATOMY", 156, 158], ["cytosolic", "ANATOMY", 168, 177], ["transmembrane", "ANATOMY", 182, 195], ["luminal", "CHEMICAL", 111, 118], ["OST", "GENE_OR_GENE_PRODUCT", 25, 28], ["ribophorin I", "GENE_OR_GENE_PRODUCT", 89, 101], ["ER", "GENE_OR_GENE_PRODUCT", 156, 158], ["cytosolic", "CELLULAR_COMPONENT", 168, 177], ["transmembrane", "CELLULAR_COMPONENT", 182, 195], ["ribophorin II", "GENE_OR_GENE_PRODUCT", 232, 245], ["OST complex", "PROTEIN", 25, 36], ["ribophorin I", "PROTEIN", 89, 101], ["luminal domains", "PROTEIN", 111, 126], ["ER", "PROTEIN", 156, 158], ["cytosolic and transmembrane sequences", "PROTEIN", 168, 205], ["ribophorin II", "PROTEIN", 232, 245], ["cytosolic and transmembrane sequences", "TEST", 168, 205], ["OST complex", "OBSERVATION_MODIFIER", 25, 36]]], ["The rough ER-localized Hsp40 family protein ERj1 interacts with ribosomes that mediate its targeting to the rough ER via a positively charged motif in its cytosolic domain [51].", [["ribosomes", "ANATOMY", 64, 73], ["ER", "ANATOMY", 114, 116], ["cytosolic", "ANATOMY", 155, 164], ["ER", "GENE_OR_GENE_PRODUCT", 10, 12], ["Hsp40", "GENE_OR_GENE_PRODUCT", 23, 28], ["ERj1", "GENE_OR_GENE_PRODUCT", 44, 48], ["ribosomes", "CELLULAR_COMPONENT", 64, 73], ["ER", "GENE_OR_GENE_PRODUCT", 114, 116], ["ER", "PROTEIN", 10, 12], ["Hsp40 family protein", "PROTEIN", 23, 43], ["ERj1", "PROTEIN", 44, 48], ["ER", "PROTEIN", 114, 116], ["positively charged motif", "PROTEIN", 123, 147], ["cytosolic domain", "PROTEIN", 155, 171]]], ["Additional translocon-associated proteins are the Sec62/Sec63 complex proteins [52].", [["translocon", "ANATOMY", 11, 21], ["Sec62", "GENE_OR_GENE_PRODUCT", 50, 55], ["Sec63", "GENE_OR_GENE_PRODUCT", 56, 61], ["translocon-associated proteins", "PROTEIN", 11, 41], ["Sec62", "PROTEIN", 50, 55], ["Sec63 complex proteins", "PROTEIN", 56, 78]]], ["The phosphorylation of Sec63p by protein kinase CK2 is required for the association of this complex with the protein translocation apparatus in yeast [53].Targeting to rough ER domainsIn addition to the directly involved translocation machinery, the rough ER also contains ER chaperones and oxidoreductases, which mediate the folding of newly synthesized polypeptides.", [["Sec63p", "GENE_OR_GENE_PRODUCT", 23, 29], ["protein kinase CK2", "GENE_OR_GENE_PRODUCT", 33, 51], ["ER", "GENE_OR_GENE_PRODUCT", 174, 176], ["ER", "GENE_OR_GENE_PRODUCT", 256, 258], ["ER", "GENE_OR_GENE_PRODUCT", 273, 275], ["Sec63p", "PROTEIN", 23, 29], ["protein kinase CK2", "PROTEIN", 33, 51], ["ER domains", "PROTEIN", 174, 184], ["ER", "PROTEIN", 256, 258], ["ER chaperones", "PROTEIN", 273, 286], ["oxidoreductases", "PROTEIN", 291, 306], ["yeast", "SPECIES", 144, 149], ["yeast", "SPECIES", 144, 149], ["The phosphorylation of Sec63p by protein kinase CK2", "TEST", 0, 51], ["the protein translocation apparatus", "PROBLEM", 105, 140], ["ER chaperones", "TREATMENT", 273, 286], ["oxidoreductases", "TREATMENT", 291, 306], ["newly synthesized polypeptides", "TREATMENT", 337, 367]]], ["Not all proteins of this group target tightly to the rough ER; some perform important and in some instances predominant roles on other parts of the ER [54].", [["ER", "ANATOMY", 59, 61], ["ER", "ANATOMY", 148, 150], ["ER", "GENE_OR_GENE_PRODUCT", 59, 61], ["ER", "GENE_OR_GENE_PRODUCT", 148, 150], ["ER", "PROTEIN", 59, 61], ["ER", "PROTEIN", 148, 150]]], ["Another caveat is that some chaperones and oxidoreductases associate with translocons that are not bound to ribosomes, suggesting they are preferentially associated with retro-translocation of misfolded proteins on domains of the smooth ER (see below).", [["ribosomes", "ANATOMY", 108, 117], ["smooth ER", "ANATOMY", 230, 239], ["oxidoreductases", "GENE_OR_GENE_PRODUCT", 43, 58], ["translocons", "GENE_OR_GENE_PRODUCT", 74, 85], ["ribosomes", "CELLULAR_COMPONENT", 108, 117], ["ER", "GENE_OR_GENE_PRODUCT", 237, 239], ["oxidoreductases", "PROTEIN", 43, 58], ["translocons", "PROTEIN", 74, 85], ["misfolded proteins", "PROTEIN", 193, 211], ["smooth ER", "PROTEIN", 230, 239], ["translocons", "PROBLEM", 74, 85], ["misfolded proteins", "PROBLEM", 193, 211], ["misfolded", "OBSERVATION", 193, 202], ["smooth", "OBSERVATION_MODIFIER", 230, 236]]], ["GRP78/BiP is among the chaperones that interact with active, importing translocons and serves to close the translocon during protein integration into the ER membrane [55], [56], [57].", [["translocon", "ANATOMY", 107, 117], ["ER membrane", "ANATOMY", 154, 165], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["BiP", "GENE_OR_GENE_PRODUCT", 6, 9], ["ER", "GENE_OR_GENE_PRODUCT", 154, 156], ["GRP78", "PROTEIN", 0, 5], ["BiP", "PROTEIN", 6, 9], ["translocons", "PROTEIN", 71, 82], ["ER", "PROTEIN", 154, 156]]], ["In yeast, it has been shown that this interaction boosts the ATPase activity of GRP78/BiP and depends on the binding to Sec63p, a member of the DnaJ family [58].", [["ATPase", "GENE_OR_GENE_PRODUCT", 61, 67], ["GRP78", "GENE_OR_GENE_PRODUCT", 80, 85], ["BiP", "GENE_OR_GENE_PRODUCT", 86, 89], ["Sec63p", "GENE_OR_GENE_PRODUCT", 120, 126], ["DnaJ", "GENE_OR_GENE_PRODUCT", 144, 148], ["ATPase", "PROTEIN", 61, 67], ["GRP78", "PROTEIN", 80, 85], ["BiP", "PROTEIN", 86, 89], ["Sec63p", "PROTEIN", 120, 126], ["DnaJ family", "PROTEIN", 144, 155], ["yeast", "SPECIES", 3, 8], ["yeast", "SPECIES", 3, 8], ["GRP78/BiP", "TREATMENT", 80, 89]]], ["ER oxidoreductases are also found on ribosome-associated translocons, among them in particular ERp57 [59].", [["ribosome", "ANATOMY", 37, 45], ["ER", "GENE_OR_GENE_PRODUCT", 0, 2], ["ribosome", "CELLULAR_COMPONENT", 37, 45], ["ERp57", "GENE_OR_GENE_PRODUCT", 95, 100], ["ER oxidoreductases", "PROTEIN", 0, 18], ["ribosome-associated translocons", "PROTEIN", 37, 68], ["ERp57", "PROTEIN", 95, 100]]], ["Another example is the lectin chaperone calnexin, a transmembrane protein, which associates with incompletely translocated polypeptides at the translocon [60], [61].", [["transmembrane", "ANATOMY", 52, 65], ["lectin", "GENE_OR_GENE_PRODUCT", 23, 29], ["calnexin", "GENE_OR_GENE_PRODUCT", 40, 48], ["transmembrane", "CELLULAR_COMPONENT", 52, 65], ["lectin chaperone", "PROTEIN", 23, 39], ["calnexin", "PROTEIN", 40, 48], ["transmembrane protein", "PROTEIN", 52, 73], ["the lectin chaperone calnexin", "TREATMENT", 19, 48], ["a transmembrane protein", "TEST", 50, 73], ["incompletely translocated polypeptides", "PROBLEM", 97, 135]]], ["Like Sec63, calnexin is a substrate of protein kinase CK2, but also of extracellular signal-regulated kinase 1 (ERK1); when phosphorylated, calnexin interacts more strongly with ribosomes, suggesting that phosphorylated calnexin targets to the rough ER [62].", [["ribosomes", "ANATOMY", 178, 187], ["Sec63", "GENE_OR_GENE_PRODUCT", 5, 10], ["calnexin", "GENE_OR_GENE_PRODUCT", 12, 20], ["protein kinase CK2", "GENE_OR_GENE_PRODUCT", 39, 57], ["extracellular signal-regulated kinase 1", "GENE_OR_GENE_PRODUCT", 71, 110], ["ERK1", "GENE_OR_GENE_PRODUCT", 112, 116], ["calnexin", "GENE_OR_GENE_PRODUCT", 140, 148], ["ribosomes", "CELLULAR_COMPONENT", 178, 187], ["calnexin", "GENE_OR_GENE_PRODUCT", 220, 228], ["ER", "GENE_OR_GENE_PRODUCT", 250, 252], ["Sec63", "PROTEIN", 5, 10], ["calnexin", "PROTEIN", 12, 20], ["protein kinase CK2", "PROTEIN", 39, 57], ["extracellular signal-regulated kinase 1", "PROTEIN", 71, 110], ["ERK1", "PROTEIN", 112, 116], ["calnexin", "PROTEIN", 140, 148], ["calnexin", "PROTEIN", 220, 228], ["ER", "PROTEIN", 250, 252], ["calnexin", "TREATMENT", 12, 20], ["protein kinase CK2", "TEST", 39, 57], ["extracellular signal", "TEST", 71, 91], ["kinase", "TEST", 102, 108], ["calnexin", "TREATMENT", 140, 148], ["phosphorylated calnexin", "TREATMENT", 205, 228]]], ["However, calnexin is one of many ER chaperones, which perform additional functions within the ER and which therefore is not restricted to the rough ER [63].", [["ER", "ANATOMY", 94, 96], ["calnexin", "GENE_OR_GENE_PRODUCT", 9, 17], ["ER", "GENE_OR_GENE_PRODUCT", 33, 35], ["ER", "GENE_OR_GENE_PRODUCT", 94, 96], ["ER", "GENE_OR_GENE_PRODUCT", 148, 150], ["calnexin", "PROTEIN", 9, 17], ["ER chaperones", "PROTEIN", 33, 46], ["ER", "PROTEIN", 94, 96], ["ER", "PROTEIN", 148, 150], ["calnexin", "TREATMENT", 9, 17], ["many ER chaperones", "TREATMENT", 28, 46]]], ["Consistent with this, a considerable portion of calnexin localizes to tubular, smooth ER [64], and in particular the MAM, to which it targets with the assistance of phosphofurin acidic cluster sorting protein 2 (PACS-2) [63].Targeting to rough ER domainsA major determinant of the ribosome and translocon aggregation on the membranes of the rough ER appears to be the extent of ER membrane curvature.", [["tubular", "ANATOMY", 70, 77], ["ribosome", "ANATOMY", 281, 289], ["translocon", "ANATOMY", 294, 304], ["membranes", "ANATOMY", 324, 333], ["ER", "ANATOMY", 347, 349], ["ER membrane", "ANATOMY", 378, 389], ["phosphofurin", "CHEMICAL", 165, 177], ["calnexin", "GENE_OR_GENE_PRODUCT", 48, 56], ["tubular", "TISSUE", 70, 77], ["ER", "GENE_OR_GENE_PRODUCT", 86, 88], ["MAM", "CELLULAR_COMPONENT", 117, 120], ["phosphofurin acidic cluster sorting protein 2", "GENE_OR_GENE_PRODUCT", 165, 210], ["PACS-2", "GENE_OR_GENE_PRODUCT", 212, 218], ["ER", "GENE_OR_GENE_PRODUCT", 244, 246], ["ribosome", "CELLULAR_COMPONENT", 281, 289], ["translocon", "CELLULAR_COMPONENT", 294, 304], ["membranes", "CELLULAR_COMPONENT", 324, 333], ["ER", "GENE_OR_GENE_PRODUCT", 347, 349], ["ER", "GENE_OR_GENE_PRODUCT", 378, 380], ["membrane", "CELLULAR_COMPONENT", 381, 389], ["calnexin", "PROTEIN", 48, 56], ["phosphofurin acidic cluster sorting protein 2", "PROTEIN", 165, 210], ["PACS", "PROTEIN", 212, 216], ["ER domains", "PROTEIN", 244, 254], ["ER", "PROTEIN", 347, 349], ["ER", "PROTEIN", 378, 380], ["calnexin", "TREATMENT", 48, 56], ["phosphofurin acidic", "TREATMENT", 165, 184], ["PACS", "TEST", 212, 216], ["translocon aggregation", "PROBLEM", 294, 316], ["tubular", "ANATOMY_MODIFIER", 70, 77], ["smooth", "OBSERVATION_MODIFIER", 79, 85], ["major", "OBSERVATION_MODIFIER", 256, 261], ["ribosome", "OBSERVATION", 281, 289], ["translocon aggregation", "OBSERVATION", 294, 316], ["membranes", "OBSERVATION_MODIFIER", 324, 333], ["appears to be", "UNCERTAINTY", 350, 363], ["extent", "OBSERVATION_MODIFIER", 368, 374], ["membrane curvature", "OBSERVATION", 381, 399]]], ["The rough ER is characterized by low curvature, resulting in sheet-like appearance [65], [66].", [["ER", "GENE_OR_GENE_PRODUCT", 10, 12], ["ER", "PROTEIN", 10, 12], ["low curvature", "PROBLEM", 33, 46], ["low curvature", "OBSERVATION_MODIFIER", 33, 46]]], ["Contrary to mechanisms that determine the formation of peripheral tubular ER, the formation of ER sheets is not well understood [67].", [["peripheral tubular ER", "ANATOMY", 55, 76], ["ER sheets", "ANATOMY", 95, 104], ["peripheral tubular", "MULTI-TISSUE_STRUCTURE", 55, 73], ["ER", "GENE_OR_GENE_PRODUCT", 74, 76], ["ER", "GENE_OR_GENE_PRODUCT", 95, 97], ["peripheral tubular ER", "PROTEIN", 55, 76], ["ER", "PROTEIN", 95, 97], ["peripheral", "ANATOMY_MODIFIER", 55, 65], ["tubular", "ANATOMY_MODIFIER", 66, 73]]], ["A mammalian coiled-coil protein, the cytoskeleton-linking membrane protein of 63 kDa (Climp63), actively promotes the formation of these ER sheets, to which ribosomes can attach [64], but also limits the diffusion of translocons within ER membranes [68].", [["cytoskeleton", "ANATOMY", 37, 49], ["ER sheets", "ANATOMY", 137, 146], ["ribosomes", "ANATOMY", 157, 166], ["ER membranes", "ANATOMY", 236, 248], ["cytoskeleton", "CELLULAR_COMPONENT", 37, 49], ["membrane", "CELLULAR_COMPONENT", 58, 66], ["Climp63", "GENE_OR_GENE_PRODUCT", 86, 93], ["ER", "GENE_OR_GENE_PRODUCT", 137, 139], ["ribosomes", "CELLULAR_COMPONENT", 157, 166], ["ER", "GENE_OR_GENE_PRODUCT", 236, 238], ["mammalian coiled-coil protein", "PROTEIN", 2, 31], ["cytoskeleton-linking membrane protein", "PROTEIN", 37, 74], ["63 kDa", "PROTEIN", 78, 84], ["Climp63", "PROTEIN", 86, 93], ["translocons", "PROTEIN", 217, 228], ["ER", "PROTEIN", 236, 238], ["A mammalian coiled-coil protein", "TREATMENT", 0, 31], ["the cytoskeleton", "TEST", 33, 49], ["membrane protein", "TEST", 58, 74]]], ["The ER-localized, ribosome-interacting protein p180 plays a central role in the attachment of ribosomes to ER sheets in mammalian cells [69], [70].", [["ribosomes", "ANATOMY", 94, 103], ["ER sheets", "ANATOMY", 107, 116], ["cells", "ANATOMY", 130, 135], ["ER", "GENE_OR_GENE_PRODUCT", 4, 6], ["ribosome-interacting protein p180", "GENE_OR_GENE_PRODUCT", 18, 51], ["ribosomes", "CELLULAR_COMPONENT", 94, 103], ["ER", "GENE_OR_GENE_PRODUCT", 107, 109], ["mammalian cells", "CELL", 120, 135], ["ER", "PROTEIN", 4, 6], ["ribosome-interacting protein p180", "PROTEIN", 18, 51], ["ER", "PROTEIN", 107, 109], ["mammalian cells", "CELL_TYPE", 120, 135]]], ["Expression levels of this protein determine the speed of ER-associated protein synthesis and the extent of ribosome attachment [70].", [["ribosome", "ANATOMY", 107, 115], ["ER", "GENE_OR_GENE_PRODUCT", 57, 59], ["ribosome", "CELLULAR_COMPONENT", 107, 115], ["ER", "PROTEIN", 57, 59], ["Expression levels", "TEST", 0, 17], ["this protein", "TEST", 21, 33], ["protein synthesis", "PROBLEM", 71, 88], ["ribosome attachment", "OBSERVATION", 107, 126]]], ["Interestingly, both Climp63 and p180 also tether the ER to microtubules [68], [69], which could have implications into the intracellular distribution of the rough ER domains.", [["ER", "ANATOMY", 53, 55], ["microtubules", "ANATOMY", 59, 71], ["intracellular", "ANATOMY", 123, 136], ["ER", "ANATOMY", 163, 165], ["Climp63", "GENE_OR_GENE_PRODUCT", 20, 27], ["p180", "GENE_OR_GENE_PRODUCT", 32, 36], ["ER", "GENE_OR_GENE_PRODUCT", 53, 55], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 123, 136], ["ER", "GENE_OR_GENE_PRODUCT", 163, 165], ["Climp63", "PROTEIN", 20, 27], ["p180", "PROTEIN", 32, 36], ["ER", "PROTEIN", 53, 55], ["ER domains", "PROTEIN", 163, 173], ["intracellular", "ANATOMY_MODIFIER", 123, 136]]], ["This is evident in particular in yeast that lacks both Climp63 and p180 and whose ER does not fill the entire cell volume [64].", [["cell", "ANATOMY", 110, 114], ["Climp63", "GENE_OR_GENE_PRODUCT", 55, 62], ["ER", "GENE_OR_GENE_PRODUCT", 82, 84], ["cell", "CELL", 110, 114], ["Climp63", "PROTEIN", 55, 62], ["p180", "PROTEIN", 67, 71], ["ER", "PROTEIN", 82, 84], ["yeast", "SPECIES", 33, 38], ["yeast", "SPECIES", 33, 38], ["the entire cell volume", "TEST", 99, 121]]], ["In addition, the abundance of tubule- and curvature-promoting smooth ER proteins also governs the abundance of rough ER sheets.", [["tubule", "ANATOMY", 30, 36], ["ER sheets", "ANATOMY", 117, 126], ["tubule", "TISSUE", 30, 36], ["ER", "GENE_OR_GENE_PRODUCT", 69, 71], ["ER", "GENE_OR_GENE_PRODUCT", 117, 119], ["smooth ER proteins", "PROTEIN", 62, 80], ["ER", "PROTEIN", 117, 119], ["tubule", "ANATOMY_MODIFIER", 30, 36], ["curvature", "OBSERVATION_MODIFIER", 42, 51], ["smooth", "OBSERVATION_MODIFIER", 62, 68], ["abundance", "OBSERVATION_MODIFIER", 98, 107]]], ["Since mammalian cells are able to adapt their ER structure and function to particular demands, as seen for example during B cell development, ER domains are likely dynamically defined by their redox homeostasis and the extent of oxidative protein folding [23], [71], [72], [73].Targeting to rough ER domainsThe nuclear envelope, which delineates the nucleus, is contiguous with the rough ER.", [["cells", "ANATOMY", 16, 21], ["B cell", "ANATOMY", 122, 128], ["ER domains", "ANATOMY", 142, 152], ["nuclear envelope", "ANATOMY", 311, 327], ["nucleus", "ANATOMY", 350, 357], ["ER", "ANATOMY", 388, 390], ["mammalian cells", "CELL", 6, 21], ["ER", "GENE_OR_GENE_PRODUCT", 46, 48], ["B cell", "CELL", 122, 128], ["ER", "GENE_OR_GENE_PRODUCT", 142, 144], ["ER", "GENE_OR_GENE_PRODUCT", 297, 299], ["nuclear", "CELLULAR_COMPONENT", 311, 318], ["nucleus", "CELLULAR_COMPONENT", 350, 357], ["ER", "GENE_OR_GENE_PRODUCT", 388, 390], ["mammalian cells", "CELL_TYPE", 6, 21], ["ER", "PROTEIN", 46, 48], ["ER domains", "PROTEIN", 142, 152], ["ER domains", "PROTEIN", 297, 307], ["ER", "PROTEIN", 388, 390], ["mammalian cells", "PROBLEM", 6, 21], ["oxidative protein folding", "TEST", 229, 254], ["mammalian cells", "OBSERVATION", 6, 21], ["redox homeostasis", "OBSERVATION", 193, 210], ["nuclear envelope", "OBSERVATION", 311, 327], ["nucleus", "ANATOMY_MODIFIER", 350, 357]]], ["This membrane is equipped with ribosomes on the cytoplasmic face, called the outer nuclear membrane, but lacks them on the nuclear face, the inner nuclear membrane [74].", [["membrane", "ANATOMY", 5, 13], ["ribosomes", "ANATOMY", 31, 40], ["cytoplasmic face", "ANATOMY", 48, 64], ["outer nuclear membrane", "ANATOMY", 77, 99], ["nuclear face", "ANATOMY", 123, 135], ["inner nuclear membrane", "ANATOMY", 141, 163], ["membrane", "CELLULAR_COMPONENT", 5, 13], ["ribosomes", "CELLULAR_COMPONENT", 31, 40], ["cytoplasmic", "ORGANISM_SUBSTANCE", 48, 59], ["outer nuclear membrane", "CELLULAR_COMPONENT", 77, 99], ["nuclear", "CELLULAR_COMPONENT", 123, 130], ["inner nuclear membrane", "CELLULAR_COMPONENT", 141, 163], ["outer", "ANATOMY_MODIFIER", 77, 82], ["nuclear membrane", "ANATOMY", 83, 99], ["inner", "ANATOMY_MODIFIER", 141, 146], ["nuclear membrane", "ANATOMY", 147, 163]]], ["The inner nuclear membrane distinguishes itself from ER membranes by an extensive, unique set of proteins.", [["inner nuclear membrane", "ANATOMY", 4, 26], ["ER membranes", "ANATOMY", 53, 65], ["inner nuclear membrane", "CELLULAR_COMPONENT", 4, 26], ["ER membranes", "CELLULAR_COMPONENT", 53, 65], ["ER", "PROTEIN", 53, 55], ["inner", "ANATOMY_MODIFIER", 4, 9], ["nuclear membrane", "ANATOMY", 10, 26], ["membranes", "OBSERVATION_MODIFIER", 56, 65], ["extensive", "OBSERVATION_MODIFIER", 72, 81]]], ["Many of these proteins are integral membrane proteins that connect the inner nuclear membrane to chromatin or the nuclear lamina, such as the lamin B receptor [75], [76].", [["membrane", "ANATOMY", 36, 44], ["inner nuclear membrane", "ANATOMY", 71, 93], ["chromatin", "ANATOMY", 97, 106], ["nuclear lamina", "ANATOMY", 114, 128], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["inner nuclear membrane", "CELLULAR_COMPONENT", 71, 93], ["chromatin", "CELLULAR_COMPONENT", 97, 106], ["nuclear lamina", "CELLULAR_COMPONENT", 114, 128], ["lamin B receptor", "GENE_OR_GENE_PRODUCT", 142, 158], ["integral membrane proteins", "PROTEIN", 27, 53], ["chromatin", "DNA", 97, 106], ["lamin B receptor", "PROTEIN", 142, 158], ["integral membrane proteins", "PROBLEM", 27, 53], ["proteins", "OBSERVATION", 14, 22], ["membrane proteins", "OBSERVATION", 36, 53], ["inner", "ANATOMY_MODIFIER", 71, 76], ["nuclear membrane", "ANATOMY", 77, 93], ["nuclear lamina", "ANATOMY", 114, 128]]], ["The sorting of these proteins to the inner nuclear membrane is thought to involve diverse mechanisms based on diffusion through the nuclear envelope membrane, translocation by vesicular transport from the inner nuclear envelope membrane and transport via the nuclear pore complex [77], [78].", [["inner nuclear membrane", "ANATOMY", 37, 59], ["nuclear envelope membrane", "ANATOMY", 132, 157], ["vesicular", "ANATOMY", 176, 185], ["inner nuclear envelope membrane", "ANATOMY", 205, 236], ["nuclear pore", "ANATOMY", 259, 271], ["inner nuclear membrane", "CELLULAR_COMPONENT", 37, 59], ["nuclear", "CELLULAR_COMPONENT", 132, 139], ["envelope membrane", "CELLULAR_COMPONENT", 140, 157], ["vesicular", "CELLULAR_COMPONENT", 176, 185], ["inner nuclear envelope membrane", "CELLULAR_COMPONENT", 205, 236], ["nuclear pore", "CELLULAR_COMPONENT", 259, 271], ["nuclear pore complex", "PROTEIN", 259, 279], ["diverse mechanisms", "PROBLEM", 82, 100], ["inner", "ANATOMY_MODIFIER", 37, 42], ["nuclear membrane", "ANATOMY", 43, 59], ["thought to involve", "UNCERTAINTY", 63, 81], ["envelope membrane", "OBSERVATION", 140, 157], ["inner", "ANATOMY_MODIFIER", 205, 210], ["envelope membrane", "OBSERVATION", 219, 236]]], ["The outer nuclear contains a unique set of proteins that distinguishes it from the remainder of the rough ER.", [["outer nuclear", "ANATOMY", 4, 17], ["ER", "ANATOMY", 106, 108], ["ER", "GENE_OR_GENE_PRODUCT", 106, 108], ["ER", "PROTEIN", 106, 108], ["outer", "ANATOMY_MODIFIER", 4, 9]]], ["Among these proteins are members of the nesprin protein family [79], [80].", [["nesprin", "GENE_OR_GENE_PRODUCT", 40, 47], ["nesprin protein family", "PROTEIN", 40, 62]]], ["The nesprins bridge nuclear lamina to the cytoskeleton with the help of inner nuclear membrane proteins, thus regulating nuclear migration and anchoring [81].", [["nuclear lamina", "ANATOMY", 20, 34], ["cytoskeleton", "ANATOMY", 42, 54], ["inner nuclear membrane", "ANATOMY", 72, 94], ["nuclear", "ANATOMY", 121, 128], ["nesprins", "GENE_OR_GENE_PRODUCT", 4, 12], ["nuclear lamina", "CELLULAR_COMPONENT", 20, 34], ["cytoskeleton", "CELLULAR_COMPONENT", 42, 54], ["inner nuclear membrane", "CELLULAR_COMPONENT", 72, 94], ["nuclear", "CELLULAR_COMPONENT", 121, 128], ["nesprins", "PROTEIN", 4, 12], ["inner nuclear membrane proteins", "PROTEIN", 72, 103], ["inner nuclear membrane proteins", "TREATMENT", 72, 103], ["lamina", "ANATOMY_MODIFIER", 28, 34], ["cytoskeleton", "ANATOMY_MODIFIER", 42, 54], ["inner", "ANATOMY_MODIFIER", 72, 77], ["nuclear membrane proteins", "OBSERVATION", 78, 103], ["nuclear migration", "OBSERVATION", 121, 138]]], ["The outer nuclear membrane targeting mechanism of nesprins relies on their interaction with inner nuclear membrane proteins with a nesprin klarsicht/ANC-1/syne homology (KASH) domain [82], [83], [84], [85].The smooth ERIn most cells, the sheet-like rough ER is interspersed with smooth ER tubules [15], [86].", [["nuclear membrane", "ANATOMY", 10, 26], ["inner nuclear membrane", "ANATOMY", 92, 114], ["cells", "ANATOMY", 227, 232], ["ER", "ANATOMY", 255, 257], ["smooth ER tubules", "ANATOMY", 279, 296], ["outer nuclear membrane", "CELLULAR_COMPONENT", 4, 26], ["nesprins", "GENE_OR_GENE_PRODUCT", 50, 58], ["nesprin", "GENE_OR_GENE_PRODUCT", 131, 138], ["ANC-1", "GENE_OR_GENE_PRODUCT", 149, 154], ["syne", "GENE_OR_GENE_PRODUCT", 155, 159], ["cells", "CELL", 227, 232], ["ER", "GENE_OR_GENE_PRODUCT", 255, 257], ["ER", "GENE_OR_GENE_PRODUCT", 286, 288], ["nesprins", "PROTEIN", 50, 58], ["inner nuclear membrane proteins", "PROTEIN", 92, 123], ["nesprin klarsicht/ANC-1/syne homology (KASH) domain", "PROTEIN", 131, 182], ["ER", "PROTEIN", 255, 257], ["The outer nuclear membrane", "TREATMENT", 0, 26], ["a nesprin klarsicht/ANC", "TREATMENT", 129, 152], ["the sheet", "TEST", 234, 243], ["outer", "ANATOMY_MODIFIER", 4, 9], ["nuclear membrane", "ANATOMY", 10, 26], ["smooth", "OBSERVATION_MODIFIER", 210, 216], ["ERIn", "OBSERVATION_MODIFIER", 217, 221], ["most cells", "OBSERVATION", 222, 232], ["smooth", "OBSERVATION_MODIFIER", 279, 285]]], ["The over-expression of certain smooth ER proteins such as cytochrome b(5) or a mutant form of vesicle-associated membrane protein-associated protein B (VAPB) can induce the proliferation of smooth tubules, which then become stacked against each other [87], [88].", [["vesicle", "ANATOMY", 94, 101], ["membrane", "ANATOMY", 113, 121], ["smooth tubules", "ANATOMY", 190, 204], ["smooth ER", "GENE_OR_GENE_PRODUCT", 31, 40], ["cytochrome b(5)", "GENE_OR_GENE_PRODUCT", 58, 73], ["vesicle-associated membrane protein-associated protein B", "GENE_OR_GENE_PRODUCT", 94, 150], ["VAPB", "GENE_OR_GENE_PRODUCT", 152, 156], ["smooth tubules", "TISSUE", 190, 204], ["smooth ER proteins", "PROTEIN", 31, 49], ["cytochrome b(5)", "PROTEIN", 58, 73], ["vesicle-associated membrane protein-associated protein B", "PROTEIN", 94, 150], ["VAPB", "PROTEIN", 152, 156], ["certain smooth ER proteins", "PROBLEM", 23, 49], ["cytochrome b", "TEST", 58, 70], ["vesicle-associated membrane protein", "PROBLEM", 94, 129], ["protein B (VAPB)", "PROBLEM", 141, 157], ["the proliferation of smooth tubules", "PROBLEM", 169, 204], ["smooth", "OBSERVATION_MODIFIER", 31, 37], ["smooth tubules", "OBSERVATION", 190, 204]]], ["While the mechanism behind these observations is not entirely clear, recent research has identified a group of proteins composed of reticulons and DP1/Yop1p that promotes the curvature of ER membranes by transforming sheet-like ER (as found on the rough ER or the nuclear envelope) into tubular ER.", [["ER membranes", "ANATOMY", 188, 200], ["ER", "ANATOMY", 254, 256], ["nuclear envelope", "ANATOMY", 264, 280], ["tubular ER", "ANATOMY", 287, 297], ["reticulons", "GENE_OR_GENE_PRODUCT", 132, 142], ["DP1", "GENE_OR_GENE_PRODUCT", 147, 150], ["Yop1p", "GENE_OR_GENE_PRODUCT", 151, 156], ["ER", "GENE_OR_GENE_PRODUCT", 188, 190], ["membranes", "CELLULAR_COMPONENT", 191, 200], ["transforming sheet-like ER", "GENE_OR_GENE_PRODUCT", 204, 230], ["ER", "GENE_OR_GENE_PRODUCT", 254, 256], ["nuclear", "CELLULAR_COMPONENT", 264, 271], ["tubular ER", "GENE_OR_GENE_PRODUCT", 287, 297], ["reticulons", "PROTEIN", 132, 142], ["DP1", "PROTEIN", 147, 150], ["Yop1p", "PROTEIN", 151, 156], ["ER", "PROTEIN", 188, 190], ["ER", "PROTEIN", 228, 230], ["ER", "PROTEIN", 254, 256], ["tubular ER", "PROTEIN", 287, 297], ["reticulons", "PROBLEM", 132, 142], ["DP1/Yop1p", "TREATMENT", 147, 156], ["not entirely", "UNCERTAINTY", 49, 61], ["clear", "OBSERVATION", 62, 67], ["curvature", "OBSERVATION_MODIFIER", 175, 184], ["tubular", "ANATOMY_MODIFIER", 287, 294]]], ["Conversely, the loss of these proteins leads to the loss of tubule-shaped ER in both yeast and mammalian cells [89].", [["tubule", "ANATOMY", 60, 66], ["ER", "ANATOMY", 74, 76], ["cells", "ANATOMY", 105, 110], ["tubule", "TISSUE", 60, 66], ["ER", "GENE_OR_GENE_PRODUCT", 74, 76], ["mammalian cells", "CELL", 95, 110], ["tubule-shaped ER", "PROTEIN", 60, 76], ["yeast and mammalian cells", "CELL_TYPE", 85, 110], ["yeast", "SPECIES", 85, 90], ["yeast", "SPECIES", 85, 90], ["the loss of these proteins", "PROBLEM", 12, 38], ["the loss of tubule", "PROBLEM", 48, 66], ["shaped", "OBSERVATION_MODIFIER", 67, 73], ["mammalian cells", "OBSERVATION", 95, 110]]], ["Reticulons span the ER membrane at least twice with two hydrophobic domains, thus forming a hairpin-like structure, which is required for their function, but also for their targeting to the smooth ER [90], [91].", [["ER membrane", "ANATOMY", 20, 31], ["ER membrane", "CELLULAR_COMPONENT", 20, 31], ["ER", "GENE_OR_GENE_PRODUCT", 197, 199], ["ER", "PROTEIN", 20, 22], ["hydrophobic domains", "PROTEIN", 56, 75], ["hairpin-like structure", "PROTEIN", 92, 114], ["ER", "PROTEIN", 197, 199], ["two hydrophobic domains", "PROBLEM", 52, 75], ["a hairpin-like structure", "PROBLEM", 90, 114], ["ER membrane", "OBSERVATION_MODIFIER", 20, 31], ["hairpin", "OBSERVATION", 92, 99]]], ["Additionally, reticulon 4a also localizes to the X. laevis nuclear envelope, where it may promote nuclear envelope growth [92].", [["nuclear envelope", "ANATOMY", 59, 75], ["nuclear", "ANATOMY", 98, 105], ["reticulon 4a", "GENE_OR_GENE_PRODUCT", 14, 26], ["X. laevis", "ORGANISM", 49, 58], ["nuclear", "CELLULAR_COMPONENT", 98, 105], ["reticulon 4a", "PROTEIN", 14, 26], ["X. laevis", "SPECIES", 49, 58], ["X. laevis", "SPECIES", 49, 58]]], ["Similarly, the combined deletion of S. cerevisiae RTN1 and YOP1 leads to the clustering of nuclear pore complexes and a defect in nuclear import [9].The smooth ERThe atlastin protein family, related to dynamin and the mitofusins, interacts with reticulons and DP1/Yop1p and complements their function, likely promoting the homotypic fusion of ER tubules and catalyzing the branching of ER tubules at the expense of GTP [93], [94].", [["nuclear pore", "ANATOMY", 91, 103], ["nuclear", "ANATOMY", 130, 137], ["ER tubules", "ANATOMY", 343, 353], ["ER tubules", "ANATOMY", 386, 396], ["GTP", "CHEMICAL", 415, 418], ["GTP", "CHEMICAL", 415, 418], ["S. cerevisiae", "ORGANISM", 36, 49], ["RTN1", "GENE_OR_GENE_PRODUCT", 50, 54], ["YOP1", "GENE_OR_GENE_PRODUCT", 59, 63], ["nuclear", "CELLULAR_COMPONENT", 130, 137], ["smooth ERThe atlastin", "GENE_OR_GENE_PRODUCT", 153, 174], ["dynamin", "GENE_OR_GENE_PRODUCT", 202, 209], ["mitofusins", "GENE_OR_GENE_PRODUCT", 218, 228], ["reticulons", "GENE_OR_GENE_PRODUCT", 245, 255], ["DP1", "GENE_OR_GENE_PRODUCT", 260, 263], ["Yop1p", "GENE_OR_GENE_PRODUCT", 264, 269], ["ER", "GENE_OR_GENE_PRODUCT", 343, 345], ["ER", "GENE_OR_GENE_PRODUCT", 386, 388], ["tubules", "TISSUE", 389, 396], ["GTP", "SIMPLE_CHEMICAL", 415, 418], ["S. cerevisiae RTN1", "PROTEIN", 36, 54], ["YOP1", "PROTEIN", 59, 63], ["nuclear pore complexes", "PROTEIN", 91, 113], ["smooth ERThe atlastin protein family", "PROTEIN", 153, 189], ["dynamin", "PROTEIN", 202, 209], ["mitofusins", "PROTEIN", 218, 228], ["reticulons", "PROTEIN", 245, 255], ["DP1", "PROTEIN", 260, 263], ["Yop1p", "PROTEIN", 264, 269], ["S. cerevisiae", "SPECIES", 36, 49], ["S. cerevisiae", "SPECIES", 36, 49], ["S. cerevisiae RTN1", "PROBLEM", 36, 54], ["a defect in nuclear import", "PROBLEM", 118, 144], ["reticulons", "TREATMENT", 245, 255], ["DP1/Yop1p", "TREATMENT", 260, 269], ["the homotypic fusion of ER tubules", "TREATMENT", 319, 353], ["GTP", "TEST", 415, 418], ["nuclear pore complexes", "OBSERVATION", 91, 113], ["defect", "OBSERVATION", 120, 126], ["smooth", "OBSERVATION_MODIFIER", 153, 159], ["homotypic fusion", "OBSERVATION", 323, 339], ["branching", "OBSERVATION_MODIFIER", 373, 382]]], ["The absence of atlastins leads to fragmented, unbranched smooth ER, whereas their over-expression promotes sheet-like ER.", [["smooth ER", "ANATOMY", 57, 66], ["ER", "ANATOMY", 118, 120], ["atlastins", "GENE_OR_GENE_PRODUCT", 15, 24], ["ER", "GENE_OR_GENE_PRODUCT", 64, 66], ["ER", "GENE_OR_GENE_PRODUCT", 118, 120], ["atlastins", "PROTEIN", 15, 24], ["ER", "PROTEIN", 64, 66], ["ER", "PROTEIN", 118, 120], ["fragmented", "OBSERVATION_MODIFIER", 34, 44], ["unbranched", "OBSERVATION_MODIFIER", 46, 56], ["smooth", "OBSERVATION_MODIFIER", 57, 63]]], ["Interestingly, mitochondria structure may be maintained by a related and connected mechanism, since mitofusin-2, a GTPase closely related to the atlastins not only mediates the fusion of mitochondrial tubules, but also the attachment of mitochondria to the ER at the MAM [95].", [["mitochondria", "ANATOMY", 15, 27], ["mitochondrial tubules", "ANATOMY", 187, 208], ["mitochondria", "ANATOMY", 237, 249], ["ER", "ANATOMY", 257, 259], ["mitochondria", "CELLULAR_COMPONENT", 15, 27], ["mitofusin-2", "GENE_OR_GENE_PRODUCT", 100, 111], ["atlastins", "GENE_OR_GENE_PRODUCT", 145, 154], ["mitochondrial tubules", "CELLULAR_COMPONENT", 187, 208], ["mitochondria", "CELLULAR_COMPONENT", 237, 249], ["ER", "GENE_OR_GENE_PRODUCT", 257, 259], ["mitofusin-2", "PROTEIN", 100, 111], ["GTPase", "PROTEIN", 115, 121], ["atlastins", "PROTEIN", 145, 154], ["ER", "PROTEIN", 257, 259], ["mitofusin", "TREATMENT", 100, 109], ["a GTPase", "PROBLEM", 113, 121], ["mitochondria structure", "OBSERVATION", 15, 37], ["fusion", "OBSERVATION", 177, 183], ["mitochondrial tubules", "OBSERVATION", 187, 208]]], ["At the moment, it is unclear if and how dynamin-related protein 1 (Drp1), the dynamin-related GTPase that mediates mitochondria fission, also influences the structure of the ER [96].The smooth EROther proteins with functions in intracellular sorting and trafficking have been associated with the formation and maintenance of the rough ER/smooth ER domain formation.", [["mitochondria", "ANATOMY", 115, 127], ["intracellular", "ANATOMY", 228, 241], ["ER", "ANATOMY", 335, 337], ["smooth ER", "ANATOMY", 338, 347], ["dynamin-related protein 1", "GENE_OR_GENE_PRODUCT", 40, 65], ["Drp1", "GENE_OR_GENE_PRODUCT", 67, 71], ["dynamin", "GENE_OR_GENE_PRODUCT", 78, 85], ["mitochondria", "CELLULAR_COMPONENT", 115, 127], ["ER", "GENE_OR_GENE_PRODUCT", 174, 176], ["smooth EROther proteins", "GENE_OR_GENE_PRODUCT", 186, 209], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 228, 241], ["ER", "GENE_OR_GENE_PRODUCT", 335, 337], ["ER", "GENE_OR_GENE_PRODUCT", 345, 347], ["dynamin-related protein 1", "PROTEIN", 40, 65], ["Drp1", "PROTEIN", 67, 71], ["dynamin", "PROTEIN", 78, 85], ["GTPase", "PROTEIN", 94, 100], ["ER", "PROTEIN", 174, 176], ["smooth EROther proteins", "PROTEIN", 186, 209], ["ER", "PROTEIN", 335, 337], ["smooth ER domain", "PROTEIN", 338, 354], ["dynamin", "TEST", 40, 47], ["protein", "TEST", 56, 63], ["Drp1", "TEST", 67, 71], ["the dynamin-related GTPase", "PROBLEM", 74, 100], ["intracellular sorting", "TEST", 228, 249], ["mitochondria fission", "OBSERVATION", 115, 135], ["smooth", "OBSERVATION_MODIFIER", 186, 192], ["intracellular sorting", "OBSERVATION", 228, 249], ["smooth", "OBSERVATION_MODIFIER", 338, 344]]], ["For example, interference with the ER-Golgi SNARE protein syntaxin 18 specifically alters the distribution of smooth ER proteins, but not of rough ER proteins, although the exact mechanism for this observation is currently not known [97].", [["ER-Golgi", "ANATOMY", 35, 43], ["smooth ER", "ANATOMY", 110, 119], ["ER", "GENE_OR_GENE_PRODUCT", 35, 37], ["Golgi", "CELLULAR_COMPONENT", 38, 43], ["syntaxin 18", "GENE_OR_GENE_PRODUCT", 58, 69], ["ER", "GENE_OR_GENE_PRODUCT", 117, 119], ["ER", "GENE_OR_GENE_PRODUCT", 147, 149], ["ER", "PROTEIN", 35, 37], ["Golgi SNARE protein syntaxin 18", "PROTEIN", 38, 69], ["smooth ER proteins", "PROTEIN", 110, 128], ["ER proteins", "PROTEIN", 147, 158], ["Golgi SNARE protein syntaxin", "TREATMENT", 38, 66], ["smooth ER proteins", "PROBLEM", 110, 128], ["rough ER proteins", "PROBLEM", 141, 158], ["this observation", "TEST", 193, 209], ["smooth", "OBSERVATION_MODIFIER", 110, 116]]], ["Moreover, some members of the Rab protein family can regulate the structure of the ER (Rab5) and its apposition to lipid droplets (Rab18) [98], [99].", [["ER", "ANATOMY", 83, 85], ["lipid droplets", "ANATOMY", 115, 129], ["Rab", "GENE_OR_GENE_PRODUCT", 30, 33], ["ER", "GENE_OR_GENE_PRODUCT", 83, 85], ["Rab5", "GENE_OR_GENE_PRODUCT", 87, 91], ["lipid droplets", "CELLULAR_COMPONENT", 115, 129], ["Rab protein family", "PROTEIN", 30, 48], ["ER", "PROTEIN", 83, 85], ["Rab5", "PROTEIN", 87, 91], ["lipid droplets", "TEST", 115, 129]]], ["Although commonly associated with endosomal trafficking in mammalian cells, the absence of Rab5 in C. elegans recapitulates the phenotype of a reticulon knockout and results in a loss of peripheral tubules.", [["endosomal", "ANATOMY", 34, 43], ["mammalian cells", "ANATOMY", 59, 74], ["peripheral tubules", "ANATOMY", 187, 205], ["loss of peripheral tubules", "DISEASE", 179, 205], ["endosomal", "CELLULAR_COMPONENT", 34, 43], ["mammalian cells", "CELL", 59, 74], ["Rab5", "GENE_OR_GENE_PRODUCT", 91, 95], ["C. elegans", "ORGANISM", 99, 109], ["reticulon", "GENE_OR_GENE_PRODUCT", 143, 152], ["peripheral tubules", "MULTI-TISSUE_STRUCTURE", 187, 205], ["mammalian cells", "CELL_TYPE", 59, 74], ["Rab5", "PROTEIN", 91, 95], ["C. elegans", "SPECIES", 99, 109], ["C. elegans", "SPECIES", 99, 109], ["endosomal trafficking in mammalian cells", "PROBLEM", 34, 74], ["Rab5 in C. elegans", "TEST", 91, 109], ["a loss of peripheral tubules", "PROBLEM", 177, 205], ["endosomal trafficking", "OBSERVATION", 34, 55], ["mammalian cells", "OBSERVATION", 59, 74], ["peripheral tubules", "OBSERVATION", 187, 205]]], ["Conversely, the over-expression of Rab18 leads to increased apposition of lipid droplets to the rough ER.The smooth EROne of the major functions of the smooth ER is the storage of calcium [100], [101].", [["lipid droplets", "ANATOMY", 74, 88], ["ER", "ANATOMY", 102, 104], ["smooth ER", "ANATOMY", 152, 161], ["calcium", "CHEMICAL", 180, 187], ["calcium", "CHEMICAL", 180, 187], ["Rab18", "GENE_OR_GENE_PRODUCT", 35, 40], ["lipid droplets", "CELLULAR_COMPONENT", 74, 88], ["ER", "GENE_OR_GENE_PRODUCT", 102, 104], ["ER", "GENE_OR_GENE_PRODUCT", 159, 161], ["calcium", "SIMPLE_CHEMICAL", 180, 187], ["Rab18", "PROTEIN", 35, 40], ["ER", "PROTEIN", 102, 104], ["smooth ER", "PROTEIN", 152, 161], ["increased apposition of lipid droplets", "TREATMENT", 50, 88], ["calcium", "TEST", 180, 187], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["apposition", "OBSERVATION_MODIFIER", 60, 70], ["lipid droplets", "OBSERVATION", 74, 88], ["smooth", "OBSERVATION_MODIFIER", 109, 115], ["major", "OBSERVATION_MODIFIER", 129, 134], ["smooth", "OBSERVATION_MODIFIER", 152, 158]]], ["Whereas luminal calcium binding proteins such as calreticulin [102] and SERCA calcium pumps appear to be widely distributed throughout the ER, IP3R and ryanodine receptor calcium channels often cluster within the smooth endoplasmic reticulum [103], [104], not overlapping perfectly with SERCA calcium pumps [105].", [["luminal", "ANATOMY", 8, 15], ["ER", "ANATOMY", 139, 141], ["smooth endoplasmic reticulum", "ANATOMY", 213, 241], ["luminal", "CHEMICAL", 8, 15], ["calcium", "CHEMICAL", 16, 23], ["calcium", "CHEMICAL", 78, 85], ["ryanodine", "CHEMICAL", 152, 161], ["calcium", "CHEMICAL", 171, 178], ["calcium", "CHEMICAL", 293, 300], ["calcium", "CHEMICAL", 16, 23], ["calcium", "CHEMICAL", 78, 85], ["ryanodine", "CHEMICAL", 152, 161], ["calcium", "CHEMICAL", 171, 178], ["calcium", "CHEMICAL", 293, 300], ["luminal calcium binding proteins", "GENE_OR_GENE_PRODUCT", 8, 40], ["calreticulin [102]", "GENE_OR_GENE_PRODUCT", 49, 67], ["SERCA calcium pumps", "GENE_OR_GENE_PRODUCT", 72, 91], ["ER", "GENE_OR_GENE_PRODUCT", 139, 141], ["IP3R", "GENE_OR_GENE_PRODUCT", 143, 147], ["ryanodine receptor", "GENE_OR_GENE_PRODUCT", 152, 170], ["calcium", "SIMPLE_CHEMICAL", 171, 178], ["smooth", "CELLULAR_COMPONENT", 213, 219], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 220, 241], ["SERCA", "GENE_OR_GENE_PRODUCT", 287, 292], ["luminal calcium binding proteins", "PROTEIN", 8, 40], ["calreticulin [102]", "PROTEIN", 49, 67], ["SERCA", "PROTEIN", 72, 77], ["ER", "PROTEIN", 139, 141], ["IP3R", "PROTEIN", 143, 147], ["ryanodine receptor calcium channels", "PROTEIN", 152, 187], ["SERCA", "PROTEIN", 287, 292], ["luminal calcium binding proteins", "PROBLEM", 8, 40], ["calreticulin", "TEST", 49, 61], ["SERCA calcium pumps", "TREATMENT", 72, 91], ["IP3R and ryanodine receptor calcium channels", "TREATMENT", 143, 187], ["SERCA calcium pumps", "TREATMENT", 287, 306], ["smooth", "OBSERVATION_MODIFIER", 213, 219], ["endoplasmic reticulum", "OBSERVATION", 220, 241]]], ["The result of these distinct distributions is the formation of ER subcompartments with different calcium uptake and release abilities [106], [107], [108].", [["ER subcompartments", "ANATOMY", 63, 81], ["calcium", "CHEMICAL", 97, 104], ["calcium", "CHEMICAL", 97, 104], ["ER", "GENE_OR_GENE_PRODUCT", 63, 65], ["calcium", "SIMPLE_CHEMICAL", 97, 104], ["ER", "PROTEIN", 63, 65], ["different calcium uptake", "PROBLEM", 87, 111], ["release abilities", "TEST", 116, 133], ["distinct", "OBSERVATION_MODIFIER", 20, 28], ["distributions", "OBSERVATION_MODIFIER", 29, 42], ["calcium uptake", "OBSERVATION", 97, 111]]], ["An ER domain termed MAM fulfills a central role in ER calcium release, suggesting that this domain could be an important location of ER calcium release channels [54], [109].", [["ER", "ANATOMY", 51, 53], ["ER", "ANATOMY", 133, 135], ["calcium", "CHEMICAL", 54, 61], ["calcium", "CHEMICAL", 136, 143], ["calcium", "CHEMICAL", 54, 61], ["calcium", "CHEMICAL", 136, 143], ["ER", "GENE_OR_GENE_PRODUCT", 3, 5], ["MAM", "CELLULAR_COMPONENT", 20, 23], ["ER", "GENE_OR_GENE_PRODUCT", 51, 53], ["calcium", "SIMPLE_CHEMICAL", 54, 61], ["ER", "GENE_OR_GENE_PRODUCT", 133, 135], ["calcium", "SIMPLE_CHEMICAL", 136, 143], ["ER domain", "PROTEIN", 3, 12], ["MAM", "PROTEIN", 20, 23], ["ER", "PROTEIN", 51, 53], ["ER", "PROTEIN", 133, 135], ["ER calcium release", "TEST", 51, 69], ["ER calcium release channels", "TEST", 133, 160], ["central", "OBSERVATION_MODIFIER", 35, 42]]], ["However, IP3Rs are not particularly enriched on this domain [110], [111] and rather show a pan-ER distribution that includes in particular ER domains close to the plasma membrane, as seen for example in confluent, polarized Madin-Darby canine kidney cells [112], [113].", [["plasma membrane", "ANATOMY", 163, 178], ["kidney cells", "ANATOMY", 243, 255], ["IP3Rs", "GENE_OR_GENE_PRODUCT", 9, 14], ["ER", "GENE_OR_GENE_PRODUCT", 139, 141], ["plasma membrane", "CELLULAR_COMPONENT", 163, 178], ["canine kidney cells", "CELL", 236, 255], ["IP3Rs", "PROTEIN", 9, 14], ["ER domains", "PROTEIN", 139, 149], ["confluent, polarized Madin-Darby canine kidney cells", "CELL_LINE", 203, 255], ["Darby canine kidney cells", "TEST", 230, 255], ["plasma membrane", "ANATOMY", 163, 178], ["confluent", "OBSERVATION_MODIFIER", 203, 212], ["kidney", "ANATOMY", 243, 249]]], ["Regardless of the IP3R intra-ER distribution, the MAM has clearly been identified as a major calcium release site.The smooth ERWhat mechanism could explain this apparent contradiction?", [["MAM", "CHEMICAL", 50, 53], ["calcium", "CHEMICAL", 93, 100], ["calcium", "CHEMICAL", 93, 100], ["IP3R", "GENE_OR_GENE_PRODUCT", 18, 22], ["MAM", "CELLULAR_COMPONENT", 50, 53], ["calcium", "SIMPLE_CHEMICAL", 93, 100], ["IP3R", "PROTEIN", 18, 22], ["MAM", "PROTEIN", 50, 53], ["a major calcium release site", "PROBLEM", 85, 113], ["smooth", "OBSERVATION_MODIFIER", 118, 124]]], ["One reason could be the interaction of calcium release channels and/or calcium pumps with regulatory proteins, which could be unevenly distributed throughout the ER and which would then be primarily responsible for the formation of these distinct calcium release domains.", [["ER", "ANATOMY", 162, 164], ["calcium", "CHEMICAL", 39, 46], ["calcium", "CHEMICAL", 71, 78], ["calcium", "CHEMICAL", 247, 254], ["calcium", "CHEMICAL", 39, 46], ["calcium", "CHEMICAL", 71, 78], ["calcium", "CHEMICAL", 247, 254], ["calcium", "SIMPLE_CHEMICAL", 39, 46], ["calcium", "SIMPLE_CHEMICAL", 71, 78], ["ER", "GENE_OR_GENE_PRODUCT", 162, 164], ["calcium", "SIMPLE_CHEMICAL", 247, 254], ["regulatory proteins", "PROTEIN", 90, 109], ["ER", "PROTEIN", 162, 164], ["calcium release domains", "PROTEIN", 247, 270], ["calcium release channels", "TREATMENT", 39, 63], ["calcium pumps", "TREATMENT", 71, 84], ["regulatory proteins", "TREATMENT", 90, 109], ["these distinct calcium release domains", "PROBLEM", 232, 270], ["unevenly", "OBSERVATION_MODIFIER", 126, 134]]], ["In this hypothesis, the locally distinct interaction of regulatory proteins with IP3R and SERCA would determine whether the ER takes up or releases calcium at specific points within the ER network.", [["ER network", "ANATOMY", 186, 196], ["calcium", "CHEMICAL", 148, 155], ["calcium", "CHEMICAL", 148, 155], ["IP3R", "GENE_OR_GENE_PRODUCT", 81, 85], ["SERCA", "GENE_OR_GENE_PRODUCT", 90, 95], ["ER", "GENE_OR_GENE_PRODUCT", 124, 126], ["calcium", "SIMPLE_CHEMICAL", 148, 155], ["ER", "GENE_OR_GENE_PRODUCT", 186, 188], ["regulatory proteins", "PROTEIN", 56, 75], ["IP3R", "PROTEIN", 81, 85], ["SERCA", "PROTEIN", 90, 95], ["ER", "PROTEIN", 124, 126], ["ER", "PROTEIN", 186, 188], ["IP3R", "TREATMENT", 81, 85], ["SERCA", "TREATMENT", 90, 95], ["calcium", "TREATMENT", 148, 155]]], ["Both the IP3R and SERCA are known to interact with numerous such proteins, including the ER chaperones and oxidoreductases ERp44, Ero1\u03b1 and the sigma-1 receptor (IP3) as well as ERp57 and calnexin (SERCA) [114], [115], [116], [117], [118].", [["IP3R", "GENE_OR_GENE_PRODUCT", 9, 13], ["SERCA", "GENE_OR_GENE_PRODUCT", 18, 23], ["ER", "GENE_OR_GENE_PRODUCT", 89, 91], ["ERp44", "GENE_OR_GENE_PRODUCT", 123, 128], ["Ero1\u03b1", "GENE_OR_GENE_PRODUCT", 130, 135], ["sigma-1 receptor", "GENE_OR_GENE_PRODUCT", 144, 160], ["IP3", "GENE_OR_GENE_PRODUCT", 162, 165], ["ERp57", "GENE_OR_GENE_PRODUCT", 178, 183], ["calnexin", "GENE_OR_GENE_PRODUCT", 188, 196], ["SERCA", "GENE_OR_GENE_PRODUCT", 198, 203], ["IP3R", "PROTEIN", 9, 13], ["SERCA", "PROTEIN", 18, 23], ["ER chaperones", "PROTEIN", 89, 102], ["oxidoreductases", "PROTEIN", 107, 122], ["ERp44", "PROTEIN", 123, 128], ["Ero1\u03b1", "PROTEIN", 130, 135], ["sigma-1 receptor", "PROTEIN", 144, 160], ["IP3", "PROTEIN", 162, 165], ["ERp57", "PROTEIN", 178, 183], ["calnexin", "PROTEIN", 188, 196], ["SERCA", "PROTEIN", 198, 203], ["the ER chaperones", "TREATMENT", 85, 102], ["oxidoreductases ERp44", "TREATMENT", 107, 128], ["Ero1\u03b1", "TREATMENT", 130, 135], ["the sigma-1 receptor (IP3)", "TREATMENT", 140, 166], ["SERCA", "ANATOMY", 18, 23]]], ["Indeed, the IP3R1 activator Ero1\u03b1 and the SERCA2b inhibitor calnexin target preferentially to the MAM [63], [111], [119].", [["IP3R1", "GENE_OR_GENE_PRODUCT", 12, 17], ["Ero1\u03b1", "GENE_OR_GENE_PRODUCT", 28, 33], ["SERCA2b", "GENE_OR_GENE_PRODUCT", 42, 49], ["calnexin", "GENE_OR_GENE_PRODUCT", 60, 68], ["IP3R1", "PROTEIN", 12, 17], ["Ero1\u03b1", "PROTEIN", 28, 33], ["SERCA2b inhibitor", "PROTEIN", 42, 59], ["calnexin", "PROTEIN", 60, 68], ["the IP3R1 activator Ero1", "TREATMENT", 8, 32], ["the SERCA2b inhibitor calnexin", "TREATMENT", 38, 68]]], ["Similar to these examples, presenilin-2, an aspartyl protease associated with Alzheimer's disease, localizes to the MAM and inhibits SERCA activity [120], [121].", [["Alzheimer's disease", "DISEASE", 78, 97], ["presenilin-2", "GENE_OR_GENE_PRODUCT", 27, 39], ["MAM", "CELLULAR_COMPONENT", 116, 119], ["SERCA", "GENE_OR_GENE_PRODUCT", 133, 138], ["presenilin-2", "PROTEIN", 27, 39], ["aspartyl protease", "PROTEIN", 44, 61], ["SERCA", "PROTEIN", 133, 138], ["presenilin", "TEST", 27, 37], ["an aspartyl protease", "PROBLEM", 41, 61], ["Alzheimer's disease", "PROBLEM", 78, 97], ["SERCA activity", "TEST", 133, 147]]], ["Another mechanism could rely on local accumulations of calcium storage proteins within the sarcoplasmic reticulum of muscle cells (calsequestrin and calreticulin) or the smooth ER of nonmuscle cells (calreticulin) [122], [123].", [["sarcoplasmic reticulum", "ANATOMY", 91, 113], ["muscle cells", "ANATOMY", 117, 129], ["smooth ER", "ANATOMY", 170, 179], ["nonmuscle cells", "ANATOMY", 183, 198], ["calcium", "CHEMICAL", 55, 62], ["calcium", "CHEMICAL", 55, 62], ["calcium", "SIMPLE_CHEMICAL", 55, 62], ["sarcoplasmic reticulum", "CELLULAR_COMPONENT", 91, 113], ["muscle cells", "CELL", 117, 129], ["calsequestrin", "GENE_OR_GENE_PRODUCT", 131, 144], ["calreticulin", "GENE_OR_GENE_PRODUCT", 149, 161], ["ER", "GENE_OR_GENE_PRODUCT", 177, 179], ["nonmuscle cells", "CELL", 183, 198], ["calreticulin", "GENE_OR_GENE_PRODUCT", 200, 212], ["calcium storage proteins", "PROTEIN", 55, 79], ["muscle cells", "CELL_TYPE", 117, 129], ["calsequestrin", "PROTEIN", 131, 144], ["calreticulin", "PROTEIN", 149, 161], ["smooth ER", "PROTEIN", 170, 179], ["nonmuscle cells", "CELL_TYPE", 183, 198], ["calreticulin", "PROTEIN", 200, 212], ["calcium storage proteins", "PROBLEM", 55, 79], ["sarcoplasmic reticulum", "ANATOMY", 91, 113], ["muscle cells", "ANATOMY", 117, 129], ["nonmuscle cells", "OBSERVATION", 183, 198]]], ["Here, the availability of calcium for intracellular signaling would be determined by the distinct intra-ER localization of releasable calcium.", [["intracellular", "ANATOMY", 38, 51], ["calcium", "CHEMICAL", 26, 33], ["calcium", "CHEMICAL", 134, 141], ["calcium", "CHEMICAL", 26, 33], ["calcium", "CHEMICAL", 134, 141], ["calcium", "SIMPLE_CHEMICAL", 26, 33], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 51], ["calcium", "SIMPLE_CHEMICAL", 134, 141], ["calcium", "TREATMENT", 26, 33], ["intracellular signaling", "PROBLEM", 38, 61], ["releasable calcium", "TEST", 123, 141], ["releasable calcium", "OBSERVATION", 123, 141]]], ["Support for this idea comes from the finding that the location of ER calcium release largely depends on the calcium buffering capacity of the ER, which is chiefly determined by calreticulin and calsequestrin, respectively [124].", [["ER", "ANATOMY", 66, 68], ["ER", "ANATOMY", 142, 144], ["calcium", "CHEMICAL", 69, 76], ["calcium", "CHEMICAL", 108, 115], ["calcium", "CHEMICAL", 69, 76], ["calcium", "CHEMICAL", 108, 115], ["ER", "GENE_OR_GENE_PRODUCT", 66, 68], ["calcium", "SIMPLE_CHEMICAL", 69, 76], ["calcium", "SIMPLE_CHEMICAL", 108, 115], ["ER", "GENE_OR_GENE_PRODUCT", 142, 144], ["calreticulin", "GENE_OR_GENE_PRODUCT", 177, 189], ["calsequestrin", "GENE_OR_GENE_PRODUCT", 194, 207], ["ER", "PROTEIN", 66, 68], ["ER", "PROTEIN", 142, 144], ["calreticulin", "PROTEIN", 177, 189], ["calsequestrin", "PROTEIN", 194, 207], ["ER calcium release", "TEST", 66, 84], ["the calcium buffering capacity", "PROBLEM", 104, 134]]], ["In the case of calsequestrin, intra-ER accumulations are mediated by a head-to-tail oligomerization mechanism [125], [126].", [["head", "ANATOMY", 71, 75], ["calsequestrin", "GENE_OR_GENE_PRODUCT", 15, 28], ["intra-ER", "GENE_OR_GENE_PRODUCT", 30, 38], ["calsequestrin", "PROTEIN", 15, 28], ["intra-ER accumulations", "PROBLEM", 30, 52], ["head", "ANATOMY", 71, 75]]], ["We will next discuss what is known about the targeting of proteins to the domains of the smooth ER.The mitochondria-associated membrane (MAM)Many of the smooth ER domains form interfaces with other organelles, an idea that was first proposed by Alex Novikoff for contacts between the smooth ER and lysosomes as the GERL (Golgi-ER-lysosome) compartment, whose presumed role is the formation of special types of lysosomes directly from the ER [127], [128].", [["smooth ER", "ANATOMY", 89, 98], ["mitochondria", "ANATOMY", 103, 115], ["membrane", "ANATOMY", 127, 135], ["smooth ER domains", "ANATOMY", 153, 170], ["organelles", "ANATOMY", 198, 208], ["smooth ER", "ANATOMY", 284, 293], ["lysosomes", "ANATOMY", 298, 307], ["Golgi-ER-lysosome) compartment", "ANATOMY", 321, 351], ["lysosomes", "ANATOMY", 410, 419], ["ER", "GENE_OR_GENE_PRODUCT", 96, 98], ["mitochondria", "CELLULAR_COMPONENT", 103, 115], ["membrane", "CELLULAR_COMPONENT", 127, 135], ["MAM", "CELLULAR_COMPONENT", 137, 140], ["ER", "GENE_OR_GENE_PRODUCT", 160, 162], ["organelles", "CELLULAR_COMPONENT", 198, 208], ["ER", "GENE_OR_GENE_PRODUCT", 291, 293], ["lysosomes", "CELLULAR_COMPONENT", 298, 307], ["GERL", "GENE_OR_GENE_PRODUCT", 315, 319], ["Golgi", "CELLULAR_COMPONENT", 321, 326], ["ER", "GENE_OR_GENE_PRODUCT", 327, 329], ["lysosome", "CELLULAR_COMPONENT", 330, 338], ["lysosomes", "CELLULAR_COMPONENT", 410, 419], ["ER", "GENE_OR_GENE_PRODUCT", 438, 440], ["smooth ER", "PROTEIN", 89, 98], ["smooth ER domains", "PROTEIN", 153, 170], ["ER", "PROTEIN", 291, 293], ["GERL", "PROTEIN", 315, 319], ["Golgi", "PROTEIN", 321, 326], ["ER", "PROTEIN", 327, 329], ["ER", "PROTEIN", 438, 440], ["membrane", "ANATOMY_MODIFIER", 127, 135]]], ["The role of ER-organelle contacts is particularly well studied in the case of the ER-mitochondria interface, the MAM subdomain [54], [109], [129], a domain of the ER that lacks ribosomes [130], [131].", [["ER-organelle contacts", "ANATOMY", 12, 33], ["ER-mitochondria", "ANATOMY", 82, 97], ["ER", "GENE_OR_GENE_PRODUCT", 12, 14], ["organelle", "CELLULAR_COMPONENT", 15, 24], ["ER", "GENE_OR_GENE_PRODUCT", 82, 84], ["mitochondria", "CELLULAR_COMPONENT", 85, 97], ["ER", "GENE_OR_GENE_PRODUCT", 163, 165], ["ER", "PROTEIN", 12, 14], ["ER", "PROTEIN", 82, 84], ["MAM subdomain", "PROTEIN", 113, 126], ["ER", "PROTEIN", 163, 165]]], ["Today, we know that as much as 20% of the mitochondria surface is in contact with the ER that itself encompasses close to 50% of the total membrane in liver cells, suggesting that the MAM is a major player in cell physiology [132], [133], [134].", [["mitochondria surface", "ANATOMY", 42, 62], ["ER", "ANATOMY", 86, 88], ["membrane", "ANATOMY", 139, 147], ["liver cells", "ANATOMY", 151, 162], ["cell", "ANATOMY", 209, 213], ["mitochondria surface", "CELLULAR_COMPONENT", 42, 62], ["ER", "GENE_OR_GENE_PRODUCT", 86, 88], ["membrane", "CELLULAR_COMPONENT", 139, 147], ["liver cells", "CELL", 151, 162], ["MAM", "CELLULAR_COMPONENT", 184, 187], ["cell", "CELL", 209, 213], ["ER", "PROTEIN", 86, 88], ["liver cells", "CELL_TYPE", 151, 162], ["MAM", "PROTEIN", 184, 187], ["liver", "ANATOMY", 151, 156]]], ["The existence of the MAM was first postulated after close contacts were observed between ER and mitochondria on electron micrographs, in which the resolution is high enough to see structures and measure distances between the two organelles [135].", [["ER", "ANATOMY", 89, 91], ["mitochondria", "ANATOMY", 96, 108], ["organelles", "ANATOMY", 229, 239], ["MAM", "CELLULAR_COMPONENT", 21, 24], ["ER", "GENE_OR_GENE_PRODUCT", 89, 91], ["mitochondria", "CELLULAR_COMPONENT", 96, 108], ["MAM", "PROTEIN", 21, 24], ["ER", "PROTEIN", 89, 91], ["electron micrographs", "TEST", 112, 132]]], ["More recently, 3D electron tomography has been used to visualize the structure of MAM in fixed and live cells [134], [136].", [["cells", "ANATOMY", 104, 109], ["MAM", "CELLULAR_COMPONENT", 82, 85], ["cells", "CELL", 104, 109], ["MAM", "PROTEIN", 82, 85], ["3D electron tomography", "TEST", 15, 37]]], ["Since the resolution of light microscopy is not sufficient to resolve the distance between ER and mitochondria at the MAM (10\u201350 nm), biochemical fractionation has been the main tool to study the MAM, beginning with the development of a Percoll MAM fractionation protocol by the Vance laboratory [111], [137], [138], although it is not clear whether this protocol reliably separates MAM from other domains of the ER, in particular from the rough ER [111].", [["ER", "ANATOMY", 91, 93], ["mitochondria", "ANATOMY", 98, 110], ["ER", "ANATOMY", 413, 415], ["ER", "GENE_OR_GENE_PRODUCT", 91, 93], ["mitochondria", "CELLULAR_COMPONENT", 98, 110], ["MAM", "CELLULAR_COMPONENT", 118, 121], ["MAM", "SIMPLE_CHEMICAL", 383, 386], ["ER", "GENE_OR_GENE_PRODUCT", 413, 415], ["ER", "GENE_OR_GENE_PRODUCT", 446, 448], ["ER", "PROTEIN", 91, 93], ["ER", "PROTEIN", 413, 415], ["ER", "PROTEIN", 446, 448], ["light microscopy", "TEST", 24, 40], ["biochemical fractionation", "TEST", 134, 159], ["a Percoll MAM fractionation protocol", "TREATMENT", 235, 271]]], ["Instead, such a separation can be reliably achieved on Optiprep-based gradients [63], [119], [139], [140].The mitochondria-associated membrane (MAM)Historically, the MAM has been associated with lipid exchange between the ER and mitochondria [141].", [["mitochondria", "ANATOMY", 110, 122], ["membrane", "ANATOMY", 134, 142], ["ER", "ANATOMY", 222, 224], ["mitochondria", "ANATOMY", 229, 241], ["mitochondria", "CELLULAR_COMPONENT", 110, 122], ["membrane", "CELLULAR_COMPONENT", 134, 142], ["MAM", "CELLULAR_COMPONENT", 144, 147], ["MAM", "CELLULAR_COMPONENT", 166, 169], ["lipid", "SIMPLE_CHEMICAL", 195, 200], ["ER", "GENE_OR_GENE_PRODUCT", 222, 224], ["mitochondria", "CELLULAR_COMPONENT", 229, 241], ["MAM", "PROTEIN", 166, 169], ["ER", "PROTEIN", 222, 224], ["membrane", "OBSERVATION_MODIFIER", 134, 142]]], ["This is reflected by the enrichment of lipid synthesis and transfer proteins on the MAM, which give the MAM a characteristic composition that distinguishes it from the remainder of the smooth ER [137], [138].", [["lipid", "SIMPLE_CHEMICAL", 39, 44], ["MAM", "CELLULAR_COMPONENT", 84, 87], ["ER", "GENE_OR_GENE_PRODUCT", 192, 194], ["transfer proteins", "PROTEIN", 59, 76], ["ER", "PROTEIN", 192, 194], ["lipid synthesis", "PROBLEM", 39, 54], ["lipid synthesis", "OBSERVATION", 39, 54]]], ["Enzymes that are particularly enriched on the MAM include acyl-CoA synthase 4 (ACS4/FACL4), acyl-CoA cholesteryl acyl transferase (ACAT/SOAT), and Acyl-CoA:diacylglycerol acyltransferase (DGAT) [138], [140].", [["acyl-CoA cholesteryl acyl", "CHEMICAL", 92, 117], ["diacylglycerol", "CHEMICAL", 156, 170], ["acyl-CoA", "CHEMICAL", 58, 66], ["acyl-CoA cholesteryl acyl", "CHEMICAL", 92, 117], ["Acyl-CoA", "CHEMICAL", 147, 155], ["diacylglycerol", "CHEMICAL", 156, 170], ["MAM", "SIMPLE_CHEMICAL", 46, 49], ["acyl-CoA synthase 4", "GENE_OR_GENE_PRODUCT", 58, 77], ["ACS4", "GENE_OR_GENE_PRODUCT", 79, 83], ["FACL4", "GENE_OR_GENE_PRODUCT", 84, 89], ["acyl-CoA cholesteryl acyl transferase", "GENE_OR_GENE_PRODUCT", 92, 129], ["ACAT", "GENE_OR_GENE_PRODUCT", 131, 135], ["SOAT", "GENE_OR_GENE_PRODUCT", 136, 140], ["Acyl-CoA", "SIMPLE_CHEMICAL", 147, 155], ["diacylglycerol acyltransferase", "GENE_OR_GENE_PRODUCT", 156, 186], ["DGAT", "SIMPLE_CHEMICAL", 188, 192], ["acyl-CoA synthase 4", "PROTEIN", 58, 77], ["ACS4", "PROTEIN", 79, 83], ["FACL4", "PROTEIN", 84, 89], ["acyl-CoA cholesteryl acyl transferase", "PROTEIN", 92, 129], ["ACAT", "PROTEIN", 131, 135], ["SOAT", "PROTEIN", 136, 140], ["Acyl-CoA:diacylglycerol acyltransferase", "PROTEIN", 147, 186], ["DGAT", "PROTEIN", 188, 192], ["Enzymes", "TEST", 0, 7], ["the MAM", "TEST", 42, 49], ["acyl", "TEST", 58, 62], ["CoA synthase", "TEST", 63, 75], ["ACS4", "TEST", 79, 83], ["FACL4", "TEST", 84, 89], ["acyl", "TEST", 92, 96], ["CoA cholesteryl acyl transferase", "TEST", 97, 129], ["ACAT", "TEST", 131, 135], ["/SOAT)", "TREATMENT", 135, 141], ["Acyl", "TEST", 147, 151], ["diacylglycerol acyltransferase", "TEST", 156, 186]]], ["For the proteins of this group, a MAM targeting signal has only been detected for DGAT2 in the form of a cytosolic 67 amino acid sequence that is sufficient to target RFP to mitochondria [142].The mitochondria-associated membrane (MAM)Lipid transfer between the ER and mitochondria requires proteinaceous links, since it becomes inefficient after the treatment of MAM with proteases [143], [144].", [["cytosolic", "ANATOMY", 105, 114], ["mitochondria", "ANATOMY", 174, 186], ["mitochondria", "ANATOMY", 197, 209], ["membrane", "ANATOMY", 221, 229], ["ER", "ANATOMY", 262, 264], ["mitochondria", "ANATOMY", 269, 281], ["amino acid", "CHEMICAL", 118, 128], ["amino acid", "CHEMICAL", 118, 128], ["MAM", "SIMPLE_CHEMICAL", 34, 37], ["DGAT2", "GENE_OR_GENE_PRODUCT", 82, 87], ["amino acid", "AMINO_ACID", 118, 128], ["RFP", "GENE_OR_GENE_PRODUCT", 167, 170], ["mitochondria", "CELLULAR_COMPONENT", 174, 186], ["mitochondria", "CELLULAR_COMPONENT", 197, 209], ["membrane", "CELLULAR_COMPONENT", 221, 229], ["MAM", "CELLULAR_COMPONENT", 231, 234], ["ER", "GENE_OR_GENE_PRODUCT", 262, 264], ["mitochondria", "CELLULAR_COMPONENT", 269, 281], ["MAM", "SIMPLE_CHEMICAL", 364, 367], ["DGAT2", "PROTEIN", 82, 87], ["cytosolic 67 amino acid sequence", "PROTEIN", 105, 137], ["RFP", "PROTEIN", 167, 170], ["ER", "PROTEIN", 262, 264], ["proteases", "PROTEIN", 373, 382], ["a MAM targeting signal", "TEST", 32, 54], ["a cytosolic 67 amino acid sequence", "TEST", 103, 137], ["proteinaceous links", "OBSERVATION", 291, 310]]], ["In yeast, the endoplasmic reticulum\u2013mitochondria encounter structure (ERMES) forms a protein complex that tethers the ER to mitochondria and mediates mitochondria inheritance and movement.", [["endoplasmic reticulum\u2013mitochondria", "ANATOMY", 14, 48], ["ER", "ANATOMY", 118, 120], ["mitochondria", "ANATOMY", 124, 136], ["mitochondria", "ANATOMY", 150, 162], ["endoplasmic reticulum\u2013mitochondria", "CELLULAR_COMPONENT", 14, 48], ["ER", "GENE_OR_GENE_PRODUCT", 118, 120], ["mitochondria", "CELLULAR_COMPONENT", 124, 136], ["mitochondria", "CELLULAR_COMPONENT", 150, 162], ["ERMES", "PROTEIN", 70, 75], ["protein complex", "PROTEIN", 85, 100], ["ER", "PROTEIN", 118, 120], ["yeast", "SPECIES", 3, 8], ["yeast", "SPECIES", 3, 8], ["a protein complex", "PROBLEM", 83, 100], ["mitochondria inheritance", "OBSERVATION", 150, 174]]], ["The ERMES complex is formed between the integral ER membrane protein Mmm1p, the peripheral ER membrane protein Mdm12p, and the two mitochondrial outer membrane proteins Mdm10p and Mdm34p [145], [146].", [["ER membrane", "ANATOMY", 49, 60], ["peripheral ER membrane", "ANATOMY", 80, 102], ["mitochondrial outer membrane", "ANATOMY", 131, 159], ["ERMES", "GENE_OR_GENE_PRODUCT", 4, 9], ["ER membrane", "CELLULAR_COMPONENT", 49, 60], ["Mmm1p", "GENE_OR_GENE_PRODUCT", 69, 74], ["ER membrane", "CELLULAR_COMPONENT", 91, 102], ["Mdm12p", "GENE_OR_GENE_PRODUCT", 111, 117], ["mitochondrial", "CELLULAR_COMPONENT", 131, 144], ["outer membrane", "CELLULAR_COMPONENT", 145, 159], ["Mdm10p", "GENE_OR_GENE_PRODUCT", 169, 175], ["ERMES complex", "PROTEIN", 4, 17], ["integral ER membrane protein", "PROTEIN", 40, 68], ["Mmm1p", "PROTEIN", 69, 74], ["peripheral ER membrane protein", "PROTEIN", 80, 110], ["Mdm12p", "PROTEIN", 111, 117], ["mitochondrial outer membrane proteins", "PROTEIN", 131, 168], ["Mdm10p", "PROTEIN", 169, 175], ["Mdm34p", "PROTEIN", 180, 186], ["membrane protein Mmm1p", "OBSERVATION", 52, 74], ["peripheral", "ANATOMY_MODIFIER", 80, 90]]], ["Mdm12p and Mmm1p are members of the synaptotagmin-like, mitochondrial and lipid-binding protein (SMP) family, whose members are widespread among eukaryotic species and play roles ranging from endocytosis to lipid metabolism and mitochondrial inheritance [147].", [["mitochondrial", "ANATOMY", 56, 69], ["mitochondrial", "ANATOMY", 228, 241], ["Mdm12p", "GENE_OR_GENE_PRODUCT", 0, 6], ["Mmm1p", "GENE_OR_GENE_PRODUCT", 11, 16], ["synaptotagmin", "GENE_OR_GENE_PRODUCT", 36, 49], ["mitochondrial", "CELLULAR_COMPONENT", 56, 69], ["lipid-binding protein", "GENE_OR_GENE_PRODUCT", 74, 95], ["SMP", "GENE_OR_GENE_PRODUCT", 97, 100], ["lipid", "SIMPLE_CHEMICAL", 207, 212], ["mitochondrial", "CELLULAR_COMPONENT", 228, 241], ["Mdm12p", "PROTEIN", 0, 6], ["Mmm1p", "PROTEIN", 11, 16], ["synaptotagmin", "PROTEIN", 36, 49], ["mitochondrial and lipid-binding protein (SMP) family", "PROTEIN", 56, 108], ["the synaptotagmin", "TEST", 32, 49], ["mitochondrial inheritance", "PROBLEM", 228, 253], ["eukaryotic species", "OBSERVATION", 145, 163]]], ["We currently do not know which mammalian proteins fulfill the function of the ERMES complex.The mitochondria-associated membrane (MAM)In mammalian cell systems, the MAM has revealed itself as a major cellular signaling hub that controls cellular metabolism and death via the controlled exchange of calcium between the ER and mitochondria [148], [149].", [["mitochondria", "ANATOMY", 96, 108], ["membrane", "ANATOMY", 120, 128], ["cell", "ANATOMY", 147, 151], ["cellular", "ANATOMY", 200, 208], ["cellular", "ANATOMY", 237, 245], ["ER", "ANATOMY", 318, 320], ["mitochondria", "ANATOMY", 325, 337], ["death", "DISEASE", 261, 266], ["calcium", "CHEMICAL", 298, 305], ["calcium", "CHEMICAL", 298, 305], ["ERMES", "GENE_OR_GENE_PRODUCT", 78, 83], ["mitochondria", "CELLULAR_COMPONENT", 96, 108], ["membrane", "CELLULAR_COMPONENT", 120, 128], ["MAM", "CELLULAR_COMPONENT", 130, 133], ["mammalian cell", "CELL", 137, 151], ["MAM", "CELLULAR_COMPONENT", 165, 168], ["cellular", "CELL", 200, 208], ["cellular", "CELL", 237, 245], ["calcium", "SIMPLE_CHEMICAL", 298, 305], ["ER", "GENE_OR_GENE_PRODUCT", 318, 320], ["mitochondria", "CELLULAR_COMPONENT", 325, 337], ["mammalian proteins", "PROTEIN", 31, 49], ["ERMES complex", "PROTEIN", 78, 91], ["MAM", "PROTEIN", 165, 168], ["ER", "PROTEIN", 318, 320], ["cellular metabolism", "PROBLEM", 237, 256], ["death", "PROBLEM", 261, 266], ["calcium", "TEST", 298, 305], ["membrane", "OBSERVATION_MODIFIER", 120, 128], ["mammalian cell", "OBSERVATION", 137, 151], ["cellular metabolism", "OBSERVATION", 237, 256]]], ["Whereas the IP3R-mediated calcium release during resting conditions directly boosts the mitochondrial metabolism, apoptosis triggers the release of cytochrome c, which binds to ER IP3Rs, thus potentiating and accelerating apoptosis progression.", [["mitochondrial", "ANATOMY", 88, 101], ["ER IP3Rs", "ANATOMY", 177, 185], ["calcium", "CHEMICAL", 26, 33], ["calcium", "CHEMICAL", 26, 33], ["IP3R", "GENE_OR_GENE_PRODUCT", 12, 16], ["calcium", "SIMPLE_CHEMICAL", 26, 33], ["mitochondrial", "CELLULAR_COMPONENT", 88, 101], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 148, 160], ["ER IP3Rs", "GENE_OR_GENE_PRODUCT", 177, 185], ["IP3R", "PROTEIN", 12, 16], ["cytochrome c", "PROTEIN", 148, 160], ["ER IP3Rs", "PROTEIN", 177, 185], ["the IP3R-mediated calcium release", "TREATMENT", 8, 41], ["resting conditions", "PROBLEM", 49, 67], ["the mitochondrial metabolism", "PROBLEM", 84, 112], ["cytochrome c", "PROBLEM", 148, 160], ["accelerating apoptosis progression", "PROBLEM", 209, 243], ["mitochondrial metabolism", "OBSERVATION", 88, 112], ["apoptosis", "OBSERVATION_MODIFIER", 222, 231], ["progression", "OBSERVATION_MODIFIER", 232, 243]]], ["Consistent with these functions, the disruption of ER-mitochondria contacts by depleting tethering complexes leads to delayed apoptosis progression and altered calcium homeostasis in both the ER and mitochondria [95], [110], [150].", [["ER-mitochondria", "ANATOMY", 51, 66], ["ER", "ANATOMY", 192, 194], ["mitochondria", "ANATOMY", 199, 211], ["calcium", "CHEMICAL", 160, 167], ["calcium", "CHEMICAL", 160, 167], ["ER", "GENE_OR_GENE_PRODUCT", 51, 53], ["mitochondria", "CELLULAR_COMPONENT", 54, 66], ["calcium", "SIMPLE_CHEMICAL", 160, 167], ["ER", "GENE_OR_GENE_PRODUCT", 192, 194], ["mitochondria", "CELLULAR_COMPONENT", 199, 211], ["ER", "PROTEIN", 51, 53], ["tethering complexes", "PROTEIN", 89, 108], ["ER", "PROTEIN", 192, 194], ["depleting tethering complexes", "PROBLEM", 79, 108], ["delayed apoptosis progression", "PROBLEM", 118, 147], ["altered calcium homeostasis", "PROBLEM", 152, 179], ["tethering complexes", "OBSERVATION", 89, 108], ["delayed", "OBSERVATION_MODIFIER", 118, 125], ["apoptosis", "OBSERVATION_MODIFIER", 126, 135], ["progression", "OBSERVATION_MODIFIER", 136, 147], ["calcium homeostasis", "OBSERVATION", 160, 179]]], ["The link between MAM formation and the maintenance of cellular homeostasis as well as the sensing of cellular stress is highlighted by the observations that the extent of the MAM and the proximity of the ER and mitochondria increase under conditions of ER stress [136], [151].", [["cellular", "ANATOMY", 54, 62], ["cellular", "ANATOMY", 101, 109], ["ER", "ANATOMY", 204, 206], ["mitochondria", "ANATOMY", 211, 223], ["MAM", "CELLULAR_COMPONENT", 17, 20], ["cellular", "CELL", 54, 62], ["cellular", "CELL", 101, 109], ["MAM", "CELLULAR_COMPONENT", 175, 178], ["ER", "GENE_OR_GENE_PRODUCT", 204, 206], ["mitochondria", "CELLULAR_COMPONENT", 211, 223], ["ER", "GENE_OR_GENE_PRODUCT", 253, 255], ["ER", "PROTEIN", 204, 206], ["ER", "PROTEIN", 253, 255], ["cellular homeostasis", "TREATMENT", 54, 74], ["cellular stress", "PROBLEM", 101, 116], ["ER stress", "TEST", 253, 262], ["cellular homeostasis", "OBSERVATION", 54, 74], ["cellular stress", "OBSERVATION", 101, 116], ["increase", "OBSERVATION_MODIFIER", 224, 232]]], ["The full significance of this observation is currently not clear, but juxtaposed mitochondria could in principle serve to alleviate ER stress by providing additional ATP for oxidative protein folding [54].", [["mitochondria", "ANATOMY", 81, 93], ["ATP", "CHEMICAL", 166, 169], ["ATP", "CHEMICAL", 166, 169], ["mitochondria", "CELLULAR_COMPONENT", 81, 93], ["ER", "GENE_OR_GENE_PRODUCT", 132, 134], ["ATP", "SIMPLE_CHEMICAL", 166, 169], ["ER", "PROTEIN", 132, 134], ["this observation", "TEST", 25, 41], ["juxtaposed mitochondria", "PROBLEM", 70, 93], ["ER stress", "PROBLEM", 132, 141], ["additional ATP", "TREATMENT", 155, 169], ["oxidative protein folding", "PROBLEM", 174, 199]]], ["Together, these observations highlight the significance of the MAM for cellular physiology and stress the importance of identifying protein tethers between the two organelles.", [["cellular", "ANATOMY", 71, 79], ["organelles", "ANATOMY", 164, 174], ["cellular", "CELL", 71, 79], ["organelles", "CELLULAR_COMPONENT", 164, 174], ["protein tethers", "PROTEIN", 132, 147], ["cellular physiology", "PROBLEM", 71, 90]]], ["One of these tethers is the cytosolic chaperone Grp75, which interacts with both the IP3R on the ER and the voltage-dependent anion channel on mitochondria, thus facilitating calcium transfer between the two organelles [110].", [["cytosolic", "ANATOMY", 28, 37], ["ER", "ANATOMY", 97, 99], ["mitochondria", "ANATOMY", 143, 155], ["organelles", "ANATOMY", 208, 218], ["calcium", "CHEMICAL", 175, 182], ["calcium", "CHEMICAL", 175, 182], ["cytosolic", "CELLULAR_COMPONENT", 28, 37], ["Grp75", "GENE_OR_GENE_PRODUCT", 48, 53], ["IP3R", "GENE_OR_GENE_PRODUCT", 85, 89], ["ER", "GENE_OR_GENE_PRODUCT", 97, 99], ["mitochondria", "CELLULAR_COMPONENT", 143, 155], ["calcium", "SIMPLE_CHEMICAL", 175, 182], ["cytosolic chaperone", "PROTEIN", 28, 47], ["Grp75", "PROTEIN", 48, 53], ["IP3R", "PROTEIN", 85, 89], ["ER", "PROTEIN", 97, 99], ["voltage-dependent anion channel", "PROTEIN", 108, 139], ["anion channel", "OBSERVATION", 126, 139]]], ["However, Grp75 bridging does not influence the proximity between the ER and mitochondria, suggesting that the role of this protein is restricted to calcium signaling.", [["ER", "ANATOMY", 69, 71], ["mitochondria", "ANATOMY", 76, 88], ["calcium", "CHEMICAL", 148, 155], ["calcium", "CHEMICAL", 148, 155], ["Grp75", "GENE_OR_GENE_PRODUCT", 9, 14], ["ER", "GENE_OR_GENE_PRODUCT", 69, 71], ["mitochondria", "CELLULAR_COMPONENT", 76, 88], ["calcium", "SIMPLE_CHEMICAL", 148, 155], ["Grp75", "PROTEIN", 9, 14], ["ER", "PROTEIN", 69, 71], ["Grp75 bridging", "PROBLEM", 9, 23], ["this protein", "PROBLEM", 118, 130], ["calcium signaling", "PROBLEM", 148, 165], ["bridging", "OBSERVATION", 15, 23]]], ["Another protein complex at the MAM is formed when mitochondrial Fis1 and the smooth ER protein BAP31 (see also Section 5) interact with each during the onset of apoptosis.", [["mitochondrial", "ANATOMY", 50, 63], ["MAM", "CELLULAR_COMPONENT", 31, 34], ["mitochondrial", "CELLULAR_COMPONENT", 50, 63], ["Fis1", "GENE_OR_GENE_PRODUCT", 64, 68], ["ER", "GENE_OR_GENE_PRODUCT", 84, 86], ["BAP31", "GENE_OR_GENE_PRODUCT", 95, 100], ["protein complex", "PROTEIN", 8, 23], ["MAM", "PROTEIN", 31, 34], ["mitochondrial Fis1", "PROTEIN", 50, 68], ["smooth ER protein", "PROTEIN", 77, 94], ["BAP31", "PROTEIN", 95, 100], ["Section 5", "PROTEIN", 111, 120], ["Another protein complex", "PROBLEM", 0, 23], ["apoptosis", "PROBLEM", 161, 170], ["apoptosis", "OBSERVATION", 161, 170]]], ["The formation of this complex leads to recruitment of procaspase-8 to the MAM, but how this is connected to pro-apoptotic, IP3R-mediated calcium release is currently not clear [152].", [["calcium", "CHEMICAL", 137, 144], ["calcium", "CHEMICAL", 137, 144], ["procaspase-8", "GENE_OR_GENE_PRODUCT", 54, 66], ["MAM", "GENE_OR_GENE_PRODUCT", 74, 77], ["IP3R", "GENE_OR_GENE_PRODUCT", 123, 127], ["calcium", "SIMPLE_CHEMICAL", 137, 144], ["procaspase-8", "PROTEIN", 54, 66], ["MAM", "PROTEIN", 74, 77], ["IP3R", "PROTEIN", 123, 127], ["recruitment of procaspase", "TREATMENT", 39, 64], ["IP3R-mediated calcium release", "TREATMENT", 123, 152], ["recruitment", "OBSERVATION_MODIFIER", 39, 50]]], ["Another example is the formation of complexes of ER- and mitochondria-localized mitofusin-2, a dynamin-related GTPase.", [["mitochondria", "ANATOMY", 57, 69], ["ER", "GENE_OR_GENE_PRODUCT", 49, 51], ["mitochondria", "CELLULAR_COMPONENT", 57, 69], ["mitofusin-2", "GENE_OR_GENE_PRODUCT", 80, 91], ["dynamin", "GENE_OR_GENE_PRODUCT", 95, 102], ["ER", "PROTEIN", 49, 51], ["mitofusin-2", "PROTEIN", 80, 91], ["dynamin", "PROTEIN", 95, 102], ["GTPase", "PROTEIN", 111, 117], ["mitochondria", "TEST", 57, 69], ["mitofusin", "TEST", 80, 89], ["a dynamin-related GTPase", "PROBLEM", 93, 117]]], ["Mitofusin-2 complexes are required for the formation of the MAM and the efficient transfer of calcium between the ER and mitochondria in mammalian cells [95].", [["ER", "ANATOMY", 114, 116], ["mitochondria", "ANATOMY", 121, 133], ["cells", "ANATOMY", 147, 152], ["calcium", "CHEMICAL", 94, 101], ["calcium", "CHEMICAL", 94, 101], ["Mitofusin-2", "GENE_OR_GENE_PRODUCT", 0, 11], ["MAM", "CELLULAR_COMPONENT", 60, 63], ["calcium", "SIMPLE_CHEMICAL", 94, 101], ["ER", "GENE_OR_GENE_PRODUCT", 114, 116], ["mitochondria", "CELLULAR_COMPONENT", 121, 133], ["mammalian cells", "CELL", 137, 152], ["Mitofusin-2 complexes", "PROTEIN", 0, 21], ["ER", "PROTEIN", 114, 116], ["mammalian cells", "CELL_TYPE", 137, 152], ["Mitofusin-2 complexes", "TREATMENT", 0, 21], ["calcium", "TREATMENT", 94, 101]]], ["Moreover, the complete absence of mitofusin-2 leads to the formation of swollen and aggregated ER that shows reduced branching, whereas the mitochondria undergo fragmentation [95].", [["ER", "ANATOMY", 95, 97], ["mitochondria", "ANATOMY", 140, 152], ["mitofusin-2", "GENE_OR_GENE_PRODUCT", 34, 45], ["ER", "GENE_OR_GENE_PRODUCT", 95, 97], ["mitochondria", "CELLULAR_COMPONENT", 140, 152], ["mitofusin-2", "PROTEIN", 34, 45], ["ER", "PROTEIN", 95, 97], ["mitofusin", "PROBLEM", 34, 43], ["swollen", "PROBLEM", 72, 79], ["reduced branching", "PROBLEM", 109, 126], ["swollen", "OBSERVATION", 72, 79], ["reduced", "OBSERVATION_MODIFIER", 109, 116], ["branching", "OBSERVATION_MODIFIER", 117, 126], ["fragmentation", "OBSERVATION_MODIFIER", 161, 174]]], ["Since ER-targeted mitofusin-2 can rescue the ER, but not the mitochondria or the MAM phenotype, it has been hypothesized that the altered ER morphology in mitofusin-2 knockout cells stems from a so far uncharacterized function of mitofusin-2 on the ER.", [["ER", "ANATOMY", 45, 47], ["mitochondria", "ANATOMY", 61, 73], ["ER", "ANATOMY", 138, 140], ["mitofusin-2 knockout cells", "ANATOMY", 155, 181], ["ER", "ANATOMY", 249, 251], ["ER", "GENE_OR_GENE_PRODUCT", 6, 8], ["mitofusin-2", "GENE_OR_GENE_PRODUCT", 18, 29], ["ER", "GENE_OR_GENE_PRODUCT", 45, 47], ["mitochondria", "CELLULAR_COMPONENT", 61, 73], ["ER", "GENE_OR_GENE_PRODUCT", 138, 140], ["mitofusin-2", "GENE_OR_GENE_PRODUCT", 155, 166], ["mitofusin-2", "GENE_OR_GENE_PRODUCT", 230, 241], ["ER", "GENE_OR_GENE_PRODUCT", 249, 251], ["ER", "PROTEIN", 6, 8], ["mitofusin-2", "PROTEIN", 18, 29], ["ER", "PROTEIN", 45, 47], ["ER", "PROTEIN", 138, 140], ["mitofusin-2 knockout cells", "CELL_LINE", 155, 181], ["mitofusin-2", "PROTEIN", 230, 241], ["ER", "PROTEIN", 249, 251], ["mitofusin", "TEST", 155, 164], ["mitofusin", "TEST", 230, 239]]], ["Interestingly, such a function appears to mirror the impact of atlastins on the equilibrium between the smooth and the rough ER, since the absence of atlastins also leads to tubulated, poorly branched ER [67], [93].", [["ER", "ANATOMY", 125, 127], ["atlastins", "GENE_OR_GENE_PRODUCT", 63, 72], ["ER", "GENE_OR_GENE_PRODUCT", 125, 127], ["atlastins", "GENE_OR_GENE_PRODUCT", 150, 159], ["ER", "GENE_OR_GENE_PRODUCT", 201, 203], ["atlastins", "PROTEIN", 63, 72], ["ER", "PROTEIN", 125, 127], ["atlastins", "PROTEIN", 150, 159], ["ER", "PROTEIN", 201, 203], ["smooth", "OBSERVATION_MODIFIER", 104, 110], ["rough", "OBSERVATION_MODIFIER", 119, 124], ["branched", "OBSERVATION_MODIFIER", 192, 200]]], ["Despite these parallels, it is currently not known whether the atlastins and mitofusins functionally or physically interact with each other.", [["atlastins", "GENE_OR_GENE_PRODUCT", 63, 72], ["mitofusins", "GENE_OR_GENE_PRODUCT", 77, 87], ["atlastins", "PROTEIN", 63, 72], ["mitofusins", "PROTEIN", 77, 87]]], ["The mechanism that determines ER or mitochondria targeting of mitofusin-2 is also unclear at this point.The mitochondria-associated membrane (MAM)To date, four MAM targeting mechanisms are known.", [["ER", "ANATOMY", 30, 32], ["mitochondria", "ANATOMY", 36, 48], ["mitochondria", "ANATOMY", 108, 120], ["membrane", "ANATOMY", 132, 140], ["ER", "GENE_OR_GENE_PRODUCT", 30, 32], ["mitochondria", "CELLULAR_COMPONENT", 36, 48], ["mitofusin-2", "GENE_OR_GENE_PRODUCT", 62, 73], ["mitochondria", "CELLULAR_COMPONENT", 108, 120], ["membrane", "CELLULAR_COMPONENT", 132, 140], ["MAM", "SIMPLE_CHEMICAL", 160, 163], ["ER", "PROTEIN", 30, 32], ["mitofusin-2", "PROTEIN", 62, 73], ["mitofusin", "PROBLEM", 62, 71]]], ["The first described MAM targeting mechanism requires the cytosolic sorting protein PACS-2.", [["cytosolic", "ANATOMY", 57, 66], ["MAM", "CELLULAR_COMPONENT", 20, 23], ["PACS-2", "GENE_OR_GENE_PRODUCT", 83, 89], ["cytosolic sorting protein PACS-2", "PROTEIN", 57, 89], ["the cytosolic sorting protein PACS", "TREATMENT", 53, 87]]], ["PACS-2 had initially been identified as a possible MAM-organizing protein, since its knockdown leads to a disruption of the MAM, whose consequences on ER-mitochondria calcium and apoptosis signaling are similar to what is known about mitofusin-2 knockout [150].", [["ER-mitochondria", "ANATOMY", 151, 166], ["calcium", "CHEMICAL", 167, 174], ["calcium", "CHEMICAL", 167, 174], ["PACS-2", "GENE_OR_GENE_PRODUCT", 0, 6], ["MAM", "SIMPLE_CHEMICAL", 51, 54], ["MAM", "GENE_OR_GENE_PRODUCT", 124, 127], ["ER", "GENE_OR_GENE_PRODUCT", 151, 153], ["mitochondria", "CELLULAR_COMPONENT", 154, 166], ["calcium", "SIMPLE_CHEMICAL", 167, 174], ["mitofusin-2", "GENE_OR_GENE_PRODUCT", 234, 245], ["MAM-organizing protein", "PROTEIN", 51, 73], ["MAM", "PROTEIN", 124, 127], ["ER", "PROTEIN", 151, 153], ["mitofusin", "PROTEIN", 234, 243], ["PACS", "TEST", 0, 4], ["organizing protein", "PROBLEM", 55, 73], ["mitochondria calcium", "TEST", 154, 174], ["apoptosis signaling", "PROBLEM", 179, 198], ["mitofusin", "TEST", 234, 243]]], ["However, in cooperation with the cytosolic protein coat COPI, PACS-2 also contributes to the MAM-enrichment of the chaperone calnexin [63], a repressor of SERCA2b [117].", [["cytosolic", "ANATOMY", 33, 42], ["COPI", "GENE_OR_GENE_PRODUCT", 56, 60], ["PACS-2", "GENE_OR_GENE_PRODUCT", 62, 68], ["MAM", "SIMPLE_CHEMICAL", 93, 96], ["calnexin [63]", "GENE_OR_GENE_PRODUCT", 125, 138], ["SERCA2b", "GENE_OR_GENE_PRODUCT", 155, 162], ["cytosolic protein coat COPI", "PROTEIN", 33, 60], ["PACS", "PROTEIN", 62, 66], ["chaperone calnexin [63]", "PROTEIN", 115, 138], ["SERCA2b", "PROTEIN", 155, 162], ["the cytosolic protein coat COPI", "TEST", 29, 60], ["PACS", "TEST", 62, 66], ["the chaperone calnexin", "TREATMENT", 111, 133], ["a repressor of SERCA2b", "TREATMENT", 140, 162]]], ["PACS-2 interacts with calnexin on two serines that are substrates for protein kinase CK2 [63].", [["serines", "CHEMICAL", 38, 45], ["PACS-2", "GENE_OR_GENE_PRODUCT", 0, 6], ["calnexin", "GENE_OR_GENE_PRODUCT", 22, 30], ["protein kinase CK2", "GENE_OR_GENE_PRODUCT", 70, 88], ["calnexin", "PROTEIN", 22, 30], ["protein kinase CK2", "PROTEIN", 70, 88], ["calnexin", "TREATMENT", 22, 30], ["protein kinase CK2", "TEST", 70, 88]]], ["Since COPI mediates retrieval from the cis-Golgi to the ER [153], these findings suggest an involvement of ER-to-Golgi trafficking in the distribution of ER proteins to specific smooth ER domains and the MAM in particular.", [["cis-Golgi", "ANATOMY", 39, 48], ["Golgi", "ANATOMY", 113, 118], ["smooth ER", "ANATOMY", 178, 187], ["COPI", "GENE_OR_GENE_PRODUCT", 6, 10], ["cis-Golgi", "CELLULAR_COMPONENT", 39, 48], ["ER", "GENE_OR_GENE_PRODUCT", 56, 58], ["ER", "GENE_OR_GENE_PRODUCT", 107, 109], ["Golgi", "CELLULAR_COMPONENT", 113, 118], ["ER", "GENE_OR_GENE_PRODUCT", 154, 156], ["ER", "GENE_OR_GENE_PRODUCT", 185, 187], ["COPI", "PROTEIN", 6, 10], ["cis-Golgi", "PROTEIN", 39, 48], ["ER", "PROTEIN", 56, 58], ["ER", "PROTEIN", 107, 109], ["ER proteins", "PROTEIN", 154, 165], ["smooth ER domains", "PROTEIN", 178, 195], ["smooth", "OBSERVATION_MODIFIER", 178, 184]]], ["Rab32 is another trafficking molecule that regulates the composition of the MAM [139].", [["Rab32", "GENE_OR_GENE_PRODUCT", 0, 5], ["Rab32", "PROTEIN", 0, 5], ["trafficking molecule", "PROTEIN", 17, 37], ["trafficking molecule", "OBSERVATION", 17, 37]]], ["Upon its activation, select MAM-localized ER proteins are relocated to the cellular periphery, concomitant with altered ER calcium handling.The mitochondria-associated membrane (MAM)A second MAM targeting mechanism has been demonstrated for the ER oxidoreductase Ero1\u03b1, which requires oxidizing conditions to target to the MAM [119].", [["cellular periphery", "ANATOMY", 75, 93], ["ER", "ANATOMY", 120, 122], ["mitochondria", "ANATOMY", 144, 156], ["membrane", "ANATOMY", 168, 176], ["calcium", "CHEMICAL", 123, 130], ["calcium", "CHEMICAL", 123, 130], ["MAM", "GENE_OR_GENE_PRODUCT", 28, 31], ["ER", "GENE_OR_GENE_PRODUCT", 42, 44], ["cellular periphery", "CELLULAR_COMPONENT", 75, 93], ["ER", "GENE_OR_GENE_PRODUCT", 120, 122], ["calcium", "SIMPLE_CHEMICAL", 123, 130], ["mitochondria", "CELLULAR_COMPONENT", 144, 156], ["membrane", "CELLULAR_COMPONENT", 168, 176], ["MAM", "CELLULAR_COMPONENT", 178, 181], ["ER oxidoreductase", "GENE_OR_GENE_PRODUCT", 245, 262], ["Ero1\u03b1", "GENE_OR_GENE_PRODUCT", 263, 268], ["MAM", "PROTEIN", 28, 31], ["ER proteins", "PROTEIN", 42, 53], ["ER", "PROTEIN", 120, 122], ["ER oxidoreductase", "PROTEIN", 245, 262], ["Ero1\u03b1", "PROTEIN", 263, 268], ["altered ER calcium handling", "PROBLEM", 112, 139], ["cellular", "ANATOMY_MODIFIER", 75, 83], ["periphery", "ANATOMY_MODIFIER", 84, 93], ["altered", "OBSERVATION_MODIFIER", 112, 119], ["calcium handling", "OBSERVATION", 123, 139], ["membrane", "OBSERVATION_MODIFIER", 168, 176]]], ["This enzyme can recharge PDI to allow for efficient production of disulfide bonds in secretory proteins [154], but also is a target of the CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP), an ER-stress-triggered transcription factor.", [["disulfide", "CHEMICAL", 66, 75], ["PDI", "GENE_OR_GENE_PRODUCT", 25, 28], ["CCAAT/enhancer binding protein (C/EBP) homologous protein", "GENE_OR_GENE_PRODUCT", 139, 196], ["CHOP", "GENE_OR_GENE_PRODUCT", 198, 202], ["ER", "GENE_OR_GENE_PRODUCT", 208, 210], ["PDI", "PROTEIN", 25, 28], ["secretory proteins", "PROTEIN", 85, 103], ["CCAAT/enhancer binding protein (C/EBP) homologous protein", "PROTEIN", 139, 196], ["CHOP", "PROTEIN", 198, 202], ["ER", "PROTEIN", 208, 210], ["transcription factor", "PROTEIN", 228, 248], ["This enzyme", "TEST", 0, 11], ["recharge PDI", "TREATMENT", 16, 28], ["efficient production of disulfide bonds", "PROBLEM", 42, 81], ["secretory proteins", "TEST", 85, 103], ["the CCAAT/enhancer binding protein", "TEST", 135, 169], ["an ER", "TEST", 205, 210]]], ["Increased amounts of Ero1\u03b1 after extended periods of ER stress promote ER calcium release through a direct interaction with IP3R1 [115].", [["ER", "ANATOMY", 71, 73], ["calcium", "CHEMICAL", 74, 81], ["calcium", "CHEMICAL", 74, 81], ["Ero1\u03b1", "GENE_OR_GENE_PRODUCT", 21, 26], ["ER", "GENE_OR_GENE_PRODUCT", 53, 55], ["ER", "GENE_OR_GENE_PRODUCT", 71, 73], ["calcium", "SIMPLE_CHEMICAL", 74, 81], ["IP3R1 [115]", "GENE_OR_GENE_PRODUCT", 124, 135], ["Ero1\u03b1", "PROTEIN", 21, 26], ["ER", "PROTEIN", 53, 55], ["ER", "PROTEIN", 71, 73], ["IP3R1", "PROTEIN", 124, 129], ["Ero1", "TREATMENT", 21, 25], ["ER stress", "TREATMENT", 53, 62], ["ER calcium release", "TREATMENT", 71, 89], ["amounts", "OBSERVATION_MODIFIER", 10, 17]]], ["However, we currently do not know where this interaction occurs, since Ero1\u03b1 quickly relocates from the MAM upon redox or oxygen stress [119].The mitochondria-associated membrane (MAM)A small number of MAM proteins utilize a mitochondria targeting sequence in their cytosolic domains to target to the MAM, for example DGAT2 [142].", [["mitochondria", "ANATOMY", 146, 158], ["membrane", "ANATOMY", 170, 178], ["mitochondria", "ANATOMY", 225, 237], ["cytosolic", "ANATOMY", 266, 275], ["oxygen", "CHEMICAL", 122, 128], ["oxygen", "CHEMICAL", 122, 128], ["Ero1\u03b1", "GENE_OR_GENE_PRODUCT", 71, 76], ["MAM", "SIMPLE_CHEMICAL", 104, 107], ["oxygen", "SIMPLE_CHEMICAL", 122, 128], ["mitochondria", "CELLULAR_COMPONENT", 146, 158], ["membrane", "CELLULAR_COMPONENT", 170, 178], ["MAM proteins", "GENE_OR_GENE_PRODUCT", 202, 214], ["mitochondria", "CELLULAR_COMPONENT", 225, 237], ["MAM", "CELLULAR_COMPONENT", 301, 304], ["Ero1\u03b1", "PROTEIN", 71, 76], ["MAM proteins", "PROTEIN", 202, 214], ["cytosolic domains", "PROTEIN", 266, 283], ["MAM", "PROTEIN", 301, 304], ["oxygen stress", "TEST", 122, 135], ["a mitochondria", "TREATMENT", 223, 237], ["small", "OBSERVATION_MODIFIER", 186, 191]]], ["DGAT2 does not target exclusively to the MAM, as shown by its relocation to lipid droplets in cells loaded with oleic acid [142].The mitochondria-associated membrane (MAM)The presence of large quantities of lipid synthesizing enzymes on the MAM might be at the basis of ER lipid microdomains [155], [156], [157].", [["lipid droplets", "ANATOMY", 76, 90], ["cells", "ANATOMY", 94, 99], ["mitochondria", "ANATOMY", 133, 145], ["membrane", "ANATOMY", 157, 165], ["ER lipid microdomains", "ANATOMY", 270, 291], ["oleic acid", "CHEMICAL", 112, 122], ["oleic acid", "CHEMICAL", 112, 122], ["DGAT2", "GENE_OR_GENE_PRODUCT", 0, 5], ["MAM", "CELLULAR_COMPONENT", 41, 44], ["cells", "CELL", 94, 99], ["oleic acid", "SIMPLE_CHEMICAL", 112, 122], ["mitochondria", "CELLULAR_COMPONENT", 133, 145], ["membrane", "CELLULAR_COMPONENT", 157, 165], ["MAM", "CELLULAR_COMPONENT", 167, 170], ["lipid synthesizing enzymes", "GENE_OR_GENE_PRODUCT", 207, 233], ["MAM", "SIMPLE_CHEMICAL", 241, 244], ["ER", "GENE_OR_GENE_PRODUCT", 270, 272], ["DGAT2", "PROTEIN", 0, 5], ["lipid synthesizing enzymes", "PROTEIN", 207, 233], ["ER", "PROTEIN", 270, 272], ["lipid droplets in cells", "TREATMENT", 76, 99], ["oleic acid", "TREATMENT", 112, 122], ["large quantities of lipid synthesizing enzymes", "PROBLEM", 187, 233], ["ER lipid microdomains", "TEST", 270, 291], ["large", "OBSERVATION_MODIFIER", 187, 192]]], ["For example, the MAM contains glycosphingolipid-enriched microdomains [158], [159].", [["microdomains", "ANATOMY", 57, 69], ["MAM", "CHEMICAL", 17, 20], ["MAM", "SIMPLE_CHEMICAL", 17, 20], ["glycosphingolipid", "SIMPLE_CHEMICAL", 30, 47]]], ["Moreover, staining of the ER with filipin that binds to cholesterol rafts, shows the presence of isolated such structures [160].", [["ER", "ANATOMY", 26, 28], ["cholesterol rafts", "ANATOMY", 56, 73], ["filipin", "CHEMICAL", 34, 41], ["cholesterol", "CHEMICAL", 56, 67], ["filipin", "CHEMICAL", 34, 41], ["cholesterol", "CHEMICAL", 56, 67], ["ER", "GENE_OR_GENE_PRODUCT", 26, 28], ["filipin", "SIMPLE_CHEMICAL", 34, 41], ["cholesterol", "SIMPLE_CHEMICAL", 56, 67], ["ER", "PROTEIN", 26, 28], ["filipin", "TREATMENT", 34, 41], ["cholesterol rafts", "TEST", 56, 73], ["isolated such structures", "PROBLEM", 97, 121]]], ["In contrast to the rough ER, which contains little raft-associated cholesterol compared to the plasma membrane [161], [162], [163], the MAM is apparently enriched for it, despite the absence of cholesterol-synthesizing enzymes on the MAM [164].", [["raft", "ANATOMY", 51, 55], ["plasma membrane", "ANATOMY", 95, 110], ["cholesterol", "CHEMICAL", 67, 78], ["cholesterol", "CHEMICAL", 194, 205], ["cholesterol", "CHEMICAL", 67, 78], ["cholesterol", "CHEMICAL", 194, 205], ["ER", "GENE_OR_GENE_PRODUCT", 25, 27], ["raft", "CELLULAR_COMPONENT", 51, 55], ["cholesterol", "SIMPLE_CHEMICAL", 67, 78], ["plasma membrane", "CELLULAR_COMPONENT", 95, 110], ["MAM", "SIMPLE_CHEMICAL", 136, 139], ["cholesterol", "SIMPLE_CHEMICAL", 194, 205], ["ER", "PROTEIN", 25, 27], ["cholesterol-synthesizing enzymes", "PROTEIN", 194, 226], ["the plasma membrane", "TEST", 91, 110], ["little", "OBSERVATION_MODIFIER", 44, 50], ["raft", "OBSERVATION_MODIFIER", 51, 55]]], ["Interestingly, the sigma-1 receptor, a regulator of the IP3R3, localizes to lipid rafts within the ER in a cholesterol-dependent manner [59], [165].", [["lipid rafts", "ANATOMY", 76, 87], ["ER", "ANATOMY", 99, 101], ["cholesterol", "CHEMICAL", 107, 118], ["cholesterol", "CHEMICAL", 107, 118], ["sigma-1 receptor", "GENE_OR_GENE_PRODUCT", 19, 35], ["IP3R3", "GENE_OR_GENE_PRODUCT", 56, 61], ["lipid rafts", "CELLULAR_COMPONENT", 76, 87], ["ER", "GENE_OR_GENE_PRODUCT", 99, 101], ["cholesterol", "SIMPLE_CHEMICAL", 107, 118], ["sigma-1 receptor", "PROTEIN", 19, 35], ["IP3R3", "PROTEIN", 56, 61], ["ER", "PROTEIN", 99, 101], ["the IP3R3", "TREATMENT", 52, 61]]], ["Normally found on the MAM in a complex with the chaperone BiP/GRP78, the sigma-1 receptor interacts with the IP3R3 upon IP3R stimulation or ER stress to boost this calcium channel's activity [114].", [["calcium", "CHEMICAL", 164, 171], ["calcium", "CHEMICAL", 164, 171], ["MAM", "CELLULAR_COMPONENT", 22, 25], ["BiP", "GENE_OR_GENE_PRODUCT", 58, 61], ["GRP78", "GENE_OR_GENE_PRODUCT", 62, 67], ["sigma-1 receptor", "GENE_OR_GENE_PRODUCT", 73, 89], ["IP3R3", "GENE_OR_GENE_PRODUCT", 109, 114], ["IP3R", "GENE_OR_GENE_PRODUCT", 120, 124], ["ER", "GENE_OR_GENE_PRODUCT", 140, 142], ["calcium", "SIMPLE_CHEMICAL", 164, 171], ["MAM", "PROTEIN", 22, 25], ["BiP", "PROTEIN", 58, 61], ["GRP78", "PROTEIN", 62, 67], ["sigma-1 receptor", "PROTEIN", 73, 89], ["IP3R3", "PROTEIN", 109, 114], ["IP3R", "PROTEIN", 120, 124], ["ER", "PROTEIN", 140, 142], ["the IP3R3", "TREATMENT", 105, 114], ["IP3R stimulation", "TREATMENT", 120, 136], ["this calcium channel's activity", "TEST", 159, 190]]], ["Moreover, the sigma-1 receptor, through its ability to bind cholesterol, regulates the distribution of cholesterol within the ER; cholesterol rafts within the ER dissipate upon transfection of sigma-1 receptor mutants unable to bind to cholesterol [160].", [["ER", "ANATOMY", 126, 128], ["cholesterol rafts", "ANATOMY", 130, 147], ["ER", "ANATOMY", 159, 161], ["cholesterol", "CHEMICAL", 60, 71], ["cholesterol", "CHEMICAL", 103, 114], ["cholesterol", "CHEMICAL", 130, 141], ["cholesterol", "CHEMICAL", 236, 247], ["cholesterol", "CHEMICAL", 60, 71], ["cholesterol", "CHEMICAL", 103, 114], ["cholesterol", "CHEMICAL", 130, 141], ["cholesterol", "CHEMICAL", 236, 247], ["sigma-1 receptor", "GENE_OR_GENE_PRODUCT", 14, 30], ["cholesterol", "SIMPLE_CHEMICAL", 60, 71], ["cholesterol", "SIMPLE_CHEMICAL", 103, 114], ["ER", "GENE_OR_GENE_PRODUCT", 126, 128], ["cholesterol", "SIMPLE_CHEMICAL", 130, 141], ["ER", "GENE_OR_GENE_PRODUCT", 159, 161], ["sigma-1 receptor", "GENE_OR_GENE_PRODUCT", 193, 209], ["cholesterol", "SIMPLE_CHEMICAL", 236, 247], ["sigma-1 receptor", "PROTEIN", 14, 30], ["ER", "PROTEIN", 126, 128], ["ER", "PROTEIN", 159, 161], ["sigma-1 receptor mutants", "PROTEIN", 193, 217], ["cholesterol rafts", "TREATMENT", 130, 147], ["sigma-1 receptor mutants", "TREATMENT", 193, 217], ["cholesterol", "TEST", 236, 247], ["cholesterol rafts", "OBSERVATION", 130, 147]]], ["Interestingly, increased free ER cholesterol also inhibits the import of calcium via SERCA2b, suggesting that ER cholesterol homeostasis is a powerful control mechanism for ER calcium content [166].", [["ER", "ANATOMY", 173, 175], ["cholesterol", "CHEMICAL", 33, 44], ["calcium", "CHEMICAL", 73, 80], ["cholesterol", "CHEMICAL", 113, 124], ["calcium", "CHEMICAL", 176, 183], ["cholesterol", "CHEMICAL", 33, 44], ["calcium", "CHEMICAL", 73, 80], ["cholesterol", "CHEMICAL", 113, 124], ["calcium", "CHEMICAL", 176, 183], ["ER", "GENE_OR_GENE_PRODUCT", 30, 32], ["cholesterol", "SIMPLE_CHEMICAL", 33, 44], ["calcium", "SIMPLE_CHEMICAL", 73, 80], ["SERCA2b", "GENE_OR_GENE_PRODUCT", 85, 92], ["ER", "GENE_OR_GENE_PRODUCT", 110, 112], ["cholesterol", "SIMPLE_CHEMICAL", 113, 124], ["ER", "GENE_OR_GENE_PRODUCT", 173, 175], ["calcium", "SIMPLE_CHEMICAL", 176, 183], ["ER", "PROTEIN", 30, 32], ["SERCA2b", "PROTEIN", 85, 92], ["ER", "PROTEIN", 110, 112], ["ER", "PROTEIN", 173, 175], ["increased free ER cholesterol", "PROBLEM", 15, 44], ["calcium via SERCA2b", "TREATMENT", 73, 92], ["ER cholesterol homeostasis", "PROBLEM", 110, 136], ["ER calcium content", "TEST", 173, 191], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["free", "OBSERVATION_MODIFIER", 25, 29], ["cholesterol homeostasis", "OBSERVATION", 113, 136]]], ["Together, these observations suggest important connections between a modulation of ER cholesterol content and ER calcium homeostasis.Other smooth ER domains: ER exit sites, plasma membrane-associated ER, ER quality control compartmentLess information is available on targeting mechanisms to other smooth ER domains, including ER exit sites (ERES), the PAM, which is apposed to the plasma membrane, and the ER Quality Control Compartment (ERQC).", [["ER", "ANATOMY", 83, 85], ["ER", "ANATOMY", 110, 112], ["ER exit sites", "ANATOMY", 158, 171], ["plasma membrane", "ANATOMY", 173, 188], ["ER", "ANATOMY", 200, 202], ["plasma membrane", "ANATOMY", 381, 396], ["cholesterol", "CHEMICAL", 86, 97], ["calcium", "CHEMICAL", 113, 120], ["cholesterol", "CHEMICAL", 86, 97], ["calcium", "CHEMICAL", 113, 120], ["ER", "GENE_OR_GENE_PRODUCT", 83, 85], ["cholesterol", "SIMPLE_CHEMICAL", 86, 97], ["ER", "GENE_OR_GENE_PRODUCT", 110, 112], ["calcium", "SIMPLE_CHEMICAL", 113, 120], ["ER", "GENE_OR_GENE_PRODUCT", 146, 148], ["ER", "GENE_OR_GENE_PRODUCT", 158, 160], ["plasma membrane", "CELLULAR_COMPONENT", 173, 188], ["ER", "GENE_OR_GENE_PRODUCT", 200, 202], ["ER", "GENE_OR_GENE_PRODUCT", 204, 206], ["ER", "GENE_OR_GENE_PRODUCT", 304, 306], ["ER", "GENE_OR_GENE_PRODUCT", 326, 328], ["plasma membrane", "CELLULAR_COMPONENT", 381, 396], ["ER", "GENE_OR_GENE_PRODUCT", 406, 408], ["ER", "PROTEIN", 83, 85], ["ER", "PROTEIN", 110, 112], ["smooth ER domains", "PROTEIN", 139, 156], ["ER exit sites", "PROTEIN", 158, 171], ["ER", "PROTEIN", 200, 202], ["ER", "PROTEIN", 204, 206], ["smooth ER domains", "PROTEIN", 297, 314], ["ER exit sites", "PROTEIN", 326, 339], ["ERES", "PROTEIN", 341, 345], ["PAM", "PROTEIN", 352, 355], ["ER", "PROTEIN", 406, 408], ["ER cholesterol content", "TEST", 83, 105], ["ER calcium homeostasis", "TEST", 110, 132], ["plasma membrane", "TEST", 173, 188], ["the PAM", "TEST", 348, 355], ["cholesterol content", "OBSERVATION", 86, 105], ["calcium homeostasis", "OBSERVATION", 113, 132], ["smooth", "OBSERVATION_MODIFIER", 139, 145], ["plasma membrane", "OBSERVATION", 173, 188]]], ["ERES mediate the bulk of secretory protein export from the ER and generate the ER-Golgi intermediate compartment (ERGIC) [167], [168].", [["ER", "ANATOMY", 59, 61], ["ER-Golgi intermediate compartment", "ANATOMY", 79, 112], ["ERES", "GENE_OR_GENE_PRODUCT", 0, 4], ["ER", "GENE_OR_GENE_PRODUCT", 59, 61], ["ER", "GENE_OR_GENE_PRODUCT", 79, 81], ["Golgi", "CELLULAR_COMPONENT", 82, 87], ["ERES", "PROTEIN", 0, 4], ["secretory protein", "PROTEIN", 25, 42], ["ER", "PROTEIN", 59, 61], ["ER", "PROTEIN", 79, 81], ["bulk", "OBSERVATION_MODIFIER", 17, 21]]], ["ER exit sites are part of the transitional ER, which is characterized by its overlap with the rough ER and its juxtaposition to the Golgi complex [169].", [["ER exit sites", "ANATOMY", 0, 13], ["transitional ER", "ANATOMY", 30, 45], ["ER", "ANATOMY", 100, 102], ["Golgi", "ANATOMY", 132, 137], ["ER", "GENE_OR_GENE_PRODUCT", 0, 2], ["ER", "GENE_OR_GENE_PRODUCT", 43, 45], ["ER", "GENE_OR_GENE_PRODUCT", 100, 102], ["Golgi", "CELLULAR_COMPONENT", 132, 137], ["ER", "PROTEIN", 0, 2], ["ER", "PROTEIN", 43, 45], ["ER", "PROTEIN", 100, 102], ["Golgi complex", "PROTEIN", 132, 145], ["transitional", "OBSERVATION_MODIFIER", 30, 42]]], ["It is thought that the transitional ER mediates the enrichment of fully folded, export-competent proteins [170].", [["transitional ER", "ANATOMY", 23, 38], ["ER", "GENE_OR_GENE_PRODUCT", 36, 38], ["ER", "PROTEIN", 36, 38], ["export-competent proteins", "PROTEIN", 80, 105], ["the transitional ER mediates", "PROBLEM", 19, 47], ["transitional", "OBSERVATION_MODIFIER", 23, 35]]], ["Targeting to and formation of ERES is thought to depend on an interactor of COPII family proteins [167], the peripherally membrane associated protein Sec16, in mammals present as Sec16A and Sec16B, which can form a heteromeric complex in mammalian cells [171].", [["peripherally membrane", "ANATOMY", 109, 130], ["cells", "ANATOMY", 248, 253], ["ERES", "GENE_OR_GENE_PRODUCT", 30, 34], ["COPII", "GENE_OR_GENE_PRODUCT", 76, 81], ["peripherally membrane", "CELLULAR_COMPONENT", 109, 130], ["Sec16", "GENE_OR_GENE_PRODUCT", 150, 155], ["Sec16A", "GENE_OR_GENE_PRODUCT", 179, 185], ["Sec16B", "GENE_OR_GENE_PRODUCT", 190, 196], ["mammalian cells", "CELL", 238, 253], ["ERES", "PROTEIN", 30, 34], ["COPII family proteins", "PROTEIN", 76, 97], ["167", "PROTEIN", 99, 102], ["peripherally membrane associated protein", "PROTEIN", 109, 149], ["Sec16", "PROTEIN", 150, 155], ["Sec16A", "PROTEIN", 179, 185], ["Sec16B", "PROTEIN", 190, 196], ["heteromeric complex", "PROTEIN", 215, 234], ["mammalian cells", "CELL_TYPE", 238, 253], ["the peripherally membrane associated protein Sec16", "PROBLEM", 105, 155], ["peripherally", "ANATOMY_MODIFIER", 109, 121], ["protein Sec16", "OBSERVATION", 142, 155], ["mammalian cells", "OBSERVATION", 238, 253]]], ["RNAi-mediated knockdown of this protein results in the disruption of ERES [171], [172].", [["RNAi", "TEST", 0, 4], ["this protein", "TEST", 27, 39]]], ["Sec16A localizes to ERES without the help of other COPII components in an area that is spatially distinct from the location of the COPII proteins Sec24C and Sec31A [173].", [["Sec", "CHEMICAL", 0, 3], ["Sec16A", "GENE_OR_GENE_PRODUCT", 0, 6], ["ERES", "GENE_OR_GENE_PRODUCT", 20, 24], ["COPII", "GENE_OR_GENE_PRODUCT", 51, 56], ["COPII", "GENE_OR_GENE_PRODUCT", 131, 136], ["Sec24C", "GENE_OR_GENE_PRODUCT", 146, 152], ["Sec31A [173]", "GENE_OR_GENE_PRODUCT", 157, 169], ["Sec16A", "PROTEIN", 0, 6], ["ERES", "PROTEIN", 20, 24], ["COPII components", "PROTEIN", 51, 67], ["COPII proteins", "PROTEIN", 131, 145], ["Sec24C", "PROTEIN", 146, 152], ["Sec31A [173]", "PROTEIN", 157, 169]]], ["Targeting of Sec16 to ERES requires the presence of a central conserved domain, which contains a positively charged stretch, a potential interaction site with polar phospholipids or a yet-to-be-identified receptor protein [171], [173], [174].", [["Sec16", "GENE_OR_GENE_PRODUCT", 13, 18], ["ERES", "GENE_OR_GENE_PRODUCT", 22, 26], ["phospholipids", "SIMPLE_CHEMICAL", 165, 178], ["Sec16", "PROTEIN", 13, 18], ["ERES", "PROTEIN", 22, 26], ["a central conserved domain", "PROBLEM", 52, 78], ["a positively charged stretch", "PROBLEM", 95, 123], ["polar phospholipids", "TEST", 159, 178], ["receptor protein", "TEST", 205, 221]]], ["Following the targeting of Sec16 to ERES, assembly of the COPII coat drives vesicle budding and export from the ER toward the ERGIC and Golgi complex [175], [176].Other smooth ER domains: ER exit sites, plasma membrane-associated ER, ER quality control compartmentFor a long time, it was thought that this export and protein secretion in general occurs by bulk flow, even though it had been known for quite a while that the lack of anterograde signals can lead to the retention of mutant proteins along the secretory pathway [177].", [["vesicle", "ANATOMY", 76, 83], ["ER", "ANATOMY", 112, 114], ["Golgi", "ANATOMY", 136, 141], ["ER exit sites", "ANATOMY", 188, 201], ["plasma membrane", "ANATOMY", 203, 218], ["ER", "ANATOMY", 230, 232], ["ER", "ANATOMY", 234, 236], ["Sec16", "GENE_OR_GENE_PRODUCT", 27, 32], ["ERES", "GENE_OR_GENE_PRODUCT", 36, 40], ["COPII", "GENE_OR_GENE_PRODUCT", 58, 63], ["vesicle", "CELLULAR_COMPONENT", 76, 83], ["ER", "GENE_OR_GENE_PRODUCT", 112, 114], ["ERGIC", "GENE_OR_GENE_PRODUCT", 126, 131], ["Golgi", "CELLULAR_COMPONENT", 136, 141], ["ER", "GENE_OR_GENE_PRODUCT", 176, 178], ["ER", "GENE_OR_GENE_PRODUCT", 188, 190], ["plasma membrane", "CELLULAR_COMPONENT", 203, 218], ["ER", "GENE_OR_GENE_PRODUCT", 230, 232], ["ER", "GENE_OR_GENE_PRODUCT", 234, 236], ["Sec16", "PROTEIN", 27, 32], ["ERES", "PROTEIN", 36, 40], ["COPII coat", "PROTEIN", 58, 68], ["ER", "PROTEIN", 112, 114], ["ERGIC", "PROTEIN", 126, 131], ["Golgi complex", "PROTEIN", 136, 149], ["smooth ER domains", "PROTEIN", 169, 186], ["ER", "PROTEIN", 188, 190], ["ER", "PROTEIN", 230, 232], ["ER", "PROTEIN", 234, 236], ["mutant proteins", "PROTEIN", 481, 496], ["plasma membrane", "TEST", 203, 218], ["this export and protein secretion", "PROBLEM", 301, 334], ["bulk flow", "TEST", 356, 365], ["mutant proteins", "PROBLEM", 481, 496], ["COPII coat", "OBSERVATION", 58, 68], ["smooth", "OBSERVATION_MODIFIER", 169, 175], ["plasma membrane", "OBSERVATION", 203, 218], ["bulk flow", "OBSERVATION", 356, 365]]], ["The properties of secretory protein transmembrane domains have recently emerged as one determinant of membrane protein sorting to ERES and subsequent incorporation into transport vesicles.", [["membrane", "ANATOMY", 102, 110], ["vesicles", "ANATOMY", 179, 187], ["membrane", "CELLULAR_COMPONENT", 102, 110], ["ERES", "GENE_OR_GENE_PRODUCT", 130, 134], ["vesicles", "CELLULAR_COMPONENT", 179, 187], ["secretory protein transmembrane domains", "PROTEIN", 18, 57], ["membrane protein", "PROTEIN", 102, 118], ["ERES", "PROTEIN", 130, 134], ["secretory protein transmembrane domains", "PROBLEM", 18, 57], ["membrane protein sorting to ERES", "PROBLEM", 102, 134], ["secretory protein", "OBSERVATION", 18, 35], ["transport vesicles", "OBSERVATION", 169, 187]]], ["For example, a 22 residue transmembrane domain leads to COPII interaction and ER export of a fluorescent fusion chimeric protein, but it was shown that a 17 residue transmembrane domain did not give such an effect [178].", [["COPII", "ANATOMY", 56, 61], ["COPII", "GENE_OR_GENE_PRODUCT", 56, 61], ["ER", "GENE_OR_GENE_PRODUCT", 78, 80], ["22 residue transmembrane domain", "PROTEIN", 15, 46], ["COPII", "PROTEIN", 56, 61], ["ER", "PROTEIN", 78, 80], ["fluorescent fusion chimeric protein", "PROTEIN", 93, 128], ["17 residue transmembrane domain", "PROTEIN", 154, 185], ["a 22 residue transmembrane domain", "PROBLEM", 13, 46], ["a fluorescent fusion chimeric protein", "TREATMENT", 91, 128], ["a 17 residue transmembrane domain", "PROBLEM", 152, 185], ["COPII interaction", "OBSERVATION", 56, 73]]], ["Furthermore, lipid modifications may lead to ER domain sorting, since the presence of a palmitoylation acceptor site on the Wnt signaling protein LRP6 mediates its targeting to the secretory pathway via ERES [179].", [["ER", "GENE_OR_GENE_PRODUCT", 45, 47], ["Wnt", "GENE_OR_GENE_PRODUCT", 124, 127], ["LRP6", "GENE_OR_GENE_PRODUCT", 146, 150], ["ER", "PROTEIN", 45, 47], ["palmitoylation acceptor site", "PROTEIN", 88, 116], ["Wnt signaling protein", "PROTEIN", 124, 145], ["LRP6", "PROTEIN", 146, 150], ["lipid modifications", "TREATMENT", 13, 32], ["ER domain sorting", "TEST", 45, 62], ["a palmitoylation acceptor site", "PROBLEM", 86, 116], ["the Wnt signaling protein LRP6 mediates", "TREATMENT", 120, 159]]], ["In yeast, chitin synthase Chs3 also requires palmitoylation for its export from the ER [180].", [["chitin", "CHEMICAL", 10, 16], ["chitin synthase", "GENE_OR_GENE_PRODUCT", 10, 25], ["Chs3", "GENE_OR_GENE_PRODUCT", 26, 30], ["ER", "GENE_OR_GENE_PRODUCT", 84, 86], ["chitin synthase", "PROTEIN", 10, 25], ["Chs3", "PROTEIN", 26, 30], ["ER", "PROTEIN", 84, 86], ["yeast", "SPECIES", 3, 8], ["yeast", "SPECIES", 3, 8], ["chitin synthase Chs3", "TREATMENT", 10, 30], ["palmitoylation", "TREATMENT", 45, 59]]], ["Whether these signals correspond to bona fide anterograde transport signals or whether they are based on different mechanisms remains to be tested.Other smooth ER domains: ER exit sites, plasma membrane-associated ER, ER quality control compartmentInterestingly, the control of ER cholesterol content takes advantage of export from the transitional ER as well.", [["ER exit sites", "ANATOMY", 172, 185], ["plasma membrane", "ANATOMY", 187, 202], ["ER", "ANATOMY", 214, 216], ["ER", "ANATOMY", 218, 220], ["ER", "ANATOMY", 278, 280], ["transitional ER", "ANATOMY", 336, 351], ["cholesterol", "CHEMICAL", 281, 292], ["cholesterol", "CHEMICAL", 281, 292], ["ER", "GENE_OR_GENE_PRODUCT", 160, 162], ["ER", "GENE_OR_GENE_PRODUCT", 172, 174], ["plasma membrane", "CELLULAR_COMPONENT", 187, 202], ["ER", "GENE_OR_GENE_PRODUCT", 214, 216], ["ER", "GENE_OR_GENE_PRODUCT", 218, 220], ["ER", "GENE_OR_GENE_PRODUCT", 278, 280], ["cholesterol", "SIMPLE_CHEMICAL", 281, 292], ["ER", "GENE_OR_GENE_PRODUCT", 349, 351], ["smooth ER domains", "PROTEIN", 153, 170], ["ER", "PROTEIN", 172, 174], ["ER", "PROTEIN", 214, 216], ["ER", "PROTEIN", 218, 220], ["ER", "PROTEIN", 278, 280], ["ER", "PROTEIN", 349, 351], ["plasma membrane", "TEST", 187, 202], ["smooth", "OBSERVATION_MODIFIER", 153, 159], ["plasma membrane", "OBSERVATION", 187, 202], ["cholesterol content", "OBSERVATION", 281, 300]]], ["Sterol-regulatory element-binding protein-2 (SREBP-2) is exported from the ER in a complex with the polytopic transmembrane protein Scap through interaction with COPII at ERES as long as the ER cholesterol content is below 5% [162].", [["ER", "ANATOMY", 75, 77], ["transmembrane", "ANATOMY", 110, 123], ["ER", "ANATOMY", 191, 193], ["cholesterol", "CHEMICAL", 194, 205], ["Sterol", "CHEMICAL", 0, 6], ["cholesterol", "CHEMICAL", 194, 205], ["Sterol-regulatory element-binding protein-2", "GENE_OR_GENE_PRODUCT", 0, 43], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 45, 52], ["ER", "GENE_OR_GENE_PRODUCT", 75, 77], ["transmembrane", "CELLULAR_COMPONENT", 110, 123], ["Scap", "GENE_OR_GENE_PRODUCT", 132, 136], ["COPII", "GENE_OR_GENE_PRODUCT", 162, 167], ["ERES", "GENE_OR_GENE_PRODUCT", 171, 175], ["ER", "GENE_OR_GENE_PRODUCT", 191, 193], ["Sterol-regulatory element-binding protein-2 (SREBP-2", "PROTEIN", 0, 52], ["ER", "PROTEIN", 75, 77], ["polytopic transmembrane protein Scap", "PROTEIN", 100, 136], ["COPII", "PROTEIN", 162, 167], ["ERES", "PROTEIN", 171, 175], ["ER", "PROTEIN", 191, 193], ["Sterol", "TEST", 0, 6], ["binding protein", "TEST", 26, 41], ["the polytopic transmembrane protein Scap", "TREATMENT", 96, 136], ["COPII at ERES", "TREATMENT", 162, 175], ["the ER cholesterol content", "TEST", 187, 213]]], ["This export from the ER subsequently allows proteolytic cleavage of SREBP-2 at the level of Golgi complex [181].", [["ER", "ANATOMY", 21, 23], ["Golgi", "ANATOMY", 92, 97], ["ER", "GENE_OR_GENE_PRODUCT", 21, 23], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 68, 75], ["Golgi", "CELLULAR_COMPONENT", 92, 97], ["ER", "PROTEIN", 21, 23], ["SREBP-2", "PROTEIN", 68, 75], ["Golgi complex", "PROTEIN", 92, 105], ["SREBP", "TEST", 68, 73]]], ["The proteolytic fragments of SREBP then boost production of cholesterol by promoting transcription of the cholesterol metabolism genes.", [["cholesterol", "CHEMICAL", 60, 71], ["cholesterol", "CHEMICAL", 106, 117], ["cholesterol", "CHEMICAL", 60, 71], ["cholesterol", "CHEMICAL", 106, 117], ["SREBP", "GENE_OR_GENE_PRODUCT", 29, 34], ["cholesterol", "SIMPLE_CHEMICAL", 60, 71], ["cholesterol", "SIMPLE_CHEMICAL", 106, 117], ["SREBP", "PROTEIN", 29, 34], ["cholesterol metabolism genes", "DNA", 106, 134], ["The proteolytic fragments of SREBP", "PROBLEM", 0, 34], ["boost production of cholesterol", "TREATMENT", 40, 71], ["fragments", "OBSERVATION_MODIFIER", 16, 25], ["cholesterol metabolism genes", "OBSERVATION", 106, 134]]], ["Conversely, if ER cholesterol content rises above 5%, Scap binds cholesterol and undergoes a conformational change that allows Scap to bind the ER resident protein insulin-induced gene (Insig), precluding interaction of the Scap/SREBP complex with COPII at ERES [182].", [["cholesterol", "CHEMICAL", 18, 29], ["cholesterol", "CHEMICAL", 65, 76], ["cholesterol", "CHEMICAL", 18, 29], ["cholesterol", "CHEMICAL", 65, 76], ["ER", "GENE_OR_GENE_PRODUCT", 15, 17], ["Scap", "SIMPLE_CHEMICAL", 54, 58], ["cholesterol", "SIMPLE_CHEMICAL", 65, 76], ["Scap", "GENE_OR_GENE_PRODUCT", 127, 131], ["ER", "GENE_OR_GENE_PRODUCT", 144, 146], ["insulin", "GENE_OR_GENE_PRODUCT", 164, 171], ["Insig", "GENE_OR_GENE_PRODUCT", 186, 191], ["Scap", "GENE_OR_GENE_PRODUCT", 224, 228], ["SREBP", "GENE_OR_GENE_PRODUCT", 229, 234], ["COPII", "GENE_OR_GENE_PRODUCT", 248, 253], ["ER", "PROTEIN", 15, 17], ["Scap", "PROTEIN", 54, 58], ["Scap", "PROTEIN", 127, 131], ["ER resident protein insulin-induced gene", "DNA", 144, 184], ["Insig", "DNA", 186, 191], ["Scap", "PROTEIN", 224, 228], ["SREBP complex", "PROTEIN", 229, 242], ["COPII", "PROTEIN", 248, 253], ["ER cholesterol content", "TEST", 15, 37], ["Scap binds cholesterol", "TEST", 54, 76], ["a conformational change", "PROBLEM", 91, 114], ["insulin", "TEST", 164, 171]]], ["A similar mechanism utilizes the translocation in renal cancer from chromosome 8 protein (TRC8), which also hampers COPII interaction with the Scap/SREBP complex [183].Other smooth ER domains: ER exit sites, plasma membrane-associated ER, ER quality control compartmentRecent research has demonstrated that the ER is not only the point of origin for classical secretory pathway protein traffic to the cell surface, but also influences the plasma membrane in other, unexpected ways.", [["renal cancer", "ANATOMY", 50, 62], ["COPII", "ANATOMY", 116, 121], ["ER exit sites", "ANATOMY", 193, 206], ["plasma membrane", "ANATOMY", 208, 223], ["ER", "ANATOMY", 235, 237], ["ER", "ANATOMY", 239, 241], ["cell surface", "ANATOMY", 401, 413], ["plasma membrane", "ANATOMY", 439, 454], ["renal cancer", "DISEASE", 50, 62], ["renal cancer", "CANCER", 50, 62], ["chromosome 8", "GENE_OR_GENE_PRODUCT", 68, 80], ["TRC8", "GENE_OR_GENE_PRODUCT", 90, 94], ["COPII", "GENE_OR_GENE_PRODUCT", 116, 121], ["Scap", "GENE_OR_GENE_PRODUCT", 143, 147], ["SREBP", "GENE_OR_GENE_PRODUCT", 148, 153], ["ER", "GENE_OR_GENE_PRODUCT", 181, 183], ["ER", "GENE_OR_GENE_PRODUCT", 193, 195], ["plasma membrane", "CELLULAR_COMPONENT", 208, 223], ["ER", "GENE_OR_GENE_PRODUCT", 235, 237], ["ER", "GENE_OR_GENE_PRODUCT", 239, 241], ["ER", "GENE_OR_GENE_PRODUCT", 311, 313], ["cell surface", "CELLULAR_COMPONENT", 401, 413], ["plasma membrane", "CELLULAR_COMPONENT", 439, 454], ["chromosome 8 protein", "PROTEIN", 68, 88], ["TRC8", "PROTEIN", 90, 94], ["COPII", "PROTEIN", 116, 121], ["Scap", "PROTEIN", 143, 147], ["SREBP complex", "PROTEIN", 148, 161], ["smooth ER domains", "PROTEIN", 174, 191], ["ER", "PROTEIN", 193, 195], ["ER", "PROTEIN", 235, 237], ["ER", "PROTEIN", 239, 241], ["ER", "PROTEIN", 311, 313], ["A similar mechanism", "PROBLEM", 0, 19], ["renal cancer", "PROBLEM", 50, 62], ["chromosome 8 protein (TRC8)", "PROBLEM", 68, 95], ["the Scap/SREBP complex", "TEST", 139, 161], ["plasma membrane", "TEST", 208, 223], ["renal", "ANATOMY", 50, 55], ["cancer", "OBSERVATION", 56, 62], ["COPII interaction", "OBSERVATION", 116, 133], ["smooth", "OBSERVATION_MODIFIER", 174, 180], ["plasma membrane", "OBSERVATION", 208, 223], ["cell surface", "OBSERVATION", 401, 413], ["plasma membrane", "OBSERVATION", 439, 454]]], ["During the past decade, a domain of the smooth ER that is in close contact with the plasma membrane has been designated as PAM.", [["smooth ER", "ANATOMY", 40, 49], ["plasma membrane", "ANATOMY", 84, 99], ["ER", "GENE_OR_GENE_PRODUCT", 47, 49], ["plasma membrane", "CELLULAR_COMPONENT", 84, 99], ["smooth ER", "PROTEIN", 40, 49], ["PAM", "CELL_TYPE", 123, 126], ["smooth", "OBSERVATION_MODIFIER", 40, 46]]], ["The PAM interacts with the plasma membrane extensively on as many as 1100 contact sites [184].", [["plasma membrane", "ANATOMY", 27, 42], ["plasma membrane", "CELLULAR_COMPONENT", 27, 42], ["PAM", "PROTEIN", 4, 7], ["the plasma membrane", "TREATMENT", 23, 42]]], ["Most of the research on this domain has so far been done in yeast, where this domain is known to mediate direct sterol trafficking to the plasma membrane [185], [186].", [["plasma membrane", "ANATOMY", 138, 153], ["sterol", "CHEMICAL", 112, 118], ["sterol", "SIMPLE_CHEMICAL", 112, 118], ["plasma membrane", "CELLULAR_COMPONENT", 138, 153], ["yeast", "SPECIES", 60, 65], ["yeast", "SPECIES", 60, 65]]], ["The interaction between translocons and components of the exocyst complex on this domain of the ER also mediates the inheritance of the cortical ER in yeast [187], [188], as well as the targeting of secretory and basolateral proteins in polarized mammalian cells [189].", [["exocyst", "ANATOMY", 58, 65], ["ER", "ANATOMY", 96, 98], ["cortical ER", "ANATOMY", 136, 147], ["basolateral", "ANATOMY", 213, 224], ["cells", "ANATOMY", 257, 262], ["translocons", "GENE_OR_GENE_PRODUCT", 24, 35], ["exocyst", "GENE_OR_GENE_PRODUCT", 58, 65], ["ER", "GENE_OR_GENE_PRODUCT", 96, 98], ["ER", "GENE_OR_GENE_PRODUCT", 145, 147], ["mammalian cells", "CELL", 247, 262], ["translocons", "PROTEIN", 24, 35], ["exocyst complex", "PROTEIN", 58, 73], ["ER", "PROTEIN", 96, 98], ["cortical ER", "PROTEIN", 136, 147], ["secretory and basolateral proteins", "PROTEIN", 199, 233], ["polarized mammalian cells", "CELL_TYPE", 237, 262], ["yeast", "SPECIES", 151, 156], ["the exocyst complex", "PROBLEM", 54, 73], ["cortical", "ANATOMY_MODIFIER", 136, 144], ["basolateral", "ANATOMY_MODIFIER", 213, 224], ["mammalian cells", "OBSERVATION", 247, 262]]], ["In this cell system, the proximity of the ER at contact sites has been estimated at 10\u201325 nm [190].", [["cell", "ANATOMY", 8, 12], ["ER", "ANATOMY", 42, 44], ["cell", "CELL", 8, 12], ["ER", "GENE_OR_GENE_PRODUCT", 42, 44], ["ER", "PROTEIN", 42, 44], ["cell system", "OBSERVATION", 8, 19]]], ["In yeast and mammalian cells, the PAM is a major site of synthesis for phosphatidylserine.", [["mammalian cells", "ANATOMY", 13, 28], ["phosphatidylserine", "CHEMICAL", 71, 89], ["phosphatidylserine", "CHEMICAL", 71, 89], ["yeast", "CELL", 3, 8], ["mammalian cells", "CELL", 13, 28], ["PAM", "GENE_OR_GENE_PRODUCT", 34, 37], ["phosphatidylserine", "SIMPLE_CHEMICAL", 71, 89], ["mammalian cells", "CELL_TYPE", 13, 28], ["PAM", "CELL_TYPE", 34, 37], ["yeast", "SPECIES", 3, 8], ["yeast", "SPECIES", 3, 8], ["phosphatidylserine", "TREATMENT", 71, 89], ["mammalian cells", "OBSERVATION", 13, 28]]], ["This prominent plasma membrane lipid is predominantly found on the cytoplasmic leaflet of the plasma membrane [184], [191].", [["plasma membrane", "ANATOMY", 15, 30], ["cytoplasmic leaflet", "ANATOMY", 67, 86], ["plasma membrane", "ANATOMY", 94, 109], ["plasma membrane", "CELLULAR_COMPONENT", 15, 30], ["lipid", "CELLULAR_COMPONENT", 31, 36], ["cytoplasmic leaflet", "CELLULAR_COMPONENT", 67, 86], ["plasma membrane", "CELLULAR_COMPONENT", 94, 109], ["This prominent plasma membrane lipid", "PROBLEM", 0, 36], ["prominent", "OBSERVATION_MODIFIER", 5, 14], ["plasma membrane lipid", "OBSERVATION", 15, 36], ["predominantly", "OBSERVATION_MODIFIER", 40, 53], ["cytoplasmic leaflet", "OBSERVATION", 67, 86], ["plasma membrane", "ANATOMY", 94, 109]]], ["Phosphatidylserine plays an important role during apoptosis, when it becomes exposed on the outer leaflet of the plasma membrane [192], [193].", [["outer leaflet", "ANATOMY", 92, 105], ["plasma membrane", "ANATOMY", 113, 128], ["Phosphatidylserine", "CHEMICAL", 0, 18], ["Phosphatidylserine", "CHEMICAL", 0, 18], ["Phosphatidylserine", "GENE_OR_GENE_PRODUCT", 0, 18], ["outer leaflet", "CELLULAR_COMPONENT", 92, 105], ["plasma membrane", "CELLULAR_COMPONENT", 113, 128], ["Phosphatidylserine", "TREATMENT", 0, 18], ["outer", "ANATOMY_MODIFIER", 92, 97], ["leaflet", "ANATOMY_MODIFIER", 98, 105]]], ["This exposure enables phagocytes to recognize apoptotic cells and subsequently engulf them [194], [195].", [["phagocytes", "ANATOMY", 22, 32], ["cells", "ANATOMY", 56, 61], ["phagocytes", "CELL", 22, 32], ["cells", "CELL", 56, 61], ["phagocytes", "CELL_TYPE", 22, 32], ["apoptotic cells", "CELL_TYPE", 46, 61], ["apoptotic cells", "PROBLEM", 46, 61], ["apoptotic cells", "OBSERVATION", 46, 61]]], ["Similar to the MAM, the PAM also plays an important role in cellular calcium homeostasis.", [["cellular", "ANATOMY", 60, 68], ["calcium", "CHEMICAL", 69, 76], ["calcium", "CHEMICAL", 69, 76], ["PAM", "GENE_OR_GENE_PRODUCT", 24, 27], ["cellular", "CELL", 60, 68], ["calcium", "SIMPLE_CHEMICAL", 69, 76], ["PAM", "PROTEIN", 24, 27], ["cellular calcium homeostasis", "TREATMENT", 60, 88], ["calcium homeostasis", "OBSERVATION", 69, 88]]], ["This became evident, when ER-localized stromal interaction molecule 1 (STIM1) and Orai1, a plasma membrane calcium channel, two key players of store-operated calcium exchange were discovered to interact with each other [196], [197].", [["plasma membrane", "ANATOMY", 91, 106], ["calcium", "CHEMICAL", 107, 114], ["calcium", "CHEMICAL", 158, 165], ["calcium", "CHEMICAL", 107, 114], ["calcium", "CHEMICAL", 158, 165], ["ER-localized stromal interaction molecule 1", "GENE_OR_GENE_PRODUCT", 26, 69], ["STIM1", "GENE_OR_GENE_PRODUCT", 71, 76], ["Orai1", "GENE_OR_GENE_PRODUCT", 82, 87], ["plasma membrane", "CELLULAR_COMPONENT", 91, 106], ["calcium", "SIMPLE_CHEMICAL", 107, 114], ["calcium", "SIMPLE_CHEMICAL", 158, 165], ["ER", "PROTEIN", 26, 28], ["stromal interaction molecule 1", "PROTEIN", 39, 69], ["STIM1", "PROTEIN", 71, 76], ["Orai1", "PROTEIN", 82, 87], ["plasma membrane calcium channel", "PROTEIN", 91, 122], ["Orai1", "TEST", 82, 87], ["a plasma membrane calcium channel", "TEST", 89, 122], ["operated calcium exchange", "TREATMENT", 149, 174]]], ["The interaction between the two calcium handling proteins is triggered when ER calcium stores have been depleted [198], [199].", [["ER", "ANATOMY", 76, 78], ["calcium", "CHEMICAL", 32, 39], ["calcium", "CHEMICAL", 79, 86], ["calcium", "CHEMICAL", 32, 39], ["calcium", "CHEMICAL", 79, 86], ["calcium", "SIMPLE_CHEMICAL", 32, 39], ["ER", "GENE_OR_GENE_PRODUCT", 76, 78], ["calcium", "SIMPLE_CHEMICAL", 79, 86], ["calcium handling proteins", "PROTEIN", 32, 57], ["ER", "PROTEIN", 76, 78], ["the two calcium handling proteins", "TREATMENT", 24, 57], ["ER calcium stores", "TEST", 76, 93]]], ["The translocation of STIM1 to the PAM coincides with its multimerization [200], [201] and requires the cytosolic domain of STIM1, which can interact with Orai1 to promote calcium funneling to the ER [202], [203], [204].", [["cytosolic", "ANATOMY", 103, 112], ["calcium", "CHEMICAL", 171, 178], ["calcium", "CHEMICAL", 171, 178], ["STIM1", "GENE_OR_GENE_PRODUCT", 21, 26], ["STIM1", "GENE_OR_GENE_PRODUCT", 123, 128], ["Orai1", "GENE_OR_GENE_PRODUCT", 154, 159], ["calcium", "SIMPLE_CHEMICAL", 171, 178], ["ER", "GENE_OR_GENE_PRODUCT", 196, 198], ["STIM1", "PROTEIN", 21, 26], ["PAM", "DNA", 34, 37], ["cytosolic domain", "PROTEIN", 103, 119], ["STIM1", "PROTEIN", 123, 128], ["Orai1", "PROTEIN", 154, 159], ["the cytosolic domain of STIM1", "TREATMENT", 99, 128]]], ["Another parallel to the MAM is that the PAM undergoes massive remodeling upon interference with ER calcium homeostasis.", [["ER", "ANATOMY", 96, 98], ["calcium", "CHEMICAL", 99, 106], ["calcium", "CHEMICAL", 99, 106], ["ER", "GENE_OR_GENE_PRODUCT", 96, 98], ["calcium", "SIMPLE_CHEMICAL", 99, 106], ["PAM", "CELL_TYPE", 40, 43], ["ER", "PROTEIN", 96, 98], ["massive remodeling", "PROBLEM", 54, 72], ["ER calcium homeostasis", "TEST", 96, 118], ["massive", "OBSERVATION_MODIFIER", 54, 61], ["remodeling", "OBSERVATION", 62, 72]]], ["Upon calcium depletion, preformed precortical ER containing STIM1 translocates to the plasma membrane, where it loses its ribosomes and becomes smooth PAM that is sometimes stacked close to the plasma membrane [205].Other smooth ER domains: ER exit sites, plasma membrane-associated ER, ER quality control compartmentIn addition to export of proteins and lipids, the ER can also segregate folding intermediates.", [["precortical ER", "ANATOMY", 34, 48], ["plasma membrane", "ANATOMY", 86, 101], ["ribosomes", "ANATOMY", 122, 131], ["plasma membrane", "ANATOMY", 194, 209], ["ER exit sites", "ANATOMY", 241, 254], ["plasma membrane", "ANATOMY", 256, 271], ["ER", "ANATOMY", 283, 285], ["ER", "ANATOMY", 287, 289], ["calcium", "CHEMICAL", 5, 12], ["calcium", "CHEMICAL", 5, 12], ["calcium", "SIMPLE_CHEMICAL", 5, 12], ["ER", "GENE_OR_GENE_PRODUCT", 46, 48], ["STIM1", "GENE_OR_GENE_PRODUCT", 60, 65], ["plasma membrane", "CELLULAR_COMPONENT", 86, 101], ["ribosomes", "CELLULAR_COMPONENT", 122, 131], ["plasma membrane", "CELLULAR_COMPONENT", 194, 209], ["ER", "GENE_OR_GENE_PRODUCT", 229, 231], ["ER", "GENE_OR_GENE_PRODUCT", 241, 243], ["plasma membrane", "CELLULAR_COMPONENT", 256, 271], ["ER", "GENE_OR_GENE_PRODUCT", 283, 285], ["ER", "GENE_OR_GENE_PRODUCT", 287, 289], ["lipids", "SIMPLE_CHEMICAL", 355, 361], ["ER", "GENE_OR_GENE_PRODUCT", 367, 369], ["precortical ER", "PROTEIN", 34, 48], ["STIM1", "PROTEIN", 60, 65], ["smooth PAM", "CELL_TYPE", 144, 154], ["smooth ER domains", "PROTEIN", 222, 239], ["ER", "PROTEIN", 241, 243], ["ER", "PROTEIN", 283, 285], ["ER", "PROTEIN", 287, 289], ["ER", "PROTEIN", 367, 369], ["calcium depletion", "PROBLEM", 5, 22], ["smooth PAM", "PROBLEM", 144, 154], ["plasma membrane", "TEST", 256, 271], ["lipids", "TREATMENT", 355, 361], ["calcium depletion", "OBSERVATION", 5, 22], ["STIM1", "OBSERVATION", 60, 65], ["plasma membrane", "ANATOMY", 86, 101], ["smooth PAM", "OBSERVATION", 144, 154], ["smooth", "OBSERVATION_MODIFIER", 222, 228], ["plasma membrane", "OBSERVATION", 256, 271]]], ["This is the function of the ER quality control compartment (ERQC), where incompletely folded proteins await ER-associated degradation (ERAD) [206].", [["ER", "ANATOMY", 28, 30], ["ER", "GENE_OR_GENE_PRODUCT", 28, 30], ["ER", "GENE_OR_GENE_PRODUCT", 108, 110], ["ER", "PROTEIN", 28, 30], ["ER", "PROTEIN", 108, 110], ["ERAD", "PROTEIN", 135, 139], ["incompletely folded proteins", "PROBLEM", 73, 101]]], ["The ER chaperone calnexin was the first protein found to localize to this ER domain upon ER stress that results in the accumulation of unfolded proteins [207], [208].", [["ER", "GENE_OR_GENE_PRODUCT", 4, 6], ["calnexin", "GENE_OR_GENE_PRODUCT", 17, 25], ["ER", "GENE_OR_GENE_PRODUCT", 74, 76], ["ER", "GENE_OR_GENE_PRODUCT", 89, 91], ["ER", "PROTEIN", 4, 6], ["calnexin", "PROTEIN", 17, 25], ["ER domain", "PROTEIN", 74, 83], ["ER", "PROTEIN", 89, 91], ["unfolded proteins", "PROTEIN", 135, 152], ["The ER chaperone calnexin", "TREATMENT", 0, 25], ["the accumulation of unfolded proteins", "PROBLEM", 115, 152], ["unfolded", "OBSERVATION_MODIFIER", 135, 143]]], ["The presence of calnexin on the MAM and its absence from the ERQC under resting conditions, suggests that this lectin can shuttle from the MAM to the ERQC upon ER stress [63].", [["calnexin", "GENE_OR_GENE_PRODUCT", 16, 24], ["MAM", "CELLULAR_COMPONENT", 32, 35], ["lectin", "GENE_OR_GENE_PRODUCT", 111, 117], ["MAM", "CELLULAR_COMPONENT", 139, 142], ["ER", "GENE_OR_GENE_PRODUCT", 160, 162], ["calnexin", "PROTEIN", 16, 24], ["lectin", "PROTEIN", 111, 117], ["ER", "PROTEIN", 160, 162], ["calnexin", "TREATMENT", 16, 24], ["calnexin", "OBSERVATION", 16, 24]]], ["On the MAM, calnexin likely modulates calcium handling, whereas on the ERQC, this chaperone either promotes or inhibits ERAD in a substrate-dependent manner [209].", [["calcium", "CHEMICAL", 38, 45], ["calcium", "CHEMICAL", 38, 45], ["calnexin", "GENE_OR_GENE_PRODUCT", 12, 20], ["calcium", "SIMPLE_CHEMICAL", 38, 45], ["ERQC", "GENE_OR_GENE_PRODUCT", 71, 75], ["ERAD", "GENE_OR_GENE_PRODUCT", 120, 124], ["calnexin", "PROTEIN", 12, 20], ["ERQC", "PROTEIN", 71, 75], ["ERAD", "PROTEIN", 120, 124], ["calnexin", "TREATMENT", 12, 20], ["calcium handling", "PROBLEM", 38, 54]]], ["Analogous to calnexin, the smooth ER protein BAP31 can interact with mitochondrial Fis1 on the MAM [152], but is also a component of the ERQC and an interactor of calnexin [210].", [["mitochondrial", "ANATOMY", 69, 82], ["calnexin", "GENE_OR_GENE_PRODUCT", 13, 21], ["ER", "GENE_OR_GENE_PRODUCT", 34, 36], ["BAP31", "GENE_OR_GENE_PRODUCT", 45, 50], ["mitochondrial", "CELLULAR_COMPONENT", 69, 82], ["Fis1", "GENE_OR_GENE_PRODUCT", 83, 87], ["ERQC", "GENE_OR_GENE_PRODUCT", 137, 141], ["calnexin", "GENE_OR_GENE_PRODUCT", 163, 171], ["calnexin", "PROTEIN", 13, 21], ["smooth ER protein", "PROTEIN", 27, 44], ["BAP31", "PROTEIN", 45, 50], ["mitochondrial Fis1", "PROTEIN", 69, 87], ["ERQC", "PROTEIN", 137, 141], ["calnexin", "PROTEIN", 163, 171], ["calnexin", "TREATMENT", 13, 21], ["an interactor of calnexin", "TREATMENT", 146, 171]]], ["Within the ERQC, BAP31 promotes retrotranslocation of misfolded proteins through an interaction with the translocon components Sec61\u03b2 and TRAM, as well as the Derlin-1 ERAD translocation complex [211].", [["translocon", "ANATOMY", 105, 115], ["BAP31", "CHEMICAL", 17, 22], ["BAP31", "GENE_OR_GENE_PRODUCT", 17, 22], ["Sec61\u03b2", "GENE_OR_GENE_PRODUCT", 127, 133], ["TRAM", "GENE_OR_GENE_PRODUCT", 138, 142], ["Derlin-1", "GENE_OR_GENE_PRODUCT", 159, 167], ["ERQC", "DNA", 11, 15], ["BAP31", "PROTEIN", 17, 22], ["misfolded proteins", "PROTEIN", 54, 72], ["translocon components", "PROTEIN", 105, 126], ["Sec61\u03b2", "PROTEIN", 127, 133], ["TRAM", "PROTEIN", 138, 142], ["Derlin-1 ERAD translocation complex", "PROTEIN", 159, 194], ["misfolded proteins", "PROBLEM", 54, 72], ["TRAM", "TREATMENT", 138, 142], ["the Derlin", "TEST", 155, 165], ["misfolded proteins", "OBSERVATION", 54, 72]]], ["Import of BAP31 into the ERQC requires microtubules and depends on Arf1 and COPII, suggesting that an intra-ER vesicular transport step may regulate transition from the rough ER to the ERQC [212].", [["microtubules", "ANATOMY", 39, 51], ["vesicular", "ANATOMY", 111, 120], ["BAP31", "GENE_OR_GENE_PRODUCT", 10, 15], ["ERQC", "GENE_OR_GENE_PRODUCT", 25, 29], ["microtubules", "CELLULAR_COMPONENT", 39, 51], ["Arf1", "GENE_OR_GENE_PRODUCT", 67, 71], ["COPII", "GENE_OR_GENE_PRODUCT", 76, 81], ["ER", "GENE_OR_GENE_PRODUCT", 175, 177], ["BAP31", "PROTEIN", 10, 15], ["ERQC", "PROTEIN", 25, 29], ["Arf1", "PROTEIN", 67, 71], ["COPII", "PROTEIN", 76, 81], ["ER", "PROTEIN", 175, 177], ["COPII", "TREATMENT", 76, 81], ["an intra-ER vesicular transport step", "TREATMENT", 99, 135]]], ["Additional enzymes of the ERQC include the oxidoreductases PDI and ERp57, which promote retro-translocation of ERAD substrates [207], [213].", [["ERQC", "GENE_OR_GENE_PRODUCT", 26, 30], ["PDI", "GENE_OR_GENE_PRODUCT", 59, 62], ["ERp57", "GENE_OR_GENE_PRODUCT", 67, 72], ["ERQC", "PROTEIN", 26, 30], ["oxidoreductases", "PROTEIN", 43, 58], ["PDI", "PROTEIN", 59, 62], ["ERp57", "PROTEIN", 67, 72], ["ERAD", "PROTEIN", 111, 115], ["Additional enzymes", "TEST", 0, 18], ["the oxidoreductases PDI", "TEST", 39, 62], ["ERp57", "TEST", 67, 72]]], ["Whether these two proteins are enriched on or specifically targeted to the ERQC is currently not known.", [["ERQC", "GENE_OR_GENE_PRODUCT", 75, 79], ["ERQC", "DNA", 75, 79]]], ["Moreover, it is unclear, whether there is a relationship between the ERQC and the so-called EDEMosomes, where the ER disposes of unused ERAD components [214], [215].", [["ER", "GENE_OR_GENE_PRODUCT", 114, 116], ["ERQC", "PROTEIN", 69, 73], ["EDEMosomes", "PROTEIN", 92, 102], ["ER", "PROTEIN", 114, 116], ["ERAD", "PROTEIN", 136, 140]]], ["EDEMosomes are decorated with non-lipidated LC3 and are capable to fuse with the endosomal/lysosomal compartment, suggesting a direct pathway and connection from the smooth ER to lysosomes.The smooth ER as a point of origin for Russell body, peroxisome and lipid droplet biogenesisThe functional differentiation of the ER is now known to go one step further by providing the point of origin for entire organelles.", [["endosomal", "ANATOMY", 81, 90], ["lysosomal compartment", "ANATOMY", 91, 112], ["smooth ER", "ANATOMY", 166, 175], ["lysosomes", "ANATOMY", 179, 188], ["smooth ER", "ANATOMY", 193, 202], ["body", "ANATOMY", 236, 240], ["lipid droplet", "ANATOMY", 257, 270], ["ER", "ANATOMY", 319, 321], ["organelles", "ANATOMY", 402, 412], ["EDEMosomes", "SIMPLE_CHEMICAL", 0, 10], ["LC3", "GENE_OR_GENE_PRODUCT", 44, 47], ["endosomal", "CELLULAR_COMPONENT", 81, 90], ["lysosomal compartment", "CELLULAR_COMPONENT", 91, 112], ["ER", "GENE_OR_GENE_PRODUCT", 173, 175], ["lysosomes", "CELLULAR_COMPONENT", 179, 188], ["ER", "GENE_OR_GENE_PRODUCT", 200, 202], ["peroxisome", "GENE_OR_GENE_PRODUCT", 242, 252], ["lipid droplet", "CELLULAR_COMPONENT", 257, 270], ["ER", "GENE_OR_GENE_PRODUCT", 319, 321], ["organelles", "CELLULAR_COMPONENT", 402, 412], ["EDEMosomes", "PROTEIN", 0, 10], ["LC3", "PROTEIN", 44, 47], ["ER", "PROTEIN", 173, 175], ["ER", "PROTEIN", 200, 202], ["ER", "PROTEIN", 319, 321], ["lipid droplet biogenesis", "TREATMENT", 257, 281], ["lysosomal compartment", "OBSERVATION", 91, 112], ["smooth", "OBSERVATION_MODIFIER", 193, 199], ["peroxisome", "ANATOMY", 242, 252], ["lipid", "OBSERVATION", 257, 262], ["droplet biogenesis", "OBSERVATION", 263, 281], ["functional", "OBSERVATION_MODIFIER", 285, 295], ["differentiation", "OBSERVATION_MODIFIER", 296, 311]]], ["This is exemplified with Russell bodies, which were first described at the end of the 19th century as a characteristic of cancer cells, and were mistakenly thought to be a fungal parasite [216].", [["cancer cells", "ANATOMY", 122, 134], ["cancer", "DISEASE", 122, 128], ["cancer cells", "CELL", 122, 134], ["cancer cells", "CELL_TYPE", 122, 134], ["Russell bodies", "PROBLEM", 25, 39], ["cancer cells", "PROBLEM", 122, 134], ["a fungal parasite", "PROBLEM", 170, 187], ["Russell bodies", "OBSERVATION", 25, 39], ["cancer cells", "OBSERVATION", 122, 134], ["thought to be", "UNCERTAINTY", 156, 169], ["fungal", "OBSERVATION_MODIFIER", 172, 178]]], ["Indeed, we now know that plasma cells of multiple myeloma patients frequently exhibit Russell bodies [217].", [["plasma cells", "ANATOMY", 25, 37], ["myeloma", "ANATOMY", 50, 57], ["multiple myeloma", "DISEASE", 41, 57], ["plasma cells", "CELL", 25, 37], ["myeloma", "CANCER", 50, 57], ["patients", "ORGANISM", 58, 66], ["plasma cells", "CELL_TYPE", 25, 37], ["patients", "SPECIES", 58, 66], ["plasma cells", "PROBLEM", 25, 37], ["multiple myeloma", "PROBLEM", 41, 57], ["multiple", "OBSERVATION_MODIFIER", 41, 49], ["myeloma", "OBSERVATION", 50, 57]]], ["However, over a hundred years of research have shown that Russell bodies represent a differentiation of the ER and are used to store mutant, detergent-insoluble immunoglobulin that can neither be secreted nor degraded [218].", [["ER", "ANATOMY", 108, 110], ["ER", "GENE_OR_GENE_PRODUCT", 108, 110], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 161, 175], ["ER", "PROTEIN", 108, 110], ["detergent-insoluble immunoglobulin", "PROTEIN", 141, 175], ["insoluble immunoglobulin", "PROBLEM", 151, 175]]], ["These condensations are generated by covalent disulfide bonds between multiple immunoglobulins, which explain why mild reducing agents can lead to the dissolution of Russell bodies [219].", [["disulfide", "CHEMICAL", 46, 55], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 79, 94], ["immunoglobulins", "PROTEIN", 79, 94], ["covalent disulfide bonds between multiple immunoglobulins", "PROBLEM", 37, 94], ["mild reducing agents", "PROBLEM", 114, 134], ["covalent", "OBSERVATION", 37, 45], ["disulfide bonds", "OBSERVATION", 46, 61], ["multiple", "OBSERVATION_MODIFIER", 70, 78], ["immunoglobulins", "OBSERVATION", 79, 94], ["mild", "OBSERVATION_MODIFIER", 114, 118]]], ["Dependent on the type of immunoglobulin present, Russell bodies form either at the rough or at the smooth ER, suggesting that both domains are equipped to remove unwanted waste [220].", [["smooth ER", "ANATOMY", 99, 108], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 25, 39], ["ER", "GENE_OR_GENE_PRODUCT", 106, 108], ["immunoglobulin", "PROTEIN", 25, 39], ["smooth ER", "PROTEIN", 99, 108], ["immunoglobulin", "TREATMENT", 25, 39]]], ["Their formation requires the recognition of immunoglobulins by the ERES-associated ER proteins ERGIC-53 and ERp44, which recognize the immunoglobulin sugar structure and unpaired disulfide bonds, respectively [220], [221].", [["sugar", "CHEMICAL", 150, 155], ["disulfide", "CHEMICAL", 179, 188], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 44, 59], ["ERES", "GENE_OR_GENE_PRODUCT", 67, 71], ["ER", "GENE_OR_GENE_PRODUCT", 83, 85], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 95, 103], ["ERp44", "GENE_OR_GENE_PRODUCT", 108, 113], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 135, 149], ["immunoglobulins", "PROTEIN", 44, 59], ["ERES", "PROTEIN", 67, 71], ["ER proteins", "PROTEIN", 83, 94], ["ERGIC", "PROTEIN", 95, 100], ["53", "PROTEIN", 101, 103], ["ERp44", "PROTEIN", 108, 113], ["immunoglobulin sugar structure", "PROTEIN", 135, 165], ["immunoglobulins", "TREATMENT", 44, 59], ["ER proteins ERGIC", "TEST", 83, 100], ["ERp44", "TEST", 108, 113], ["the immunoglobulin sugar structure", "TEST", 131, 165]]], ["These two chaperones thus serve as Russell body sorting molecules at the level of ERES and ERGIC.", [["body", "ANATOMY", 43, 47], ["ERES", "GENE_OR_GENE_PRODUCT", 82, 86], ["Russell body sorting molecules", "PROTEIN", 35, 65], ["ERES", "PROTEIN", 82, 86], ["ERGIC", "PROTEIN", 91, 96]]], ["Future research will have to examine whether there is a relationship between the ERQC and Russell bodies and whether there are any distinguishing characteristics of the Russell body membrane.The smooth ER as a point of origin for Russell body, peroxisome and lipid droplet biogenesisThe smooth ER is also involved in the formation of peroxisomes, the organelles that mediate the degradation of fatty acids and the synthesis of ether lipids such as plasmalogens [222], [223].", [["body membrane", "ANATOMY", 177, 190], ["smooth ER", "ANATOMY", 195, 204], ["body", "ANATOMY", 238, 242], ["lipid droplet", "ANATOMY", 259, 272], ["peroxisomes", "ANATOMY", 334, 345], ["organelles", "ANATOMY", 351, 361], ["fatty acids", "CHEMICAL", 394, 405], ["fatty acids", "CHEMICAL", 394, 405], ["ether", "CHEMICAL", 427, 432], ["plasmalogens", "CHEMICAL", 448, 460], ["body membrane", "MULTI-TISSUE_STRUCTURE", 177, 190], ["ER", "GENE_OR_GENE_PRODUCT", 202, 204], ["peroxisome", "GENE_OR_GENE_PRODUCT", 244, 254], ["lipid droplet", "CELLULAR_COMPONENT", 259, 272], ["ER", "GENE_OR_GENE_PRODUCT", 294, 296], ["peroxisomes", "CELLULAR_COMPONENT", 334, 345], ["organelles", "CELLULAR_COMPONENT", 351, 361], ["fatty acids", "SIMPLE_CHEMICAL", 394, 405], ["ether lipids", "SIMPLE_CHEMICAL", 427, 439], ["plasmalogens", "SIMPLE_CHEMICAL", 448, 460], ["ER", "PROTEIN", 202, 204], ["ER", "PROTEIN", 294, 296], ["lipid droplet biogenesis", "TREATMENT", 259, 283], ["fatty acids", "TREATMENT", 394, 405], ["plasmalogens", "TEST", 448, 460], ["smooth", "OBSERVATION_MODIFIER", 195, 201], ["peroxisome", "ANATOMY", 244, 254], ["lipid", "OBSERVATION", 259, 264], ["droplet biogenesis", "OBSERVATION", 265, 283], ["smooth", "OBSERVATION_MODIFIER", 287, 293], ["fatty acids", "OBSERVATION", 394, 405]]], ["Although cell biologists first classified peroxisomes as endosymbionts, not unlike what had initially been suspected about Russell bodies, these organelles actually derive from a special domain of the ER, the pre-peroxisomal compartment [224], [225].", [["cell", "ANATOMY", 9, 13], ["peroxisomes", "ANATOMY", 42, 53], ["organelles", "ANATOMY", 145, 155], ["ER", "ANATOMY", 201, 203], ["pre-peroxisomal compartment", "ANATOMY", 209, 236], ["cell", "CELL", 9, 13], ["peroxisomes", "CELLULAR_COMPONENT", 42, 53], ["organelles", "CELLULAR_COMPONENT", 145, 155], ["ER", "GENE_OR_GENE_PRODUCT", 201, 203], ["ER", "PROTEIN", 201, 203]]], ["Here, a subset of Pex proteins, a group of proteins that are required for peroxisome biogenesis, target to peroxisome-generating domains of the ER and are then incorporated into the nascent organelle [224].", [["peroxisome", "ANATOMY", 74, 84], ["peroxisome", "ANATOMY", 107, 117], ["ER", "ANATOMY", 144, 146], ["organelle", "ANATOMY", 190, 199], ["Pex", "GENE_OR_GENE_PRODUCT", 18, 21], ["peroxisome", "GENE_OR_GENE_PRODUCT", 74, 84], ["ER", "GENE_OR_GENE_PRODUCT", 144, 146], ["organelle", "CELLULAR_COMPONENT", 190, 199], ["Pex proteins", "PROTEIN", 18, 30], ["peroxisome-generating domains", "PROTEIN", 107, 136], ["ER", "PROTEIN", 144, 146], ["Pex proteins", "PROBLEM", 18, 30], ["peroxisome biogenesis", "PROBLEM", 74, 95]]], ["The Pex proteins that have such a function are Pex3, Pex16 and Pex19.", [["Pex", "GENE_OR_GENE_PRODUCT", 4, 7], ["Pex3", "GENE_OR_GENE_PRODUCT", 47, 51], ["Pex16", "GENE_OR_GENE_PRODUCT", 53, 58], ["Pex19", "GENE_OR_GENE_PRODUCT", 63, 68], ["Pex proteins", "PROTEIN", 4, 16], ["Pex3", "PROTEIN", 47, 51], ["Pex16", "PROTEIN", 53, 58], ["Pex19", "PROTEIN", 63, 68], ["The Pex proteins", "TEST", 0, 16], ["Pex16", "TEST", 53, 58], ["Pex19", "TEST", 63, 68], ["Pex", "OBSERVATION", 4, 7]]], ["The correct targeting of Pex3p requires the formation of a Sec20p, Sec39p and Dsl1p protein complex at the ER in yeast [226].", [["Pex3p", "GENE_OR_GENE_PRODUCT", 25, 30], ["Sec20p", "GENE_OR_GENE_PRODUCT", 59, 65], ["Sec39p", "GENE_OR_GENE_PRODUCT", 67, 73], ["Dsl1p protein complex", "GENE_OR_GENE_PRODUCT", 78, 99], ["ER", "GENE_OR_GENE_PRODUCT", 107, 109], ["Pex3p", "PROTEIN", 25, 30], ["Sec20p", "PROTEIN", 59, 65], ["Sec39p", "PROTEIN", 67, 73], ["Dsl1p protein complex", "PROTEIN", 78, 99], ["ER", "PROTEIN", 107, 109], ["yeast", "SPECIES", 113, 118], ["yeast", "SPECIES", 113, 118], ["a Sec20p, Sec39p and Dsl1p protein complex", "TREATMENT", 57, 99]]], ["Similar to Russell body biogenesis, peroxisome biogenesis might be influenced by the secretory pathway [227].", [["body", "ANATOMY", 19, 23], ["peroxisome", "ANATOMY", 36, 46], ["peroxisome", "CELLULAR_COMPONENT", 36, 46], ["peroxisome biogenesis", "PROBLEM", 36, 57], ["peroxisome biogenesis", "OBSERVATION", 36, 57]]], ["Specifically, proteins of the coatomer coat complex and members of the Arf protein family might be involved in the anterograde and retrograde transport to and from peroxisomes [228], [229].", [["peroxisomes", "ANATOMY", 164, 175], ["coatomer", "GENE_OR_GENE_PRODUCT", 30, 38], ["Arf", "GENE_OR_GENE_PRODUCT", 71, 74], ["peroxisomes", "CELLULAR_COMPONENT", 164, 175], ["coatomer coat complex", "PROTEIN", 30, 51], ["Arf protein family", "PROTEIN", 71, 89], ["coatomer coat complex", "OBSERVATION", 30, 51]]], ["The role of Sec20p and Sec39p in ER-Golgi trafficking again highlights the potential connection between protein secretion and peroxisome biogenesis [230], [231].", [["ER-Golgi", "ANATOMY", 33, 41], ["Sec20p", "GENE_OR_GENE_PRODUCT", 12, 18], ["Sec39p", "GENE_OR_GENE_PRODUCT", 23, 29], ["ER", "GENE_OR_GENE_PRODUCT", 33, 35], ["Golgi", "CELLULAR_COMPONENT", 36, 41], ["peroxisome", "CELLULAR_COMPONENT", 126, 136], ["Sec20p", "PROTEIN", 12, 18], ["Sec39p", "PROTEIN", 23, 29], ["ER", "PROTEIN", 33, 35], ["the potential connection between protein secretion", "PROBLEM", 71, 121], ["peroxisome biogenesis", "TEST", 126, 147]]], ["However, peroxisome biogenesis at the level of the ER does not depend on ongoing protein secretion, since peroxisome targeting is maintained in the presence of COPII transport inhibitors [232].The smooth ER as a point of origin for Russell body, peroxisome and lipid droplet biogenesisYet another complex relationship between the ER, protein secretion and organelle biogenesis exists in the case of lipid droplets.", [["peroxisome", "ANATOMY", 9, 19], ["ER", "ANATOMY", 51, 53], ["peroxisome", "ANATOMY", 106, 116], ["smooth ER", "ANATOMY", 197, 206], ["body", "ANATOMY", 240, 244], ["lipid droplet", "ANATOMY", 261, 274], ["ER", "ANATOMY", 330, 332], ["organelle", "ANATOMY", 356, 365], ["lipid droplets", "ANATOMY", 399, 413], ["peroxisome", "CELLULAR_COMPONENT", 9, 19], ["ER", "GENE_OR_GENE_PRODUCT", 51, 53], ["peroxisome", "CELLULAR_COMPONENT", 106, 116], ["COPII", "GENE_OR_GENE_PRODUCT", 160, 165], ["ER", "GENE_OR_GENE_PRODUCT", 204, 206], ["peroxisome", "GENE_OR_GENE_PRODUCT", 246, 256], ["lipid droplet", "CELLULAR_COMPONENT", 261, 274], ["ER", "GENE_OR_GENE_PRODUCT", 330, 332], ["organelle", "CELLULAR_COMPONENT", 356, 365], ["lipid droplets", "CELLULAR_COMPONENT", 399, 413], ["ER", "PROTEIN", 51, 53], ["COPII", "PROTEIN", 160, 165], ["ER", "PROTEIN", 204, 206], ["ER", "PROTEIN", 330, 332], ["peroxisome biogenesis", "PROBLEM", 9, 30], ["ongoing protein secretion", "PROBLEM", 73, 98], ["COPII transport inhibitors", "TREATMENT", 160, 186], ["lipid droplet biogenesis", "TREATMENT", 261, 285], ["protein secretion", "PROBLEM", 334, 351], ["organelle biogenesis", "TEST", 356, 376], ["lipid droplets", "PROBLEM", 399, 413], ["peroxisome biogenesis", "OBSERVATION", 9, 30], ["protein secretion", "OBSERVATION", 81, 98], ["smooth", "OBSERVATION_MODIFIER", 197, 203], ["peroxisome", "ANATOMY", 246, 256], ["lipid", "OBSERVATION", 261, 266], ["droplet biogenesis", "OBSERVATION", 267, 285], ["organelle biogenesis", "OBSERVATION", 356, 376], ["lipid droplets", "OBSERVATION", 399, 413]]], ["In this case, trafficking between the ER and the Golgi mediated by COPI coated vesicles is essential for lipid droplet biogenesis [233].", [["ER", "ANATOMY", 38, 40], ["Golgi", "ANATOMY", 49, 54], ["COPI", "ANATOMY", 67, 71], ["vesicles", "ANATOMY", 79, 87], ["lipid droplet", "ANATOMY", 105, 118], ["ER", "GENE_OR_GENE_PRODUCT", 38, 40], ["Golgi", "CELLULAR_COMPONENT", 49, 54], ["COPI", "GENE_OR_GENE_PRODUCT", 67, 71], ["vesicles", "CELLULAR_COMPONENT", 79, 87], ["lipid droplet", "CELLULAR_COMPONENT", 105, 118], ["ER", "PROTEIN", 38, 40], ["COPI", "PROTEIN", 67, 71], ["COPI coated vesicles", "TREATMENT", 67, 87], ["lipid droplet biogenesis", "TREATMENT", 105, 129]]], ["Lipid droplets have been well known to be closely associated with ER membranes since the early 1970s [234].", [["Lipid droplets", "ANATOMY", 0, 14], ["ER membranes", "ANATOMY", 66, 78], ["Lipid droplets", "SIMPLE_CHEMICAL", 0, 14], ["ER membranes", "CELLULAR_COMPONENT", 66, 78], ["ER", "PROTEIN", 66, 68], ["Lipid droplets", "PROBLEM", 0, 14]]], ["Proteomic analysis of their content showed that the ER oxidoreductases ERp29 and peroxiredoxin 4 as well as the chaperones BiP/GRP78 and calnexin are found on lipid droplet membranes [235], [236].", [["lipid droplet membranes", "ANATOMY", 159, 182], ["ER", "GENE_OR_GENE_PRODUCT", 52, 54], ["ERp29", "GENE_OR_GENE_PRODUCT", 71, 76], ["peroxiredoxin 4", "GENE_OR_GENE_PRODUCT", 81, 96], ["BiP", "GENE_OR_GENE_PRODUCT", 123, 126], ["GRP78", "GENE_OR_GENE_PRODUCT", 127, 132], ["calnexin", "GENE_OR_GENE_PRODUCT", 137, 145], ["ER oxidoreductases", "PROTEIN", 52, 70], ["ERp29", "PROTEIN", 71, 76], ["peroxiredoxin 4", "PROTEIN", 81, 96], ["BiP", "PROTEIN", 123, 126], ["GRP78", "PROTEIN", 127, 132], ["calnexin", "PROTEIN", 137, 145], ["Proteomic analysis", "TEST", 0, 18], ["the ER oxidoreductases ERp29", "TREATMENT", 48, 76], ["peroxiredoxin", "TREATMENT", 81, 94], ["the chaperones BiP/GRP78", "TREATMENT", 108, 132], ["calnexin", "TREATMENT", 137, 145], ["lipid droplet membranes", "TEST", 159, 182]]], ["Proteins found in the lipid droplet membrane such as 17\u03b2-hydroxysteroid dehydrogenase type 11 and methyltransferase-like 7B (also known as AAM-B) target to the lipid droplet membrane from the ER using N-terminal hydrophobic sequences [237], [238].", [["lipid droplet membrane", "ANATOMY", 22, 44], ["lipid droplet membrane", "ANATOMY", 160, 182], ["ER", "ANATOMY", 192, 194], ["17\u03b2-hydroxysteroid", "CHEMICAL", 53, 71], ["N", "CHEMICAL", 201, 202], ["lipid droplet membrane", "CELLULAR_COMPONENT", 22, 44], ["17\u03b2-hydroxysteroid dehydrogenase type 11", "GENE_OR_GENE_PRODUCT", 53, 93], ["methyltransferase-like 7B", "GENE_OR_GENE_PRODUCT", 98, 123], ["AAM-B", "GENE_OR_GENE_PRODUCT", 139, 144], ["lipid droplet membrane", "CELLULAR_COMPONENT", 160, 182], ["ER", "GENE_OR_GENE_PRODUCT", 192, 194], ["17\u03b2-hydroxysteroid dehydrogenase type 11", "PROTEIN", 53, 93], ["methyltransferase-like 7B", "PROTEIN", 98, 123], ["AAM", "PROTEIN", 139, 142], ["B", "PROTEIN", 143, 144], ["ER", "PROTEIN", 192, 194], ["N-terminal hydrophobic sequences", "PROTEIN", 201, 233], ["Proteins", "TEST", 0, 8], ["the lipid droplet membrane", "TEST", 18, 44], ["hydroxysteroid dehydrogenase type", "PROBLEM", 57, 90], ["methyltransferase-like 7B", "PROBLEM", 98, 123], ["N-terminal hydrophobic sequences", "TREATMENT", 201, 233], ["droplet membrane", "OBSERVATION", 28, 44]]], ["Interestingly, this targeting is reversible, suggesting the existence of modifiable lipid droplet targeting signals and mechanisms [239].", [["lipid droplet", "ANATOMY", 84, 97], ["modifiable lipid droplet targeting signals", "PROBLEM", 73, 115], ["lipid droplet", "OBSERVATION", 84, 97]]], ["Lipid droplet biogenesis also appears to require the spatial confinement of enzymes that synthesize their lipid contents, mostly triacylglycerides and cholesterol esters [240].", [["cholesterol esters", "CHEMICAL", 151, 169], ["triacylglycerides", "CHEMICAL", 129, 146], ["cholesterol esters", "CHEMICAL", 151, 169], ["Lipid", "SIMPLE_CHEMICAL", 0, 5], ["lipid", "SIMPLE_CHEMICAL", 106, 111], ["triacylglycerides", "SIMPLE_CHEMICAL", 129, 146], ["cholesterol esters", "SIMPLE_CHEMICAL", 151, 169], ["enzymes", "PROTEIN", 76, 83], ["Lipid droplet biogenesis", "PROBLEM", 0, 24], ["cholesterol esters", "TEST", 151, 169]]], ["DGAT1 and DGAT2 catalyze the final step in the synthesis of triacylglycerides, but only DGAT2 can translocate from the MAM to sites of lipid droplet biogenesis upon oleate treatment of cells [142].", [["sites", "ANATOMY", 126, 131], ["lipid droplet", "ANATOMY", 135, 148], ["cells", "ANATOMY", 185, 190], ["DGAT2", "CHEMICAL", 88, 93], ["oleate", "CHEMICAL", 165, 171], ["triacylglycerides", "CHEMICAL", 60, 77], ["oleate", "CHEMICAL", 165, 171], ["DGAT1", "GENE_OR_GENE_PRODUCT", 0, 5], ["DGAT2", "GENE_OR_GENE_PRODUCT", 10, 15], ["triacylglycerides", "SIMPLE_CHEMICAL", 60, 77], ["DGAT2", "GENE_OR_GENE_PRODUCT", 88, 93], ["MAM", "SIMPLE_CHEMICAL", 119, 122], ["lipid droplet", "CELLULAR_COMPONENT", 135, 148], ["oleate", "SIMPLE_CHEMICAL", 165, 171], ["cells", "CELL", 185, 190], ["DGAT1", "PROTEIN", 0, 5], ["DGAT2", "PROTEIN", 10, 15], ["DGAT2", "PROTEIN", 88, 93], ["triacylglycerides", "TREATMENT", 60, 77], ["lipid droplet biogenesis upon oleate treatment of cells", "TREATMENT", 135, 190]]], ["At these sites, the DGAT2 enzymatic activity may channel triacylglycerides into nascent cytosolic lipid droplets [241].", [["cytosolic", "ANATOMY", 88, 97], ["triacylglycerides", "CHEMICAL", 57, 74], ["DGAT2", "GENE_OR_GENE_PRODUCT", 20, 25], ["triacylglycerides", "SIMPLE_CHEMICAL", 57, 74], ["DGAT2", "PROTEIN", 20, 25]]], ["Studies using mistargeted DGAT2 have shown that the intracellular localization of the DGAT2 enzymatic activity determines the site of lipid droplet formation [242].", [["intracellular", "ANATOMY", 52, 65], ["lipid droplet", "ANATOMY", 134, 147], ["DGAT2", "GENE_OR_GENE_PRODUCT", 26, 31], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 52, 65], ["DGAT2", "GENE_OR_GENE_PRODUCT", 86, 91], ["lipid droplet", "CELLULAR_COMPONENT", 134, 147], ["mistargeted DGAT2", "PROTEIN", 14, 31], ["DGAT2", "PROTEIN", 86, 91], ["lipid droplet formation", "PROBLEM", 134, 157], ["lipid droplet", "OBSERVATION", 134, 147]]], ["Subsequently, lipid droplets become coated with proteins of the perilipin, adipose differentiation-related protein, tail-interacting protein of 47 kDa (PAT) family [243].", [["lipid droplets", "ANATOMY", 14, 28], ["adipose", "ANATOMY", 75, 82], ["lipid droplets", "SIMPLE_CHEMICAL", 14, 28], ["perilipin", "GENE_OR_GENE_PRODUCT", 64, 73], ["adipose differentiation-related protein", "GENE_OR_GENE_PRODUCT", 75, 114], ["tail-interacting protein of 47 kDa", "GENE_OR_GENE_PRODUCT", 116, 150], ["PAT", "GENE_OR_GENE_PRODUCT", 152, 155], ["perilipin", "PROTEIN", 64, 73], ["adipose differentiation-related protein", "PROTEIN", 75, 114], ["tail-interacting protein", "PROTEIN", 116, 140], ["47 kDa (PAT) family", "PROTEIN", 144, 163], ["lipid droplets", "TREATMENT", 14, 28], ["the perilipin", "TEST", 60, 73], ["perilipin", "ANATOMY", 64, 73], ["adipose", "ANATOMY", 75, 82]]], ["PAT proteins such as tail-interacting protein of 47 kDa (TIP47) target to lipid droplets using multiple amphipathic helices as targeting information to influence the structure of lipid droplets [244].", [["lipid droplets", "ANATOMY", 74, 88], ["lipid droplets", "ANATOMY", 179, 193], ["PAT", "GENE_OR_GENE_PRODUCT", 0, 3], ["tail-interacting protein of 47 kDa", "GENE_OR_GENE_PRODUCT", 21, 55], ["TIP47", "GENE_OR_GENE_PRODUCT", 57, 62], ["PAT proteins", "PROTEIN", 0, 12], ["tail-interacting protein", "PROTEIN", 21, 45], ["47 kDa", "PROTEIN", 49, 55], ["TIP47", "PROTEIN", 57, 62], ["amphipathic helices", "PROTEIN", 104, 123], ["PAT proteins", "TEST", 0, 12], ["lipid droplets", "TREATMENT", 74, 88], ["multiple amphipathic helices", "TREATMENT", 95, 123]]], ["The trafficking to lipid droplets of the proteins of this family also requires COPI and COPII-based mechanisms, suggesting that lipid droplets like Russell bodies are in close contact with ERES and ERGIC [245].", [["lipid droplets", "ANATOMY", 19, 33], ["lipid droplets", "ANATOMY", 128, 142], ["COPI", "GENE_OR_GENE_PRODUCT", 79, 83], ["COPII", "GENE_OR_GENE_PRODUCT", 88, 93], ["lipid droplets", "SIMPLE_CHEMICAL", 128, 142], ["COPI", "PROTEIN", 79, 83], ["COPII", "PROTEIN", 88, 93], ["ERES", "PROTEIN", 189, 193], ["lipid droplets", "PROBLEM", 128, 142], ["Russell bodies", "OBSERVATION", 148, 162]]], ["PAT proteins regulate the metabolism of triacylglycerides contained in lipid droplets.", [["lipid droplets", "ANATOMY", 71, 85], ["triacylglycerides", "CHEMICAL", 40, 57], ["PAT", "GENE_OR_GENE_PRODUCT", 0, 3], ["triacylglycerides", "SIMPLE_CHEMICAL", 40, 57], ["lipid droplets", "CELLULAR_COMPONENT", 71, 85], ["PAT proteins", "PROTEIN", 0, 12], ["triacylglycerides", "TREATMENT", 40, 57], ["lipid droplets", "TREATMENT", 71, 85], ["lipid droplets", "OBSERVATION", 71, 85]]], ["For example, protein kinase A (PKA) phosphorylates perilipin on multiple sites [243], which leads to the activation of lipid droplet-associated lipid hydrolases and the translocation of lipid hydrolases to lipid droplets [246].The smooth ER as a point of origin for Russell body, peroxisome and lipid droplet biogenesisTogether, the findings on Russell bodies, peroxisomes and lipid droplets demonstrate how the ER functions as a point of origin for organelle biogenesis.", [["lipid droplets", "ANATOMY", 206, 220], ["body", "ANATOMY", 274, 278], ["lipid droplet", "ANATOMY", 295, 308], ["peroxisomes", "ANATOMY", 361, 372], ["lipid droplets", "ANATOMY", 377, 391], ["ER", "ANATOMY", 412, 414], ["organelle", "ANATOMY", 450, 459], ["protein kinase A", "GENE_OR_GENE_PRODUCT", 13, 29], ["PKA", "GENE_OR_GENE_PRODUCT", 31, 34], ["perilipin", "GENE_OR_GENE_PRODUCT", 51, 60], ["ER", "GENE_OR_GENE_PRODUCT", 238, 240], ["peroxisome", "CELLULAR_COMPONENT", 280, 290], ["lipid droplet", "CELLULAR_COMPONENT", 295, 308], ["peroxisomes", "CELLULAR_COMPONENT", 361, 372], ["lipid droplets", "CELLULAR_COMPONENT", 377, 391], ["ER", "GENE_OR_GENE_PRODUCT", 412, 414], ["organelle", "CELLULAR_COMPONENT", 450, 459], ["protein kinase A", "PROTEIN", 13, 29], ["PKA", "PROTEIN", 31, 34], ["perilipin", "PROTEIN", 51, 60], ["lipid hydrolases", "PROTEIN", 144, 160], ["lipid hydrolases", "PROTEIN", 186, 202], ["ER", "PROTEIN", 238, 240], ["ER", "PROTEIN", 412, 414], ["protein kinase A (PKA) phosphorylates perilipin", "TEST", 13, 60], ["lipid droplet", "TREATMENT", 119, 132], ["lipid hydrolases", "PROBLEM", 144, 160], ["lipid hydrolases to lipid droplets", "TREATMENT", 186, 220], ["lipid droplet biogenesis", "TREATMENT", 295, 319], ["lipid droplets", "TREATMENT", 377, 391], ["organelle biogenesis", "PROBLEM", 450, 470], ["lipid hydrolases", "OBSERVATION", 144, 160], ["smooth", "OBSERVATION_MODIFIER", 231, 237], ["peroxisome", "ANATOMY", 280, 290], ["lipid", "OBSERVATION", 295, 300], ["droplet biogenesis", "OBSERVATION", 301, 319], ["lipid droplets", "OBSERVATION", 377, 391], ["organelle biogenesis", "OBSERVATION", 450, 470]]], ["The fact that all three organelles originate from ER domains at or close to ERES underscores the ability of the ER to execute very tight control of membrane domain formation.ER domain enrichment and diseaseGiven the importance of ER membrane domain sorting for critical functions of the ER and organelle biogenesis of Russell bodies, peroxisomes and lipid droplets, a main area of research aims to understand which mechanisms are needed to implement the blueprint of the ER's urban planning department.", [["organelles", "ANATOMY", 24, 34], ["ER domains", "ANATOMY", 50, 60], ["ER", "ANATOMY", 112, 114], ["membrane", "ANATOMY", 148, 156], ["ER membrane", "ANATOMY", 230, 241], ["ER", "ANATOMY", 287, 289], ["organelle", "ANATOMY", 294, 303], ["Russell bodies", "ANATOMY", 318, 332], ["peroxisomes", "ANATOMY", 334, 345], ["lipid droplets", "ANATOMY", 350, 364], ["organelles", "CELLULAR_COMPONENT", 24, 34], ["ER", "GENE_OR_GENE_PRODUCT", 50, 52], ["ER", "GENE_OR_GENE_PRODUCT", 112, 114], ["membrane domain", "CELLULAR_COMPONENT", 148, 163], ["ER", "GENE_OR_GENE_PRODUCT", 174, 176], ["ER", "GENE_OR_GENE_PRODUCT", 230, 232], ["ER", "GENE_OR_GENE_PRODUCT", 287, 289], ["organelle", "CELLULAR_COMPONENT", 294, 303], ["peroxisomes", "CELLULAR_COMPONENT", 334, 345], ["lipid droplets", "CELLULAR_COMPONENT", 350, 364], ["ER", "GENE_OR_GENE_PRODUCT", 471, 473], ["ER domains", "PROTEIN", 50, 60], ["ERES", "PROTEIN", 76, 80], ["ER", "PROTEIN", 112, 114], ["membrane domain", "PROTEIN", 148, 163], ["ER", "PROTEIN", 174, 176], ["ER", "PROTEIN", 230, 232], ["ER", "PROTEIN", 287, 289], ["ER", "PROTEIN", 471, 473], ["membrane domain formation", "PROBLEM", 148, 173], ["ER domain enrichment", "PROBLEM", 174, 194], ["ER membrane domain sorting", "TREATMENT", 230, 256], ["lipid droplets", "TREATMENT", 350, 364], ["very", "OBSERVATION_MODIFIER", 126, 130], ["tight", "OBSERVATION", 131, 136], ["membrane domain", "OBSERVATION", 148, 163], ["enrichment", "OBSERVATION", 184, 194], ["Russell bodies", "OBSERVATION", 318, 332], ["lipid droplets", "OBSERVATION", 350, 364]]], ["A better understanding of these functions is expected to give insight into diseases that are associated with malfunctioning ER, but also ER-derived organelles such as the Golgi complex, lipid droplets and peroxisomes.", [["ER", "ANATOMY", 124, 126], ["organelles", "ANATOMY", 148, 158], ["Golgi complex", "ANATOMY", 171, 184], ["lipid droplets", "ANATOMY", 186, 200], ["peroxisomes", "ANATOMY", 205, 216], ["ER", "GENE_OR_GENE_PRODUCT", 124, 126], ["ER", "GENE_OR_GENE_PRODUCT", 137, 139], ["organelles", "CELLULAR_COMPONENT", 148, 158], ["Golgi", "CELLULAR_COMPONENT", 171, 176], ["lipid droplets", "CELLULAR_COMPONENT", 186, 200], ["peroxisomes", "CELLULAR_COMPONENT", 205, 216], ["ER", "PROTEIN", 124, 126], ["ER", "PROTEIN", 137, 139], ["Golgi complex", "PROTEIN", 171, 184], ["malfunctioning ER", "PROBLEM", 109, 126], ["lipid droplets", "TREATMENT", 186, 200]]], ["While numerous diseases are separately tied to those organelles, historically, ER-associated diseases were summarized as ER storage diseases and are characterized by a decreased or increased extent of ER folding or retention [247].", [["organelles", "ANATOMY", 53, 63], ["ER", "ANATOMY", 201, 203], ["organelles", "CELLULAR_COMPONENT", 53, 63], ["ER", "GENE_OR_GENE_PRODUCT", 79, 81], ["ER", "GENE_OR_GENE_PRODUCT", 121, 123], ["ER", "GENE_OR_GENE_PRODUCT", 201, 203], ["ER", "PROTEIN", 79, 81], ["ER", "PROTEIN", 121, 123], ["ER", "PROTEIN", 201, 203], ["numerous diseases", "PROBLEM", 6, 23], ["ER-associated diseases", "PROBLEM", 79, 101], ["ER storage diseases", "PROBLEM", 121, 140], ["ER folding", "PROBLEM", 201, 211], ["numerous", "OBSERVATION_MODIFIER", 6, 14], ["diseases", "OBSERVATION", 15, 23], ["diseases", "OBSERVATION", 93, 101], ["decreased", "OBSERVATION_MODIFIER", 168, 177], ["increased", "OBSERVATION_MODIFIER", 181, 190], ["extent", "OBSERVATION_MODIFIER", 191, 197]]], ["Examples include cystic fibrosis, low density lipoprotein receptor defects and coagulation factor V and VIII deficiencies.", [["cystic", "ANATOMY", 17, 23], ["fibrosis", "DISEASE", 24, 32], ["low density lipoprotein receptor", "GENE_OR_GENE_PRODUCT", 34, 66], ["coagulation factor V", "GENE_OR_GENE_PRODUCT", 79, 99], ["VIII", "GENE_OR_GENE_PRODUCT", 104, 108], ["low density lipoprotein receptor", "PROTEIN", 34, 66], ["coagulation factor V", "PROTEIN", 79, 99], ["VIII", "PROTEIN", 104, 108], ["cystic fibrosis", "PROBLEM", 17, 32], ["low density lipoprotein receptor defects", "PROBLEM", 34, 74], ["coagulation factor V and VIII deficiencies", "PROBLEM", 79, 121], ["cystic", "OBSERVATION_MODIFIER", 17, 23], ["fibrosis", "OBSERVATION", 24, 32], ["low density", "OBSERVATION_MODIFIER", 34, 45], ["lipoprotein", "OBSERVATION_MODIFIER", 46, 57], ["receptor defects", "OBSERVATION", 58, 74], ["coagulation", "OBSERVATION_MODIFIER", 79, 90], ["VIII deficiencies", "OBSERVATION", 104, 121]]], ["Conceivably, the mislocalization of the ER retention and export machinery, such as the coatomer and COPII coat or the KDEL receptor could lead to such diseases.", [["ER", "ANATOMY", 40, 42], ["ER", "GENE_OR_GENE_PRODUCT", 40, 42], ["coatomer", "CELLULAR_COMPONENT", 87, 95], ["COPII", "GENE_OR_GENE_PRODUCT", 100, 105], ["KDEL receptor", "GENE_OR_GENE_PRODUCT", 118, 131], ["ER", "PROTEIN", 40, 42], ["coatomer", "PROTEIN", 87, 95], ["COPII coat", "PROTEIN", 100, 110], ["KDEL receptor", "PROTEIN", 118, 131], ["the ER retention", "PROBLEM", 36, 52], ["export machinery", "TREATMENT", 57, 73], ["the coatomer and COPII coat", "TREATMENT", 83, 110], ["the KDEL receptor", "TREATMENT", 114, 131], ["such diseases", "PROBLEM", 146, 159], ["COPII coat", "OBSERVATION", 100, 110]]], ["Malfunctioning ERAD could also lead to such diseases.", [["ERAD", "GENE_OR_GENE_PRODUCT", 15, 19], ["ERAD", "PROTEIN", 15, 19], ["Malfunctioning ERAD", "PROBLEM", 0, 19], ["such diseases", "PROBLEM", 39, 52], ["could also lead to", "UNCERTAINTY", 20, 38]]], ["In this context, the ubiquitin ligase RNF45, also known as gp78 or autocrine motility factor receptor (AMFR) is of interest.", [["RNF45", "GENE_OR_GENE_PRODUCT", 38, 43], ["gp78", "GENE_OR_GENE_PRODUCT", 59, 63], ["autocrine motility factor receptor", "GENE_OR_GENE_PRODUCT", 67, 101], ["AMFR", "GENE_OR_GENE_PRODUCT", 103, 107], ["ubiquitin ligase", "PROTEIN", 21, 37], ["RNF45", "PROTEIN", 38, 43], ["gp78", "PROTEIN", 59, 63], ["autocrine motility factor receptor", "PROTEIN", 67, 101], ["AMFR", "PROTEIN", 103, 107], ["the ubiquitin ligase", "TEST", 17, 37]]], ["The intracellular localization of this protein has not been conclusively determined, since it has been found on the MAM and the plasma membrane [131], [248].", [["intracellular", "ANATOMY", 4, 17], ["plasma membrane", "ANATOMY", 128, 143], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["MAM", "CELLULAR_COMPONENT", 116, 119], ["plasma membrane", "CELLULAR_COMPONENT", 128, 143], ["the plasma membrane", "TEST", 124, 143]]], ["The knockdown of this ER protein leads to a block of sarcoma metastasis in primary tumor, due to RNF45/gp78/AMFR promoting the degradation of the metastasis suppressor KAI1/CD82 by the proteasome [249], [250].", [["sarcoma", "ANATOMY", 53, 60], ["primary tumor", "ANATOMY", 75, 88], ["sarcoma", "DISEASE", 53, 60], ["primary tumor", "DISEASE", 75, 88], ["ER", "GENE_OR_GENE_PRODUCT", 22, 24], ["sarcoma", "CANCER", 53, 60], ["tumor", "CANCER", 83, 88], ["RNF45", "GENE_OR_GENE_PRODUCT", 97, 102], ["gp78", "GENE_OR_GENE_PRODUCT", 103, 107], ["AMFR", "GENE_OR_GENE_PRODUCT", 108, 112], ["KAI1", "GENE_OR_GENE_PRODUCT", 168, 172], ["CD82", "GENE_OR_GENE_PRODUCT", 173, 177], ["ER protein", "PROTEIN", 22, 32], ["RNF45", "PROTEIN", 97, 102], ["gp78", "PROTEIN", 103, 107], ["AMFR", "PROTEIN", 108, 112], ["metastasis suppressor", "PROTEIN", 146, 167], ["KAI1", "PROTEIN", 168, 172], ["CD82", "PROTEIN", 173, 177], ["proteasome", "PROTEIN", 185, 195], ["this ER protein", "PROBLEM", 17, 32], ["sarcoma metastasis", "PROBLEM", 53, 71], ["primary tumor", "PROBLEM", 75, 88], ["RNF45", "TEST", 97, 102], ["AMFR", "TREATMENT", 108, 112], ["the metastasis suppressor KAI1", "PROBLEM", 142, 172], ["sarcoma", "OBSERVATION_MODIFIER", 53, 60], ["metastasis", "OBSERVATION", 61, 71], ["primary", "OBSERVATION_MODIFIER", 75, 82], ["tumor", "OBSERVATION", 83, 88], ["metastasis", "OBSERVATION", 146, 156]]], ["At the same time, cells expressing low levels of gp78 are more susceptible to ERAD-mediated apoptosis, again dependent on its relationship with KAI1/CD82.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["gp78", "GENE_OR_GENE_PRODUCT", 49, 53], ["ERAD", "GENE_OR_GENE_PRODUCT", 78, 82], ["KAI1", "GENE_OR_GENE_PRODUCT", 144, 148], ["CD82", "GENE_OR_GENE_PRODUCT", 149, 153], ["gp78", "PROTEIN", 49, 53], ["ERAD", "PROTEIN", 78, 82], ["KAI1", "PROTEIN", 144, 148], ["CD82", "PROTEIN", 149, 153], ["cells expressing low levels of gp78", "PROBLEM", 18, 53], ["ERAD-mediated apoptosis", "PROBLEM", 78, 101], ["KAI1/CD82", "TREATMENT", 144, 153], ["apoptosis", "OBSERVATION", 92, 101]]], ["Another connection of ER protein folding and degradation with cancer is the role of the unfolded protein response in tumor cell metabolism.", [["cancer", "ANATOMY", 62, 68], ["tumor cell", "ANATOMY", 117, 127], ["cancer", "DISEASE", 62, 68], ["tumor", "DISEASE", 117, 122], ["ER", "GENE_OR_GENE_PRODUCT", 22, 24], ["cancer", "CANCER", 62, 68], ["tumor cell", "CELL", 117, 127], ["ER", "PROTEIN", 22, 24], ["ER protein folding", "PROBLEM", 22, 40], ["cancer", "PROBLEM", 62, 68], ["the unfolded protein response in tumor cell metabolism", "PROBLEM", 84, 138], ["protein folding", "OBSERVATION", 25, 40], ["cancer", "OBSERVATION", 62, 68], ["unfolded", "OBSERVATION_MODIFIER", 88, 96], ["protein response", "OBSERVATION", 97, 113], ["tumor cell metabolism", "OBSERVATION", 117, 138]]], ["Ire1, a type I transmembrane endonuclease, cleaves the XBP-1 mRNA, but also activates apoptosis signal regulating kinase 1 (ASK1) [251], [252].", [["Ire1", "GENE_OR_GENE_PRODUCT", 0, 4], ["type I", "GENE_OR_GENE_PRODUCT", 8, 14], ["transmembrane", "CELLULAR_COMPONENT", 15, 28], ["XBP-1", "GENE_OR_GENE_PRODUCT", 55, 60], ["apoptosis signal regulating kinase 1", "GENE_OR_GENE_PRODUCT", 86, 122], ["ASK1", "GENE_OR_GENE_PRODUCT", 124, 128], ["Ire1", "PROTEIN", 0, 4], ["type I transmembrane endonuclease", "PROTEIN", 8, 41], ["XBP-1 mRNA", "RNA", 55, 65], ["apoptosis signal regulating kinase 1", "PROTEIN", 86, 122], ["ASK1", "PROTEIN", 124, 128], ["a type I transmembrane endonuclease", "TREATMENT", 6, 41], ["the XBP", "TEST", 51, 58]]], ["Similarly, protein kinase (PKR)-like endoplasmic reticulum kinase (PERK) induces the production of the pro-apoptotic transcription factor CHOP [253], [254].", [["protein kinase (PKR)-like endoplasmic reticulum kinase", "GENE_OR_GENE_PRODUCT", 11, 65], ["PERK", "GENE_OR_GENE_PRODUCT", 67, 71], ["CHOP", "GENE_OR_GENE_PRODUCT", 138, 142], ["protein kinase (PKR)-like endoplasmic reticulum kinase", "PROTEIN", 11, 65], ["PERK", "PROTEIN", 67, 71], ["pro-apoptotic transcription factor", "PROTEIN", 103, 137], ["CHOP", "PROTEIN", 138, 142], ["protein kinase (PKR)", "TEST", 11, 31], ["endoplasmic reticulum kinase", "TEST", 37, 65], ["reticulum kinase", "OBSERVATION", 49, 65]]], ["Together, Ire1 and PERK promote cancer cell survival under hypoxic conditions [255], [256].", [["cancer cell", "ANATOMY", 32, 43], ["cancer", "DISEASE", 32, 38], ["Ire1", "GENE_OR_GENE_PRODUCT", 10, 14], ["PERK", "GENE_OR_GENE_PRODUCT", 19, 23], ["cancer cell", "CELL", 32, 43], ["Ire1", "PROTEIN", 10, 14], ["PERK", "PROTEIN", 19, 23], ["hypoxic conditions", "PROBLEM", 59, 77], ["cancer cell", "OBSERVATION", 32, 43]]], ["Moreover, ER stress sensor proteins have been implicated in the development of diabetes [257], [258].", [["diabetes", "DISEASE", 79, 87], ["ER", "GENE_OR_GENE_PRODUCT", 10, 12], ["ER", "PROTEIN", 10, 12], ["ER stress sensor proteins", "PROBLEM", 10, 35], ["diabetes", "PROBLEM", 79, 87], ["diabetes", "OBSERVATION", 79, 87]]], ["Although the intra-ER localization of the two ER stress sensor proteins Ire1 and PERK is not known, their sorting and enrichment could be envisaged as critical for their signaling function in cancer and diabetes.ER domain enrichment and diseaseThe center of the recent attention lies however on the links between the MAM and human disease, since this smooth ER domain is the calcium and apoptosis signaling hub of the ER [54], [109], [259].", [["cancer", "ANATOMY", 192, 198], ["cancer", "DISEASE", 192, 198], ["diabetes", "DISEASE", 203, 211], ["human disease", "DISEASE", 325, 338], ["calcium", "CHEMICAL", 375, 382], ["calcium", "CHEMICAL", 375, 382], ["ER", "GENE_OR_GENE_PRODUCT", 46, 48], ["Ire1", "GENE_OR_GENE_PRODUCT", 72, 76], ["PERK", "GENE_OR_GENE_PRODUCT", 81, 85], ["cancer", "CANCER", 192, 198], ["ER", "GENE_OR_GENE_PRODUCT", 212, 214], ["MAM", "CELLULAR_COMPONENT", 317, 320], ["human", "ORGANISM", 325, 330], ["ER", "GENE_OR_GENE_PRODUCT", 358, 360], ["calcium", "SIMPLE_CHEMICAL", 375, 382], ["ER", "GENE_OR_GENE_PRODUCT", 418, 420], ["ER stress sensor proteins", "PROTEIN", 46, 71], ["Ire1", "PROTEIN", 72, 76], ["PERK", "PROTEIN", 81, 85], ["ER", "PROTEIN", 212, 214], ["smooth ER domain", "PROTEIN", 351, 367], ["ER", "PROTEIN", 418, 420], ["human", "SPECIES", 325, 330], ["human", "SPECIES", 325, 330], ["cancer", "PROBLEM", 192, 198], ["diabetes", "PROBLEM", 203, 211], ["ER domain enrichment", "PROBLEM", 212, 232], ["disease", "PROBLEM", 237, 244], ["human disease", "PROBLEM", 325, 338], ["the calcium", "TEST", 371, 382], ["cancer", "OBSERVATION", 192, 198], ["enrichment", "OBSERVATION", 222, 232], ["disease", "OBSERVATION", 237, 244], ["center", "OBSERVATION_MODIFIER", 248, 254], ["disease", "OBSERVATION", 331, 338]]], ["Here, the ER is enriched for numerous disease-associated proteins, including presenilins (Alzheimer's disease [120]), mitofusin-2 (Charcot-Marie-Tooth disease type 2A in knockout models [260]), calnexin (multiple sclerosis-like symptoms in knockout models, [261]) and the promyelocytic leukemia protein (PML), a tumor suppressor [262], [263].", [["promyelocytic leukemia", "ANATOMY", 272, 294], ["tumor", "ANATOMY", 312, 317], ["Alzheimer's disease", "DISEASE", 90, 109], ["multiple sclerosis", "DISEASE", 204, 222], ["promyelocytic leukemia", "DISEASE", 272, 294], ["tumor", "DISEASE", 312, 317], ["ER", "GENE_OR_GENE_PRODUCT", 10, 12], ["presenilins", "GENE_OR_GENE_PRODUCT", 77, 88], ["Alzheimer's disease", "GENE_OR_GENE_PRODUCT", 90, 109], ["mitofusin-2", "GENE_OR_GENE_PRODUCT", 118, 129], ["Marie-Tooth disease type 2A", "GENE_OR_GENE_PRODUCT", 139, 166], ["calnexin", "GENE_OR_GENE_PRODUCT", 194, 202], ["promyelocytic leukemia", "CANCER", 272, 294], ["PML", "GENE_OR_GENE_PRODUCT", 304, 307], ["tumor", "CANCER", 312, 317], ["ER", "PROTEIN", 10, 12], ["disease-associated proteins", "PROTEIN", 38, 65], ["presenilins", "PROTEIN", 77, 88], ["calnexin", "PROTEIN", 194, 202], ["promyelocytic leukemia protein", "PROTEIN", 272, 302], ["PML", "PROTEIN", 304, 307], ["Charcot-Marie-Tooth disease type 2A", "SPECIES", 131, 166], ["numerous disease", "PROBLEM", 29, 45], ["associated proteins", "PROBLEM", 46, 65], ["presenilins (Alzheimer's disease", "PROBLEM", 77, 109], ["mitofusin", "TEST", 118, 127], ["Tooth disease", "PROBLEM", 145, 158], ["calnexin (multiple sclerosis", "PROBLEM", 194, 222], ["symptoms in knockout models", "PROBLEM", 228, 255], ["the promyelocytic leukemia protein (PML", "PROBLEM", 268, 307], ["a tumor suppressor", "TREATMENT", 310, 328], ["disease", "OBSERVATION", 38, 45], ["Tooth", "ANATOMY", 145, 150], ["sclerosis", "OBSERVATION", 213, 222], ["promyelocytic leukemia", "OBSERVATION", 272, 294]]], ["The common denominator of these diseases is a misregulation of apoptosis onset, likely connected to dysfunctional ER-mitochondria calcium signaling.", [["mitochondria", "ANATOMY", 117, 129], ["calcium", "CHEMICAL", 130, 137], ["calcium", "CHEMICAL", 130, 137], ["ER", "GENE_OR_GENE_PRODUCT", 114, 116], ["mitochondria", "CELLULAR_COMPONENT", 117, 129], ["calcium", "SIMPLE_CHEMICAL", 130, 137], ["ER", "PROTEIN", 114, 116], ["these diseases", "PROBLEM", 26, 40], ["apoptosis onset", "PROBLEM", 63, 78], ["common", "OBSERVATION_MODIFIER", 4, 10], ["diseases", "OBSERVATION", 32, 40], ["apoptosis", "OBSERVATION_MODIFIER", 63, 72], ["mitochondria calcium signaling", "OBSERVATION", 117, 147]]], ["Since the extent of MAM targeting for these signaling regulators varies and can depend on ER and cellular homeostasis, future research will have to elucidate the targeting mechanisms of these proteins in order to gain more insight into their role in human disease.", [["ER", "ANATOMY", 90, 92], ["cellular", "ANATOMY", 97, 105], ["MAM", "GENE_OR_GENE_PRODUCT", 20, 23], ["ER", "GENE_OR_GENE_PRODUCT", 90, 92], ["cellular", "CELL", 97, 105], ["human", "ORGANISM", 250, 255], ["signaling regulators", "PROTEIN", 44, 64], ["ER", "PROTEIN", 90, 92], ["human", "SPECIES", 250, 255], ["human", "SPECIES", 250, 255], ["these signaling regulators", "PROBLEM", 38, 64], ["these proteins", "PROBLEM", 186, 200], ["human disease", "PROBLEM", 250, 263], ["human disease", "OBSERVATION", 250, 263]]], ["Interestingly, since the formation of cholesterol-dependent rafts is involved in the formation of the MAM and the targeting to this domain of the smooth ER, one such mechanism may already have been described: cholesterol-induced cytotoxicity in macrophages leads to accelerated death of this cell type in advanced atherosclerotic lesions [264].", [["smooth ER", "ANATOMY", 146, 155], ["macrophages", "ANATOMY", 245, 256], ["cell", "ANATOMY", 292, 296], ["atherosclerotic lesions", "ANATOMY", 314, 337], ["cholesterol", "CHEMICAL", 38, 49], ["cholesterol", "CHEMICAL", 209, 220], ["death", "DISEASE", 278, 283], ["atherosclerotic", "DISEASE", 314, 329], ["cholesterol", "CHEMICAL", 38, 49], ["cholesterol", "CHEMICAL", 209, 220], ["cholesterol", "SIMPLE_CHEMICAL", 38, 49], ["rafts", "CELLULAR_COMPONENT", 60, 65], ["MAM", "CELLULAR_COMPONENT", 102, 105], ["ER", "GENE_OR_GENE_PRODUCT", 153, 155], ["cholesterol", "SIMPLE_CHEMICAL", 209, 220], ["macrophages", "CELL", 245, 256], ["cell type", "CELL", 292, 301], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 314, 337], ["MAM", "PROTEIN", 102, 105], ["smooth ER", "PROTEIN", 146, 155], ["macrophages", "CELL_TYPE", 245, 256], ["cholesterol-dependent rafts", "TREATMENT", 38, 65], ["cholesterol", "TEST", 209, 220], ["cytotoxicity in macrophages", "PROBLEM", 229, 256], ["accelerated death", "PROBLEM", 266, 283], ["advanced atherosclerotic lesions", "PROBLEM", 305, 337], ["cholesterol", "OBSERVATION", 38, 49], ["dependent", "OBSERVATION_MODIFIER", 50, 59], ["rafts", "OBSERVATION", 60, 65], ["smooth", "OBSERVATION_MODIFIER", 146, 152], ["advanced", "OBSERVATION_MODIFIER", 305, 313], ["atherosclerotic", "OBSERVATION_MODIFIER", 314, 329], ["lesions", "OBSERVATION", 330, 337]]], ["Cholesterol overloading may alter the composition and functioning of the MAM, resulting in the observed accelerated apoptosis progression.ER domain enrichment and diseaseER domain formation is also a mechanism that is exploited by viruses.", [["Cholesterol", "CHEMICAL", 0, 11], ["Cholesterol", "CHEMICAL", 0, 11], ["Cholesterol", "SIMPLE_CHEMICAL", 0, 11], ["MAM", "CELLULAR_COMPONENT", 73, 76], ["ER", "GENE_OR_GENE_PRODUCT", 138, 140], ["ER", "PROTEIN", 138, 140], ["Cholesterol overloading", "PROBLEM", 0, 23], ["the observed accelerated apoptosis progression", "PROBLEM", 91, 137], ["ER domain enrichment", "PROBLEM", 138, 158], ["diseaseER domain formation", "PROBLEM", 163, 189], ["overloading", "OBSERVATION", 12, 23], ["accelerated", "OBSERVATION_MODIFIER", 104, 115], ["apoptosis", "OBSERVATION", 116, 125], ["progression", "OBSERVATION_MODIFIER", 126, 137], ["enrichment", "OBSERVATION", 148, 158], ["viruses", "OBSERVATION", 231, 238]]], ["For example, Coronaviruses utilize EDEMosomes to generate double membrane vesicles that accommodate viral replication [215].", [["membrane vesicles", "ANATOMY", 65, 82], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 13, 26], ["EDEMosomes", "GENE_OR_GENE_PRODUCT", 35, 45], ["membrane vesicles", "CELLULAR_COMPONENT", 65, 82], ["Coronaviruses", "PROTEIN", 13, 26], ["EDEMosomes", "PROTEIN", 35, 45], ["Coronaviruses", "PROBLEM", 13, 26], ["double membrane vesicles", "TREATMENT", 58, 82], ["viral replication", "TREATMENT", 100, 117]]], ["The human cytomegalovirus UL37 exon 1 protein, also known as viral mitochondrion-localized inhibitor of apoptosis (vMIA) targets to the MAM after its synthesis within the ER.", [["ER", "ANATOMY", 171, 173], ["human", "ORGANISM", 4, 9], ["cytomegalovirus", "ORGANISM", 10, 25], ["UL37 exon 1", "GENE_OR_GENE_PRODUCT", 26, 37], ["vMIA", "GENE_OR_GENE_PRODUCT", 115, 119], ["MAM", "CELLULAR_COMPONENT", 136, 139], ["ER", "GENE_OR_GENE_PRODUCT", 171, 173], ["human cytomegalovirus UL37 exon 1 protein", "PROTEIN", 4, 45], ["ER", "PROTEIN", 171, 173], ["human", "SPECIES", 4, 9], ["human cytomegalovirus", "SPECIES", 4, 25], ["The human cytomegalovirus", "TEST", 0, 25], ["viral mitochondrion", "PROBLEM", 61, 80], ["apoptosis", "PROBLEM", 104, 113], ["cytomegalovirus", "OBSERVATION", 10, 25]]], ["From here it is able to translocate to mitochondria to exert its anti-apoptotic role by sequestering Bax [265].", [["mitochondria", "ANATOMY", 39, 51], ["mitochondria", "CELLULAR_COMPONENT", 39, 51], ["Bax", "GENE_OR_GENE_PRODUCT", 101, 104], ["Bax", "PROTEIN", 101, 104]]], ["Similar to DGAT2, its targeting and role in apoptosis requires a mitochondrial targeting signal, but not the association with lipid rafts [266].", [["mitochondrial", "ANATOMY", 65, 78], ["lipid rafts", "ANATOMY", 126, 137], ["DGAT2", "GENE_OR_GENE_PRODUCT", 11, 16], ["mitochondrial", "CELLULAR_COMPONENT", 65, 78], ["DGAT2", "PROTEIN", 11, 16], ["apoptosis", "PROBLEM", 44, 53], ["a mitochondrial targeting signal", "PROBLEM", 63, 95], ["apoptosis", "OBSERVATION", 44, 53]]], ["Thus, these studies corroborate that precise intra-ER targeting dictates the functioning of cellular and viral proteins (Table 1).ConclusionsResearch during the past 2 decades has revealed that the ER resembles a city with multiple functions assigned to designated areas more than a village that specializes into one function.", [["cellular", "ANATOMY", 92, 100], ["intra-ER", "GENE_OR_GENE_PRODUCT", 45, 53], ["cellular", "CELL", 92, 100], ["Table 1", "GENE_OR_GENE_PRODUCT", 121, 128], ["ER", "GENE_OR_GENE_PRODUCT", 198, 200], ["intra-ER", "PROTEIN", 45, 53], ["cellular and viral proteins", "PROTEIN", 92, 119], ["Table 1", "PROTEIN", 121, 128], ["ER", "PROTEIN", 198, 200], ["these studies", "TEST", 6, 19]]], ["B cell to plasma cell development is just one example that shows the dynamic nature of ER domain formation and targeting.", [["B cell", "ANATOMY", 0, 6], ["plasma cell", "ANATOMY", 10, 21], ["ER domain", "ANATOMY", 87, 96], ["B cell", "CELL", 0, 6], ["plasma cell", "CELL", 10, 21], ["ER", "GENE_OR_GENE_PRODUCT", 87, 89], ["B cell", "CELL_TYPE", 0, 6], ["ER", "PROTEIN", 87, 89], ["cell", "OBSERVATION", 2, 6], ["plasma cell", "OBSERVATION", 10, 21], ["dynamic", "OBSERVATION_MODIFIER", 69, 76]]], ["Together, multiple findings highlight the importance of understanding intra-ER targeting for human disease.", [["human disease", "DISEASE", 93, 106], ["intra-ER", "GENE_OR_GENE_PRODUCT", 70, 78], ["human", "ORGANISM", 93, 98], ["intra-ER", "PROTEIN", 70, 78], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 93, 98], ["human disease", "PROBLEM", 93, 106]]], ["Given that this area of cell biology is in some ways the final frontier of intracellular sorting, great progress is expected to occur during the next decade with important insight into the biogenesis of the ER as a complex assembly of membrane domains and into the significance of this organelle for human life and death.", [["cell", "ANATOMY", 24, 28], ["intracellular", "ANATOMY", 75, 88], ["ER", "ANATOMY", 207, 209], ["membrane", "ANATOMY", 235, 243], ["organelle", "ANATOMY", 286, 295], ["death", "DISEASE", 315, 320], ["cell", "CELL", 24, 28], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 88], ["ER", "GENE_OR_GENE_PRODUCT", 207, 209], ["membrane", "CELLULAR_COMPONENT", 235, 243], ["organelle", "CELLULAR_COMPONENT", 286, 295], ["human", "ORGANISM", 300, 305], ["ER", "PROTEIN", 207, 209], ["membrane domains", "PROTEIN", 235, 251], ["human", "SPECIES", 300, 305], ["human", "SPECIES", 300, 305], ["death", "PROBLEM", 315, 320], ["cell biology", "OBSERVATION", 24, 36]]], ["An important question for future research will be to elucidate the connection of vesicular trafficking to ER domain formation, given the multiple involvements of COP coats, Rab proteins and Arf GTPases in this cell biological mechanism.", [["vesicular", "ANATOMY", 81, 90], ["ER domain", "ANATOMY", 106, 115], ["cell", "ANATOMY", 210, 214], ["vesicular", "MULTI-TISSUE_STRUCTURE", 81, 90], ["ER", "GENE_OR_GENE_PRODUCT", 106, 108], ["COP", "GENE_OR_GENE_PRODUCT", 162, 165], ["Rab", "GENE_OR_GENE_PRODUCT", 173, 176], ["Arf", "GENE_OR_GENE_PRODUCT", 190, 193], ["cell", "CELL", 210, 214], ["ER", "PROTEIN", 106, 108], ["COP coats", "PROTEIN", 162, 171], ["Rab proteins", "PROTEIN", 173, 185], ["Arf GTPases", "PROTEIN", 190, 201], ["COP coats", "PROBLEM", 162, 171], ["Rab proteins", "TEST", 173, 185], ["Arf GTPases", "PROBLEM", 190, 201], ["COP coats", "OBSERVATION", 162, 171], ["Arf GTPases", "OBSERVATION", 190, 201]]]]}